

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1	ascorbic acid	n/a	5/11/2009	Treatment of Charcot-Marie-Tooth disease type 1A.	Murigenetics SAS
2	budesonide	n/a	12/20/2006	Treatment of patients with eosinophilic esophagitis.	Meritage Pharma, Inc.
3	single chain urokinase plasminogen activator	n/a	9/11/2014	Treatment of empyema (pleural)	Lung Therapeutics, Inc.
4	(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolyethynyl-octahydro-indole-1-carboxylic acid methyl ester	n/a	10/12/2011	Treatment of Fragile X syndrome	Novartis Pharmaceuticals Corp.
5	(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-broethyl) diamidophosphate	n/a	6/5/2013	Treatment of pancreatic cancer	EMD Serono
6	(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate	n/a	3/9/2012	Treatment of soft tissue sarcoma	Threshold Pharmaceuticals, Inc.
7	(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-	n/a	2/17/2009	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	Pfizer, Inc.
8	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	8/13/2004	Treatment of acute lymphoblastic leukemia	Mundipharma Research Limited
9	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	8/10/2004	Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia	Mundipharma Research Ltd.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
10	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	1/29/2004	Treatment of T-cell non-Hodgkin's lymphoma	Mundipharma Research Limited
11	(1S,3S)-3-amino-4-(difluoromethylene)cyclopentanecarboxylic acid hydrochloride, (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride	n/a	9/15/2010	Treatment of infantile spasms.	Catalyst Pharmaceutical Partners
12	(2'R,3'S)-2'-hydroxy-N-carboxy-3'-amino-5'-methyl-hexanoic,N-tert-butyl ester, 13 ester 5B-20-epoxy-1B,2a,4a,7B,9a,10a,13a-heptahydroxy-4,10-diacetate-2-benzoate-(1"S)-7,9-acrolein acetal-11(15-1)-abeotaxane	n/a	6/23/2014	Treatment of progressive supranuclear palsy	Cortice Biosciences, Inc.
13	(2E, 4E, 6Z, 8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl) nona-2,4,6,8-tetraen-1-yl acetate	n/a	12/2/2010	Treatment of retinitis pigmentosa	QLT Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
14	(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenyl acetate 9-cis-retinyl acetate (API)	n/a	12/2/2010	Treatment of Leber congenital amaurosis (LCA) due to inherited mutations in RPE65 (encoding the protein retinal pigment epithelial protein 65) or LRAT (encoding the enzyme lecithin:retinol acyltransferase)genes.	QLT, Inc.
15	(2S)-2-[[[(2R)-2-[[[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid	n/a	10/31/2012	Treatment of primary biliary cirrhosis	Albireo AB
16	(2S)-2-[[[(2R)-2-[[[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid	n/a	10/31/2012	Treatment of progressive familial intrahepatic cholestatis	Albireo AB
17	(2Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-hepten-6-ynamide	Fk778	1/10/2005	Prevention of acute rejection following kidney, heart, and liver transplantation	Fujisawa Healthcare, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
18	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide	n/a	3/18/2011	Treatment of chronic myelogenous leukemia.	NATCO Pharma Limited
19	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide	n/a	3/18/2011	Treatment of pancreatic cancer	NATCO Pharma Limited
20	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide NRC-AN-019	n/a	3/18/2011	Treatment of Glioma	NATCO Pharma Limited
21	(3E,5E)-3,5-bis[(4-fluoro-3-nitrophenyl)methylidene]-1-(prop-2-enoyl)azepan-4-One	n/a	4/30/2014	Treatment of multiple myeloma	VivoLux AB
22	(3S)-1-azabicyclo[2.2.2]oct-3-yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl} carbamate	n/a	9/11/2014	Treatment of Gaucher disease	Genzyme
23	(3S)-1-azabicyclo[2.2.2]oct-3-yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl} carbamate	n/a	8/26/2014	Treatment of Fabry's disease	Genzyme Corporation
24	(3S)-3-(4-trifluoromethoxybenzyloxy)-6-nitro-2H-3,4-dihydroimidazo[2,1-b]oxazine	n/a	7/5/2007	Treatment of tuberculosis	Global Alliance for TB Drug Development

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
25	(3S)-3-[(2S)-2-({N-[2-tert-butyl]phenyl}carbamoyl)carbo nylamino) propanoylamino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy) pentanoci acid	n/a	8/19/2003	Treatment of patients undergoing solid organ transplantation.	Pfizer Global Research and Development
26	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of primary sclerosing cholangitis	Lumena Pharmaceuticals' Inc.
27	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of alagille syndrome	Lumena Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
28	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of progressive familial intrahepatic cholestasis	Lumena Pharmaceuticals. Inc.
29	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of primary biliary cirrhosis	Lumena Pharmaceuticals, Inc.
30	(5R)-5-(4-{[2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, hydrochloride	n/a	7/24/2013	Treatment of trigeminal neuralgia	Convergence Pharmaceuticals Ltd.
31	(6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl] amino-L-glyceroB-L-manno-heptopyranosyl]amino-9H-purine)	n/a	2/21/2014	Parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy that is refractory to conventional analgesics	DARA BioSciences, Inc.
32	(6-maleimidocaproyl)hydrazone of doxorubicin	n/a	6/29/2011	Treatment of soft tissue sarcoma	CytRx Corporation

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
33	(6R,S)5,10-methylene-tetrahydrofolic acid	Cofactor	8/13/2004	For use in combination with 5-fluorouracil for the treatment of patients with pancreatic cancer	Adventrx Pharmaceuticals, Inc.
34	(9-[N-(3-morpholinopropyl)-sulfonyl]-5,6-dihydro-5-oxo-11-H-indeno [1,2-c] isoquinoline methanesulfonic acid	n/a	12/8/2004	Prevention of post-operative complications of aortic aneurysm surgical repair	Inotek Pharmaceuticals Corporation
35	(E)-4-carboxystyryl-4-chlorobenzyl-sulfone, sodium salt	Ex-Rad(R)	9/4/2012	Treatment of acute radiation syndrome	Onconova Therapeutics, Inc.
36	(E)-4-carboxystyryl-4-chlorobenzyl-sulfone, sodium salt	Ex-Rad(R)	6/1/2012	Prevention of acute radiation toxicity, also known as Acute Radiation Syndrome (ARS)	Onconova Therapeutics, Inc.
37	(N-[2,6-bis(1-methylethyl)-pheyl-N'-[[1-4-dimethyl-amino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt	n/a	3/9/2012	Treatment of adrenocortical carcinoma	Atterocor, Inc.
38	(R)-1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide	n/a	4/24/2014	Treatment of cystic fibrosis	Vertex Pharmaceuticals Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
39	(R)-1-phenylethyl-5-(4-biphenyl-4-cyclopropanecarboxylic acid)-3-methylisoxazole-4-yl carbamate sodium salt	n/a	4/15/2011	Treatment of idiopathic pulmonary fibrosis	Bristol-Myers Squibb Company
40	(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxyethyl}-2,3-dihydroimidazo[2,1-b]oxazole	n/a	7/12/2007	Treatment of pulmonary tuberculosis.	Otsuka Pharmaceutical Company, Ltd
41	(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride	n/a	12/19/2007	Treatment of small cell lung cancer.	AbbVie, Inc
42	(R)-N-[2-(6-Chloro-methoxy-1H-indol-3-yl)propyl]acetamide	n/a	7/3/2003	Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients	Phase 2 Discovery, Inc.
43	(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide	n/a	10/3/2001	Treatment of circadian rhythm sleep disorders in blind people with no light perception	Phase 2 Discovery, Inc.
44	(RS)-baclofen, naltrexone and D-sorbitol	n/a	3/17/2014	Treatment of Charcot-Marie-Tooth disease type 1A	Pharnext SAS

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
45	(S)-10- [[dimethylamino)methyl]-4-ethyl-9hydroxy-4-O-[a-(2",4",5",7"-tetranitro-9"-fluorenylideneaminooxy)propionyl]-1H-pyrano[3',4',6',7',]indolizino [1,2-B]-quinoline-3,14-(4H, 12H)-dione, hydrochloride	Lipotecan	10/6/2010	Treatment of hepatocellular carcinoma	TLC Biopharmaceuticals, Inc.
46	(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile	n/a	1/26/2015	Treatment of pemphigus vulgaris	Almirall S.A.
47	(S)-3-((3-(1-((6-((3,4-dimethoxyphenyl)pyrazin-2-yl)amino)ethyl)phenyl)carbamoyl)-5-methylpridin-1-ium	n/a	11/17/2014	Treatment of pulmonary arterial hypertension	Pulmokine, Inc.
48	(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one	n/a	4/15/2013	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Infinity Pharmaceuticals
49	(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one	n/a	8/1/2013	Treatment of follicular lymphoma	Infinity Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
50	(S)-4,5-dihydro-2[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thioxolecarboxylic acid	n/a	2/4/2009	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Ferrokin BioSciences, Inc.
51	(S)-4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-2-carboxamide hydrochloride	n/a	6/24/2013	Treatment of Stage IIb through Stage IV BRAF mutant melanoma	BioMed Valley Discoveries, Inc.
52	(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride	n/a	11/17/2014	Treatment of inherited mitochondrial respiratory chain diseases	Khondrion BV
53	(S)-perillyl alcohol temozolomide	n/a	11/14/2014	Treatment of glioma	NeOnc Technologies, Inc.
54	(UDU-stereoisomer of c-UJUun UNU-terminal UkUnhibitor)	n/a	3/28/2006	Treatment of acute sensorineural hearing loss	Auris Medical, Inc.
55	(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide	n/a	5/14/2014	Treatment of diffuse large B-cell lymphoma	Karyopharm Therapeutics, Inc.
56	(Z)-9-{{2,2-bis-(hydroxymethyl)cyclopropylidene)methyl}guanine, cyclopropavir, ZSM-1-62 and NSC D745998	n/a	11/29/2010	Treatment of active cytomegalovirus infections.	Microbiotix, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
57	1 8-(p[1311]-iodophenyl)octadecyl phosphocholine	n/a	12/3/2014	Treatment of multiple myeloma	Collectar Biosciences, Inc.
58	1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one	n/a	11/19/2012	Treatment of erythromelalgia	Teva Pharmaceuticals
59	1,2:5,6-Dianhydrogalactitol, NSC-132313	n/a	1/31/2012	Treatment of malignant gliomas	DelMar Pharmaceuticals (BC), Ltd.
60	1,5-(Butylimino)-1,5 dideoxy,D-glucitol	n/a	5/12/1998	Treatment of Fabry's disease.	Oxford GlycoSciences
61	1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine	Sapacitabine	6/24/2010	Treatment of acute myelogenous leukemia	Cyclacel Limited
62	1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine	Sapacitabine	6/24/2010	Treatment of myelodysplastic syndrome	Cyclacel Limited
63	1-(3-chloro-5-{[4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl}-2-pyridyl) piperidine-4-carboxylic acid Monomaleate	n/a	9/1/2011	Treatment of idiopathic thrombocytopenic purpura	Eisai, Inc.
64	1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-urea	n/a	11/12/2009	Treatment of acute myeloid leukemia	Astex Therapeutics Ltd

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
65	1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy)methyl]benzene	n/a	1/9/2012	Treatment of poliovirus infection.	ViroDefense, Inc.
66	10 synthetic peptides targeting 5 tumor associated antigens	n/a	1/23/2013	Treatment of non-small cell lung cancer in patients expressing HLA-A2	Orphan Synergy Europe Pharma (OSE Pharma)
67	111Indium pentetreotide	Somatother	6/10/1999	Treatment of somatostatin receptor positive neuroendocrine tumors.	Louisiana State University Medical Center Foundation
68	12-A-p21 RAS(5-21). 12-C-p21 RAS(5-21). 12-D-p21 RAS(5-21). 12-Rp21 RAS(5-21). 12-S-p21 RAS(5-21). 12-V-p21 RAS(5-21). 13-D-p21 RAS(5-21)	n/a	6/7/2011	Treatment of pancreatic cancer	Targovax AS
69	17 amino acid peptide	n/a	1/29/2010	Prevention of ischemia reperfusion injury in the lung during lung transplantation	Apeptico
70	17-allylamino-17-demethoxygeldanamycin (17-AGG)	n/a	9/3/2004	Treatment of chronic myelogenous leukemia	Bristol-Myers Squibb Company
71	177Lu-tetraxetan-tetulumab	Betalutin	5/14/2014	Treatment of Follicular Lymphoma	Nordic Nanovector AS
72	18-(p-[124I]-iodophenyl)octadecyl phosphocholine	n/a	4/30/2014	Diagnostic for the management of glioma	Cellectar Biosciences, Inc.
73	18Fluorine-N-3-Fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl) Nortropane	n/a	1/26/2015	Diagnostic to be used in the management of multiple system atrophy (MSA)	Advanced Imaging Projects, LLC

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
74	2 dimethylbutyrate	n/a	6/18/2008	Treatment of beta thalassemia	HemaQuest Pharmaceuticals, Inc.
75	2'-O-methyl phosphorothioate 5'-GCUAGGUUUACGGGACCUCU-3'	n/a	10/31/2012	Treatment of amyotrophic lateral sclerosis	LifeSplice Pharma LLC
76	2'-deoxycytidine	n/a	9/9/1996	As a host-protective agent in the treatment of acute myelogenous leukemia.	Grant, Steven M.D.
77	2,2'-{2-[1R)-1-(((2,5-dichlorobenzoyl)amino)acetyl)amino]-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid (ixazomib citrate)	n/a	3/9/2012	Treatment of systemic light chain (AL) amyloidosis.	Millennium Pharmaceuticals, Inc.
78	2,5-dimethyl-3-[2-methyl-4-(methoxy)phenyl]-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-	n/a	1/15/2015	Treatment of congenital adrenal hyperplasia (CAH)	Neurocrine Biosciences, Inc.
79	2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione	n/a	9/21/2010	Treatment of idiopathic pulmonary fibrosis.	GenKyoTex S.A.
80	2-(2-phenylvinyl)-4-[-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	1/29/2010	Treatment of acute myeloid leukemia.	EntreMed, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
81	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	7/1/2014	Treatment of hepatocellular carcinoma	CASI Pharmaceuticals, Inc.
82	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	12/22/2008	Treatment of multiple myeloma.	EntreMed, Inc.
83	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	3/18/2009	Treatment of ovarian carcinoma	EntreMed, Inc.
84	2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile adipate	n/a	1/26/2015	Treatment of pancreatic cancer	Incyte Corporation
85	2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5]decane dimaleate	Atiprimod	9/18/2006	Treatment of carcinoid tumors	Callisto Pharmaceuticals, Inc.
86	2-(3-diethylaminopropyl)-8,8-dipropyl-2-azaspiro [4,5] decan dimaleate	Atiprimod	12/2/2003	Treatment of mulitple myeloma and associated bone resorption	Callisto Pharmaceuticals, Inc.
87	2-0-Butyryl-1-0-octyl-myo-inositol 3,4,5,6-tetrakisphosphate	n/a	8/15/2003	Treatment of cystic fibrosis	Inologic, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
88	2-0-desulfated heparin	Aeropin	9/17/1993	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
89	2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridinium sulfate	n/a	3/9/2012	Treatment of Fragile X Syndrome	Hoffmann-La Roche, Inc.
90	2-Chloro-N6--(3-iodobenzyl)adenosine-5'-N-methyluronamide	n/a	2/17/2012	Treatment of hepatocellular carcinoma	Can-Fite BioPharma Ltd.
91	2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol	Epidiolex	2/27/2014	Treatment of Lennox-Gastaut syndrome	GW Pharma Ltd.
92	2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol	Epidiolex	11/14/2013	Treatment of Dravet syndrome.	GW Pharma Ltd.
93	2-[(3-methyl-4-(2,2,2-trifluoroethoxy) pyridin-2-yl)methylsulfinyl] -1H-benzoimidazole	Prevonco (Tm)	8/27/2008	Treatment of hepatocellular carcinoma.	BioQuant, Inc.
94	2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thienol[3,2-f]-[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)-acetamide dihydrate	n/a	7/16/2014	Treatment of acute myeloid leukemia	OncoEthix SA
95	2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide	n/a	12/18/2007	Treatment of malignant melanoma stages IIb through IV.	AbbVie, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
96	2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxy-methyl]-quinoline succinic acid	n/a	6/2/2014	Treatment of Huntington's disease.	Pfizer Inc.
97	2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indian-2-carboxylic acid	n/a	5/14/2013	Treatment of patients with systemic sclerosis	Sanofi U. S., Inc.
98	2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}propyl)(ethyl)amino]ethyl dihydrogen phosphate trihydrate	n/a	1/19/2010	Treatment of acute myeloid leukemia	AstraZeneca Pharmaceuticals LP
99	2-chloroethyl-3-sarcosinamide-1-nitroso-urea	n/a	8/3/2001	Treatment for malignant gliomas	Lawrence Panasci, MD
100	2-chloroethyl-3-sarcosinamide-1-nitroso-urea	Sarmustine	11/15/2001	Treatment for malignant glioma	Pangene Corporation
101	2-hydroxypropyl-β-cyclodextrin	Kleptose	2/18/2013	Treatment of Niemann Pick disease, type C.	Vtesse, Inc.
102	2-iminobiotin	n/a	2/24/2009	Treatment of perinatal asphyxia.	Neurophyxia B.V.
103	2-methoxyestradiol	Pulmolar	4/11/2005	Treatment of pulmonary arterial hypertension	PR Pharmaceuticals, Inc.
104	2-[[[(1r,4r)-4-[[[4-chlorophenyl)(phenyl)carbamoyloxy)methyl]cyclohexyl)methoxy] acetic acid	n/a	8/28/2014	Treatment of pulmonary arterial hypertension	Arena Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
105	20-mer complementary to Akt mRNA	n/a	12/10/2004	Treatment of stomach cancer	Rexahn Corporation
106	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/8/2004	Treatment of glioblastoma	Rexahn Corporation
107	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/8/2004	Treatment of pancreatic cancer	Rexahn Corporation
108	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/1/2004	Treatment of renal cell carcinoma	Rexahn Corporation
109	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/1/2004	Treatment of ovarian cancer	Rexahn Corporation
110	225Ac-lintuzumab	n/a	11/25/2014	Treatment of acute myelogenous leukemia	Actinium Pharmaceuticals, Inc.
111	24,25 dihydroxycholecalciferol	n/a	2/27/1987	Treatment of uremic osteodystrophy.	Lemmon Company
112	2S,4R ketoconazole	n/a	3/9/2012	Treatment of endogenous Cushing's syndrome	Cortendo AB (HQ address)
113	3,4 diaminopyridine and choline bitartrate	n/a	4/30/2010	Treatment of Lambert-Eaton myasthenic syndrome	MS Therapeutics Limited
114	3,4-Diaminopyridine phosphate	n/a	11/12/2009	Treatment of Lambert-Eaton Myasthenic Syndrome	Catalyst Pharmaceutical Partners, Inc.
115	3,4-diaminopyridine	n/a	12/18/1990	Treatment of Lambert-Eaton myasthenic syndrome.	Jacobus Pharmaceutical Company

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
116	3,5,3'-triiodothyroacetate	n/a	9/20/2000	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland.	Elliot Danforth, Jr., M.D.
117	3,5-diiodothyropropionic acid	n/a	5/14/2013	Treatment of Allan-Herndon-Dudley syndrome	Zarion Pharmaceuticals P/L
118	3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one	n/a	3/23/2000	Treatment of von Hippel-Lindau disease.	Sugen, Inc.
119	3-(3,5-dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one	n/a	9/11/1998	Treatment of Kaposi's sarcoma.	Sugen, Inc.
120	3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxyl-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid	n/a	3/2/2010	Treatment of cystic fibrosis	Vertex Pharmaceuticals Inc.
121	3-[2-(4-carbamimidoyl-phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2-carboxylic acid	n/a	12/23/2014	Prevention of acute attacks of angioedema in individuals with hereditary angioedema	BioCryst Pharmaceuticals, Inc.
122	3-bromopyruvate	n/a	3/5/2013	Treatment of liver and intrahepatic bile duct cancer	Primocure Pharma, Inc.
123	3-bromopyruvate	n/a	4/29/2014	Treatment of pancreatic cancer	PreScience Labs, LLC

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
124	3-chloro-4-fluorophenyl-[4-fluoro-4-[[[5-methylpyrimidin-2-ylmethyl)amino)methyl]piperidin-1yl]methanone	n/a	10/25/2013	Treatment of Rett syndrome	Neurolix, Inc.
125	3-fluoro-5-[5-(2-menthyl-thiazol-4-ylethynyl)-pyridin-2-yl]-benzotrile dihydrochloride	n/a	7/28/2008	Treatment of behavioral abnormalities associated with fragile X syndrome.	Seaside Therapeutics
126	3-pentylbenzenacetic acid sodium salt	n/a	2/11/2015	Treatment of idiopathic pulmonary fibrosis.	ProMetic Life Sciences, Inc.
127	4, 5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/30/2008	Treatment of follicular lymphoma	Kiadis Pharma Canada, Inc.
128	4, 5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/30/2008	Treatment of diffuse large B-cell lymphoma	Kiadis Pharma Canada, Inc.
129	4,5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/23/2007	For immune reconstitution and prevention of graft versus host disease following allogeneic hematopoietic stem cell transplantation.	Kiadis Pharma Canada, Inc.
130	4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein disodium salt	n/a	4/18/2011	Treatment of hepatocellular carcinoma.	Provectus Pharmaceuticals, Inc.
131	4-(2-fluorophenyl)-6-methyl-2-(1-piperziny)	n/a	10/11/2006	Treatment of Chronic Functional Vomiting to include functional vomiting and cyclic vomiting syndrome.	Dynogen Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
132	4-(3-Methanesulfonyl-phenyl)-1-propylpiperidine HCl	n/a	12/12/2005	Treatment of Huntington's disease.	Teva Branded Pharmaceutical Products R&D
133	4-(4-([2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl)piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide	n/a	3/27/2014	Treatment of diffuse large B-cell lymphoma.	AbbVie
134	4-(4-([2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl)piperazin-1-yl)-N-({3-nitro-4-[tetrahydro-2H-pyran-4-ylmethyl]amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide	n/a	9/20/2012	Treatment of chronic lymphocytic leukemia	AbbVie, Inc.
135	4-(6-(4-(piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride	n/a	4/15/2013	Treatment of fibrodysplasia ossificans progressiva	La Jolla Pharmaceutical Company, Inc.
136	4-Amino-1-[5-O-[(2R, 4S)-2-oxido-4-(4-pyridinyl)-1, 3, 2-dioxaphosphorinan-2-yl]-b-D-arabinofuranosyl]-2(1H)-pyrimidinone	n/a	8/22/2007	Treatment of hepatocellular carcinoma.	Ligand Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
137	4-Aminopyridine	n/a	12/14/2005	Treatment chronic functional motor and sensory deficits from Guillain-Barre syndrome	Acorda Therapeutics, Inc.
138	4-[131I]iodo-L-phenylalanine	n/a	1/4/2011	Treatment of glioma.	Therapeia GmbH & Co KG
139	4-[1]benzofuro[3,2-d]pyrimidin-4-yl-N-(1,3-benzodioxol-5-ylmethyl)piperazine-1-carbothioamide	n/a	7/30/2008	Treatment, in combination with radiotherapy and temozolomide chemotherapy, of patients with glioblastoma multiforme.	SuperGen, Inc.
140	4-[2-(3-Propyl-[1,2,4]Oxadiazol-5-yl)-vinyl]-benzene-1,2-diol	n/a	10/4/2011	Treatment of chronic myeloid leukemia	Piramal Enterprises Limited
141	4-[4-[[[3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl]amino]carbonyl]-amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide, p-toluenesulfonate salt	n/a	9/3/2009	Treatment of Philadelphia chromosome positive chronic myeloid leukemia	Deciphera Pharmaceuticals, LLC
142	4-[[9-(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol	n/a	9/23/2011	Treatment of idiopathic pulmonary fibrosis	Celgene Corporation
143	4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl) cyclopent-2-en-1-yl] pyrimidin-2-one	n/a	9/23/2014	Treatment of pancreatic cancer.	Rexahn Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
144	4-aminosalicylic acid	Pamisyl (P-D), Rezipas (Squibb)	12/13/1989	Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.	Beeken, Warren M.D.
145	4-aminosalicylic acid	Paser Granules	4/26/2006	Treatment of acute flares in pediatric patients with ileo-cecal Crohn's disease	Jacobus Pharmaceutical Co., Inc.
146	4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[dimethylamino)acetyl]-4-piperidiny]phenyl]-1H-imidazole-2-carboxamide monohydrochloride	n/a	7/20/2006	Treatment of acute myeloid leukemia	Johnson & Johnson Pharmaceutical Research & Dev,
147	4-pyridinylmethyl 3(4-chlorophenyl)adamantine carboxamide	n/a	11/2/2010	Treatment of pancreatic cancer.	Apogee Biotechnology Corporation
148	4-[[[(2R,3S,4R,5S)-4-(4-Chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid	n/a	5/19/2014	Treatment of Acute Myeloid Leukemia	Roche Genentech
149	40K PEGylated recombinant factor IX	n/a	3/18/2013	Routine prophylactic administration for prevention of bleeding in patients with hemophilia B (Christmas disease).	Novo Nordisk, Inc.
150	5'-GCCATGGTTTTTCTCAGG-3'	n/a	10/31/2012	Prophylaxis for patients following documented or suspected exposure to ebolavirus	Sarepta Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
151	5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin	n/a	6/15/2007	Treatment of osteosarcoma (bone cancer)	Dr. Reddy's Laboratories, Inc.
152	5,5',5"-[Phosphinothioylidynetris(imino-2,1-ethanediyl)]tris[5-methylchelidoninium]trihydroide hexahydrochloride	n/a	8/20/2003	Treatment of pancreatic cancer	Now Pharm AG
153	5,6-dihydro-5-azacytidine	n/a	5/11/1992	Treatment of malignant mesothelioma.	ILEX Oncology, Inc.
154	5,7-dichloro-2-methylaminomethyl-8-hydroxyquinolone hydrochloride	n/a	9/4/2014	Treatment of Huntington's disease	Prana Biotechnology Limited
155	5,7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one	n/a	6/18/2007	Prevention of acute radiation syndrome	Humanetics Corporation
156	5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride	n/a	4/18/2011	Treatment of progressive supranuclear palsy.	Mithridion, Inc.
157	5-(4-Cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide	n/a	1/15/2015	Treatment pulmonary arterial hypertension	Gilead Sciences, Inc.
158	5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzop[d]oxazole	n/a	11/22/2011	Treatment of Duchenne Muscular Dystrophy	Summit Corporation plc
159	5-[(E)-2-(4-hydroxyphenyl)-ethenyl] benzene-1,3 diol	Resveratrol	3/13/2008	Treatment of MELAS syndrome	Sirtris Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
160	5-[1-(2,6-Dichlorobenzyl)-piperidin-4-yl]methoxyquinazoline-2,4-diamine	n/a	8/25/2009	Treatment of spinal muscular atrophy	Pfizer Incorporated
161	5-[8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6yl]-2-pyrimidinamine	n/a	2/10/2015	Treatment of malignant mesothelioma	Verastem, Inc.
162	5-aminolevulinic acid	Gliolan	1/15/2013	Visualization of malignant tissue during surgery for malignant glioma (WHO grade III and IV)	NX Development Corporation
163	5-aza-2'-deoxycytidine	n/a	8/3/1987	Treatment of acute leukemia.	SuperGen, Inc.
164	5-hydroxymethyl-2-furfuraldehyde	n/a	5/26/2006	Treatment of sickle cell disease	AesRx, LLC
165	5-iodo-2-pyrimidinone-2'-deoxyribose	n/a	5/26/2006	Treatment of malignant glioma	Hana Biosciences, Inc.
166	5'-GAATATTAACAIACTGACAAGTC-3'	n/a	10/31/2012	Prophylaxis following documented or suspected exposure to marburg virus	Sarepta Therapeutics, Inc.
167	6,8-bis-benzylsulfanyl-octanoic acid	n/a	9/26/2013	Treatment of myelodysplastic syndrome	Cornerstone Pharmaceuticals, Inc.
168	6,8-bis-benzylsulfanyl-octanoic acid	n/a	8/22/2011	Treatment of acute myeloid leukemia.	Cornerstone Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
169	6,8-bis-benzylsulfanyl-octanoic acid	n/a	2/6/2006	Treatment of pancreatic cancer	Cornerstone Pharmaceuticals, Inc.
170	6-((3S,4S)-4-Methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl-1-(tetrahydropyran-4-yl)-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one	n/a	9/4/2014	Treatment of sickle cell disease	Pfizer, Inc.
171	6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo-[1,2-alpha]pyrazin-8-amine bis-methanesulfonate	n/a	4/14/2014	Treatment of chronic lymphocytic leukemia	Gilead Sciences, Inc.
172	6-[4-Deoxy-4-((2E,4E)-tetradecadienoylglycyl)amino-L-glycero-B-L-manno-heptopyranosyl]amino-9H-purine	n/a	6/12/2014	Treatment of multiple myeloma	DARA BioSciences, Inc.
173	6-alpha-ethylchenodeoxycholic acid	n/a	4/9/2008	Treatment of primary sclerosing cholangitis	Intercept Pharmaceuticals, Inc.
174	6-amino-5-chloro-N-[1R)-1-[5-[[[5-hloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimidinecarboxamide	n/a	10/15/2013	Treatment of stage IIb-IV melanoma	Millennium Pharmaceuticals, Inc.
175	6-mercaptopurine oral liquid	n/a	12/7/2009	Treatment of acute lymphoblastic leukemia in the pediatric population	Orbona Pharma Ltd

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
176	68G-OPS202, small somatostatin analog labeled with 68Gallium	n/a	9/24/2014	Management of gastroenteropancreatic neuroendocrine tumors.	OctreoPharm Sciences GmbH
177	7-B-Hydroxy Cholesteryl-3-B-Oleate-Ester	n/a	6/15/2011	Treatment of gliomas.	Intsel Chimos SA
178	8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one	n/a	1/21/2015	Treatment of glioblastoma multiforme	RestorGenex Corporation
179	8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naph-thyrin-3(2H)-one mono-hydrochloride	n/a	9/3/2009	Treatment of ovarian cancer.	Merck Sharp & Dohme Corp.
180	8-methoxsalen	Uvadex	5/12/1994	For the prevention of acute rejection of cardiac allografts.	Therakos, Inc.
181	8-methoxsalen	Uvadex	6/22/1993	For use in conjunction with the UVAR photopheresis to treat diffuse systemic sclerosis.	Therakos, Inc.
182	9-nitro-20-(S)-camptothecin	Camvirex	5/15/2001	Treatment of pediatric HIV infection/AIDS	NovoMed Pharmaceuticals, Inc.
183	9-nitro-20-(S)-camptothecin	n/a	9/16/1996	Treatment of pancreatic cancer.	SuperGen, Inc.
184	90Y-hPAMA4	Pan-Cide	1/29/2004	Treatment of pancreatic cancer	Immunomedics, Inc.
185	A-dmDT390-bisFv(UCHT1)	Resimmune	10/9/2014	Treatment of cutaneous T-cell lymphoma	Angimmune, LLC
186	A10 & AS2-1 Antineoplaston	n/a	9/3/2004	Treatment for patients with brain stem glioma	Burzynski Research Institute, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
187	AAV-G6Pase vector	n/a	3/11/2013	Treatment of glycogen storage disease type Ia	GlyGenix Therapeutics, Inc.
188	ADF-APO-CCN-GUC-K67-MET-MMP-MUC-RGS; HLA class I/II binding tumor associated peptides	n/a	9/28/2012	Treatment of renal cell carcinoma in HLA-A*2 positive patients	Immatics Biotechnologies GmbH
189	ADXS11-001	n/a	8/12/2013	Treatment of HPV-positive associated anal cancer	Advaxis, Inc.
190	AEZS-108 (LHRH-agonist linked to doxorubicin)	n/a	4/30/2010	Treatment of ovarian cancer	Aeterna Zentaris
191	ALX-0081 nanobody, directed towards the human A1 domain of von Willebrand factor	n/a	4/14/2009	Treatment of thrombotic thrombocytopenic purpura	Ablynx NV
192	AQ-13 (4-aminoquinoline analog)	n/a	9/12/2008	Treatment of malaria	Immtech Pharmaceuticals, Inc.
193	Abetimus	n/a	7/28/2000	Treatment of lupus nephritis.	La Jolla Pharmaceutical Co.
194	Ac-Ile-Cys-Val-Trp(1-Me)-Gln-Asp-Trp-Gly-Ala-His-Arg-Cys-Thr-AEEA-Lys-PEG 40KDa-Lys-AEEA-Thr-Cys-Arg-His-ALa-Gly-Trp-Asp-Gln-(1-Me)Trp-Val-Cys-Ile-Ac	n/a	4/20/2014	Treatment of paroxysmal nocturnal hemoglobinuria	Apellis Pharmaceuticals, Inc.
195	Acetylcysteine	Mucomyst/Mucomyst 10 lv	8/13/1987	Intravenous treatment of patients presenting with moderate to severe acetaminophen overdose.	Bristol-Myers Squibb Company
196	ActRIIB-IgG1)	n/a	8/16/2010	Treatment of Duchenne muscular dystrophy	Acceleron Pharma, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
197	Ad5/3-D24-granulocyte-macrophage colony stimulating factor (GMCSF)-encoding oncolytic adenovirus	n/a	3/17/2014	Treatment of ovarian cancer	Oncos Therapeutics Ltd
198	Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor	n/a	1/31/2012	Treatment of homozygous familial hypercholesterolemia	ReGenX Biosciences LLC
199	Adeno-associated vector expressing the human lipoprotein lipase protein	n/a	5/21/2007	Treatment of lipoprotein lipase deficiency	uniQure B.V.
200	Adeno-associated viral vector containing the gene for human coagulation factor IX	Coagulin-B	6/13/2001	Intramuscular treatment of patients with moderate to severe hemophilia	Avigen, Inc.
201	Adeno-associated viral vector containing the gene for human coagulation factor IX	Coagulin-B	6/13/2001	Intrahepatic treatment of patients with moderate to severe hemophilia	Avigen, Inc.
202	Adeno-associated viral vector expressing human acid alpha glucosidase gene	n/a	3/20/2007	Treatment of Pompe disease	Applied Genetic Technologies Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
203	Adenoassociated virus vector (AAV) carrying a modified AAV serotype 2 backbone and coding sequence of human thymidine phosphorylase preceded by a human thyroxin-binding globulin promoter	n/a	9/4/2014	For the treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)	Columbia University Medical Center
204	Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase	n/a	3/3/2011	Treatment of myeloproliferative disorders (polycythemia vera, essential thrombocythemia, and myelofibrosis)	Eli Lilly and Company
205	Adenoviral vector expressing Herpes simplex virus thymidine kinase gene	n/a	6/17/2005	Treatment of malignant brain tumors	Advantagene, Inc.
206	Adenovirus serotype-5 (Ad5) vector that contains a modified non-oncogenic fused early 6 (E6) and early 7 (E7) gene of the human papillomavirus (HPV); (Ad5 [E1-, E2b-]-E6/E7)	n/a	9/4/2014	Treatment of human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC)	Etubics Corporation
207	Adenovirus-based vector Factor VIII complementary DNA to somatic cells	Miniadviii	12/15/1999	Treatment of hemophilia A.	GenStar Therapeutics Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
208	Albendazole	Albenza	1/18/1996	Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis.	Amedra Pharmaceuticals LLC
209	Albendazole	Albenza	1/17/1996	Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).	Amedra Pharmaceuticals LLC
210	Albuterol	n/a	3/12/2002	Prevention of paralysis due to spinal cord injury	MotoGen, Inc.
211	Aldesleukin	Proleukin	3/22/1989	Treatment of primary immunodeficiency disease associated with T-cell defects.	Prometheus Laboratories, Inc.
212	Aldesleukin	Proleukin	9/14/1988	Treatment of metastatic renal cell carcinoma.	Chiron Corporation
213	Aldesleukin	Proleukin	9/10/1996	Treatment of metastatic melanoma.	Chiron Corporation
214	Aldesleukin	Proleukin	11/24/1998	For the treatment non-Hodgkin's lymphoma.	Prometheus Laboratories, Inc.
215	Alendronate disodium	Fosamax	2/13/2001	Treatment of the bone manifestations of Gaucher disease	Richard J. Wenstrup, M.D.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
216	Alfentanil	n/a	7/8/2005	Management of postherpetic neuralgia	Cinergen, LLC
217	Alfentanil	n/a	8/9/2005	Treatment of painful HIV-associated neuropathy	Cinergen, LLC
218	Alglucerase injection	Ceredase	7/21/1995	Replacement therapy in patients with Type II and III Gaucher's disease.	Genzyme Corporation
219	Alglucerase injection	Ceredase	3/11/1985	For replacement therapy in patients with Gaucher's disease type I.	Genzyme Corporation
220	Alitretinoin	Panretin	3/24/1998	Treatment of AIDS-related Kaposi's sarcoma.	Eisai, Inc
221	Alitretinoin	Panretin	4/10/1992	Treatment of acute promyelocytic leukemia	Ligand Pharmaceuticals, Inc.
222	Allogeneic T-cells cultured with anti-CD3 and IL-2; transduced with retroviral vector (SFCMM-3), expressing herpes simplex 1 virus-thymidine kinase (HSV-TK) and truncated low affinity nerve growth factor receptor; selected with anti-low affinity nerve gro	n/a	1/28/2005	Immunotherapy for acceleration of T-cell reconstitution in patients undergoing allogeneic hematopoietic stem cell transplantation	MolMed S.p.A.
223	Allogeneic human aortic endothelial cells cultured in a porcine gelatin matrix	Vascugel (R)	4/3/2009	Prevention of arteriovenous fistula or arteriovenous graft failure in patients with end stage renal disease receiving hemodialysis or preparing for hemodialysis	Shire

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
224	Allogeneic motor neuron progenitor cells derived from human embryonic stem cells	Motorgraft (Tm)	1/17/2014	Treatment of Amyotrophic Lateral Sclerosis	California Stem Cell Inc.
225	Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture	Cytoimplant	6/13/1997	Treatment of pancreatic cancer	Applied Immunotherapeutics, LLC
226	Allogeneic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	n/a	9/1/2004	Treatment of retinitis pigmentosa	Neurotech USA, Inc.
227	Allopurinol sodium	Aloprim For Injection	10/16/1992	Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.	Catalytica Pharmaceuticals, Inc
228	Alpha-galactosidase A	Replagal	6/22/1998	Long-term enzyme replacement therapy for the treatment of Fabry disease	Shire Human Genetic Therapies, Inc.
229	Alpha-galactosidase A	Cc-Galactosidase	6/17/1991	Treatment of alpha-galactosidase A deficiency (Fabry's disease).	David Calhoun, Ph.D.
230	Alpha-galactosidase A	Fabrase	7/20/1990	Treatment of Fabry's disease.	Desnick, Robert J. M.D.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
231	Alpha-melanocyte stimulating hormone	n/a	8/19/1997	Prevention and treatment of intrinsic acute renal failure due to ischemia.	National Institute of Diabetes, and Digestive and Kidney Diseases
232	Alpha-tocopherol quinone	n/a	3/28/2006	Treatment of inherited mitochondrial respiratory chain diseases	Penwest Pharmaceuticals Company
233	Alpha1-Proteinase Inhibitor (Human)	n/a	12/22/2004	Inhalation therapy for the treatment of congenital deficiency of alpha1-proteinase inhibitor.	Kamada Ltd.
234	Alpha1-Proteinase Inhibitor (Human)	Arc-Api	9/1/2004	Treatment of cystic fibrosis	Kamada Ltd.
235	Alpha1-antitrypsin(human)	n/a	4/3/2008	Treatment of bronchiectasis	Kamada, Ltd.
236	Alpha1-proteinase inhibitor (human)	Prolastin	12/7/1984	For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.	Bayer Corporation
237	Altretamine	Hexalen	2/9/1984	Treatment of advanced adenocarcinoma of the ovary.	Medimmune Oncology, Inc.
238	Alvocidib	n/a	4/13/2007	Treatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.	Tolero Pharmaceuticals, Inc.
239	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.	Medimmune Oncology, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
240	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cyclophosphamide in the treatment of advanced ovarian carcinoma.	Clinigen Group plc
241	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of metastatic melanoma.	Clinigen Group plc
242	Amifostine	Ethyol	10/4/1999	Treatment of myelodysplastic syndromes.	Clinigen Group, plc
243	Amifostine	Ethyol	11/24/1998	For the reduction of the incidence and severity of toxicities associated with cisplatin administration.	Clinigen Group plc
244	Amifostine	Ethyol	5/12/1998	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	Medimmune Oncology, Inc.
245	Amikacin	Arikace	3/9/2006	Treatment of bronchopulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients	Insmmed, Inc.
246	Aminocaproic acid	Caprogel	1/6/1995	For the topical treatment of traumatic hyphema of the eye.	Eastern Virginia Medical School
247	Aminosalicylic acid	Paser Granules	2/19/1992	Treatment of tuberculosis infections	Jacobus Pharmaceutical Company

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
248	Aminosidine	Paromomycin	9/9/1994	Treatment of visceral leishmaniasis (kala-azar).	Kanyok, Thomas P. Pharm.D.
249	Aminosidine	Gabbromicina	5/14/1993	Treatment of tuberculosis.	Kanyok, Thomas P. Pharm.D.
250	Aminosidine	Gabbromicina	11/15/1993	Treatment of Mycobacterium avium complex.	Kanyok, Thomas P. Pharm.D.
251	Amiodarone	Amio-Aqueous	8/17/1993	Treatment of incessant ventricular tachycardia.	Academic Pharmaceuticals, Inc.
252	Amiodarone HCl	Cordarone	3/16/1994	For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.	Wyeth-Ayerst Laboratories
253	Ammonium tetrathiomolybdate	Coprexa	1/31/1994	Treatment of Wilson's disease.	Pipex Pharmaceuticals, Inc.
254	Amphotericin B inhalation powder	n/a	12/15/2005	Prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy including those receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies	Novartis Pharmaceuticals Corporation
255	Amphotericin B lipid complex	Abelcet	12/5/1991	Treatment of invasive fungal infections.	Liposome Company, Inc.
256	Amyl nitrite, sodium nitrite, sodium thiosulfate	Cyanide Antidote Kit	12/18/2006	Treatment of cyanide poisoning	Akorn, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
257	Anagrelide	Agrylin	1/27/1988	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp.
258	Anagrelide	Agrylin	7/14/1986	Treatment of thrombocytosis in chronic myelogenous leukemia.	Roberts Pharmaceutical Corp.
259	Anagrelide	Agrylin	6/11/1985	Treatment of polycythemia vera.	Roberts Pharmaceutical Corp.
260	Ananain, comosain	Vianain	1/21/1992	For the enzymatic debridement of severe burns.	Genzyme Corporation
261	Anatibant	n/a	4/15/2005	Treatment of patients having experienced a severe traumatic brain injury (Glasgow Coma Scale 3 to 8) in order to decrease early mortality and improve long-term functional and neurological outcome	Xytis, Inc.
262	Ancrod	Viprinex	10/20/1989	To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.	Knoll Pharmaceutical Company
263	Angiotensin (1-7)	n/a	11/26/2013	Treatment of limb-girdle muscular dystrophy	US Biotest, Inc.
264	Angiotensin 1-7	Marstem	8/3/2001	Treatment of myelodysplastic syndrome	Maret Pharmaceutical Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
265	Angiotensin 1-7	n/a	2/16/2000	Treatment of neutropenia associated with autologous bone marrow transplantation.	Maret Pharmaceuticals
266	Angiotensin-(1-7)	n/a	9/13/2011	Treatment of pulmonary arterial hypertension.	US Biotest, Inc.
267	Anti-Beta1 integrin monoclonal antibody	n/a	8/7/2014	Treatment of glioblastoma	OncoSynergy, Inc.
268	Anti-T cell receptor murine monoclonal antibody	n/a	4/3/2009	Prophylaxis of acute rejection of solid organ transplantation	Tolera Therapeutics, Inc.
269	Anti-tenascin 81C6 monoclonal antibody labeled w/ I 131	Neuradiab	10/4/2005	Treatment of primary malignant brain tumors	Bradmer Pharmaceuticals, Inc.
270	Anti-thymocyte serum	Nashville Rabbit Anti-Thymocyte Serum	6/2/1993	Treatment of allograft rejection, including solid organ (kidney, liver, heart, lung, and pancreas) and bone marrow transplantation.	Applied Medical Research
271	Antibody drug conjugate consisting of a humanized IgG1 anti-NaPi2b monoclonal antibody and monomethyl auristatin E	n/a	7/29/2014	Treatment of ovarian cancer	Genentech, Inc.
272	Antiepilepsirine	n/a	3/23/1989	Treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.	Children's Hospital
273	Antihemophilic factor (human)	Alphanate	1/5/1996	Treatment of von Willebrand's disease	Grifols Biologicals Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
274	Antihemophilic factor (recombinant)	Kogenate	9/25/1989	Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.	Bayer Corporation
275	Antihemophilic factor (recombinant)	Refacto	2/8/1996	For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).	Wyeth Pharmaceuticals, Inc.
276	Antihemophilic factor (recombinant) formulated with sucrose reconstituted with liposome diluent	Kogenate Fs/Liposomal Diluent	4/29/2009	Treatment of hemophilia A	Bayer HealthCare LLC
277	Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized	Humate-P	10/16/1992	Treatment of patients with von Willebrand's disease	CSL Behring
278	Antisense 20-mer oligonucleotide complementary to R2 component of ribonucleotide reductase mRNA	n/a	4/15/2005	Treatment of acute myeloid leukemia	Lorus Therapeutics, Inc.
279	Antisense oligonucleotide directed against connexin43	Nexagon	4/27/2009	Treatment of persistent corneal epithelial defects	CoDa Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
280	Antithrombin III (human)	Atnativ	2/8/1985	For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.	Pharmacia & Upjohn AB
281	Antithrombin III (human)	Thrombate lii	11/26/1984	For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.	Bayer Corporation
282	Antithrombin III human	Antithrombin lii Human	1/2/1986	Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.	American National Red Cross
283	Antivenin crotaline (pit-viper) equine immune F(ab)2)	Antivipmyn	1/29/2004	Treatment of envenomation by Crotaline snakes	Instituto Bioclon, S.A de C.V.
284	Antivenin, crotalidae polyvalent immune Fab (ovine)	Crofab	1/12/1994	Treatment of envenomations inflicted by North American crotalid snakes.	Protherics, Inc.
285	Antivenom (crotalidae) purified (avian)	n/a	2/12/1991	Treatment of envenomation by poisonous snakes belonging to the Crotalidae family.	Ophidian Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
286	Apomorphine	n/a	7/17/1995	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Pentech Pharmaceuticals, Inc.
287	Apomorphine HCl	Apokyn	4/22/1993	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	US WorldMeds, LLC
288	Apomorphine hydrochloride	n/a	5/23/2006	For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous)	NeuroHealing Pharmaceuticals, Inc.
289	Aprotinin	Trasylol	11/17/1993	For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary coronary artery bypass graft surgery where the risk of bleeding is especially high (impaired hemostasis) or where transfusion is unavailable or unacceptable.	Bayer Corporation
290	Arenegyr	n/a	8/22/2008	Treatment of malignant pleural mesothelioma	MolMed S.p.A.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
291	Arginine butyrate	n/a	4/7/1992	Treatment of beta-hemoglobinopathies and beta-thalassemia.	Perrine, Susan P., M.D.
292	Arsenic trioxide	Trisenox	3/3/1998	Treatment of acute promyelocytic leukemia.	Cephalon
293	Arsenic trioxide	Trisenox	3/4/2005	Treatment of malignant glioma	Teva Branded Pharmaceutical Products R&D, Inc.
294	Arsenic trioxide	Trisenox	4/28/2000	Treatment of multiple myeloma.	TEVA Branded Pharmaceutical Products R & D, Inc.
295	Arsenic trioxide	Trisenox	5/13/2003	Treatment of chronic lymphocytic leukemia	Teva Branded Pharmaceutical Products R&D, Inc.
296	Artesunate	n/a	7/19/1999	Treatment of malaria.	World Health Organization
297	Artesunate	n/a	3/28/2006	Immediate treatment of malaria	US Army Medical Materiel Development Activity
298	Ascorbic acid	Ascor L 500	8/31/2007	Treatment of scurvy	McGuff Pharmaceuticals Inc.
299	Asfotase alfa	n/a	9/12/2008	Treatment of hypophosphatasia	Alexion Pharmaceuticals, Inc.
300	Atovaquone	Mepron	9/10/1990	Treatment of AIDS associated Pneumocystis Carinii Pneumonia.	Glaxo Wellcome Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
301	Atovaquone	Mepron	8/14/1991	Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.	Glaxo Wellcome Research and Development
302	Attenuated autologous cancer cells and granulocyte macrophage colony stimulating factor in combination with activated autologous blood derived T-cells	n/a	4/27/2007	Treatment of primary central nervous system malignancies	TVAX Biomedical, LLC
303	Autologous CD3+ T cells transduced with retroviral vector containing a chimeric antigen receptor directed against CD19 (Autologous CD3+ T cells containing CD19 chimeric antigen receptor)	n/a	11/13/2014	Treatment of acute lymphoblastic leukemia (ALL)	Juno Therapeutics, Inc.
304	Autologous CD34+ cells transfected with lentiviral vector containing the human WAS cDNA (Telethon 003)	n/a	4/30/2010	Treatment of Wiskott Aldrich syndrome	GlaxoSmithKline Intellectual Property Development

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
305	Autologous DNP-conjugated tumor vaccine	M-Vax	2/23/1999	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Avax Technologies, Inc.
306	Autologous Engineered Skin Substitute	Permaderm	6/1/2012	Treatment of hospitalized patients with deep partial and full thickness burns requiring grafting.	Lonza
307	Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	n/a	1/31/2014	For the treatment of Acute Lymphoblastic Leukemia	Novartis Pharmaceuticals Corporation
308	Autologous cultured endothelial cells on a donor human corneal disk	n/a	6/1/2007	Treatment of Fuch's dystrophy, pseudophakic bullous keratopathy, and bullous keratopathy	Cellular Bioengineering, Inc.
309	Autologous dendritic cells pulsed with autologous antigens from primary malignant brain tumor cells	Dcvax-Brain	11/29/2002	Treatment of primary brain malignant cancer	Northwest Biotherapeutics, Inc.
310	Autologous dendritic cells pulsed with recombinant human fusion protein (mucin1-glutathione S transferase) coupled to oxidized polymannose	Cvac(Tm)	9/13/2010	Treatment of ovarian cancer.	Prima Biomed Ltd.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
311	Autologous incubated macrophage	n/a	9/3/2004	Therapy to improve the motor and sensory neurological outcome in acute cases of spinal cord injury	Proneuron Biotechnologies, Inc.
312	Autologous lymphoma-derived immunoglobulin idiotype antigen vaccine conjugated to keyhole limpet hemocyanin	Biovaxid	10/18/2011	Treatment of Waldenstrom's macroglobulinemia	Biovest International, Inc.
313	Autologous olfactory neural progenitors	Rhinocytes	2/1/2008	Treatment of spinal cord injury patients with ASIA Impairment grades A, B, or C	RhinoCyte, Inc.
314	Autologous or allogeneic limbal epithelial stem cells expanded ex vivo on human amniotic membrane	n/a	7/14/2005	Treatment of ocular surface diseases that are characterized by total limbal stem cell deficiency	TissueTech, Inc.
315	Autolymphocyte therapy	n/a	7/12/1994	Treatment of renal cell carcinoma.	Cytogen Corporation
316	Azacitidine	Vidaza	6/18/2008	Treatment of acute myeloid leukemia	Celgene Corporation
317	Azathioprine	Imuran	9/14/1999	Treatment of oral manifestations of graft-versus-host disease.	Oral Solutions, Inc.
318	BF2.649 (Pitolisant)	n/a	5/17/2010	Treatment of narcolepsy	Bioprojet Pharma
319	Bacillus Calmette-Guerin vaccine	n/a	8/9/2006	Treatment of stage IIb through IV metastatic melanoma	OncoVac Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
320	Bacitracin	Altracin	3/13/1984	Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.	A. L. Laboratories, Inc.
321	Baclofen	Lioresal Intrathecal	9/26/1994	Treatment of spasticity associated with cerebral palsy.	Medtronic, Inc.
322	Balsalazide disodium	Colazal	8/12/2005	Treatment of pediatric patients with ulcerative colitis	Salix Pharmaceuticals, Inc.
323	Bardoxolone	n/a	8/6/2008	Treatment of pancreatic cancer	Reata Pharmaceuticals, Inc.
324	Basiliximab	Simulect	12/12/1997	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals Corporation
325	Beclomethasone dipropionate	n/a	3/27/1998	For oral administration in the treatment of intestinal graft-versus-host disease.	Soligenix, Inc.
326	Belinostat	Beleodaq	9/3/2009	Treatment of peripheral T-cell lymphoma (PTCL).	Spectrum Pharmaceuticals, Inc.
327	Bendamustine hydrochloride	Treanda	8/17/2007	Treatment of chronic lymphocytic leukemia	Cephalon, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
328	Benzoate and phenylacetate	Ucephan	1/21/1986	For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency.	ImmunexImmunex
329	Benzophenone-3, octylmethoxycinnamate, avobenzene, titanium dioxide, zinc oxide	Total Block VI Spf 75	8/13/2001	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy	Fallien Cosmeceuticals Ltd.
330	Benzydamine hydrochloride	Tantum	5/18/1998	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Angelini Pharmaceuticals, Inc.
331	Benzylpenicillin, benzylpenicilloic, benzylpenilloic acid	Pre-Pen/Mdm	9/28/1987	Assessing the risk of administrating penicillin when it is the preferred drug of choice in adult patients who have previously received penicillin and have a history of clinical sensitivity.	AllerQuest LLC

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
332	Beractant	Survanta Intratracheal Suspension	12/20/1993	Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.	Ross Laboratories
333	Beractant	Survanta Intratracheal Suspension	2/5/1986	Treatment of neonatal respiratory distress syndrome.	Ross Laboratories
334	Beractant	Survanta Intratracheal Suspension	2/5/1986	Prevention of neonatal respiratory distress syndrome.	Ross Laboratories
335	Beraprost	n/a	4/29/1999	Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).	LungRx, Inc.
336	Beta alethine	Betathine	3/24/1997	Treatment of metastatic melanoma.	Dovetail Technologies, Inc.
337	Beta alethine	Betathine	3/24/1997	Treatment of multiple myeloma.	Dovetail Technologies, Inc.
338	Betahistine dihydrochloride	n/a	11/8/2007	Treatment of obesity associated with Prader Willi syndrome	Floyd R. Sallee, M.D., Ph.D.
339	Betaine	Cystadane	5/16/1994	Treatment of homocystinuria.	Jazz Pharmaceuticals
340	Betulinic acid	n/a	8/9/2007	Topical treatment of metastatic melanoma	Advanced Life Sciences, Inc. (ALS)

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
341	Bexarotene	Targretin	6/18/1999	Treatment of cutaneous T-cell lymphoma.	Eisai, Inc.
342	Bindarit	n/a	2/3/1998	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc.
343	Bio-engineered oral mucosal tissue	n/a	4/27/2006	For use as a graft for restoring a cornea-like epithelial phenotype to substitute for the normal corneal epithelium that is lost in patients due to total limbal stem cell deficiency	TissueTech, Inc.
344	Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)	n/a	2/11/2002	Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2	Excorp Medical, Inc.
345	Bis(4-fluorophenyl)phenylacetamide	n/a	3/2/2000	Treatment of sickle cell disease.	ICAgen Inc.
346	Bleomycin	n/a	12/20/2010	Treatment of pancreatic cancer.	CIRJ Company Ltd.
347	Bleomycin	Blenoxane	2/9/1999	Treatment of pancreatic cancer.	Genetronics, Inc.
348	Bleomycin sulfate	Blenoxane	9/17/1993	Treatment of malignant pleural effusion.	Bristol-Myers Squibb Pharmaceutical Research Institute
349	Blinatumomab	n/a	5/16/2008	Treatment of chronic lymphocytic leukemia	Amgen, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
350	Bone marrow-derived mononuclear cells	n/a	5/17/2010	Treatment of thromboangiitis obliterans (Buerger's disease)	t2cure GmbH
351	Bosentan	Tracleer	10/6/2000	Treatment of pulmonary arterial hypertension.	Actelion Life Sciences Ltd.
352	Botulinum toxin type A	n/a	9/15/1992	Treatment of synkinetic closure of the eyelid associated with VII cranial nerve aberrant regeneration.	Botulinum Toxin Research Associates, Inc.
353	Botulinum toxin type A	Botox	3/22/1984	Treatment of strabismus and blepharospasms	Allergan, Inc.
354	Botulinum toxin type A	Botox	8/20/1986	Treatment of cervical dystonia.	Allergan, Inc.
355	Botulinum toxin type A	Dysport	10/20/1999	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Ipsen Limited
356	Botulinum toxin type A	Dysport	3/23/1989	Treatment of essential blepharospasm.	Porton International, Inc.
357	Botulinum toxin type A	Dysport	8/12/1998	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Biopharm Limited
358	Botulinum toxin type A	Botox	12/6/1991	Treatment of dynamic muscle contracture in pediatric cerebral palsy patients.	Allergan, Inc.
359	Botulinum toxin type B	Myobloc	1/16/1992	Treatment of cervical dystonia.	Soltice Neurosciences, LLC
360	Botulinum toxin type F	n/a	10/24/1991	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Limited
361	Botulism immune globulin	Babybig	1/31/1989	Treatment of infant botulism.	California Department of Health Services

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
362	Bovine colostrum	n/a	11/19/1990	Treatment of AIDS-related diarrhea.	Hastings, Donald DVM
363	Bovine immunoglobulin concentrate, Cryptosporidium parvum	Sporidin-G	3/1/1994	Treatment and symptomatic relief of Cryptosporidium parvum infection of the gastrointestinal tract in immunocompromised patients.	GalaGen, Inc.
364	Bovine whey protein concentrate	Immuno-C	9/30/1993	Treatment of cryptosporidiosis caused by the presence of Cryptosporidium parvum in the gastrointestinal tract of patients who are immunodeficient/immunocompromised or immunocompetent.	Biomune Systems, Inc.
365	Branched chain amino acids	n/a	12/23/1988	Treatment of amyotrophic lateral sclerosis.	Mount Sinai Medical Center
366	Brilliant Blue G	Dorc IIm-Blue	7/31/2012	To selectively stain the thickened internal limiting membrane, which has formed onto the inner side of the retina in vitreo-retinal disorders	Dutch Ophthalmic Research Center
367	Brimonidine	Alphagan	2/7/2000	Treatment of anterior ischemic optic neuropathy.	Allergan, Inc.
368	Brivaracetam	n/a	10/5/2005	Treatment of symptomatic myoclonus	UCB Pharma, Inc.
369	Broxuridine	Broxine/Neomark	9/18/1995	Radiation sensitizer in the treatment of primary brain tumors.	NeoPharm, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
370	Buffered Ursodeoxycholic Acid	Ursocarb	9/3/2004	Treatment of pruritus in patients with Alagille Syndrome	Digestive Care, Inc.
371	Buffered intrathecal electrolyte/dextrose injection	Elliotts B Solution	8/24/1994	For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment of meningeal leukemia and lymphocytic lymphoma	Lukare Medical, LLC
372	Buprenorphine hydrochloride	Subutex	6/15/1994	Treatment of opiate addiction in opiate users.	Reckitt Benckiser Pharmaceuticals, Inc.
373	Busulfan	Spartaject	4/21/1994	For use as preparative therapy for malignancies treated with bone marrow transplantation.	Sparta Pharmaceuticals, Inc.
374	Busulfan	Spartaject	7/7/1997	Treatment of primary brain malignancies.	SuperGen, Inc.
375	Busulfan	Busulfex	7/28/1994	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Otsuka Pharmaceutical Company
376	Buthionine sulfoxamine	n/a	10/5/2005	For use in children as a modulator of chemotherapy for the treatment of pediatric patients with neuroblastoma	USC-CHLA Institute for Pediatric Clinical Research

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
377	Buthionine sulfoxamine	n/a	10/5/2005	Use as a modulator of chemotherapy for the treatment of pediatric patients with primary malignant brain tumors	USC-CHLA Institute for Pediatric Clinical Research
378	Butyrylcholinesterase	n/a	3/25/1992	For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.	Shire Laboratories Inc.
379	Butyrylcholinesterase	n/a	9/30/1992	Treatment of post-surgical apnea.	Shire Laboratories Inc.
380	C1 esterase inhibitor (human)	Cinryze(R)	7/16/2004	Treatment of angioedema	ViroPharma Biologics Incorporated
381	C1 esterase inhibitor (human)	n/a	8/21/1996	Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.	Alpha Therapeutic Corporation
382	C1-esterase inhibitor (recombinant)	Ruconest	2/23/1999	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Santarus, Inc.
383	C1-esterase-inhibitor, human, pasteurized	Berinerit (R)	10/16/1992	Prevention and/or treatment of acute attacks of hereditary angioedema.	CSL Behring LLC
384	C20-D3-retinyl acetate	n/a	9/16/2010	Treatment of Stargardt's disease	Alkeus pharmaceuticals, Inc.
385	C66H100N6O27	n/a	3/11/2013	Treatment of of hepatocellular carcinoma	GenSpera, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
386	CD40/CD80/CD86 modified autologous dendritic cell therapy	n/a	12/20/2013	Treatment Type 1 diabetes mellitus patients with residual beta cell function	DiaVacs, Inc.
387	CNDO-109-activated allogeneic natural killer cells	n/a	6/18/2012	Treatment of acute myeloid leukemia	Coronado Biosciences, Inc.
388	Caffeine	Cafcit	9/20/1988	Treatment of apnea of prematurity.	O.P.R. Development, L.P.
389	Calcitonin-human for injection	Cibacalcin	1/20/1987	Treatment of symptomatic Paget's disease (osteitis deformans).	Novartis Pharmaceutical Corporation
390	Calcium acetate	n/a	6/27/1989	Treatment of hyperphosphatemia in end stage renal disease.	Pharmedic Company
391	Calcium acetate	Phos-Lo	12/22/1988	Treatment of hyperphosphatemia in end stage renal failure.	Fresenius Medical Care North America
392	Calcium carbonate	R & D Calcium Carbonate/600	6/6/1990	Treatment of hyperphosphatemia in patients with end stage renal disease.	R & D Laboratories, Inc.
393	Calcium gluconate	Calgonate	11/20/1997	For use as a wash for hydrofluoric acid spills on human skin.	Calgonate Corp.
394	Calcium gluconate gel	H-F Gel	5/21/1991	For use in the emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Calgonate Corporation
395	Calcium gluconate gel 2.5%	n/a	9/10/1990	Emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Paddock Laboratories, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
396	Calfactant	Infasurf	9/5/2000	Acute respiratory distress syndrome (ARDS)	ONY, Inc.
397	Capsaicin	n/a	8/3/2005	Treatment of postherpetic neuralgia.	TheraQuest Biosciences, LLC
398	Capsaicin	n/a	9/29/2006	Treatment of intermetatarsal neuroma (Morton's Neuroma) that does not respond to conservative treatment and requires either neurectomy or neurolysis	Centrexion Corporation
399	Carmustine	n/a	7/3/2000	Treatment of intracranial malignancies.	Direct Therapeutics, Inc.
400	Cascara sagrada fluid extract	n/a	3/21/1989	Treatment of oral drug overdosage to speed lower bowel evacuation.	Intramed Corporation
401	Catumaxomab	Removab	6/9/2006	Treatment of ovarian cancer	Neoviibiotech North America, Inc.
402	Ceftriaxone sodium	Rocephin	3/28/2006	Treatment of amyotrophic lateral sclerosis	Mass General Hospital
403	Cells produced using the AastromReplicelle System and SC-I Therapy Kit	n/a	7/10/2002	For use in patients receiving high dose chemotherapy who are unable to generate an acceptable dose of peripheral blood stem cells and who have a sufficient bone marrow aspirate without morphological evidence of tumor	Aastrom Biosciences Incorporated
404	Centruroides immune F(ab)2	Anascorp	6/12/2000	Treatment of scorpion envenomations requiring medical attention.	Rare Disease Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
405	Ceramide trihexosidase/alpha-galactosidase A	Fabrazyme	1/19/1988	Treatment of Fabry's disease.	Genzyme Corporation
406	Chelating agent delivering Holmium-166	n/a	2/10/1999	Treatment of multiple myeloma.	NeoRx Corporation
407	Chenodeoxycholic acid	Chenofalk	1/29/2004	Treatment of cerebrotendinous xanthomatosis	Dr. Falk Pharma GmbH
408	Chimeric monoclonal antibodies, c-alphaStx2	n/a	10/4/2005	For treatment of shiga-toxin producing bacterial infection	Thallion Pharmaceuticals, Inc.
409	Chimeric monoclonal antibody to mesothelin	n/a	10/31/2006	Treatment of pancreatic cancer	Morphotek, Inc.
410	Chimeric, humanized monoclonal antibody to staphylococcus	n/a	8/3/2000	Prophylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.	Biosynexus, Inc.
411	Chlorhexidine gluconate mouthrinse	Peridex	8/18/1986	For use in the amelioration of oral mucositis associated with cyto-reductive therapy used in conditioning patients for bone marrow transplantation therapy.	Procter & Gamble Company
412	Chlorotoxin	n/a	12/18/2007	Treatment of malignant glioma	Morphotek, Inc.
413	Choline chloride	Intrachol	7/20/2006	Prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition	QOL Therapeutics EU, Ltd

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
414	Choline chloride	Intrachol	2/10/1994	Treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition.	QOL Therapeutics EU Ltd
415	Chondrocyte-alginate gel suspension	n/a	12/1/1997	For use in correcting vesicoureteral reflux in the pediatric population.	Curis, Inc.
416	Ciliary neurotrophic factor	n/a	1/30/1992	Treatment of amyotrophic lateral sclerosis.	Regeneron Pharmaceuticals Inc
417	Cintredekin Besudotox	n/a	4/30/2010	Treatment of idiopathic pulmonary fibrosis	Insys Therapeutics, Inc.
418	Cisplatin in liposomal formulation	Slit Cisplatin For Inhalation	3/20/2007	Treatment of osteosarcoma	Eleison Pharmaceuticals, LLC
419	Cisplatin/epinephrine	Intradose	9/7/2000	Treatment of metastatic malignant melanoma.	Matrix Pharmaceutical, Inc.
420	Cisplatin/epinephrine	Intradose	4/3/2000	Treatment of squamous cell carcinoma of the head and neck.	Matrix Pharmaceutical, Inc.
421	Citric acid, glucono-delta-lactone and magnesium carbonate	Renacidin Irrigation	8/28/1989	Treatment of renal and bladder calculi of the apatite or struvite variety.	United-Guardian, Inc.
422	Cladribine	Mylinax	4/19/1994	Treatment of the chronic progressive form of multiple sclerosis.	Johnson & Johnson Pharmaceutical R & D, LLC
423	Cladribine	Leustatin Injection	11/15/1990	Treatment of hairy cell leukemia.	R. W. Johnson Pharmaceutical Research Institute

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
424	Clazosentan	Erajel	2/16/2006	Treatment of cerebral vasospasm following subarachnoid hemorrhage	Actelion Pharmaceuticals Ltd.
425	Clindamycin	Cleocin	10/28/1988	Prevention of Pneumocystis carinii pneumonia in AIDS patients.	Pfizer Inc.
426	Clindamycin	Cleocin	10/28/1988	Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.	Pharmacia & Upjohn
427	Clindamycin hydrochloride	n/a	8/9/2006	Treatment of sarcoidosis	Autoimmunity Research Foundation
428	Clofazimine	Lamprene	6/11/1984	Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.	Novartis Pharmaceutical Corporation
429	Clonazepam	Klonopin	8/4/1994	Treatment of hyperekplexia (startle disease).	Hoffmann-La Roche, Inc.
430	Clonazepam Intranasal Spray	n/a	12/19/2007	Treatment of recurrent acute repetitive seizures	Jazz Pharmaceuticals, Inc.
431	Clonidine	Duraclon	1/24/1989	For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates.	Roxane Laboratories, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
432	Clotrimazole	n/a	6/14/2005	Topical treatment of children and adults with pouchitis	AesRx, LLC
433	Clotrimazole	n/a	3/13/2006	Treatment of Huntington's disease	EnVivo Pharmaceuticals, Inc.
434	Clotrimazole	n/a	4/24/1995	Treatment of sickle cell disease.	Brugnara, Carlo M.D.
435	Coagulation Factor IX (human)	Alphanine	7/5/1990	For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis.	Alpha Therapeutic Corporation
436	Coagulation Factor IX (recombinant)	Benefix	10/3/1994	Treatment of hemophilia B.	Genetics Institute, Inc.
437	Coagulation Factor VIIa (Recombinant)	Novoseven	7/16/2004	Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Novo Nordisk, Inc.
438	Coagulation factor IX	Mononine	6/27/1989	Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.	Armour Pharmaceutical Company
439	Coagulation factor IX (recombinant), Fc fusion protein	Alprolix	10/30/2008	Control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease)	Biogen Idec Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
440	Coagulation factor VIIa (recombinant)	Novoseven	6/6/1988	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Novo Nordisk, Inc.
441	Coagulation factor VIIa (recombinant)	Novoseven	9/10/2004	Prevention of bleeding episodes in patients with congenital Factor VII deficiency	Novo Nordisk, Inc.
442	Coagulation factor VIIa (recombinant)	Novoseven	9/10/2004	Treatment of bleeding episodes in patients with congenital factor VII deficiency	Novo Nordisk, Inc.
443	Coagulation factor VIIa (recombinant)	Novoseven	7/21/2004	Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Novo Nordisk, Inc.
444	Coagulation factor VIIa (recombinant)	Novoseven	6/18/2004	Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors	Novo Nordisk, Inc.
445	Coagulation factor VIIa (recombinant)	Novoseven	6/18/2004	Prevention of bleeding episodes in Glanzmann's thrombasthenia	Novo Nordisk, Inc.
446	Coenzyme Q10	n/a	3/5/2001	Treatment of Huntington's disease	Integrative Therapeutics, Inc.
447	Colchicine	n/a	9/25/2007	Treatment of Behcet's Syndrome	AR Scientific, Inc.
448	Colfosceril palmitate, cetyl alcohol, tyloxapol	Exosurf Neonatal For Intratracheal Suspension	10/20/1989	Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less.	Glaxo Wellcome Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
449	Colfosceril palmitate, cetyl alcohol, tyloxapol	Exosurf Neonatal For Intratracheal Suspension	10/20/1989	Treatment of established hyaline membrane disease at all gestational ages.	Glaxo Wellcome Inc.
450	Combination of nivolumab and ipilimumab	n/a	10/9/2014	Treatment of Stage IIb to Stage IV melanoma	Bristol-Myers Squibb Company
451	Combretastatin A4 Phosphate	n/a	7/23/2003	Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer	OXiGENE, Inc
452	Combretastatin A4 phosphate	n/a	5/8/2006	Treatment of ovarian cancer	OXiGENE, Inc.
453	Conjugate of a dengue virus specific small chemical ligand and an amphiphilic PEG based polymer	n/a	8/6/2013	Treatment of dengue fever (includes dengue hemorrhagic fever and dengue shock syndrome)	NanoViricides Incorporated
454	Contulakin-G	n/a	7/7/2005	Intrathecal treatment of neuropathic pain associated with spinal cord injury	Cognetix, Inc.
455	Cordycepin	n/a	7/5/2007	Treatment of TdT-positive acute lymphocytic leukemia	OncoVista, Inc.
456	Corticotropin ovine triflutate	Acthrel	11/24/1989	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.	Ferring Laboratories, Inc.
457	Corticotropin-releasing factor, human	Xerecept	4/6/1998	Treatment of peritumoral brain edema.	Neurobiological Technologies, Inc.
458	Coumarin	Onkolox	12/22/1994	Treatment of renal cell carcinoma.	Drossapharm LTD

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
459	Coxsackievirus A21	Cavatak	12/15/2005	Treatment of stage II (T4), stage III, and stage IV melanoma	Viralytics Limited
460	Creatine	Creapure	10/11/2005	Treatment of Huntington's disease	Marathon Pharmaceuticals, LLC
461	Cromolyn sodium	Gastrocrom	3/8/1984	Treatment of mastocytosis.	Fisons Corporation
462	Cromolyn sodium 4% ophthalmic solution	Opticrom 4% Ophthalmic Solution	7/24/1985	Treatment of vernal keratoconjunctivitis.	Fisons Corporation
463	Cryptosporidium hyperimmune bovine colostrum IgG concentrate	n/a	12/30/1991	Treatment of diarrhea in AIDS patients caused by infection with Cryptosporidium parvum.	ImmuCell Corporation
464	Cyclo {(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobutyl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}	n/a	12/20/2006	Treatment and chronic control of non-infectious posterior, intermediate and pan-uveitis	Lux Biosciences, Inc.
465	Cyclosporin A	Mitogard	10/29/2004	Treatment of amyotrophic lateral sclerosis and its variants	Maas Biolab, LLC
466	Cyclosporine	Pluminiq	11/25/2003	Treatment of acute rejection in patients requiring allogenic lung transplants	APT Pharmaceuticals, Inc.
467	Cyclosporine	n/a	11/25/2003	Prophylaxis of organ rejection in patients receiving allogeneic lung transplant	APT Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
468	Cyclosporine 2% ophthalmic ointment	n/a	8/1/1991	Treatment of patients at high risk of graft rejection following penetrating keratoplasty	Allergan, Inc.
469	Cyclosporine A	n/a	5/4/2007	Treatment of vernal keratoconjunctivitis	NOVAGALI Pharma SA
470	Cyclosporine in combination with omega-3 polyunsaturated fatty acids	n/a	12/6/2000	Prevention of solid organ graft rejection.	RTP Pharma Corporation
471	Cyclosporine ophthalmic	Optimmune	11/9/1988	Treatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome.	University Of Georgia
472	Cys-His-Ala-Val-Cys	n/a	2/14/2008	For use in conjunction with melphalen for the treatment of malignant melanoma, AJCC stages IIB, IIC, III and IV	Adherex Technologies, Inc.
473	Cysteamine	Lynovex	9/11/2014	Treatment of cystic fibrosis	NovaBiotics Ltd.
474	Cysteamine	Cystagon	1/25/1991	Treatment of nephropathic cystinosis.	Mylan Laboratories, Inc.
475	Cysteamine	n/a	5/1/1986	Treatment of nephropathic cystinosis.	Thoene, Jess G., M.D.
476	Cysteamine hydrochloride	Cystaran	8/19/1997	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Sigma-Tau Pharmaceuticals, Inc.
477	Cystic fibrosis Tr gene therapy (recombinant adenovirus)	Adgvcftr.10	3/9/1995	Treatment of cystic fibrosis.	GenVec, Inc.
478	Cystic fibrosis transmembrane conductance regulator gene	n/a	1/8/1993	Treatment of cystic fibrosis.	Genetic Therapy, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
479	Cytarabine liposomal	Depocyt	6/2/1993	Treatment of neoplastic meningitis.	Pacira Pharmaceuticals, Inc.
480	Cytarabine:daunorubicin liposome injection	n/a	8/22/2008	Treatment of acute myeloid leukemia	Celator Pharmaceuticals, Inc.
481	Cytomegalovirus DNA Vaccine w/Copolymer/Benzalkonium Chloride	n/a	9/23/2006	For use in prevention of clinically significant CMV viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid organ transplant populations	Vical Inc.
482	Cytomegalovirus DNA vaccine with plasmids expressing pp65 and gB genes	n/a	6/3/2005	Prevention of clinically significant cytomegalovirus (CMV) viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid transplant populations	Astellas Pharma Global Development, Inc.
483	Cytomegalovirus immune globulin (human)	Cytogam	8/3/1987	Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.	CSL Behring LLC
484	Cytomegalovirus immune globulin intravenous (human)	n/a	1/28/1991	For use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients.	Bayer Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
485	D-mannitol and L-proline	Prodarsan	4/20/2009	Treatment of Cockayne syndrome	DNage B.V.
486	D-peptide	Nerofe	2/4/2011	Treatment of acute myelogenous leukemia	Immune System Key, Ltd
487	D-peptide of the sequence AKRHHGYKRKFH - NH2	Pulmadex	10/23/2002	Treatment of cystic fibrosis	Demegen, Inc.
488	DCVAC OvCa	n/a	5/14/2013	Treatment of ovarian cancer	SOTIOS a.s.
489	DEAE-rebeccamycin	n/a	3/1/2004	Treatment of bile duct tumors	Helsinn Healthcare SA
490	DHA-paclitaxel	Taxoprexin	5/1/2003	Treatment of adenocarcinoma of the stomach or lower esophagus	Luitpold Pharmaceuticals, Inc.
491	DHA-paclitaxel	Taxoprexin	9/25/2001	Treatment of pancreatic cancer	Luitpold Pharmaceuticals, Inc..
492	DHA-paclitaxel	Taxoprexin	10/10/2002	Treatment of metastatic malignant melanoma	Luitpold Pharmaceuticals, Inc.
493	DNA plasmid expressing diphtheria toxin triggered by the presence of oncofetal gen H19	n/a	8/20/2009	Treatment of ovarian cancer	BioCancell Therapeutics Ltd.
494	DNA plasmid vector (pCK-HGFX7) expressing human hepatocyte growth factor	n/a	2/6/2014	Treatment of amyotrophic lateral sclerosis	ViroMed Co., Ltd.
495	DNA plasmid vector expressing eIF5Ak50	n/a	12/13/2010	Treatment of multiple myeloma.	Senesco Technologies, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
496	DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)	n/a	7/24/2012	Treatment of diffuse large B cell lymphoma	Senesco Technologies, Inc.
497	DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)	n/a	7/24/2012	Treatment of mantle cell lymphoma	Senesco Technologies, Inc.
498	DNA plasmid vector expressing human IL-12 gene	n/a	4/4/2005	Treatment of ovarian cancer.	Expression Genetics, Inc.
499	DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2	Leuvectin	4/28/2000	Treatment of renal cell carcinoma.	Vical Incorporated
500	DNP-Modified autologous tumor vaccine	O-Vax	9/21/2000	Adjuvant therapy for the treatment of ovarian cancer	AVAX Technologies, Inc.
501	DOXO-EMCH	n/a	4/18/2011	Treatment of adenocarcinoma of the pancreas.	CytRx Corporation
502	Daclizumab	Zenapax	3/5/1993	Prevention of acute renal allograft rejection.	Hoffmann-La Roche, Inc.
503	Dapsone	n/a	11/7/1994	Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100.	Jacobus Pharmaceutical Company, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
504	Dapsone USP	Dapsone	12/24/1991	Prophylaxis for Pneumocystis carinii pneumonia.	Jacobus Pharmaceutical Company
505	Dapsone USP	Dapsone	1/8/1992	For the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim.	Jacobus Pharmaceutical Company
506	Darinaparsin	n/a	9/13/2010	Treatment of peripheral T-cell lymphoma.	Solasia Pharma K.K.
507	Dasatinib	Sprycel	11/28/2005	Treatment of chronic myelogenous leukemia	Bristol-Myers Squibb Company
508	Dasatinib	Sprycel	11/18/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Bristol-Myers Squibb Company
509	Daunorubicin citrate liposome injection	Daunoxome	5/14/1993	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.	NeXstar Pharmaceuticals, Inc.
510	Daunorubicin liposomal	n/a	9/5/2008	Treatment of acute myeloid leukemia	Diatos USA, LLC
511	Deferasirox	Exjade	11/21/2002	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Novartis Pharmaceuticals Corporation
512	Defibrotide	n/a	7/5/1985	Treatment of thrombotic thrombocytopenic purpura.	Crinos International
513	Dehydroepiandrosterone (DHEA)	Fidelin	8/19/2003	Replacement therapy in individuals with adrenal insufficiency	Paladin Labs, Inc.
514	Dehydroepiandrosterone sulfate sodium	n/a	1/29/1997	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
515	Dehydroepiandrosterone sulfate sodium	n/a	1/28/1997	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc.
516	Dermagraft	n/a	12/13/2010	Treatment of epidermolysis bullosa	Shire Regenerative Medicine, Inc.
517	Deslorelin	Somagard	11/5/1987		Roberts Pharmaceutical Corp.
518	Desmoglein 3 synthetic peptide (PI-0824)	n/a	10/26/2004	Treatment of pemphigus vulgaris	Peptimmune, Inc.
519	Desmopressin acetate	n/a	1/22/1991	Treatment of mild hemophilia A and von Willebrand's disease.	Aventis Behring L.L.C.
520	Dexrazoxane	Zinecard	12/17/1991	For the prevention of cardiomyopathy associated with doxorubicin administration.	Pharmacia & Upjohn
521	Dextran 70	Dehydrex	3/5/1990	Treatment of recurrent corneal erosion unresponsive to conventional therapy.	Holles Laboratories, Inc.
522	Dextran and deferoxamine	Bio-Rescue	3/8/1991	Treatment of acute iron poisoning.	Biomedical Frontiers, Inc.
523	Dextran sulfate (inhaled, aerosolized)	Uendex	10/5/1990	For use as an adjunct to the treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
524	Dextran sulfate sodium	n/a	11/19/1987	Treatment of aquired immunodeficiency syndrome.	Ueno Fine Chemicals Industry, Ltd.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
525	Dianeal peritoneal dialysis solution with 1.1% amino acids	Nutrineal (Peritoneal Dialysis Solution With 1.1% Amino Acid	6/11/1992	For use as a nutritional supplement for the treatment of malnourishment in patients undergoing continuous ambulatory peritoneal dialysis.	Baxter Healthcare Corporation
526	Diazepam viscous solution for rectal administration	n/a	2/25/1992	For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity.	Valeant Pharmaceuticals
527	Diethyldithiocarbamate	Imuthiol	4/3/1986	Treatment of AIDS.	Connaught Laboratories
528	Diethylenetriaminepentaacetic acid (DTPA)	n/a	4/28/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.	Hameln Pharmaceuticals gmbh
529	Digoxin immune FAB (Ovine)	Digibind	11/1/1984	Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.	Glaxo Wellcome Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
530	Digoxin immune fab(ovine)	Digidote	3/11/1985	Treatment of life-threatening acute cardiac glycoside intoxication manifested by conduction disorders, ectopic ventricular activity and (in some cases) hyperkalemia.	Boehringer Mannheim Corp.
531	Dihydrotestosterone	Androgel -Dht	2/5/1996	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Besins Internaitonal, US Inc.
532	Dimerizing drug that binds to mutated Fas protein/drug-binding domain fusion protein (FKBP)	n/a	11/24/1999	Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.	Bellicum Pharmaceuticals, Inc.
533	Dimethyl sulfoxide	n/a	11/22/1994	Treatment of increased intracranial pressure in patients with severe, closed-head injury, also known as traumatic brain coma, for whom no other effective treatment is available.	Abela Pharmaceuticals, Inc.
534	Dimethylsulfoxide	n/a	4/15/1997	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Cancer Technologies, Inc.
535	Dimethylsulfoxide	n/a	4/6/1998	Treatment of palmar-plantar erythrodysethesia syndrome.	Cancer Technologies, Inc.
536	Dipalmitoylphosphatidylcholine /phosphatidylglycerol	Alec	7/28/1988	Prevention and treatment of neonatal respiratory distress syndrome.	Forum Products, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
537	Disaccharide tripeptide glycerol dipalmitoyl	Immther	3/1/1990	Treatment of pulmonary and hepatic metastases in patients with colorectal adenocarcinoma.	ImmunoTherapeutics, Inc.
538	Disodium clodronate	n/a	6/16/1993	Treatment of hypercalcemia of malignancy.	Discovery Experimental & Development, Inc.
539	Disodium clodronate tetrahydrate	Bonefos	3/5/1990	Treatment of increased bone resorption due to malignancy.	Anthra Pharmaceuticals, Inc.
540	Doripenem	n/a	7/16/2004	Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.	Shionogi, Inc.
541	Dornase alfa	Pulmozyme	1/16/1991	To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.	Genentech, Inc.
542	Double-stranded DNA plasmid carrying the gene for the diphtheria toxin A (DT-A) chain	n/a	8/6/2010	Treatment of pancreatic cancer	BioCancell Therapeutics Israel Ltd.
543	Doxorubicin HCl with pluronic L-61 and pluronic F-127	n/a	10/7/2005	Treatment of esophageal carcinoma	Supratek Pharma Inc.
544	Doxorubicin liposome	Doxil	11/4/1998	Treatment of ovarian cancer.	Alza Corporation

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
545	Dronabinol	Marinol	1/15/1991	For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.	Unimed Pharmaceuticals, Inc.
546	Duramycin	n/a	12/11/1997	Treatment of cystic fibrosis.	Lantibio, Inc.
547	Dynamine	n/a	10/16/1991	Treatment of hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease).	Mayo Foundation
548	Dynamine	n/a	2/5/1990	Treatment of Lambert Eaton myasthenic syndrome.	Mayo Foundation
549	Eculizumab	n/a	9/21/2000	Treatment of dermatomyositis	Alexion Pharmaceuticals, Inc.
550	Edotreotide	Onalta(Tm)	7/28/2005	Treatment of somatostatin receptor-positive neuroendocrine gastroenteropancreatic tumors	ITG Isotope Technologies Garchig GmbH
551	Efdispo (tm)	Efdispo (Tm)	1/15/2013	Treatment of Ewings Sarcoma.	TDP Biotherapeutics, Inc.
552	Eflornithine	n/a	9/29/2006	Treatment of anaplastic glioma	Orbus Therapeutics, Inc.
553	Eflornithine HCl	Ornidyl	4/23/1986	Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).	Hoechst Marion Roussel
554	Elcatonin	n/a	9/25/1995	Intrathecal treatment of intractable pain.	Innapharma, Inc.
555	Elesclomol	n/a	12/18/2007	Treatment of metastatic melanoma in combination with paclitaxel	Synta Pharmaceuticals Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
556	Enadoline hydrochloride	n/a	1/28/1997	Treatment of severe head injury.	Warner-Lambert Company
557	Encapsulated porcine islet preparation	Betarx	7/5/1995	Treatment of type I diabetic patients who are already on immunosuppression.	VivoRx
558	Engineered variant of recombinant human fibroblast growth factor 19	n/a	2/6/2014	Treatment of primary biliary cirrhosis	NGM Biopharmaceuticals, Inc.
559	Enzastaurin	n/a	9/19/2005	Treatment of glioblastoma multiforme	Eli Lilly and Company
560	Epidermal growth factor (human)	n/a	10/5/1987	For acceleration of corneal epithelial regeneration and the healing of stromal tissue in the condition of non-healing corneal defects.	Chiron Vision
561	Epirubicin	Ellence	9/14/1999	Treatment of breast cancer.	Pharmacia & Upjohn Company
562	Epitalon	n/a	9/2/2010	Treatment of retinitis pigmentosa	BioDiem Ltd
563	Epoetin alfa	n/a	12/20/1993	Treatment of myelodysplastic syndrome.	Johnson & Johnson Pharmaceutical Research & Dev.,
564	Epoetin alfa	Epogen	4/10/1986	Treatment of anemia associated with end stage renal disease.	Amgen, Inc.
565	Epoetin alfa	Epogen	7/1/1991	Treatment of anemia associated with HIV infection or HIV treatment.	Amgen, Inc.
566	Epoetin alpha	Procrit	8/27/1987	Treatment of anemia associated with end stage renal disease.	R. W. Johnson Pharmaceutical Research Institute

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
567	Epoetin alpha	Procrit	3/7/1989	Treatment of HIV associated anemia related to HIV infection or HIV treatment.	R. W. Johnson Pharmaceutical Research Institute
568	Epoetin beta	Marogen	10/22/1987	Treatment of anemia associated with end stage renal disease.	Chugai-USA, Inc.
569	Epoprostenol	Flolan	9/25/1985	Treatment of primary pulmonary hypertension.	Glaxo Wellcome Inc.
570	Eprodisate	Kiacta(Tm)	4/6/1999	Treatment of secondary amyloidosis	C. T. Development America, Inc.
571	Epstein Barr Virus specific cytotoxic T lymphocytes	n/a	12/27/2006	Prevention and treatment of EBV-post transplant lymphoproliferative disease after hematopoietic stem cell transplant or solid organ transplant.	Center for Cell and Gene Therapy
572	Epstein-Barr virus-specific autologous cytotoxic T lymphocytes	n/a	6/12/2014	Treatment of Epstein-Barr virus positive head and neck cancers (which includes nasopharyngeal carcinoma)	FFCanVac Pte Ltd
573	Erlotinib Hydrochloride	Tarceva	7/18/2003	Treatment of malignant gliomas	Genentech, Inc
574	Erwinia L-asparaginase	Erwinase	7/30/1986	Treatment of acute lymphocytic leukemia.	Jazz Pharmaceuticals, Inc.
575	Erythropoietin (recombinant human)	n/a	8/19/1987	Treatment of anemia associated with end stage renal disease.	McDonnell Douglas Corp
576	Ethanol gel	n/a	3/29/2006	Treatment of congenital venous malformations	Orfagen
577	Ethanol gel	n/a	3/13/2006	Treatment of congenital lymphatic malformations	Orfagen

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
578	Ethanolamine oleate	Ethamolin	3/22/1984	Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.	QOL Medical
579	Ethyl eicosapentaenoate	n/a	4/6/2000	Treatment of Huntington's disease.	Laxdale Ltd.
580	Etidronate disodium	Didronel	3/21/1986	Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.	MGI Pharma, Inc.
581	Etiocholanedione	n/a	5/7/1996	Treatment of Prader-Willi syndrome.	SuperGen, Inc.
582	Etiocholanedione	n/a	11/3/1995	Treatment of aplastic anemia.	SuperGen, Inc.
583	Ex vivo cultured adult human mesenchymal stem cells	Prochymal(R)	12/14/2005	Treatment of acute graft versus host disease	Mesoblast, Inc.
584	Exemestane	Aromasin	9/19/1991	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Pharmacia & Upjohn
585	Exisulind	n/a	2/14/1994	For the suppression and control of colonic adenomatous polyps in the inherited disease adenomatous polyposis coli.	OSI Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
586	Exon 44 specific phosphorothioate oligonucleotide	n/a	11/5/2009	Treatment of Duchenne Muscular Dystrophy in patients who have a mutation correctable by skipping of exon 44of the dystrophin gene.	Prosensa Therapeutics B.V.
587	Exon 45 specific phosphorothioate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 45	Prosensa Therapeutics B V
588	Exon 51 specific phosphorothioate oligonucleotide	n/a	8/25/2009	Treatment of Duchenne Muscular Dystrophy.	Prosensa Therapeutics BV
589	Exon 52 specific phosphorothiate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 52	Prosensa Therapeutics B V
590	Exon 55 specific phosphorothioate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 55	Prosensa Therapeutics B.V.
591	Extract of sea cucumber, sea sponge, shark fin, sea urchin, and sargassum grass	n/a	5/14/2012	Treatment of multiple myeloma	Unicorn Pacific Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
592	FTV1+GDP-fucose	n/a	3/18/2011	To improve homing to bone (treatment of myeloablation) in patients receiving hematopoietic stem cell transplantation.	America Stem Cell, Inc.
593	Facilitated DNA Plasmid Vaccine	n/a	3/8/1995	Treatment of cutaneous T cell lymphoma.	Wyeth-Lederle Vaccines and Pediatrics
594	Factor XIII [A2] homodimer, recombinant DNA origin	n/a	5/21/2003	Treatment of congenital FXIII deficiency	Novo Nordisk Pharmaceuticals, INC.
595	Fampridine	Neurelan	6/2/1997	Treatment of chronic, incomplete spinal cord injury.	Acorda Therapeutics, Inc.
596	Fast skeletal muscle troponin activator	n/a	3/2/2010	Treatment of amyotrophic lateral sclerosis (ALS)	Cytokinetics Inc.
597	Felbamate	Felbatol	1/24/1989	Treatment of Lennox-Gastaut syndrome.	Wallace Laboratories
598	Fenobam hydrochloride	n/a	11/20/2006	Treatment of fragile X syndrome	Neuropharm, Ltd.
599	Fenretinide	n/a	10/5/2005	Treatment of neuroblastoma	USC-CHLA Institute for Pediatric Clinical Research
600	Fenretinide	n/a	4/7/2010	Treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients	McGill University
601	Fibrin-based agent containing a N-terminally modified parathyroid hormone fragment TgPPTH1-34	n/a	2/1/2007	Treatment of solitary (unicameral) bone cysts	Kuros Biosurgery AG

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
602	Fibrinogen (human)	n/a	8/23/1995	For the control of bleeding and prophylactic treatment of patients deficient in fibrinogen.	Alpha Therapeutic Corporation
603	Fibronectin (human plasma derived)	n/a	9/5/1988	Treatment of non-healing corneal ulcers or epithelial defects which have been unresponsive to conventional therapy and the underlying cause has been eliminated.	Melville Biologics, Inc.
604	Fibronectin Peptide	n/a	6/29/2011	Prevention of burn injury progression of acute, deep dermal burns in hospitalized patients.	NeoMatrix Formulations, Inc.
605	Filgrastim	Neupogen	7/17/1995	For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.	Amgen, Inc.
606	Filgrastim	Neupogen	11/7/1990	Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm ³).	Amgen, Inc.
607	Filgrastim	Neupogen	10/1/1990	Treatment of neutropenia associated with bone marrow transplants.	Amgen, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
608	Filgrastim	Neupogen	11/7/1996	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc.
609	FliC Flagellin Deletion Variant TLR5 Agonist	n/a	11/23/2010	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Cleveland BioLabs, Inc.
610	Floxuridine, FUDR	n/a	12/22/2004	Intraperitoneal treatment of gastric cancer.	Franco Muggia, M.D.
611	Fludarabine phosphate	Fludara	4/18/1989	Treatment and management of patients with non-Hodgkins lymphoma.	Berlex Laboratories, Inc.
612	Fludarabine phosphate	Fludara	4/18/1989	Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL.	Berlex Laboratories, Inc.
613	Fludarabine phosphate oral tablets	n/a	12/18/2007	Treatment of B-cell chronic lymphocytic leukemia	Sanofi-Aventis U.S., Inc.
614	Flunarizine	Sibelium	1/6/1986	Treatment of alternating hemiplegia.	Janssen Research Foundation
615	Fluocinolone	Retisert	7/31/2000	Treatment uveitis involving the posterior segment of the eye.	Bausch & Lomb Pharmaceuticals, Inc.
616	Fluorouracil	n/a	6/29/2000	Treatment of glioblastoma multiforme.	Ethypharm SA

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
617	Fluorouracil	n/a	4/18/1990	For use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma.	Hoffmann-La Roche, Inc.
618	Fluorouracil	n/a	10/27/1989	For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc.
619	Fluoxetine	Prozac	4/14/2004	Treatment of body dysmorphic disorder in children and adolescents	Hollander, Eric MD
620	Fluoxetine	Prozac	4/30/1999	Treatment of autism.	Neuropharm, Ltd.
621	Follitropin alfa, recombinant	Gonal-F	12/21/1998	For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism. AMENDED indication 6/27/00: For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.	EMD Serono, Inc.
622	Fomepizole	Antizole	12/22/1988	Treatment of methanol or ethylene glycol poisoning.	Jazz Pharmaceuticals

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
623	Fosphenytoin	Cerebyx	6/4/1991	For the acute treatment of patients with status epilepticus of the grand mal type.	Warner-Lambert Company
624	Full Phosphorothioate Antisense Oligonucleotide against EWS-Fli-1 nanoparticles	n/a	9/22/2008	Treatment of Ewing's sarcoma	The Cure Our Children Foundation
625	Fully human anti-interferon gamma monoclonal antibody	Ni-0501	3/26/2010	Treatment of hemophagocytic lymphohistiocytosis	NovImmune S.A.
626	Fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1	n/a	1/11/2006	Treatment of X-linked hypohidrotic ectodermal dysplasia	Edimer Pharmaceuticals, Inc.
627	G17DT Immunogen	Gastrimmune(Tm)	7/10/2002	Treatment of adenocarcinoma of the pancreas	Cancer Advances, Inc.
628	G17DT Immunogen	Gastrimmune(Tm)	7/18/2002	Treatment of gastric cancer.	Cancer Advances, Inc.
629	GNE Lipoplex	n/a	11/13/2008	Treatment of hereditary inclusion body myopathy-2	Gradalis, Inc.
630	GNE plasmid(H001)	n/a	3/26/2010	Treatment of hereditary inclusion body myopathy type 2	HIBM Research Group
631	GVAX melanoma	n/a	12/23/2010	Treatment of stage IIb to IV melanoma	Aduro BioTech, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
632	Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide	n/a	12/31/2013	Diagnostic for the Management of Gastro-Entero-Pancreatic Neuroendocrine Tumors	Advanced Accelerator Applications
633	Gallium-68 (DOTA0-Phel-Tyr3)octreotide	n/a	10/23/2013	The management of neuroendocrine tumors	Society of Nuclear Medicine & Molecular Imaging
634	Gamma hydroxybutyrate	n/a	12/3/1987	Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior.	Biocraft Laboratories, Inc.
635	Gammalinolenic acid	n/a	7/27/1994	Treatment of juvenile rheumatoid arthritis.	Zurier, Robert B. M.D.
636	Ganaxolone	n/a	5/25/1994	Treatment of infantile spasms.	Marinus Pharmaceuticals, Inc.
637	Ganciclovir intravitreal implant	Vitrasert Implant	6/7/1995	Treatment of cytomegalovirus retinitis.	Bausch & Lomb Surgical, Chiron Vision Products
638	Gastrin 17C Diphtheria Toxoid Immunogen	n/a	7/7/2009	Treatment of pancreatic cancer	Astrimmune Ltd.
639	Gemtuzumab zogamicin	Mylotarg	11/24/1999	Treatment of CD33-positive acute myeloid leukemia.	Wyeth-Ayerst Laboratories

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
640	Genetically engineered human recombinant IgG4 monoclonal antibody directed against human TNF alpha	n/a	12/11/1997	Treatment of Crohn's disease.	Celltech Chiroscience Limited
641	Geneticin	n/a	6/6/2005	Treatment of amoebiasis.	ProcesScience, Inc (PSI)
642	Gentamicin impregnated PMMA beads on surgical wire	Septopal	1/31/1991	Treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin.	Lipha Pharmaceuticals, Inc.
643	Gentamicin liposome injection	Maitec	7/10/1990	Treatment of disseminated Mycobacterium avium-intracellulare infection.	Liposome Company, Inc.
644	Glatiramer acetate	Copaxone	11/9/1987	Treatment of multiple sclerosis.	Teva Pharmaceuticals USA
645	Glatiramer acetate for injection	Copaxone	6/5/2001	Treatment of primary-progressive multiple sclerosis	TEVA Pharmaceuticals, USA
646	Glutamine	Nutrestore	3/6/1995	For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).	Emmaus Medical, Inc.
647	Glutathione pegylated liposomal doxorubicin hydrochloride	n/a	8/16/2010	Treatment of glioma	to-BBB technologies BV

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
648	Glyceryl tri (4-phenylbutyrate)	n/a	5/24/2005	Treatment of spinal muscular atrophy	Ucyclyd Pharma, Inc
649	Glyceryl trioleate and glyceryl trierucate	n/a	2/14/1995	Treatment of adrenoleukodystrophy.	Moser, Hugo W. M.D.
650	Glyeraldehyde-3-phosphate dehydrogenase	Proenzy	4/30/2010	Treatment of pediatric multiple sclerosis	BPT Pharmaceuticals, Inc.
651	Gonadorelin acetate	Lutrepulse	4/22/1987	For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.	Ferring Laboratories, Inc.
652	Gossypol	n/a	10/22/1990	Treatment of cancer of the adrenal cortex.	Reidenberg, Marcus M. M.D.
653	Gp100 adenoviral gene therapy	n/a	3/25/1997	Treatment of metastatic melanoma.	Genzyme Corporation
654	Growth hormone releasing factor	n/a	8/7/1989	For the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Valeant Pharmaceuticals North America
655	H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminy-(D)arginyl-(D)arginine acetate salt	n/a	12/22/2011	For use in combination with cisplatin and pemetrexed for the treatment of patients with mesothelioma	CanBas Company, Ltd.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
656	H-Leu-Pro-Pro-Ser-Arg-OH	n/a	9/20/2012	Treatment of Kaposi sarcoma	Immuno Tech, Inc.
657	H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu- Ser-Asp-Val-OH	n/a	4/11/2014	Treatment of acute ischemic stroke patients presenting within 3 hours of symptom onset	NoNO, Inc.
658	H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-alyS-aleu-Ser-Ser-Ile-Glu-Ser-Asp-Val-OH	n/a	5/14/2013	Treatment of subarachnoid hemorrhage	NoNO, Inc.
659	HIRMAb-IDS	n/a	5/15/2013	Treatment of mucopolysaccharidosis Type II (Hunter Syndrome)	ArmaGen Technologies, Inc.
660	HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex	Allovectin-7	9/30/1999	Treatment of invasive and metastatic melanoma (Stages II, III, and IV).	Vical Incorporated
661	HPV-16 cancer therapeutic trojan peptide vaccine	n/a	1/12/2009	Treatment of HPV-16 expressing head and neck squamous cell carcinoma.	Gliknik, Inc.
662	HPV16 E6/E7 synthetic long peptides vaccine	n/a	9/1/2011	Treatment of epithelial neoplasias of the vulva positive for human papilloma virus type 16.	ISA Therapeutics BV
663	Halofantrine	Halfan	11/4/1991	Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.	SmithKline Beecham Pharmaceuticals
664	Halofuginone	Stenorol	2/7/2000	Treatment of systemic sclerosis.	Collgard Biopharmaceuticals Ltd.
665	Hanferon	Hanferon	3/9/2012	Treatment of Behcet's disease	HanAll BioPharma Co., Ltd.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
666	Hantaan virus and Puumala virus DNA vaccines	n/a	11/13/2012	Prevention of hemorrhagic fever with renal syndrome caused by Hantaan virus and Puumala virus.	Surgeon General of the U. S. Army
667	Heat Shock Protein (hsp60) antigen	Diapep277	5/21/2012	For use in type 1 diabetic mellitus patients with residual beta-cell function	Andromeda Biotech, LTD
668	Heat Shock Protein 70	n/a	3/18/2011	Treatment of amyotrophic lateral sclerosis	ALS Biopharma, LLC
669	Heme arginate	Normosang	3/10/1988	Treatment of symptomatic stage of acute porphyria.	Orphan Europe SARL
670	Heme arginate	Normosang	3/1/1994	Treatment of myelodysplastic syndromes.	Orphan Europe
671	Hemin	Panhematin	3/16/1984	Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.	Abbott Laboratories
672	Hemin and zinc mesoporphyrin	Hemex	12/20/1993	Treatment of acute porphyric syndromes.	Bonkovsky, Herbert L. M.D.
673	Hemoximer (pyridoxalated hemoglobin polyoxyethylene)	n/a	12/18/2007	Treatment of cardiogenic shock	Apex Bioscience, Inc.
674	Heparin sodium	n/a	6/29/2006	Treatment of cystic fibrosis	Ockham Biotech Limited

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
675	Heparin-binding epidermal growth factor-like growth factor	n/a	9/18/2006	Prevention and treatment of necrotizing enterocolitis (NEC) in preterm infants with birth weight less than 1,500 grams	Trillium Therapeutics, Inc.
676	Hepatitis B immune globulin intravenous (human)	Nabi-Hb	3/8/1995	Prophylaxis against hepatitis B virus reinfection in liver transplant patients.	Biotest Pharmaceuticals Corporation
677	Hepatitis C virus immune globulin (human)	Civacir(Tm)	11/14/2002	Prophylaxis of hepatitis C infection in liver transplant recipients.	Biotest Pharmaceuticals Corporation
678	Heptadecasodium salt of an 18-base residue phosphorothioate oligonucleotide	n/a	4/18/2011	Treatment of spinal muscular atrophy	Isis Pharmaceuticals, Inc.
679	Herpes simplex virus gene	n/a	10/16/1992	Treatment of primary and metastatic brain tumors.	Genetic Therapy, Inc.
680	His-His-Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr	n/a	3/11/2013	Treatment of retinal detachment	ONL Therapeutics, Inc
681	Histamine	Maxamine	2/1/2000	For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.	EpiCept Corporation
682	Histamine	Ceplene	12/15/1999	Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.	EpiCept Corporation
683	Histrelin	n/a	5/3/1991	Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria.	Anderson, Karl E., M.D.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
684	Histrelin	Supprelin La	11/18/2005	Treatment of central precocious puberty	Endo Pharmaceuticals Solutions, Inc.
685	Histrelin acetate	Supprelin Injection	8/10/1988	Treatment of central precocious puberty.	Roberts Pharmaceutical Corp.
686	Hu1D10, humanized monoclonal antibody	Remitogen	11/28/2001	For use in the treatment of 1D10+ B cell non-Hodgkin's lymphoma	PDL BioPharma, Inc.
687	Human Hemin	n/a	8/6/2013	Prevention of ischemia reperfusion injury in patients undergoing solid organ transplantation	Borders Technology Management Ltd
688	Human Monoclonal Antibody against Epidermal Growth Factor Receptor Linked to Monomethylauristatin F	n/a	5/29/2014	Treatment of glioblastoma multiforme	AbbVie, Inc.
689	Human T-lymphotropic virus type III Gp160 antigens	Vaxsyn Hiv-1	11/20/1989	Treatment of AIDS.	MicroGeneSys, Inc.
690	Human alpha 2,6 sialyltransferase adenoviral gene therapy	n/a	4/4/2005	Treatment of patients with invasive (malignant) brain and central nervous system tumors lacking alpha 2,6 sialyltransferase.	Falk Center for Molecular Therapeutics
691	Human anti-CD30 monoclonal antibody	n/a	9/27/2004	Treatment of Hodgkin's disease	Bristol-Myers Squibb, Inc.
692	Human autologous bone-forming cell derived from bone marrow stem cells	n/a	3/24/2008	Treatment of osteonecrosis	Bone Therapeutics S.A.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
693	Human cytomegalovirus immunoglobulin	n/a	12/20/2006	Prevention of congenital cytomegalovirus (CMV) infection following primary CMV infection in pregnant women	Biotest Pharmaceuticals Corporation
694	Human factor X	n/a	11/8/2007	Treatment of hereditary factor X deficiency	Bio Products Laboratory
695	Human immune globulin	Flebogamma(R) 5% Dif	3/29/2006	Treatment of post-polio syndrome	Instituto Grifols, S.A.
696	Human immunoglobulin anti-CD30 monoclonal antibody	n/a	1/10/2006	Treatment of CD30+ T-cell lymphoma	Bristol-Myers Squibb
697	Human monoclonal antibody against platelet-derived growth factor D	n/a	11/2/2004	To slow the progression of IgA nephropathy and delay kidney failure in patients affected by the disease.	CuraGen Corporation
698	Human monoclonal antibody directed against serotype 011 Pseudomonas aeruginosa	Aerumab 11	9/18/2006	Treatment of hospital acquired pneumonia caused by serotype 011 positive Pseudomonas aeruginosa	Kenta Biotech Limited
699	Human monoclonal antibody inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2)	n/a	12/16/2013	Prevention (inhibition) of complement-mediated thrombotic microangiopathy	Omeros Corporation
700	Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)	n/a	4/30/2010	Treatment of ovarian cancer	Ortho Biotech

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
701	Human plasma coagulation Factor VIII and human plasma von Willebrand Factor	Wilate	4/18/2007	Treatment of von Willebrand disease except for surgical and/or invasive procedures in patients with von Willebrand disease in whom desmopressin is either ineffective or contraindicated	Octapharma USA, Inc.
702	Human plasma derived conagulation protein-Factor XI	n/a	4/30/2014	For the treatment of congenital Factor XI deficiency	Cambryn Biologics
703	Human prothrombin complex concentrate	Octaplex	2/1/2008	Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures	Octapharma USA, Inc.
704	Human telomerase reverse transcriptase peptide vaccine	n/a	7/20/2006	Treatment of pancreatic cancer	GemVax A/S
705	Humanized 3F8-IgG1 monoclonal antibody	n/a	6/24/2013	Treatment of neuroblastoma	Memorial Sloan-Kettering Cancer Center
706	Humanized IgG monoclonal antibody hRS7 conjugated to topoisomerase I inhibitor	n/a	5/29/2014	Treatment of pancreatic cancer.	Immunomedics, Inc.
707	Humanized anti-CD3 monoclonal antibody	n/a	9/29/2006	Treatment of recent-onset Type I diabetes	MacroGenics, Inc.
708	Humanized anti-tac	Zenapax	3/5/1993	Prevention of acute graft-vs-host disease following bone marrow transplantation.	Hoffmann-La Roche, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
709	Humanized monoclonal antibody to TumorEndothelial Marker-1	n/a	4/29/2011	Treatment of soft tissue sarcoma	Morphotek
710	Hydralazine	n/a	4/9/2004	Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy	Bioniche Pharma USA LLC
711	Hydroxocobalamin	n/a	9/22/2000	Treatment of acute cyanide poisoning	Jazz Pharmaceuticals
712	Hydroxocobalamin	Cyanokit	11/25/2003	Treatment of acute cyanide poisoning	Merck Sante, s.a.a.
713	Hydroxy-Propyl-Beta-Cyclodextrin	Trappsol	5/17/2010	Treatment of Niemann Pick Disease, Type C	Childrens Hospital & Research Center Oakland
714	Hydroxyurea	Droxia	10/1/1990	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb Pharmaceutical Research Institute
715	Hypericin	n/a	8/3/2000	Treatment of glioblastoma multiforme.	HyBiopharma, Inc.
716	Hypericin	n/a	2/7/2000	Treatment of cutaneous T-cell lymphoma.	Soligenix, Inc.
717	Hypothiocyanite and lactoferrin	Meveol	11/5/2009	Treatment of cystic fibrosis	Alaxia Biotechnologies Sante

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
718	I(131)-TM-601 (chlorotoxin)	n/a	2/14/2002	Treatment of malignant glioma	Morphotek, Inc.
719	IDUA-HIRMAb fusion protein	Agt-181	1/10/2008	Treatment of mucopolysaccharidosis Type 1 (MPS)	ArmaGen Technologies, Inc.
720	IL-12 secreting dendritic cells loaded with autologous tumor lysate	n/a	6/24/2013	Treatment of malignant glioma	Activartis Biotech GmbH
721	IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL)	n/a	4/6/2000	Treatment of astrocytic glioma.	Medicenna Therapeutics, Inc.
722	IL13-PE38QQR	n/a	11/2/2001	Treatment of malignant glioma	Insys Therapeutics, Inc.
723	Ibuprofen i.v. solution	Salprofen	10/29/1996	Prevention of patent ductus arteriosus.	Farmacon-IL, LLC
724	Ibuprofen lysine	Neoprofen	10/29/1996	Treatment of patent ductus arteriosus	Lundbeck, Inc.
725	Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution	Extraneal (With 7.5% Icodextrin) Peritoneal Dialysis Solutio	7/18/1997	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Baxter Healthcare Corporation
726	Idarubicin HCl for injection	Idamycin	7/25/1988	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Adria Laboratories, Inc.
727	Idoxuridine	n/a	4/8/1996	Treatment of nonparenchymatous sarcomas.	NeoPharm, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
728	Ifosfamide	Ifex	8/7/1985	Treatment of soft tissue sarcomas.	Bristol-Myers Squibb Pharmaceutical Research Institute
729	Ifosfamide	Ifex	1/20/1987	Treatment of testicular cancer.	Bristol-Myers Squibb Pharmaceutical Research Institute
730	Ifosfamide	Ifex	8/7/1985	Treatment of bone sarcomas	Bristol-Myers Squibb Company
731	IgG1 chimeric monoclonal antibody	n/a	6/22/2011	Treatment of multiple myeloma.	Immune System Therapeutics Ltd
732	Iloprost inhalation solution	Ventavis	8/17/2004	Treatment of pulmonary arterial hypertension	CoTherix, Inc.
733	Imatinib	Gleevec	1/31/2001	Treatment of chronic myelogenous leukemia	Novartis Pharmaceuticals Corporation
734	Imatinib mesylate	Gleevec	9/9/2005	Treatment of systemic mastocytosis without the D816V c-kit mutation	Novartis Pharmaceuticals Corporation
735	Imatinib mesylate	Gleevec	8/25/2005	Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia	Novartis Pharmaceuticals Corporation
736	Imatinib mesylate	Gleevec	10/5/2005	Treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements	Novartis Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
737	Imciromab pentetate	Myoscint	1/25/1989	Detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.	Centocor, Inc.
738	Imexon	n/a	11/8/1996	Treatment of multiple myeloma.	AmpliMed Corporation
739	Imiglucerase	Cerezyme	11/5/1991	Replacement therapy in patients with types I, II, and III Gaucher's disease.	Genzyme Corporation
740	Imiquimod	n/a	12/3/2014	Treatment of carcinoma in situ (CIS) of the urinary bladder	Telormedix SA
741	Immortalized human liver cells found in the extracorporeal liver assist device	Elad	7/16/2004	Treatment of fulminant hepatic failure (acute liver failure)	Vital Therapies, Inc.
742	Immune Globulin (Human)	Gamunex(R)-C	7/27/2004	Treatment of chronic inflammatory demyelinating polyneuropathy	Grifols Therapeutics, Inc.
743	Immune Globulin (Human) containing high titers of West Nile virus antibodies	Omr-Igg-Am (Tm) 5% (Wnv)	3/17/2004	Treatment of the West Nile virus infection	OMRIX Biopharmaceuticals, Ltd.
744	Immune Globulin Intravenous (human)	Carimune Nf	5/4/2004	Treatment for Guillain Barre Syndrome	ZLB Bioplasma AG
745	Immune Globulin Subcutaneous (Human), 20% Liquid	Hizentra	8/18/2014	Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)	CSL Behring
746	Immune globulin intravenous, human	Gamimune N	2/18/1993	Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.	Bayer Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
747	Immunotherapeutic vaccine consisting of (PAM)2-Lys-Ser-Ser-Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Ala-Ala-Ala-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val	n/a	3/16/1994	Treatment of chronic active hepatitis B infection in HLA-A2 positive patients.	Cytel Corporation
748	Imported fire ant venom, allergenic extract	n/a	5/12/1992	For skin testing of victims of fire ant stings to confirm fire ant sensitivity and if positive, for use as immunotherapy for the prevention of IgE-mediated anaphylactic reactions.	ALK Laboratories, Inc.
749	Inalimarev and falimarev	n/a	1/10/2006	Treatment of adenocarcinoma of the pancreas	Therion Biologics Corporation
750	Indium-111 pentetreotide	Neuroendomedix	6/16/2006	Treatment of neuroendocrine tumors	Radiolotope Therapy of America (RITA) Foundation
751	Inecalcitol	n/a	5/14/2014	Treatment of chronic lymphocytic leukemia	Hybrigenics, S.A.
752	Infliximab	Remicade	5/21/2003	Treatment of chronic sarcoidosis	Centocor, Inc.
753	Infliximab	Remicade	11/12/2003	Treatment of pediatric (0 to 16 years of age) Crohn's Disease	Centocor, Inc.
754	Inhibitor of Tissue Factor Pathway Inhibitor (TFPI)	n/a	1/29/2010	Treatment of hemophilia A and hemophilia B.	Baxter Healthcare Corporation, Baxter BioScience

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
755	Inhibitor of primary and secondary KIT and PDGFR alpha kinase mutants found in GIST	n/a	10/2/2014	Treatment of gastrointestinal stromal tumors (GIST)	Deciphera Pharmaceuticals, LLC
756	Inosine pranobex	Isoprinosine	9/20/1988	Treatment of subacute sclerosing panencephalitis.	Newport Pharmaceuticals
757	Interferon alfa-2a	Roferon A	6/6/1989	Treatment of chronic myelogenous leukemia.	Hoffmann-La Roche, Inc.
758	Interferon alfa-2a (recombinant)	Roferon-A	12/14/1987	Treatment of AIDS related Kaposi's sarcoma.	Hoffmann-La Roche, Inc.
759	Interferon alfa-2a (recombinant)	Roferon-A	5/14/1990	For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer.	Hoffmann-La Roche, Inc.
760	Interferon alfa-2a (recombinant)	Roferon-A	5/11/1990	For the treatment of metastatic malignant melanoma in combination with Teceleukin.	Hoffmann-La Roche, Inc.
761	Interferon alfa-2a (recombinant)	Roferon-A	5/2/1990	For the concomitant administration with Teceleukin for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
762	Interferon alfa-2a (recombinant)	Roferon-A	10/27/1989	For use in combination with fluorouracil for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc.
763	Interferon alfa-2a (recombinant)	Roferon-A	4/18/1988	Treatment of renal cell carcinoma.	Hoffmann-La Roche, Inc.
764	Interferon alfa-2b (recombinant)	Intron A	6/24/1987	Treatment of AIDS-related Kaposi's sarcoma.	Schering Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
765	Interferon beta-1a	Rebif	3/11/1996	Treatment of patients with secondary progressive multiple sclerosis.	EMD Serono, Inc.
766	Interferon beta-1a	Avonex	12/16/1991	Treatment of multiple sclerosis.	Biogen, Inc.
767	Interferon beta-1a (recombinant human)	n/a	7/24/1992	Treatment of acute non-A, non-B hepatitis.	Biogen, Inc.
768	Interferon beta-1a (recombinant)	Rebif	12/2/1992	Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells per mm ³ .	EMD Serono, Inc.
769	Interferon beta-1b	Betaseron	11/17/1988	Treatment of multiple sclerosis.	Chiron Corp. & Berlex Laboratories
770	Interferon gamma	n/a	10/11/2007	Treatment of idiopathic pulmonary fibrosis	mondoBIOTECH Laboratories AG
771	Interferon gamma 1-b	Actimmune	9/30/1988	Treatment of chronic granulomatous disease.	Horizon Pharma Ireland Limited
772	Interferon gamma-1b	Actimmune	12/4/1995	Treatment of renal cell carcinoma.	Horizon Pharma Ireland Limited
773	Interferon gamma-1b	Actimmune	9/30/1996	Delaying time to disease progression in patients with severe, malignant osteopetrosis.	Horizon Pharma Ireland Limited
774	Interferon-alfa-1b	n/a	4/17/2001	Treatment of multiple myeloma	Ernest C.Borden
775	Interleukin-1 Trap	n/a	4/4/2005	Treatment of Still's disease including juvenile rheumatoid arthritis and adult-onset Still's disease	Regeneron Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
776	Interleukin-1 receptor antagonist, human recombinant	Antril	10/16/1992	Prevention and treatment of graft versus host disease in transplant recipients.	Swedish Orphan Biovitrum AB (publ) (SOBI)
777	Interleukin-1 receptor antagonist, human recombinant	Antril	9/23/1991	Treatment of juvenile rheumatoid arthritis.	Swedish Orphan Biovitrum AB (publ) (SOBI)
778	Interleukin-2	Teceleukin	2/5/1990	Treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
779	Interleukin-2	Teleleukin	2/6/1990	Treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc.
780	Interleukin-2	Teceleukin	5/11/1990	In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc.
781	Interleukin-2	Teceleukin	5/3/1990	In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
782	Intraoral fluoride releasing system	lfrs	7/31/2001	Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer	Digestive Care, Inc.
783	Intravenous immune globulin	Vitigam	7/26/2007	Treatment of Stage IIB to IV malignant melanoma	GammaCan Ltd.
784	Intravenous immune globulin (human) 10%	Octagam(R)	7/31/2008	Treatment of stiff-person syndrome	Octapharma USA, Inc.
785	lobenguane I 123	Adreview	12/1/2006	For the diagnosis of pheochromocytomas	GE Healthcare, Inc.
786	lobenguane I 123	Adreview	12/1/2006	For the diagnosis of neuroblastomas	GE Healthcare, Inc.
787	lobenguane I 131	Azedra Ultratrace	1/18/2006	Treatment of neuroendocrine tumors	Molecular Insight Pharmaceuticals

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
788	Iobenguane Sulfate I-123	Omaclear	10/17/2005	For scintigraphic detection, localization and staging of neuroblastoma.	Brogan Pharmaceuticals, LLC
789	Iodine 131 6B-iodomethyl-19-norcholesterol	n/a	8/1/1984	For use in adrenal cortical imaging.	David E. Kuhl, M.D.
790	Iodine I 123 murine monoclonal antibody to hCG	n/a	11/7/1988	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Immunomedics, Inc.
791	Iodine I 131 bis(indium-diethylenetriaminepentaacetic acid)tyrosyllysine/hMN-14 x m734 F(ab') ₂ bispecific monoclonal antibody	Pentacea	2/22/2000	Treatment of small-cell lung cancer.	IBC Pharmaceuticals, L.L.C.
792	Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B)	131ichtnt-1	2/12/1999	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Peregrine Pharmaceuticals, Inc.
793	Ipatasertib	n/a	4/30/2014	For the treatment of gastric cancer including cancer of the gastro-esophageal junction.	Genentech, Inc.
794	Isobutyramide	n/a	5/25/1994	Treatment of sickle cell disease and beta thalassemia.	Alpha Therapeutic Corporation
795	Isobutyramide	Isobutyramide Oral Solution	12/18/1992	Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.	Perrine, Susan P., M.D.
796	Itraconazole suspension	n/a	10/30/2008	Topical treatment of fungal otitis externa (otomycosis)	Fairfield Clinical Trials, LLC

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
797	Japanese encephalitis vaccine (live, attenuated)	n/a	5/19/1999	Prevention of Japanese encephalitis.	Glovax Co., Ltd.
798	Japanese encephalitis vaccine, inactivated, adsorbed	Ixiaro	9/25/2012	Prevention of Japanese encephalitis virus in pediatric patients.	Intercell AG
799	Kre-Celazine	n/a	4/1/2013	Treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population	All American Pharmaceutical & Natural Foods Corpor
800	L-2-oxothiazolidine-4-carboxylic acid	Procysteine	7/30/1996	Treatment of amyotrophic lateral sclerosis.	Transcend Therapeutics, Inc.
801	L-2-oxothiazolidine-4-carboxylic acid	Procysteine	6/14/1994	Treatment of adult respiratory distress syndrome.	Transcend Therapeutics, Inc.
802	L-5 Hydroxytryptophan	n/a	11/1/1984	Treatment of postanoxic intention myoclonus.	Watson Laboratories, Inc.
803	L-5-hydroxytryptophan	n/a	1/20/1999	Treatment of tetrahydrobiopterin deficiency.	Watson Laboratories, Inc.
804	L-amino acids, vitamins and minerals combined with omega-3 fatty acids	n/a	1/12/2011	Treatment of patients with pediatric Crohn's disease	Immunopath Profile, Inc.
805	L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal	n/a	1/18/2006	Treatment of Duchenne and Becker muscular dystrophy	CepTor Corporation
806	L-arginyl-L-isooleucyl-L-valyl-L-prolyl-L-alanine-amide	n/a	9/11/2013	Treatment of acute radiation syndrome	Soligenix, Inc.
807	L-asparaginase	n/a	3/27/2014	Treatment of acute myeloid leukemia	ERYTECH Pharma S.A.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
808	L-asparaginase encapsulated in red blood cells	Graspa	7/6/2012	Treatment of pancreatic cancer.	ERYTECH Pharma
809	L-asparaginase encapsulated in red blood cells	Graspa	1/6/2010	Treatment of acute lymphoblastic leukemia	Erytech Pharma
810	L-baclofen	n/a	1/6/1998	Treatment of trigeminal neuralgia	Osmotica Pharmaceutical Corp.
811	L-baclofen	n/a	7/13/1990	Treatment of trigeminal neuralgia.	Fromm, Gerhard M.D.
812	L-baclofen	Neuralgon	12/17/1991	Treatment of spasticity associated with spinal cord injury or multiple sclerosis.	Osmotica Pharmaceutical Corp.
813	L-baclofen	Neuralgon	1/30/1992	Treatment of intractable spasticity in children with cerebral palsy.	Osmotica Pharmaceutical Corp.
814	L-cycloserine	n/a	8/1/1989	Treatment of Gaucher's disease.	Lev, Meir M.D.
815	L-cysteine	n/a	5/16/1994	For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.	Brigham and Women's Hospital
816	L-glutamine	n/a	8/1/2001	Treatment of sickle cell disease	Emmaus Medical, Inc.
817	L-glutamyl-L-tryptophan	n/a	10/20/1999	Treatment of AIDS-related Kaposi's sarcoma.	Implicit Bioscience Pty Ltd

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
818	L-ornithine phenylacetate	n/a	4/7/2010	Treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure or acute on chronic liver disease	Ocera Therapeutics, Inc.
819	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	9/18/2009	Prevention of delayed graft function following renal transplant	Araim Pharmaceuticals, Inc.
820	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	9/13/2011	Treatment of neuropathic pain in patients with sarcoidosis.	Araim Pharmaceuticals, Inc.
821	L-threonyl-L-prolyl-L-prolyl-L-threonine	n/a	4/26/2005	Treatment of neuropathic pain associated with spinal cord injury	Nyxis Neurotherapies, Inc.
822	L-tyrosine-L-serine-L-leucine	Cms-024	9/10/2004	Treatment of hepatocellular carcinoma.	CMS Peptides Patent Holding Company Limited
823	L. reuteri	n/a	8/1/2013	Prevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams	Infant Bacterial Therapeutics
824	Lactic acid	Aphthaid	6/29/1999	Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.	Frontier Pharmaceutical, Inc.
825	Lamotrigine	Lamictal	8/23/1995	Treatment of Lennox-Gastaut syndrome.	Glaxo Wellcome Research and Development
826	Lanreotide	Somatuline Depot	9/11/2000	Treatment for acromegly	IPSEN, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
827	Laromustine	Cloretazine	3/27/2014	Treatment of acute myelogenous leukemia	Nanotherapeutics, Inc.
828	Latrodectus immune F(ab)2	Analatro	6/18/2001	Treatment of black widow spider envenomations	Instituto Bioclon, S.A. de C.V.
829	Leflunomide	n/a	10/18/1996	Prevention of acute and chronic rejection in patients who have received solid organ transplants.	Williams, MD, James W.
830	Lentiviral vector containing the human ABCA4 gene	Stargen (Tm)	4/30/2010	Treatment of Stargardt disease	Sanofi US Services, Inc.
831	Lentiviral vector containing the human MYO7A gene	Ushstat(Tm)	5/17/2010	Treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.	Sanofi US Services, Inc.
832	Lentiviral vector encoded with a human beta-globin gene plasmid	Thalagen	1/11/2006	Treatment of beta-thalassemia major and beta-thalassemia intermedia	Memorial Sloan-Kettering Cancer Center
833	Lepirudin	Refluden	2/13/1997	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel
834	Lestaurtinib	n/a	3/24/2006	Treatment of acute myeloid leukemia	Teva Branded Pharmaceutical Products R&D, Inc.
835	Leucovorin	Leucovorin Calcium	12/8/1986	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Immunex Corporation
836	Leucovorin	Leucovorin Calcium	8/17/1988	For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.	Immunex Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
837	Leupeptin	n/a	9/18/1990	For use as an adjunct to microsurgical peripheral nerve repair.	Neuromuscular Adjuncts, Inc.
838	Leuprolide acetate	Lupron Injection	7/25/1988	Treatment of central precocious puberty	Tap Pharmaceuticals, Inc.
839	Levocarnitine	Carnitor	11/22/1993	Treatment of pediatric cardiomyopathy.	Sigma-Tau Pharmaceuticals, Inc.
840	Levocarnitine	Carnitor	11/15/1989	For the treatment of secondary carnitine deficiency in valproic acid toxicity.	Sigma-Tau Pharmaceuticals, Inc.
841	Levocarnitine	Carnitor	9/6/1988	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Sigma-Tau Pharmaceuticals, Inc.
842	Levocarnitine	Carnitor	4/7/1997	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc.
843	Levocarnitine	Carnitor	7/26/1984	Treatment of primary and secondary carnitine deficiency of genetic origin.	Sigma-Tau Pharmaceuticals, Inc.
844	Levocarnitine	Carnitor	2/28/1984	Treatment of genetic carnitine deficiency.	Sigma-Tau Pharmaceuticals, Inc.
845	Levocarnitine	Carnitor	11/15/1989	For the prevention of secondary carnitine deficiency in valproic acid toxicity.	Sigma-Tau Pharmaceuticals, Inc.
846	Levodopa and carbidopa	Duodopa	1/18/2000	Treatment of late stage Parkinson's disease	AbbVie, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
847	Levofloxacin	n/a	2/27/2008	Treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis patients	Forest Research Institute, Inc.
848	Levoleucovorin	Fusilev	8/1/1991	For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.	Spectrum Pharmaceuticals, Inc.
849	Levomethadyl acetate hydrochloride	Orlaam	1/24/1985	Treatment of heroin addicts suitable for maintenance on opiate agonists.	Biodevelopment Corporation
850	Lidocaine patch 5%	Lidoderm Patch	10/24/1995	For relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia.	Teikoku Pharma USA, Inc.
851	Liothyronine sodium injection	Triostat	7/30/1990	Treatment of myxedema coma/precoma.	SmithKline Beecham Pharmaceuticals
852	Lipid/DNA human cystic fibrosis gene	n/a	4/8/1996	Treatment of cystic fibrosis.	Genzyme Corporation
853	Liposomal Glutathione	n/a	4/30/2010	Support of glutathione deficiency in individuals with inborn errors of metabolism of glutathione (IEMG)	Your Energy Systems, LLC
854	Liposomal N-Acetylglucosminyl-N-Acetylmuramyl-L-Ala-D-isoGln-L-Ala - glycerolipalmitoyl	Immther	6/10/1998	Treatment of osteosarcoma.	Endorex Corp.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
855	Liposomal N-Acetylglucosminyl-N-Acetylmuramyl-L-Ala-D-isoGln-L-Ala - glycerolidpalmitoyl	Immther	6/10/1998	Treatment of Ewing's sarcoma.	Endorex Corp.
856	Liposomal amphotericin B	Ambisome	12/10/1996	Treatment of histoplasmosis.	Fujisawa USA, Inc.
857	Liposomal amphotericin B	Ambisome	12/10/1996	Treatment of cryptococcal meningitis.	Fujisawa USA, Inc.
858	Liposomal amphotericin B	Ambisome	12/6/1996	Treatment of visceral leishmaniasis.	Fujisawa USA, Inc.
859	Liposomal annamycin	n/a	6/17/2005	Treatment of acute lymphoblastic leukemia	Callisto Pharmaceuticals, Inc.
860	Liposomal annamycin	n/a	6/17/2005	Treatment of acute myeloid leukemia	Callisto Pharmaceuticals, Inc.
861	Liposomal ciprofloxacin for inhalation	n/a	4/19/2006	Management of cystic fibrosis	Aradigm Corporation
862	Liposomal ciprofloxacin for inhalation	n/a	12/27/2006	Management of bronchiectasis	Aradigm Corporation
863	Liposomal cisplatin	Lipova-Pt	5/23/2006	Treatment of ovarian cancer	Eleison Pharmaceuticals, LLC
864	Liposomal cyclosporin A	Cyclospire	4/30/1998	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Vernon Knight, M.D.
865	Liposomal doxorubicin hydrochloride	Sarcodoxome	12/27/2006	Treatment of soft tissue sarcomas	GP-Pharm SA

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
866	Liposomal nystatin	Nyotran	6/13/2000	Treatment of invasive fungal infections.	The University of Texas
867	Liposome encapsulated recombinant interleukin-2	n/a	11/25/1991	Treatment of brain and CNS tumors.	Oncothyreon Canada, Inc.
868	Liposome encapsulated recombinant interleukin-2	n/a	6/20/1994	Treatment of cancers of the kidney and renal pelvis	Oncothyreon Canada, Inc.
869	Lisofylline	n/a	6/10/1999	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Cell Therapeutics, Inc.
870	Lodoxamide tromethamine	Alomide Ophthalmic Solution	10/16/1991	Treatment of vernal keratoconjunctivitis.	Alcon Laboratories, Inc.
871	Lonafarnib	n/a	11/19/2013	Treatment of Hepatitis Delta Virus (HDV)infection	Eiger Biopharmaceuticals, Inc.
872	Lucinactant	Surfaxin(R), Aerosurf(R)	10/21/2010	Treatment of cystic fibrosis.	Discovery Laboratories, Inc.
873	Lucinactant	Surfaxin	7/17/1995	Treatment of acute respiratory distress syndrome in adults.	Discovery Laboratories, Inc.
874	Lucinactant	Surfaxin	10/18/1995	Treatment of respiratory distress syndrome in premature infants.	Discovery Laboratories, Inc.
875	Lucinactant	Surfaxin	5/23/2006	Prevention of bronchopulmonary dysplasia in premature infants	Discovery Laboratories, Inc
876	Lucinactant	Surfaxin	10/21/2005	Treatment of bronchopulmonary dysplasia in premature infants.	Discovery Laboratories, Inc.
877	MA09-hRPE cells	n/a	2/2/2010	Treatment of Stargardt's macular dystrophy.	Advanced Cell Technology, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
878	MAGE-A3 cancer therapeutic Trojan peptide vaccine	n/a	11/24/2008	Treatment of MAGE-A3 expressing head and neck squamous cell carcinoma	Gliknik, Inc.
879	MCMV5322A/MCMV3068A	n/a	11/22/2011	Prevention of maternal-fetal transmission of congenital CMV in pregnant women who acquire CMV infection during pregnancy	Genentech
880	MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	n/a	2/4/2011	Treatment of acute myelogenous leukemia.	Millennium Pharmaceuticals
881	MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	n/a	2/4/2011	Treatment of Myelodysplastic syndrome	Millennium Pharmaceuticals, Inc.
882	MN14 monoclonal antibody to carcinoembryonic antigen	Cea-Cide	9/18/1998	Treatment of small cell lung cancer	Immunomedics, Inc.
883	MN14 monoclonal antibody to carcinoembryonic antigen	Cea-Cide	11/24/1998	Treatment of pancreatic cancer.	Immunomedics, Inc.
884	MOD-423 hGH analogue	n/a	9/29/2010	Treatment of growth hormone deficiency	OPKO Biologics Ltd.
885	MTC-DOX for Injection	n/a	1/3/2001	Treatment of hepatocellular carcinoma	FeRx Incorporated
886	MV-NB-02, its bivalent ganglioside vaccine consisting of GD2-lactone and GD3-lactone each covalently conjugated to keyhole hemocyanin	n/a	9/23/2014	Treatment of Neuroblastoma	MabVax Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
887	Mafenide acetate solution	Sulfamylon Solution	7/18/1990	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Mylan Laboratories, Inc.
888	Mafosfamide	n/a	1/21/2003	Treatment of neoplastic meningitis	Baxter Healthcare Corporation
889	Manganese superoxide dismutase mimetic	n/a	2/27/2008	Prevention of radiation- or chemotherapy-induced oral mucositis in cancer patients	Galera Therapeutics, LLC
890	Mannitol	Bronchitol	2/11/2005	For use to facilitate clearance of mucus in patients with bronchiectasis and in patients with cystic fibrosis at risk for bronchiectasis	Pharmaxis Ltd.
891	Marijuana	n/a	5/25/1999	Treatment of HIV-associated wasting syndrome.	Multidisciplinary Association for Psychedelic Studies, Inc.
892	Marizomib	n/a	12/13/2013	Treatment of multiple myeloma	Triphase Research and Development I Corp.
893	Matrix metalloproteinase inhibitor	Galardin	12/5/1991	Treatment of corneal ulcers.	Glycomed, Inc
894	MaxAdFVIII	n/a	3/3/2003	Treatment of Hemophilia A	GenStar Therapeutics Corporation
895	Mazindol	Sanorex	12/8/1986	Treatment of Duchenne muscular dystrophy.	Collipp, Platon J. M.D.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
896	Mecamylamine	Inversine	10/14/1998	Treatment of Tourette's syndrome.	Targacept, Inc.
897	Mecasermin	Increlex	12/12/1995	Treatment of growth hormone insensitivity syndrome.	Ipsen Biopharmaceuticals, Inc.
898	Medroxyprogesterone acetate	Hematrol	2/22/2001	Treatment of immune thrombocytopenic purpura.	ZaBeCor Pharmaceutical Company, LLC
899	Mefloquine HCl	Mephaquin	7/22/1987	Prevention of chloroquine-resistant Falciparum malaria.	Mepha AG
900	Mefloquine HCl	Mephaquin	7/22/1987	Treatment of chloroquine-resistant Falciparum malaria.	Mepha AG
901	Megestrol acetate	Megace	4/13/1988	Treatment of patients with anorexia, cachexia, or significant weight loss (= $>$ 10% of baseline body weight) and confirmed diagnosis of AIDS.	Bristol-Myers Squibb Pharmaceutical Research Institute
902	Melanoma autologous dendritic cell vaccine	n/a	9/6/2006	Treatment of stage IIIb through IV metastatic melanoma	California Stem Cell, Inc.
903	Melanoma cell vaccine	Canvaxin	10/13/1994	Treatment of invasive melanoma.	CancerVax Corporation
904	Melanoma peptide vaccine	n/a	3/29/2005	Treatment of HLA-A2+ patients with stage IIB, IIC, III, and IV malignant melanoma	Bristol-Myers Squibb Research Inst
905	Melanoma vaccine	Melacine	12/20/1989	Treatment of stage III - IV melanoma.	Ribi ImmunoChem Research, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
906	Melatonin	n/a	11/15/1993	Treatment of circadian rhythm sleep disorders in blind people with no light perception.	Sack, Robert, M.D.
907	Melatonin	Circadin	7/9/2004	Treatment of non-24-hour sleep-wake disorder in blind individuals without light perception	Neurim Pharmaceuticals, Ltd.
908	Melphalan	Alkeran For Injection	2/24/1992	Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.	Glaxo Wellcome Inc.
909	Menadione Sodium Bisulfite	n/a	5/14/2014	For the treatment of autosomal dominant polycystic kidney disease	IC-MedTech Corporation
910	Mesna	Mesnex	11/14/1985	For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.	Degussa Corporation
911	Methionine/L-methionine	n/a	8/21/1996	Treatment of AIDS myelopathy.	Genopia USA, Inc.
912	Methotrexate	Amethopterin	8/28/2014	Treatment of Myasthenia Gravis	The Universtiy of Kanasa Medical Center
913	Methotrexate sodium	Methotrexate	10/21/1985	Treatment of osteogenic sarcoma.	Lederle Laboratories
914	Methotrexate with laurocapram	Methotrexate/Azone	10/15/1990	Topical treatment of mycosis fungoides.	Echo Therapeutics, Ltd.
915	Methoxsalen	Uvadex	10/14/1998	For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.	Therakos, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
916	Methyl O-4-O-[2-[2-[2-[2-[[N- [(1R)-1-[[4- (aminoiminomethyl)phenyl]m ethyl]-2-oxo-2-(1- piperidiny)ethyl]-N2-[(4- methoxy-2,3,6- trimethylphenyl)sulfonyl]-L- Ã?Â Ã?→ Ã?Â &Ã?→Ã?Â½ Ã?Â Ã?→ Ã?Â Ã?→Ã?Â±- aspararginyl-4-aminobutanoyl- N6-[5-[(3aS,4S,6aR)-hexahydro- 2-oxo-1H-thieno[n/a	4/18/2011	Prevention of ischemia reperfusion injury associated wth solid organ transplantation	Endotis Pharma
917	Metronidazole	Metrogel	10/24/1991	Treatment of perioral dermatitis.	Galderma Laboratories, Inc.
918	Metronidazole (topical)	Metrogel	10/22/1987	Treatment of acne rosacea.	Galderma Laboratories, Inc.
919	Metronidazole 10% ointment	n/a	11/8/2007	Topical treatment of active perianal Crohn's disease	SLA Pharma (UK) Ltd
920	Microbubble contrast agent	Filmix Neurosonographic Contrast Agent	11/16/1990	Intraoperative aid in the identification and localization of intracranial tumors.	Cav-Con, Inc.
921	Microvesiculated modified glycosylated tissue factor	n/a	1/25/2007	Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in hemophiliac patients	Thrombotargets Corp.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
922	Microvesiculated modified glycosylated tissue factor	n/a	10/11/2007	Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in patients with von Willebrand disease.	Thrombotargets Corp.
923	Midodrine HCl	Amatine	6/21/1985	Treatment of patients with symptomatic orthostatic hypotension.	Shire
924	Midostaurin	n/a	7/7/2009	Treatment of acute myeloid leukemia	Novartis Pharmaceuticals Corporation
925	Midostaurin	Rydapt	4/30/2010	Treatment of mastocytosis	Novartis Oncology
926	Mifepristone	n/a	2/7/2005	Treatment of Cushing's syndrome secondary to ectopic ACTH secretion	HRA Pharma
927	Minnelide	Minnelide (Tm)	2/18/2013	Treatment of pancreatic cancer	Minneamrita Therapeutics, LLC
928	Minocycline hydrochloride	n/a	3/28/2006	Treatment of sarcoidosis	Autoimmunity Research Foundation
929	Mitoguazone	Apep	3/18/1994	Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.	ILEX Oncology, Inc.
930	Mitolactol	n/a	7/12/1995	As adjuvant therapy in the treatment of primary brain tumors.	Targent, Inc.
931	Mitolactol	n/a	1/23/1989	Treatment of invasive carcinoma of the uterine cervix	Targent, Inc..

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
932	Mitomycin-C	n/a	8/20/1993	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	IOP Inc.
933	Mitoxantrone	Novantrone	8/13/1999	Treatment of secondary-progressive multiple sclerosis.	Serono, Inc.
934	Mitoxantrone	Novantrone	8/21/1996	Treatment of hormone refractory prostate cancer.	Serono
935	Mitoxantrone	Novantrone	8/13/1999	Treatment of progressive-relapsing multiple sclerosis.	Serono, Inc.
936	Mitoxantrone HCl	Novantrone	7/13/1987	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Lederle Laboratories
937	Mocetinostat	n/a	6/12/2014	Treatment of myelodysplastic syndrome	Mirati Therapeutics, Inc.
938	Modafinil	Provigil	3/15/1993	Treatment of excessive daytime sleepiness in narcolepsy.	Cephalon, Inc.
939	Monoclonal antibody for immunization against lupus nephritis	n/a	1/7/1993	Treatment of lupus nephritis.	VivoRx Autoimmune, Inc.
940	Monoclonal antibody-B43.13	Ovarex Mab-B43.13	11/25/1996	Treatment of epithelial ovarian cancer.	Quest PharmaTech, Inc.
941	Monolaurin	Glylorin	4/29/1993	Treatment of congenital primary ichthyosis.	Glaxo Wellcome Inc.
942	Monoctanoin	Moctanin	5/30/1984	For dissolution of cholesterol gallstones retained in the common bile duct.	Ethitek Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
943	Morphine sulfate concentrate (preservative free)	Infumorph	7/12/1990	For use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.	Elkins-Sinn, Inc.
944	Multi-ligand somatostatin analog	n/a	7/27/2004	Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma.	Novartis Pharmaceuticals Corporation
945	Multi-peptide cancer vaccine	n/a	6/23/2013	Treatment of multiple myeloma	OncoPep, Inc.
946	Multi-vitamin infusion (neonatal formula)	n/a	12/12/1989	For establishment and maintenance of total parenteral nutrition in very low birth weight infants.	Astra Pharmaceuticals, L.P.
947	Multistem(r)	n/a	9/15/2010	Prophylaxis of graft vs host disease	Athersys, Inc.
948	Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma	Oncolym	11/27/1998	Treatment of B-cell non-Hodgkin's lymphoma.	Peregrine Pharmaceuticals, Inc.
949	Murine MAb to polymorphic epithelial mucin, human milk fat globule 1	Theragyn	3/22/1999	Adjuvant treatment of ovarian cancer.	Antisoma plc
950	Mx-dnG1	Rexin-G	6/24/2008	Treatment of osteosarcoma.	Epeius Biotechnologies Corporation

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
951	Mx-dnG1	Rexin-G(R)	6/24/2008	Treatment of soft tissue sarcoma	Epeius Biotechnologies Corporation
952	Mx-dnG1 or Rexin-G retroviral vector	Rexin-G	8/15/2003	Treatment of pancreatic cancer	Epeius Biotechnologies Corporation
953	Mycobacterium avium sensitin RS-10	n/a	10/11/1995	For use in the diagnosis of invasive Mycobacterium avium disease in immunocompetent individuals.	Statens Seruminstitut
954	N,N'-bis(2-mercaptoethyl)isophthalamide (NBMI)	n/a	4/6/2012	Treatment of mercury toxicity	CTI Science Limited
955	N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide	n/a	11/17/2014	Treatment of Duchenne muscular dystrophy	Catabasis Pharmaceuticals, Inc.
956	N-(2-amino-2-oxoethyl)-2-(2-((4-fluorophenethyl)amino)-N-isobutylacetamido)-N-(3-(2-oxopyrrolidin-1-yl)propyl)acetamide N-({Carbamoylmethyl-[3-(2-oxopyrrolidin-1-yl)propyl]-carbamoyl}-methyl)-2-[2-(2-fluorophenyl)-ethylamino]-N-isobutyl-acetamide	n/a	11/17/2014	Treatment of optic neuritis	Bionure Farma SL

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
957	N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	n/a	2/1/2008	Treatment of acute myeloid leukemia	Mirati Therapeutics, Inc.
958	N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	n/a	8/8/2007	Treatment of Hodgkin's lymphoma	Mirati Therapeutics, Inc.
959	N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl)prop-2-enamide mesylate salt	n/a	9/4/2014	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	AstraZeneca Pharmaceuticals LP
960	N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide	n/a	10/15/2014	Treatment of AL Amyloidosis	ProteoTech, Inc.
961	N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl) pyridin-2-yl) Acetamide Besylate	n/a	11/26/2013	Treatment of gliomas	Kinex Pharmaceuticals, Inc.
962	N-(4-Fluoro-benzoyl)-L-arginyl-L-arginyl-[L-3-(naphthyl-alanyl)-L-cysteinyl-L-tyrosyl-L-citrullinyl-L-lysyl-D-lysyl-L-prolyl-L-trosyl-L-arginyl-L-citrullinyl-L-cysteinyl-L-arginine amide, cyclic (4-13)-disulfide	n/a	7/6/2012	For use in combination with G-CSF to mobilize HSCs from the marrow to peripheral blood for collection for autologous or allogeneic transplantation	BioLineRx, Ltd.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
963	N-(4-{3-(2-aminopyrimidin-4-yl)pyridin-2-yl}oxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine bis-mesylate dihydrate	n/a	10/21/2014	Treatment of ovarian cancer	Amgen, Inc.
964	N-(5-tert-Butylisoxazol-3-yl)-N'-(4-[7-(2-(morpholin-4-yl)ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl)urea dihydrochloride salt	n/a	3/18/2009	Treatment of acute myeloid leukemia	Ambit Biosciences Corporation
965	N-(9-methoxynonyl)-1-deoxynojirimycin hydrochloride	n/a	11/17/2014	Treatment of acute dengue illness (inclusive of acute dengue illness, dengue fever, dengue hemorrhagic fever, and dengue shock syndrome)	Unither Virology, LLC
966	N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl(phenyl)amino)pyrimidin-4-yl]benzamide	n/a	8/5/2010	Treatment of myelofibrosis	Gilead Sciences, Inc.
967	N-(methyl-diazacyclohexylmethylbenzamide)-azaphenylaminothiopyrrole) mesylate	n/a	10/17/2005	Treatment of multiple myeloma.	AB Science
968	N-Acetylmannosamine (ManNAc)	n/a	4/5/2010	Treatment of hereditary inclusion body myopathy type 2	New Zealand Pharmaceuticals Ltd

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
969	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butrylamino)benzamide	n/a	1/13/2012	Treatment of Schwannoma of the central nervous system	Arno Therapeutics, Inc.
970	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butrylamino)benzamide	n/a	1/13/2012	Treatment of meningioma	Arno Therapeutics, Inc.
971	N-Methanocarbathymidine	n/a	10/15/2014	Treatment of neonatal herpes	N & N Pharmaceuticals, Inc.
972	N-[(2S)-2,3-dihydroxypropyl]-3-[[2-fluoro-4-iodophenyl]amino]isonicotinamide hydrochloride	n/a	1/29/2010	Treatment of pancreatic cancer	EMD Serono, Inc.
973	N-[(2S)-2,3-dihydroxypropyl]-3-[[2-fluoro-4-iodophenyl]amino]isonicotinamide hydrochloride	n/a	1/12/2011	Treatment of acute myeloid leukemia (AML).	EMD Serono, Inc.
974	N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt	n/a	1/7/2015	For the treatment of Cushing's Syndrome	Atterocor, Inc.
975	N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide	n/a	9/30/2004	Treatment of neuroblastoma	AbbVie, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
976	N-[3-(4',5'-bipyrimidin-2-ylamino)-4-methylphenyl]-4-[[{(3S)-3-(dimethylamino)pyrrolidin-1-yl)methyl}-3-(trifluoromethyl)benzamide	n/a	12/27/2006	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia.	CytRx Corporation
977	N-[4-(trifluoromethyl)phenyl] 5 methylisoxazole-4-carboxamide	n/a	5/25/1995	Treatment of malignant glioma.	Sugen, Inc.
978	N-[4-(trifluoromethyl)phenyl]-5-methylisoxazole-4-carboxamide	n/a	3/12/1996	Treatment of ovarian cancer.	Sugen, Inc.
979	N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide	n/a	2/3/2015	Treatment of TrkA-positive, TrkB-positive, TrkC-positive ROS1-positive and ALK-positive non-small cell lung cancer	Ignyta, Inc.
980	N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide	n/a	12/22/2014	Treatment of neuroblastoma.	Ignyta, Inc.
981	N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide	n/a	2/12/2015	Treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive, or ALK-positive colorectal cancer.	Ignyta, Inc.
982	N-acetyl cysteine amide	n/a	12/31/2013	Treatment of retinitis pigmentosa	Brighton Biotech, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
983	N-acetyl-glucosamine thiazoline	n/a	2/6/2006	Treatment of adult Tay-Sachs disease	ExSAR Corporation
984	N-acetyl-procainamide	n/a	12/10/1996	Prevention of life-threatening ventricular arrhythmias in patients with documented procainamide-induced lupus.	NAPA of the Bahamas
985	N-acetylcysteinate Lysine	Nacystelyn Dry Powder Inhaler	12/27/2000	For the management of cystic fibrosis	Galephar Pharmaceutical Research, Inc.
986	N-acetylcysteine	n/a	7/19/2012	Prevention of ototoxicity caused by platinum-based chemotherapeutic agents used to treat pediatric cancers	Edward A. Neuwelt, MD
987	N-acetylcysteine	n/a	9/9/2002	Treatment of acute liver failure	Cumberland Pharmaceuticals, Inc.
988	N-acetylgalactosamine-4-sulfatase, recombinant human	Naglazyme	2/17/1999	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	BioMarin Pharmaceutical, Inc.
989	N-adamantanyl-N'-Geranyl-ethylenediamine	n/a	10/16/2007	Treatment of tuberculosis.	Sequella, Inc.
990	N-methyl-4-({4-[(3-methyl(methylsulfonyl)amino)pyrazin-2-yl)methyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide hydrochloride	n/a	7/18/2013	Treatment of mesothelioma	Verastem, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
991	N-tert-butyl-3-[[5-methyl-2-[[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino]pyrimidin-4-yl]amino]benzenesulfonamide dihydrochloride monohydrate	n/a	3/21/2013	Treatment of polycythemia vera	sanofi-aventis U.S. LLC
992	N-tert-butyl-3-[5-methyl-2-[[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino]pyrimidin-4-yl-amino]benzenesulfonamide dihydrochloride monohydrate	n/a	5/18/2009	Treatment of secondary and primary myelofibrosis	Sanofi-Aventis US, LLC a Sanofi company
993	N-{3-[(2-[[4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl]amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl}prop-2-enamide	n/a	5/14/2013	Treatment of non-small cell lung cancer and mutations in the epidermal growth factor receptor	Clovis Oncology, Inc.
994	N-[[[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide	n/a	2/4/2011	Treatment of tuberculosis.	Sequella, Inc.
995	N1,N14,-diethyl-3,12,-dihydroxyhomospermine	n/a	8/7/2014	Treatment of pancreatic cancer	Sun BioPharma, Inc.
996	N2'-Deacetyl-N2'-[4-methyl-4-(oxobuthyldithio)-1-oxopentyl]-maytansine-chimerized anti-CD138 IgG4 Monoclonal Antibody	n/a	2/27/2008	Treatment of multiple myeloma	Biotest Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
997	N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maytansine-Conjugated Humanized C242 Monoclonal Antibody	n/a	12/7/2000	For pancreatic cancer	SmithKline Beecham Pharmaceuticals
998	NDX-peptides	n/a	12/14/2010	Treatment of amyotrophic lateral sclerosis	NeoDiagnostic Research Ltd
999	Nafarelin acetate	Synarel Nasal Solution	7/20/1988	Treatment of central precocious puberty.	Syntex (USA), Inc.
1000	Naltrexone HCl	Trexan	3/11/1985	For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.	DuPont Pharmaceuticals
1001	NanoDTPA(tm)	n/a	6/17/2011	Treatment of known or suspected cases of internal contamination with plutonium, americium, or curium	Nanotherapeutics, Inc.
1002	Natural human lymphoblastoid interferon-alpha	n/a	1/18/2000	Treatment of Behcet's disease	Amarillo Biosciences, Inc.
1003	Natural human lymphoblastoid interferon-alpha	n/a	8/10/2000	Treatment of papillomavirus warts in the oral cavity of HIV positive patients.	Amarillo Biosciences, Inc.
1004	Nebacumab	Centoxin	10/1/1986	Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.	Centocor, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1005	Neurotrophin-1	n/a	9/13/1994	Treatment of motor neuron disease/amyotrophic lateral sclerosis.	Ericsson, Arthur Dale, M.D.
1006	Neutrophil-endothelial interaction inhibitor	Cylexin	12/22/1993	Treatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.	Cytel Corporation
1007	Nifedipine	n/a	6/13/1991	Treatment of interstitial cystitis.	Fleischmann, Jonathan M.D.
1008	Nikkomycin Z	n/a	2/14/2006	Treatment of coccidioidomycosis	Valley Fever Center for Excellence (1-111 INF)
1009	Nimotuzumab	n/a	11/17/2004	Treatment of glioma	InnoKeys PTE Ltd.
1010	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of acute myelogenous leukemia	The Vaccine Company
1011	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of chronic myelogenous leukemia.	The Vaccine Company
1012	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of myelodysplastic syndromes requiring therapy	The Vaccine Company
1013	Nitazoxanide	Alinia	12/12/1996	Treatment of cryptosporidiosis.	Romark Laboratories, L.C.
1014	Nitisinone	Orfadin	10/19/2001	Treatment of alkaptonuria	Swedish Orphan AB
1015	Nitisinone	Orfadin	5/16/1995	Treatment of tyrosinemia type 1.	Swedish Orphan Biovitrum AB (PUBL)

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1016	Nitric oxide	Inomax	9/27/2004	To reduce the risk of chronic lung disease in premature neonates	INO Therapeutics
1017	Nitric oxide	n/a	2/16/2005	Diagnosis of sarcoidosis	SensorMedics Corporation
1018	Nitric oxide	n/a	9/11/2013	Treatment of cystic fibrosis	Novoteris, LLC
1019	Nitric oxide	n/a	7/10/1995	Treatment of acute respiratory distress syndrome in adults.	INO Therapeutics, Inc.
1020	Nitric oxide	Inomax	6/22/1993	Treatment of persistent pulmonary hypertension in the newborn.	INO Therapeutics, Inc.
1021	Nitroprusside	n/a	2/21/2001	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Thomas, MD, Jeffrey Evan
1022	NorLeu3-Angiotensin(1-7) [NorLeu3-A(1-7)]	n/a	12/31/2013	Treatment of leakage from the surgical site following penetrating keratoplasty	US Biotest, Inc.
1023	NorLeu3-Angiotensin(1-7) [NorLeu3-A(1-7)]	n/a	1/31/2014	Treatment of dermal injury due to nuclear/radiation incident	US Biotest, Inc.
1024	Nucleic acid aptamer binding to tumor cell nucleolin	n/a	9/10/2009	Treatment of acute myeloid leukemia	Antisoma, Inc.
1025	Nucleic acid aptamer binding to tumor cell nucleolin	n/a	8/17/2004	Treatment of pancreatic cancer	Antisoma Research Ltd.
1026	Nucleic acid aptamer binding to tumor cell nucleon	n/a	7/28/2005	Treatment of renal cell carcinoma	Antisoma Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1027	O-(3-piperidino-2-hydroxyl-1-propyl)-nicotinic acid amidoxime hydrochloride	n/a	1/15/2013	Treatment of Duchenne Muscular Dystrophy	N-Gen Research Laboratories, Inc.
1028	O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazene-1,1,2-diolate	n/a	3/16/2012	Treatment of acute myeloid leukemia	JSK Therapeutics, Inc.
1029	O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazene-1,1,2-diolate	n/a	12/13/2013	Treatment of multiple myeloma	JSK Therapeutics, Inc.
1030	OTL38; conjugate of pteroi acid and S0456 near infrared dye	n/a	12/23/2014	Detecting folic receptor alpha positive lesions in ovarian cancer patients (diagnostic for the management of ovarian cancer)	On Target Laboratories, LLC
1031	Octreotide	Sandostatin Lar	8/24/1998	Treatment of acromegaly.	Novartis Pharmaceuticals Corporation
1032	Octreotide	Sandostatin Lar	8/24/1998	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Novartis Pharmaceuticals Corporation
1033	Octreotide	Sandostatin Lar	8/24/1998	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Novartis Pharmaceuticals Corporation
1034	Ofloxacin	Ocuflox Ophthalmic Solution	4/18/1991	Treatment of bacterial corneal ulcers.	Allergan, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1035	Omega-3 (n-3) polyunsaturated fatty acid with all double bonds in the cis configuration	n/a	11/22/1995	Prevention of organ graft rejection.	Research Triangle Pharmaceuticals
1036	Omega-3 (n-3) polyunsaturated fatty acids	Omacor	5/4/2000	Treatment of IgA nephropathy.	Pronova Biocare, AS
1037	Omegaven emulsion	Omegaven	2/27/2008	Treatment of parenteral nutrition-associated liver disease	Fresenius Kabi Deutschland GmbH
1038	Oncolytic adenovirus coding for granulocyte macrophage colony stimulating factor (ONCOS-102)	n/a	12/22/2014	Treatment of malignant mesothelioma	Oncos Therapeutics, Ltd.
1039	Oprelvekin	Neumega	12/17/1996	Prevention of severe chemotherapy-induced thrombocytopenia.	Genetics Institute, Inc.
1040	Oxaliplatin	n/a	10/6/1992	Treatment of ovarian cancer.	Debio Pharm S.A.
1041	Oxalobacter formigenes	n/a	3/29/2006	Treatment of primary hyperoxaluria	OxThera, Inc.
1042	Oxandrolone	Oxandrin	4/22/1997	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Savient Pharmaceuticals, Inc.
1043	Oxandrolone	Oxandrin	9/6/1991	Adjunctive therapy for AIDS patients suffering from HIV-wasting syndrome.	Bio-Technology General Corp.
1044	Oxymorphone	Numorphan H.P.	3/19/1985	For relief of severe intractable pain in narcotic-tolerant patients.	DuPont Merck Pharmaceutical Company

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1045	Oxypurinol	n/a	11/9/1998	Treatment of hyperuricemia in patients intolerant to allopurinol.	Cardiome Pharma Corp.
1046	P140K MGMT transduced human CD34 cells	n/a	1/9/2013	For bone marrow protection in the treatment of glioblastoma multiforme	Lentigen Corporation
1047	PEG-glucocerebrosidase	Lysodase	12/9/1992	For use as chronic enzyme replacement therapy in patients with Gaucher's disease who are deficient in glucocerebrosidase.	National Institute of Mental Health, NIH
1048	PEG-interleukin-2	n/a	2/1/1990	Treatment of primary immunodeficiencies associated with T-cell defects.	Chiron Corporation
1049	PEGylated recombinant anti-Pseudomonas aeruginosa PcrV Fab' antibody	n/a	10/25/2013	Treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infections	KaloBios Pharmaceuticals, Inc.
1050	PEGylated recombinant human hyaluronidase PH20	n/a	10/1/2014	Treatment of pancreatic cancer	Halozyme Therapeutics, Inc.
1051	PG2 (Astragalus polysaccharides extracted and purified from the dry root of Astragalus membranaceus)	n/a	7/5/2012	Treatment of idiopathic thrombocytopenic purpura	PhytoHealth Corporation
1052	PGC-C12E-terlipressin	n/a	12/27/2012	Treatment of refractory ascites due to all etiologies except for cancer	PharmaIN Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1053	Paclitaxel	Taxol	3/25/1997	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute
1054	Paclitaxel	Paxene	4/15/1997	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc.
1055	Paclitaxel protein-bound particles for injection suspension	Abraxane	10/1/2009	Treatment of stage IIb to IV melanoma	Abraxis BioScience, LLC
1056	Pafuramidine maleate	n/a	5/14/2007	Treatment of malaria	Immtech Pharmaceuticals, Inc.
1057	Pafuramidine maleate	n/a	8/31/2007	Treatment of human African trypanosomiasis (sleeping sickness)	Immtech Pharmaceuticals, Inc.
1058	Palifosfamide	n/a	5/5/2008	Treatment of soft tissue sarcomas	ZIOPHARM Oncology, Inc.
1059	Papain, trypsin, and chymotrypsin	Wobe-Mugos	12/21/1998	Treatment of multiple myeloma.	Marlyn Nutraceuticals, Inc.
1060	Parvovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine	Medi-491	5/7/1999	Prevention of transient aplastic crisis in patients with sickle cell anemia.	MedImmune, Inc.
1061	Pegademase bovine	Adagen	5/29/1984	For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.	Sigma-tau Pharmaceuticals, Inc.
1062	Pegaspargase	Oncaspar	10/20/1989	Treatment of acute lymphocytic leukemia.	Sigma-tau Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1063	Pegfilgrastim	Neulasta	11/20/2013	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Amgen, Inc.
1064	Peginterferon alfa-2a	Pegasys	7/13/1998	Treatment of renal cell carcinoma.	Hoffman-La Roche Inc.
1065	Peginterferon alfa-2a	Pegasys	9/30/1999	Treatment of chronic myelogenous leukemia.	Hoffman-La Roche Inc.
1066	Pegvisomant	Somavert	6/24/1997	Treatment of acromegaly.	Sensus Corporation
1067	Pegylated arginine deiminase	Melanocid	4/12/1999	Treatment of invasive malignant melanoma.	Polaris Pharmaceuticals, Inc.
1068	Peldesine	n/a	10/5/1993	Treatment of cutaneous T-cell lymphoma.	BioCryst Pharmaceuticals, Inc.
1069	Pentamidine isethionate	Pentam 300	2/28/1984	Treatment of Pneumocystis carinii pneumonia.	Fujisawa USA, Inc.
1070	Pentamidine isethionate	Nebupent	1/12/1988	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Fujisawa USA, Inc.
1071	Pentamidine isethionate	n/a	10/29/1984	Treatment of Pneumocystis carinii pneumonia.	Aventis Behring L.L.C.
1072	Pentamidine isethionate (inhalation)	Pneumopent	10/5/1987	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Fisons Corporation

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1073	Pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-D-glucopyranosyl unit, and one alpha-L-fucopyranosyl unit	Cylexin	7/18/1997	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Cytel Corporation
1074	Pentastarch	Pentaspan	8/28/1985	As an adjunct in leukapheresis to improve the harvesting and increase the yield of leukocytes by centrifugal means.	Du Pont Pharmaceuticals
1075	Pentosan polysulfate sodium	Elmiron	8/7/1985	Treatment of interstitial cystitis.	Alza Corporation
1076	Pentostatin	Nipent	1/29/1991	Treatment of patients with chronic lymphocytic leukemia.	SuperGen, Inc.
1077	Pentostatin	Nipent	3/27/1998	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc.
1078	Pentostatin	Nipent	11/24/1999	Treatment of peripheral T-cell lymphomas.	SuperGen, Inc.
1079	Pentostatin for injection	Nipent	9/10/1987	Treatment of hairy cell leukemia.	SuperGen, Inc.
1080	Peptide 144 TGF beta-1 inhibitor	n/a	4/27/2006	Treatment of systemic sclerosis	Digna Biotech, S.L.
1081	Peptide 144 TGF beta-1-inhibitor	n/a	4/26/2006	Treatment of localized scleroderma	Digna Biotech, S.L.
1082	Peptide that inhibits mechanosensitive ion channel (MSC) activity	n/a	9/15/2010	Treatment of Duchenne Muscular Dystrophy (DMD.)	Rose Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1083	Peptidomimetic analog of hexarelin	n/a	5/14/2007	Diagnosis of growth hormone deficiency	Aeterna Zentaris GmbH
1084	Perflubron	Liquivent(Tm)	4/26/2001	Treatment of acute respiratory distress disease (ARDS) in adults	PFC Development/New Alliance Pharmaceutical
1085	Phenylacetate	n/a	3/6/1998	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Elan Drug Delivery, Inc.
1086	Phenylalanine ammonia-lyase	Phenylase. Ravpal-Peg	3/8/1995	Treatment of hyperphenylalaninemia	BioMarin Pharmaceutical
1087	Phenylbutyrate	n/a	1/19/2000	Treatment of acute promyelocytic leukemia.	Elan Drug Delivery, Inc.
1088	Phosphatidylinositol 3-Kinase "PI3K" Inhibitor	n/a	11/2/2010	Treatment of chronic lymphocytic leukemia (CLL)	Semafore Pharmaceuticals
1089	Picoplatin	n/a	11/2/2005	Treatment of small cell lung cancer	Poniard Pharmaceuticals
1090	Pilocarpine	Salagen	9/24/1990	Treatment of xerostomia induced by radiation therapy for head and neck cancer.	MGI Pharma, Inc.
1091	Pilocarpine HCl	Salagen	2/28/1992	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc.
1092	Plasmid DNA vector expressing cystic fibrosis transmembrane gene	n/a	3/29/2005	Treatment of cystic fibrosis	Copernicus Therapeutics, Inc.
1093	Plitidepsin	Aplidin	9/30/2004	Treatment of multiple myeloma	PharmaMar USA, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1094	Poloxamer 188	Florcor	2/22/1990	Treatment of severe burns requiring hospitalization.	CytRx Corporation
1095	Poloxamer 188	n/a	8/5/1997	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	CytRx Corporation
1096	Poloxamer 331	Protox	3/21/1991	Initial therapy of toxoplasmosis in patients with AIDS.	CytRx Corporation
1097	Poly I: poly C12U	Ampligen	12/9/1993	Treatment of chronic fatigue syndrome.	Hemispherx Biopharma, Inc.
1098	Poly I: poly C12U	Ampligen	12/9/1993	Treatment of invasive metastatic melanoma (stage IIb, III, IV).	Hemispherx Biopharma, Inc.
1099	Poly I: poly C12U	Ampligen	5/20/1991	Treatment of renal cell carcinoma.	Hemispherx Biopharma, Inc.
1100	Poly-ICLC	Hiltonol	3/17/1997	Treatment of primary brain tumors.	Oncovir
1101	Polyethylene glycol-modified uricase	n/a	6/6/2005	Treatment of hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicated	EnzymeRx, LLC
1102	Polyethylene glycol-modified uricase	Zurase	12/21/1998	Treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.	EnzymeRx, LLC

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1103	Polyethylene glycol-modified uricase	Zurase	9/14/1999	Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.	EnzymeRx, LLC
1104	Polymeric oxygen	n/a	3/25/1992	Treatment of sickle cell anemia.	Capmed USA
1105	Polyribonucleotide; Polyribo-inosinic/-cyclidylic/-uridylic acid	Ampligen	7/19/1988	Treatment of AIDS.	Hemispherx Biopharma, Inc.
1106	Polyvalent, shed-antigen melanoma vaccine	n/a	6/9/2006	Treatment of stage IIb to stage IV melanoma	Polynoma LLC
1107	Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue	N-Graft	6/24/1997	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Titan Pharmaceuticals, Inc.
1108	Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Neurocell-Pd	12/17/1996	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC
1109	Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared for intracerebral implantation.	Neurocell-Pd	12/17/1996	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1110	Porcine fetal neural gabaergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Neurocell-Hd	12/10/1996	Treatment of Huntington's disease.	Diacrin/Genzyme LLC
1111	Porcine fetal neural gabaergic cells and/or precursors aseptically prepared for intracerebral implantation for Huntington's disease.	Neurocell-Hd	12/10/1996	Treatment of Huntington's disease.	Diacrin/Genzyme LLC
1112	Porfimer sodium	Photofrin	6/6/1989	For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.	QLT Phototherapeutics, Inc.
1113	Porfimer sodium	Photofrin	11/15/1989	For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.	QLT Phototherapeutics, Inc.
1114	Porfimer sodium	Photofrin	11/18/2004	Treatment of cholangiocarcinoma	Concordia Laboratories, Inc.
1115	Porfiromycin	Promycin	3/13/1997	Treatment of cervical cancer.	Boehringer Ingelheim Pharmaceuticals, Inc.
1116	Porfiromycin	Promycin	9/19/1995	Treatment of head and neck cancer.	Boehringer Ingelheim Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1117	Posaconazole	Posoril	7/16/2004	Treatment of zygomycosis	Schering-Plough Corporation
1118	Potassium Iodide Oral Solution	Thyroshield	11/17/2004	For use as a thyroid blocking agent in pediatric patients exposed to radioactive iodine	Fleming & Company, Pharmaceuticals
1119	Potassium citrate	Urocit-K	11/1/1984	Prevention of uric acid nephrolithiasis.	University of Texas Health Science Center at Dallas
1120	Potassium citrate	Urocit-K	11/1/1984	Prevention of calcium renal stones in patients with hypocitraturia.	University of Texas Health Science Center at Dallas
1121	Potassium citrate	Urocit-K	11/1/1984	For avoidance of the complication of calcium stone formation in patients with uric lithiasis.	University of Texas Health Science Center at Dallas
1122	Primaquine phosphate	n/a	7/23/1993	For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS.	Sanofi Winthrop, Inc.
1123	Procarbazine HCl	Matulane	8/8/2006	Treatment of malignant glioma	Sigma-Tau Pharmaceuticals, Inc.
1124	Prostaglandin E1 enol ester (AS-013)	Circulase	6/12/1998	Treatment of Fontaine Stage IV chronic critical limb ischemia.	LTT Baio-Pharma Co., Ltd
1125	Protaxel	n/a	5/21/2003	Treatment of ovarian cancer	Biophysica, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1126	Protein C concentrate	Ceprotin	6/23/1992	For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans.	Baxter Healthcare Corporation
1127	Protein C concentrate	Protein C Concentrate (Human) Vapor Heated, Immuno	6/19/1992	For replacement therapy in patients with congenital or acquired protein C deficiency for the prevention and treatment of warfarin-induced skin necrosis during oral anticoagulation.	Immuno Clinical Research Corp.
1128	Pulmonary surfactant replacement, porcine	Curosurf	8/2/1993	For the treatment and prevention of respiratory distress syndrome in premature infants.	Chiesi USA, Inc.
1129	Purified extract of Pseudomonas aeruginosa	Immudyn	9/22/1997	Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.	Able Laboratories, Inc.
1130	Purified type II collagen	Colloral	2/9/1995	Treatment of juvenile rheumatoid arthritis.	AutoImmune, Inc.
1131	PyNTTTTGT class of oligodeoxynucleotide with a 24-base single chain composed of nucleotide sequence 5'TCATCATTTTGTCA TT 3'	lmt504	11/24/2014	Treatment of rabies virus infections	Mid-Atlantic BioTherapeutics, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1132	Pyruvate	n/a	2/21/2001	Treatment of interstitial lung disease.	Cellular Sciences, Inc
1133	R-(-)-gossypol	n/a	10/24/2006	Treatment of chronic lymphocytic leukemia.	Ascenta Therapeutics, Inc.
1134	R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1H-1,4-benzodiazepine-3-yl]-3-(3-methylaminophenyl)urea	n/a	9/10/2009	Treatment of gastric carcinoids	Trio Medicines Ltd.
1135	R-4-amino-3-(4-chlorophenyl)butanoic acid	n/a	11/28/2008	Treatment of the behavioral abnormalities associated with fragile X syndrome	Seaside Therapeutics, Inc.
1136	REMUNE HIV 1	n/a	2/14/2014	Treatment of pediatric HIV/AIDS (age through 16 years)	Immune Response BioPharma, Inc.
1137	R11 retinamide	n/a	5/6/1993	Treatment of myelodysplastic syndromes.	Sparta Pharmaceuticals, Inc.
1138	Rabbit anti-human thymocyte globulin (rATG)	Thymoglobulin	9/26/2006	Induction treatment to prevent rejection and to minimize maintenance immunosuppression in pediatric liver transplant recipients	Children's Hospital of Pittsburgh
1139	Rapamycin	n/a	3/20/2007	Treatment of tuberous sclerosis complex	Oncolmune, Inc.
1140	Re188 P2045 somatostatin analog	n/a	2/6/2014	Treatment of small cell lung cancer	Andarix Pharmaceuticals
1141	Re188 P2045 somatostatin peptide analogue	n/a	6/19/2014	Treatment of pancreatic cancer.	Andarix Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1142	Recombinant AAV9 expressing human alpha-N-acetylglucosaminidase	n/a	4/30/2014	Mucopolysaccharidosis III-B (Sanfilippo Syndrome Type B)	Abeona Therapeutics LLC
1143	Recombinant Epstein-Barr virus gp350 glycoprotein vaccine	n/a	8/18/2005	Prevention of post-transplantation lymphoproliferative disorders in pediatric recipients of solid-organ transplantation	Henogen S.A.
1144	Recombinant Fusion Protein	n/a	7/24/2012	Treatment of Myelodysplastic Syndrome	Apogenix GmbH
1145	Recombinant Human Alpha-Fetoprotein (rhAFP)	n/a	2/22/2001	Treatment of myasthenia gravis	Merrimack Pharmaceuticals, Inc.
1146	Recombinant Human Factor VIIa Variant	n/a	11/30/2012	Routine prophylaxis to prevent bleeding episodes in patients with hemophilia A and B patients with inhibitors	Pfizer, Inc.
1147	Recombinant Human Interleukin-21 (rIL-21)	n/a	10/4/2005	Treatment of stage II (T4), III or IV malignant melanoma.	Zymo Genetics, Inc
1148	Recombinant Human soluble Fc-gamma Receptor IIb	n/a	3/22/2010	Treatment of idiopathic thrombocytopenic purpura	SuppreMol GmbH
1149	Recombinant P-Selectin glycoprotein ligand	n/a	3/29/2006	Prevention of delayed graft function in renal transplant patients	Y's Therapeutics, Inc.
1150	Recombinant P-selectin glycoprotein ligand-immunoglobulin Ig	n/a	7/26/2007	Prevention of ischemia reperfusion injury in all solid organ transplants	Y's Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1151	Recombinant T-cell receptor ligand	n/a	5/2/2003	Treatment of multiple sclerosis patients who are both HLA-DR2 positive and autoreactive to myelin oligodendrocyte glycoprotein residues 35-55	Artielle ImmunoTherapeutics, Inc.
1152	Recombinant adeno-associated virus (serotype 2) (rAAV2) gene transfer agent expressing RPE65	n/a	5/11/2009	Treatment of Leber's congenital amaurosis	AmpliPhi Biosciences Corporation
1153	Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2	n/a	6/24/2008	Treatment of Leber congenital amaurosis due to RPE65 mutations.	Spark Therapeutics, Inc.
1154	Recombinant antibody construct against human CD30 and CD16A	n/a	8/20/2009	Treatment of Hodgkin lymphoma	Affimed Therapeutics AG
1155	Recombinant coagulation factor VIIa	n/a	4/26/2006	Treatment of diffuse alveolar hemorrhage	PharmaOrigin ApS
1156	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	n/a	7/29/2008	Treatment of thrombotic thrombocytopenic purpura including its congenial, acquired idiopathic, and secondary forms.	Baxter Healthcare Corporation
1157	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	n/a	7/29/2008	Prevention of thrombotic thrombocytopenic purpura including its congenial, acquired idiopathic and secondary forms.	Baxter Healthcare Corporation
1158	Recombinant fully human monoclonal antibody to anthrax protective antigen	Valortim	2/16/2006	Treatment of anthrax infection	PharmAthene, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1159	Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7	n/a	3/19/2001	Treatment of recurrent respiratory papillomatosis (RRP)	StressGen Biotechnologies, Inc. is now Nventa
1160	Recombinant fusion protein-extracellular portion of CD95 fused to the Fc part of human IgG1	n/a	10/13/2009	Treatment of glioblastoma multiforme	Apogenix GmbH
1161	Recombinant human C1 inhibitor	n/a	6/9/2006	Treatment of capillary leakage syndrome	Pharming Technologies B.V.
1162	Recombinant human C1 inhibitor	n/a	6/9/2006	Prevention and/or treatment of delayed graft function after solid organ transplantation	Pharming Group N.V.
1163	Recombinant human C1-esterase inhibitor	n/a	2/23/1999	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming Group N.V.
1164	Recombinant human CD4 immunoglobulin G	n/a	8/30/1990	Treatment of AIDS resulting from infection with HIV-1.	Genentech, Inc.
1165	Recombinant human Clara Cell 10kDa protein	n/a	7/13/1998	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	Clarassance, Inc.
1166	Recombinant human acid alpha-glucosidase; alglucosidase alfa	1. Myozyme 2. Lumizyme	8/19/1997	Treatment of glycogen storage disease type II.	Genzyme Corporation
1167	Recombinant human alpha 1-antitrypsin	n/a	4/28/2005	Prevention of bronchopulmonary dysplasia	Arriva Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1168	Recombinant human alpha-mannosidase	n/a	2/2/2006	Treatment of alpha-mannosidosis	Zymenex A/S
1169	Recombinant human antithrombin III	n/a	4/6/2000	Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.	AT III LLC
1170	Recombinant human endostatin protein	n/a	8/13/2001	Treatment of neuroendocrine tumors	EntreMed, Inc.
1171	Recombinant human fibrinogen	n/a	10/4/2007	Treatment of bleeding in patients deficient in fibrinogen	Pharming Technologies B.V.
1172	Recombinant human gelsolin	n/a	3/6/1995	Treatment of acute and chronic respiratory symptoms of bronchiectasis.	BioAgeis, Therapeutics, Inc.
1173	Recombinant human gelsolin	n/a	1/12/1994	Treatment of the respiratory symptoms of cystic fibrosis.	BioAegis Therapeutics, Inc.
1174	Recombinant human glutamic acid decarboxylase 65KDa isoform	n/a	3/22/2010	Treatment of Type I diabetes with residual beta cell function	Diamyd Therapeutics AB
1175	Recombinant human granulocyte colony stimulating factor	n/a	7/24/2006	Prevention of implantation failure	Nora Therapeutics, Inc.
1176	Recombinant human highly phosphorylated acid alpha-glucosidase	Tbd	9/20/2000	For enzyme replacement therapy in patients with all subtypes of glycogen storage disease type II (GSDII, Pompe Disease)	Novazyme Pharmaceuticals, Inc.
1177	Recombinant human highly phosphorylated alpha-L-iduronidase (rhHP-IDUA)	n/a	4/11/2001	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Novazyme Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1178	Recombinant human insulin-like growth factor-I	Pv802	2/16/2000	Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.	GroPep Pty Ltd.
1179	Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3	n/a	6/15/1999	Treatment of major burns that require hospitalization.	Insmed, Inc.
1180	Recombinant human interleukin-12	n/a	10/20/1997	Treatment of renal cell carcinoma.	Genetics Institute, Inc.
1181	Recombinant human keratinocyte growth factor	n/a	12/20/1999	Reducing the incidence and severity of radiation-induced xerostomia.	Swedish Orphan Biovitrum AB (publ) (SOBI)
1182	Recombinant human luteinizing hormone	Luveris	10/7/1994	For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.	EMD Serono, Inc.
1183	Recombinant human lysosomal acid lipase or cholesteryl ester hydrolase	Cholestrase	7/14/2005	Treatment of lipase deficiencies, including Wolman Disease and cholesteryl ester storage disease	Lysosomal Acid Lipase, LLC
1184	Recombinant human microplasmin	n/a	1/23/2006	Treatment of peripheral arterial occlusion	ThromboGenics Ltd
1185	Recombinant human nerve growth factor	n/a	4/16/1999	Treatment of HIV-associated sensory neuropathy.	Genentech, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1186	Recombinant human platelet derived growth factor BB	n/a	2/1/2007	Treatment of osteonecrosis of the jaws	Luitpold Pharmaceuticals, Inc.
1187	Recombinant human thrombopoietin	n/a	9/29/1997	For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.	Genentech, Inc.
1188	Recombinant humanized MAb 5c8	n/a	10/14/1998	Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.	Biogen, Inc.
1189	Recombinant humanized MAb 5c8	n/a	3/22/1999	Prevention of rejection of solid organ transplants.	Biogen, Inc.
1190	Recombinant humanized MAb 5c8	n/a	3/22/1999	Prevention of rejection of pancreatic islet cell transplants.	Biogen, Inc.
1191	Recombinant humanized anti-LOXL2 monoclonal antibody	n/a	4/18/2011	Treatment of idiopathic pulmonary fibrosis	Gilead Sciences, Inc.
1192	Recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)	n/a	6/1/2011	Treatment of myelofibrosis.	Gilead Sciences, Inc.
1193	Recombinant humanized monclonal antibody 5c8	n/a	2/3/1998	Treatment of immune thrombocytopenic purpura.	Biogen, Inc.
1194	Recombinant humanized monoclonal antibody 5c8	n/a	2/18/1998	Treatment of systemic lupus erythematosus.	Biogen, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1195	Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	n/a	2/11/2002	Treatment of malignant mesothelioma	National Institutes of Health
1196	Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	n/a	2/11/2002	Treatment of epithelial ovarian cancer	National Institutes of Health
1197	Recombinant methionyl brain-derived neurotrophic factor	n/a	11/28/1994	Treatment of amyotrophic lateral sclerosis.	Amgen, Inc.
1198	Recombinant replication deficient adenovirus vector carrying human p53 gene	n/a	4/12/1999	Treatment of primary ovarian cancer.	Schering Corporation
1199	Recombinant retroviral vector - glucocerebrosidase	n/a	11/15/1993	For use as enzyme replacement therapy for patients with types I, II, or III Gaucher disease.	Genetic Therapy, Inc.
1200	Recombinant secretory leucocyte protease inhibitor	n/a	3/29/1991	Treatment of cystic fibrosis.	Amgen, Inc.
1201	Recombinant soluble human CD4 (rCD4)	n/a	3/23/1989	Treatment of AIDS in patients infected with HIV virus.	Genentech, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1202	Recombinant truncated SPINT2 protease inhibitor	n/a	6/24/2005	Treatment of cystic fibrosis	Aerovance, Inc.
1203	Recombinant urate oxidase	n/a	10/11/2000	Prophylaxis of chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research
1204	Reduced L-glutathione	Cachexon	2/14/1994	Treatment of AIDS-associated cachexia.	Telluride Pharmaceutical Corporation
1205	Replication defective recombinant adenovirus serotype 5 vector carrying the p53 gene in its E1 deleted region	Advexin	1/27/2003	Treatment of head and neck cancer	Introgen Therapeutics, Inc.
1206	Replication-incompetent GM-CSF-expressing gene-modified allogeneic acute myeloid leukemia cancer cell lines	Gvax Acute Myeloid Leukemia	3/2/2010	Treatment of acute myeloid leukemia	Aduro BioTech, Inc.
1207	Replication-incompetent GM-CSF-expressing gene-modified allogeneic chronic myeloid leukemia cancer cell lines	Gvax Chronic Myeloid Leukemia	4/30/2010	Treatment of chronic myeloid leukemia	Aduro BioTech, Inc.
1208	Replication-incompetent GM-CSF-expressing gene-modified allogeneic pancreatic cancer cell lines	Gvax Pancreas	3/1/2010	Treatment of pancreatic cancer.	Aduro BioTech, Inc.
1209	Respiratory Syncytial Virus Immune Globulin (human)	Hyperimmune Rsv	9/27/1990	Treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children.	MedImmune, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1210	Respiratory syncytial virus immune globulin (Human)	Respigam	9/27/1990	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.	MedImmune & Massachusetts Public Health Biologics Labs.
1211	Reversal agent linked to chloroquine-like moiety	n/a	3/26/2010	Treatment of malaria	DesignMedix
1212	Revimmune	n/a	2/18/2011	Treatment of autoimmune hemolytic anemia.	Accentia Biopharmaceuticals
1213	Reviparin sodium	Clivarine	6/18/2001	Long-term treatment of acute deep vein thrombosis with or without pulmonary embolism in pregnant patients	Abbott
1214	Reviparin sodium	Clivarine	6/18/2001	Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients	Abbott
1215	Rho (D) immune globulin intravenous (human)	Winrho Sd	11/9/1993	Treatment of immune thrombocytopenic purpura.	Rh Pharmaceuticals, Inc.
1216	Rifabutin	Mycobutin	12/18/1989	Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.	Adria Laboratories, Inc.
1217	Rifabutin	n/a	12/18/1989	Treatment of disseminated Mycobacterium avium complex disease.	Pfizer, Inc.
1218	Rifalazil	n/a	4/13/1999	Treatment of pulmonary tuberculosis.	PathoGenesis Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1219	Rifampin	Rifadin I.V.	12/9/1985	For antituberculosis treatment where use of the oral form of the drug is not feasible.	Hoechst Marion Roussel
1220	Rifampin, isoniazid, pyrazinamide	Rifater	9/12/1985	For the short-course treatment of tuberculosis.	Hoechst Marion Roussel
1221	Rifapentine	Priftin	6/9/1995	Treatment of pulmonary tuberculosis.	Hoechst Marion Roussel
1222	Rifapentine	Priftin	6/9/1995	Treatment of Mycobacterium avium complex in patients with AIDS.	Hoechst Marion Roussel , Inc.
1223	Rifapentine	Priftin	3/12/1996	Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.	Hoechst Marion Roussel, Inc.
1224	Rilonacept	Arcalyst	12/20/2004	Treatment of CIAS1-Associated Periodic Syndromes	Regeneron Pharmaceuticals, Inc.
1225	Riluzole	Rilutek	10/15/1996	Treatment of Huntington's disease.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
1226	Riluzole	Rilutek	3/16/1993	Treatment of amyotrophic lateral sclerosis.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
1227	Rose Bengal Disodium	n/a	12/20/2006	Treatment of metastatic melanoma	Provectus Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1228	Roseburia hominis	Rosburix	8/4/2014	Treatment of ulcerative colitis in pediatric patients age 0 through 16 years	GT Biologics Ltd
1229	S(-)-3-[3-amino-phthalimido]-glutaramide	n/a	3/14/2002	Treatment of multiple myeloma	EntreMed Incorporated
1230	S-59 treated FFP (plasma treated with amotosalen hydrochloride & ultraviolet A light	Intercept Blood System For	2/14/2011	Treatment of thrombotic thrombocytopenic purpura	Cerus Corporation
1231	S-[2,3-bispalmitoyloxy-(2R)-propyl]-cysteinly-GNNDENISFKEK	n/a	10/20/2009	Treatment of pancreatic cancer	MBiotec GmbH
1232	S-adenosylmethionine	n/a	4/30/1998	Treatment of AIDS-myelopathy.	Genopia USA, Inc.
1233	S-nitrosoglutathione	n/a	5/12/2009	Management of cystic fibrosis patients to improve airway clearance and to improve or stabilize pulmonary function	N30 PHARMAceuticals, LLC
1234	S-nitrosoglutathione	n/a	12/28/2012	Treatment of severe pre-eclampsia	Salupont Consulting Ltd
1235	S3,S13-cyclo(D-tyrosyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminy-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)	n/a	10/9/2014	Treatment of paroxysmal nocturnal hemoglobinuria (PNH)	Amyndas Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1236	SC-1 monoclonal antibody	n/a	11/12/2003	Treatment of patients with CD55 (sc-1) positive gastric tumors	Patrys Limited
1237	SDF-1 (108) Lysine Dimer	n/a	7/7/2005	Treatment of osteogenic sarcoma	Chemokine Therapeutics Corporation
1238	Sacrosidase	Sucraid	12/10/1993	Treatment of congenital sucrase-isomaltase deficiency	QOL Medical, LLC
1239	Sar9, Met(O2)11-Substance P	Homspera	3/16/2011	Treatment of idiopathic pulmonary fibrosis	ImmuneRegen BioSciences, Inc.
1240	Sargramostim	Leukine	3/6/1995	To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.	Immunex Corporation
1241	Sargramostim	Leukine	5/3/1990	Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.	Immunex Corporation
1242	Satumomab pendetide	Oncoscint Cr/Ov	9/25/1989	Detection of ovarian carcinoma.	Cytogen Corporation
1243	Secalciferol	Osteo-D	7/26/1993	Treatment of familial hypophosphatemic rickets.	Teva Pharmaceuticals USA
1244	Secretory leukocyte protease inhibitor	n/a	6/30/1992	Treatment of bronchopulmonary dysplasia.	Synergen, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1245	Selective inhibitor of polymorphonuclear leukocyte (PMN) elastase	n/a	6/4/1996	Therapeutic management of patients with lung disease attributable to cystic fibrosis.	DuPont Pharmaceuticals Company
1246	Selegiline HCl	Eldepryl	11/7/1984	As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.	Somerset Pharmaceuticals, Inc.
1247	Selinexor; (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide	n/a	5/14/2014	Treatment of acute myeloid leukemia	Karyopharm Therapeutics, Inc.
1248	Seneca Valley virus	n/a	8/22/2008	Treatment of neuroendocrine tumors	Neotropix, Inc.
1249	Sermorelin acetate	Geref	9/14/1988	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	EMD Serono, Inc.
1250	Serratia marcescens extract (polyribosomes)	Imuvert	9/7/1988	Treatment of primary brain malignancies.	Cell Technology, Inc.
1251	Short chain fatty acid enema	Colomed	8/19/1997	Treatment of chronic radiation proctitis.	Richard I. Breuer, M.D.
1252	Short chain fatty acid solution	Colomed	5/29/1990	Treatment of the active phase of ulcerative colitis with involvement restricted to the left side of the colon.	Richard I. Breuer
1253	Silibinin-C-2',3-dihydrogensuccinate, disodium salt	Legalon Sil	2/17/2012	Prevention of recurrent hepatitis C in liver transplant patients	Rottapharm S.p.A.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1254	Silver sulfadiazine and cerium nitrate	Flammacerium	11/17/1999	Treatment of patients with severe dermal burns	Sinclair Pharmaceuticals Ltd
1255	Siponimod	n/a	11/26/2013	Treatment of polymyositis	Novartis Pharmaceuticals Corporation
1256	Sitaxsentan Sodium	n/a	11/2/2004	For the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure.	Pfizer Global Research and Development
1257	Sodium Monomercaptoundecahydro-closo-dodecaborate	Borocell	4/15/1992	For use in boron neutron capture therapy (BNCT) in the treatment of glioblastoma multiforme.	Neutron Technology Corp.& Neutron R&D Partner
1258	Sodium Thiosulfate	n/a	2/16/2012	Treatment of uremic and non-uremic calciphylaxis	Luitpold Pharmaceuticals, Inc.
1259	Sodium aluminosilicate	n/a	3/4/2005	Treatment of chronic hepatic encephalopathy	Framework Therapeutics, LLC
1260	Sodium ascorbate and menadione sodium bisulfite	Apatone	7/31/2007	Treatment of metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium (stage III and IV bladder cancer)	IC-MedTech Corporation
1261	Sodium dichloroacetate	n/a	6/11/1990	Treatment of congenital lactic acidosis	Stacpoole, Peter W. M.D., Ph.D.
1262	Sodium dichloroacetate	n/a	6/11/1990	Treatment of homozygous familial hypercholesterolemia.	Stacpoole, Peter W. M.D., Ph.D.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1263	Sodium dichloroacetate	n/a	11/10/1994	Treatment of lactic acidosis in patients with severe malaria.	Stacpoole, Peter W. M.D., Ph.D.
1264	Sodium nitrite	n/a	4/18/2007	Treatment of cyanide poisoning	Hope Pharmaceuticals
1265	Sodium nitrite	n/a	1/17/2007	Prevention of vasospasm associated with subarachnoid hemorrhage	Hope Pharmaceuticals
1266	Sodium nitrite	n/a	4/2/2007	Treatment of vaso-occlusive crisis associated with sickle cell disease	Hope Pharmaceuticals
1267	Sodium nitrite/sodium thiosulfate	Cyanide Antidote Package	3/23/2007	Treatment of cyanide poisoning	Keystone Pharmaceuticals, Inc.
1268	Sodium phenylacetate/sodium benzoate 10%/10% Injection	Ammonul(R)	6/3/2005	Treatment of grade III and IV hepatic encephalopathy	Ucyclyd Pharma, Inc.
1269	Sodium phenylbutyrate	n/a	4/24/1998	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Elan Drug Delivery, Inc.
1270	Sodium phenylbutyrate	n/a	3/20/2007	Treatment of spinal muscular atrophy	Tikvah Therapeutics, Inc.
1271	Sodium phenylbutyrate	Buphenyl	1/25/2007	Treatment of spinal muscular atrophy	OrphaMed, Inc.
1272	Sodium pyruvate	n/a	3/31/2003	Treatment of cystic fibrosis	Cellular Sciences, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1273	Sodium stibogluconate	n/a	6/16/2006	Treatment of cutaneous leishmaniasis	VioQuest Pharmaceuticals, Inc.
1274	Sodium tetradecyl sulfate	Sotradecol	6/10/1986	Treatment of bleeding esophageal varices.	Elkins-Sinn, Inc.
1275	Sodium thiosulfate	n/a	3/17/2004	Prevention of platinum-induced ototoxicity in pediatric patients	Adherex Technologies, Inc.
1276	Sodium thiosulfate and sodium nitrite	n/a	12/18/2006	Treatment of cyanide poisoning	Akorn, Inc.
1277	Sodium thiosulfate, sodium nitrite, amyl nitrite	Cyanide Antidote Package	6/16/2006	Treatment of cyanide poisoning	Keystone Pharmaceuticals, Inc.
1278	Solasonine and solamargine	Coramsine	2/6/2006	Treatment of high risk stage II, stage III and stage IV melanoma	Solbec Pharmaceuticals Limited
1279	Solasonine and solamargine	Coramsine	11/2/2005	Treatment of renal cell carcinoma	Solbec Pharmaceuticals Limited
1280	Soluble complement receptor type 1	n/a	3/6/2000	Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.	Avant Immunotherapeutics, Inc.
1281	Soluble recombinant human complement receptor type 1	n/a	11/21/1994	Prevention or reduction of adult respiratory distress syndrome.	T Cell Sciences, Inc.
1282	Somatostatin	n/a	12/22/1994	Treatment of bleeding esophageal varices.	Eumedita Pharmaceuticals A.G. (Schweiz)

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1283	Somatostatin	Zecnil	6/20/1988	Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.	Ferring Laboratories, Inc.
1284	Somatrem for injection	Protropin	12/9/1985	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc.
1285	Somatrem for injection	Protropin	12/9/1985	For long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
1286	Somatropin	Nutropin	3/6/1987	For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
1287	Somatropin	Serostim	3/16/2004	Treatment of patients with HIV-associated adipose redistribution syndrome	EMD Serono, Inc.
1288	Somatropin	Norditropin	8/9/2006	Treatment of short stature in patients with Noonan syndrome	Novo Nordisk Inc.
1289	Somatropin	Genotropin	9/6/1994	Treatment of adults with growth hormone deficiency.	Pharmacia & Upjohn
1290	Somatropin	Humatrope	5/8/1990	Treatment of short stature associated with Turner syndrome.	Eli Lilly and Company

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1291	Somatropin	Humatrope	12/15/2005	Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency	Eli Lilly and Company
1292	Somatropin (rDNA)	Saizen	5/3/1989	For the enhancement of nitrogen retention in hospitalized patients suffering from severe burns.	EMD Serono, Inc.
1293	Somatropin (r-DNA)	Zorbtive	3/6/1995	For use alone or in combination with glutamine in the treatment of short bowel syndrome.	EMD Serono, Inc.
1294	Somatropin (r-DNA) for injection	Serostim	3/26/1996	Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.	EMD Serono, Inc.
1295	Somatropin (rDNA origin)	Saizen	3/6/1987	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	EMD Serono, Inc.
1296	Somatropin (rDNA origin)	Nutropin Depot	10/28/1999	Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
1297	Somatropin (rDNA origin) injection	Norditropin	7/10/1987	Treatment of growth failure in children due to inadequate growth hormone secretion.	Novo Nordisk Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1298	Somatropin [rDNA]	Genotropin	7/6/1999	Treatment of short stature in patients with Prader-Willi syndrome.	Pharmacia & Upjohn
1299	Somatropin for injection	Serostim	11/15/1991	Treatment of AIDS-associated catabolism/weight loss.	EMD Serono, Inc.
1300	Somatropin for injection	Nutropin	8/4/1989	Treatment of growth retardation associated with chronic renal failure.	Genentech, Inc.
1301	Somatropin for injection	Nutropin	3/23/1989	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc.
1302	Somatropin for injection	Humatrope	6/12/1986	For the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.	Eli Lilly and Company
1303	Somatropin for injection	Nutropin	11/18/1996	As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.	Genentech, Inc.
1304	Sorafenib	Nexavar	10/8/2004	Treatment of renal cell carcinoma.	Bayer Pharmaceutical Corporation
1305	Sorafenib	Nexavar	4/20/2006	Treatment of hepatocellular carcinoma	Bayer Pharmaceuticals Corporation
1306	Sotalol HCl	Betapace	9/23/1988	Treatment of life-threatening ventricular tachyarrhythmias.	Berlex Laboratories, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1307	Staphylococcus aureus Immune Globulin (Human)	Altastaph	1/29/2004	Prophylaxis against Staphylococcus aureus infections in low birth weight neonates	Biotest Pharmaceuticals Corporation
1308	Sterile Bicarbonate Infusate, Hemofiltration, Hemodiafiltration, and Hemodialysis Solution	Accusol	5/29/2009	For use as a replacement solution in adults and children during Continuous Renal Replacement Therapy	Baxter Healthcare Corporation
1309	Sterile talc	Steritalc	12/8/1997	Treatment of pneumothorax.	Novatech SA
1310	Sterile talc	Steritalc	12/8/1997	Treatment of malignant pleural effusion.	Novatech SA
1311	Sterile talc powder	Sclerosol Intrapleural Aerosol	9/18/1995	Treatment of malignant pleural effusion.	Bryan Corporation
1312	Succimer	Chemet	11/5/1990	Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.	Sanofi Winthrop, Inc.
1313	Succimer	Chemet Capsules	5/9/1984	Treatment of lead poisoning in children.	Bock Pharmacal Company
1314	Succimer	Chemet	3/22/1991	Treatment of mercury intoxication.	Sanofi Winthrop, Inc.
1315	Sucralfate suspension	n/a	3/4/1991	Treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.	Darby Pharmaceuticals, Inc.
1316	Sucralfate suspension	n/a	3/12/1990	Treatment of oral complications of chemotherapy in bone marrow transplant patients.	Darby Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1317	Sulfadiazine	n/a	3/14/1994	For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS.	Eon Labs Manufacturing, Inc.
1318	Sulfapyridine	n/a	9/10/1990	Treatment of dermatitis herpetiformis.	Jacobus Pharmaceutical Company
1319	Superoxide dismutase (human)	n/a	3/6/1985	For protection of donor organ tissue from damage or injury mediated by oxygen-derived free radicals that are generated during the necessary periods of ischemia (hypoxia, anoxia), and especially reperfusion, associated with the operative procedure.	Pharmacia-Chiron Partnership
1320	Suramin	Metaret	5/6/1997	Treatment of hormone-refractory prostate cancer.	Warner-Lambert Company
1321	Surface active extract of saline lavage of bovine lungs	Infasurf	6/7/1985	Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.	ONY, Inc.
1322	Synsorb Pk	n/a	7/17/1995	Treatment of verocytotoxogenic E. coli infections.	Synsorb Biotech Inc.
1323	Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid	Drepanol	10/24/1991	Prophylactic treatment of sickle cell disease.	Omex International, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1324	Synthetic double-stranded siRNA oligonucleotide against caspase 2 mRNA	n/a	9/25/2012	Treatment of ischemic optic neuropathy	Quark Pharmaceuticals, Inc.
1325	Synthetic human secretin	n/a	6/16/1999	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc.
1326	Synthetic human secretin	n/a	9/18/2006	For use in conjunction with diagnostic procedures (excluding ERCP) for pancreatic disorders to increase pancreatic fluid secretion	Repligen Corporation
1327	Synthetic human secretin	Chirostim	6/16/1999	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc.
1328	Synthetic human secretin	n/a	6/16/1999	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc.
1329	Synthetic human secretin	n/a	3/7/2000	For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc.
1330	Synthetic porcine secretin	Secreflo	6/18/1999	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc.
1331	Synthetic porcine secretin	Secreflo	6/18/1999	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1332	Synthetic porcine secretin	Secreflo	3/7/2000	For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc.
1333	Synthetic porcine secretin	n/a	6/18/1999	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc.
1334	T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine	Neurovax	2/6/2014	Treatment of Pediatric Multiple Sclerosis	Immune Response BioPharma, Inc.
1335	T-cell depleted stem cell enriched cellular product from peripheal b lood stem cells	n/a	11/1/2001	Treatment of chronic granulomatous disease	Nexell Therapeutics Inc.
1336	T4 endonuclease V, liposome encapsulated	n/a	6/27/1989	To prevent cutaneous neoplasms and other skin abnormalities in xeroderma pigmentosum.	AGI Dermatics
1337	TD-K6a.513a.12	Reveker	6/15/2006	Treatment of pachyonychia congenita	TransDerm, Inc.
1338	TXA127	n/a	10/25/2013	Treatment of acute radiation syndrome	US Biotest, Inc.
1339	Tacrolimus	n/a	12/20/2013	Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant	Veloxis Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1340	Tacrolimus	Prograf	4/6/1998	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc.
1341	Tacrolimus	Prograf	6/6/2005	Prophylaxis of organ rejection in patients receiving heart transplants.	Astellas Pharma US, Inc.
1342	Taliglucerase alfa	Elelyso For Injection	9/3/2009	Treatment of Gaucher's disease	Pfizer, Inc.
1343	Tamibarotene	n/a	10/11/2007	Treatment of acute promyelocytic leukemia (APL).	CytRx Corporation
1344	Tanespimycin	n/a	9/9/2004	Treatment of multiple myeloma	Bristol-Myers Squibb
1345	Targeted Gastrin 17 Complexed Peptide	n/a	5/14/2014	Treatment of pancreatic cancer	Tyg Oncology Ltd
1346	Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell	Lymphoscan	4/7/1992	Diagnostic imaging in the evaluation of the extent of disease in patients with histologically confirmed diagnosis of non-Hodgkin's B-cell lymphoma, acute B-cell lymphoblastic leukemia (in children and adults), and chronic B-cell lymphocytic leukemia.	Immunomedics, Inc.
1347	Technetium Tc99m rh-Annexin V	Apomate	11/3/2000	Diagnosis or assessment of rejection status in heart, heart-lung, single lung, or bilateral lung transplants.	Theseus Imaging Corporation
1348	Technetium Tc99m sulfur colloid injection, lyophilized	Technetium Tc99m Sulfur Colloi	3/17/2009	For localization of sentinel lymph nodes in patients with melanoma.	Pharmalucence, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1349	Tegafur/gimeracil/oteracil	n/a	7/20/2006	Treatment of gastric cancer	Taiho Pharma USA, Inc.
1350	Temoporfin	Foscan	10/28/1999	Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.	Biolitec Pharma Ireland Ltd.
1351	Temozolomide	Temodal	10/18/2004	Treatment of newly diagnosed high grade glioma	Schering-Plough Research Institute
1352	Temozolomide	Temodal	10/14/1998	Treatment of advanced metastatic melanoma.	Schering-Plough Research Institute
1353	Temsirolimus	Torisel	12/16/2004	Treatment of renal cell carcinoma	Wyeth Pharmaceuticals, Inc.
1354	Teniposide	Vumon For Injection	11/1/1984	Treatment of refractory childhood acute lymphocytic leukemia.	Bristol-Myers Squibb Pharmaceutical Research Institute
1355	Teriparatide	Parathar	10/28/1999	Treatment of idiopathic osteoporosis.	Biomeasure, Inc.
1356	Teriparatide	Parathar	1/9/1987	Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
1357	Terlipressin	Glypressin	3/6/1986	Treatment of bleeding esophageal varices.	Ferring Laboratories, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1358	Testosterone	Theraderm Testosterone Transdermal System	9/22/1997	For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.	Watson Laboratories
1359	Testosterone propionate ointment 2%	n/a	7/31/1991	Treatment of vulvar dystrophies.	Star Pharmaceuticals, Inc.
1360	Tetrabenazine	Xenazine	12/11/1997	Treatment of Huntington's disease	Prestwick Pharmaceuticals, Inc
1361	Tetrabenazine	n/a	5/12/1998	Treatment of moderate/severe tardive dyskinesia.	Prestwick Pharmaceuticals, Inc.
1362	Tetraiodothyroacetic acid	n/a	5/1/2000	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Danforth, Jr., MD, Elliot
1363	Tezacitabine	n/a	1/27/2003	Treatment of adenocarcinoma of the esophagus and stomach	Sanofi-Aventis US, Inc.
1364	Thalidomide	n/a	7/29/1998	Treatment of Kaposi's sarcoma.	Celgene Corporation
1365	Thalidomide	Thalomid	10/14/1998	Treatment of multiple myeloma	Celgene Corporation
1366	Thalidomide	Thalomid	4/6/1999	Treatment of Crohn's disease.	Celgene Corporation
1367	Thalidomide	n/a	9/19/1988	Treatment of graft versus host disease in patients receiving bone marrow transplantation.	Pediatric Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1368	Thalidomide	n/a	9/19/1988	Prevention of graft versus host disease in patients receiving bone marrow transplantation.	Pediatric Pharmaceuticals, Inc.
1369	Thalidomide	n/a	11/15/1988	Treatment and maintenance of reactional lepromatous leprosy.	Pediatric Pharmaceuticals, Inc.
1370	Thalidomide	n/a	3/5/1990	Prevention of graft versus host disease.	Andrulis Research Corporation
1371	Thalidomide	n/a	3/5/1990	Treatment of graft versus host disease.	Andrulis Research Corporation
1372	Thalidomide	n/a	1/12/1993	Treatment of the clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.	Celgene Corporation
1373	Thalidomide	n/a	5/1/1995	Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients.	Celgene Corporation
1374	Thalidomide	n/a	5/15/1995	Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients.	Andrulis Research Corporation
1375	Thalidomide	Thalomid	7/26/1995	Treatment of erythema nodosum leprosum.	Celgene Corporation
1376	Thalidomide	Synovir	3/11/1996	Treatment of HIV-associated wasting syndrome.	Celgene Corporation

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1377	Thalidomide	n/a	2/27/1998	Treatment of primary brain malignancies.	Celgene Corporation
1378	Thalidomide	Thalomid	9/27/2004	Treatment of myelodysplastic syndrome	Celgene Corporation
1379	Thawed donor matched banked umbilical cord blood enriched by cell sorting to produce a subpopulation expressing high levels of intracellular aldehyde dehydrogenase	n/a	10/23/2008	To improve patient outcomes by decreasing time to platlet and neutrophil engraftment in patients with inherited metabolic diseases (IMD) undergoing umbilical cord blood transplantation.	Aldagen, Inc.
1380	Theranost 68 Ga RGD	n/a	10/1/2014	A Diagnostic for the management of Moyamoya disease (MMD)	Advanced Imaging Projects, LLC (AIP)
1381	Theranost 68Ga RGD	n/a	1/26/2015	Diagnostic for the clinical management of patients with tuberculosis	Advanced Imaging Projects, LLC
1382	Thiotepa	Tepadina	4/2/2007	Conditioning treatment prior to hematopoietic stem cell transplantation	Adienne S.A.
1383	Thymalfasin	Zadaxin	3/6/2000	Treatment of hepatocellular carcinoma.	SciClone Pharmaceuticals, Inc.
1384	Thymalfasin	Zadaxin	3/13/2006	Treatment of stage IIb through Stage IV malignant melanoma	SciClone Pharmaceuticals, Inc.
1385	Thymalfasin	Zadaxin	1/8/1998	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc.
1386	Thymalfasin	Zadaxin	5/3/1991	Treatment of chronic active hepatitis B.	SciClone Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1387	Thymosin beta 4	n/a	5/28/2004	Treatment of epidermolysis bullosa.	RegeneRx Biopharmaceuticals, Inc.
1388	Thyrotropin alfa	Thyrogen	8/3/2001	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid	Genzyme Corporation
1389	Thyrotropin alpha	Thyrogen	2/24/1992	As an adjunct in the diagnosis of thyroid cancer.	Genzyme Corporation
1390	Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolecarboxamide)	n/a	12/27/2000	Chronic myelogenous leukemia (CML)	Valeant Pharmaceuticals North America
1391	Tilarginine acetate	n/a	4/11/2005	Treatment of cardiogenic shock	Arginox Pharmceuticals, Inc.
1392	Tinidazole	Tindamax	8/20/2003	Treatment of amebiasis	Presutti Laboratories, Inc.
1393	Tiopronin	Thiola	1/17/1986	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Pak, Charles Y.C. M.D.
1394	Tiotropium bromide	Spiriva	1/8/2008	To improve pulmonary function in conjunction with standard therapy in the management of patients with cystic fibrosis	Boehringer Ingelheim Pharmaceuticals, Inc.
1395	Tipifarnib	Zarnestra	7/6/2004	Treatment of acute myeloid leukemia	Johnson & Johnson Pharmaceutical Research & Dev.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1396	Tiratricol	Triacana	8/13/1991	For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.	Laphal Laboratoires
1397	Tissue Plasminogen activator	n/a	4/18/2011	Treatment of acute ischemic stroke (AIS) in children age 16 years and younger.	Catherine Amlié-Lefond, MD
1398	Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	n/a	3/13/2006	Treatment of osteonecrosis.	Aastrom Biosciences, Inc.
1399	Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	n/a	1/25/2007	Treatment of dilated cardiomyopathy	Vericel Corporation.
1400	Tizanidine HCl	Zanaflex	1/31/1994	Treatment of spasticity associated with multiple sclerosis and spinal cord injury.	Athena Neurosciences, Inc.
1401	Tobramycin	Tobi	6/18/1999	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	Novartis Pharmaceuticals Corp.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1402	Tobramycin for inhalation	Tobi	10/13/1994	Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.	Novartis Pharmaceuticals Corp
1403	Tolcapone	n/a	12/24/2013	Treatment of transthyretin amyloidosis	SOM Innovation Biotech SL (SOM Biotech)
1404	Topiramate	Topamax	11/25/1992	Treatment of Lennox-Gastaut syndrome.	Johnson & Johnson Pharmaceutical R & D, LLC
1405	Toremifene	Fareston	9/19/1991	Hormonal therapy of metastatic carcinoma of the breast.	Orion Corporation
1406	Toremifene	n/a	8/17/1993	Treatment of desmoid tumors.	Orion Corporation
1407	Tosedostat	n/a	12/10/2008	Treatment of acute myeloid leukemia	CTI BioPharma Corporation
1408	Tositumomab and iodine I 131 tositumomab	Bexxar	5/16/1994	Treatment of non-Hodgkin's B-cell lymphoma.	GlaxoSmithKline LLC
1409	Tramadol hydrochloride	n/a	4/26/2005	Management of postherpetic neuralgia	TheraQuest Biosciences, LLC
1410	Tramadol hydrochloride	n/a	1/28/2005	Treatment of painful HIV-associated neuropathy	TheraQuest Biosciences, LLC
1411	Tranilast	Rizaben	12/2/2003	For the treatment of malignant glioma	Angiogen Pharmaceuticals, Pty. Ltd.
1412	Transforming growth factor-beta 2	n/a	12/18/1992	Treatment of full thickness macular holes.	Celtrix Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1413	Transgenic human alpha 1 antitrypsin	n/a	5/19/1999	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	PPL Therapeutics (Scotland) Limited
1414	Treosulfan	Ovastat	5/16/1994	Treatment of ovarian cancer.	Medac GmbH
1415	Tretinoin	Atra-iv	4/11/2003	Treatment of T-cell non-Hodgkin's lymphoma	Antigenics, Inc.
1416	Tretinoin	Vesanoid	10/24/1990	Treatment of acute promyelocytic leukemia.	Hoffmann-La Roche, Inc.
1417	Tretinoin	n/a	4/15/1985	Treatment of squamous metaplasia of the ocular surface epithelia (conjunctiva and/or cornea) with mucous deficiency and keratinization.	Hannan Ophthalmic Marketing Services, Inc
1418	Tretinoin	Atra-iv	1/14/1993	Treatment of acute and chronic leukemia.	Antigenics, Inc.
1419	Trientine HCl	Syprine	12/24/1984	Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine.	Merck Sharp & Dohme Research
1420	Triheptanoin	Triheptanoin-Sasol Special Oil	2/1/2008	Treatment of glycogen storage disorder II (Pompe disease)	Baylor Research Institute
1421	Triheptanoin	Triheptanoim-Sasol Special Oil	5/26/2006	Treatment of fatty acid disorders	Baylor Research Institute
1422	Trimetrexate glucuronate	Neutrexin	5/15/1986	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Medimmune Oncology, Inc.
1423	Trisaccharides A and B	Biosynject	4/20/1987	For use in ABO-incompatible solid organ transplantation, including kidney, heart, liver and pancreas.	Chembiomed, Ltd.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1424	Trisaccharides A and B	Biosynject	4/12/1987	Treatment of moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances A and B.	Chembiomed, Ltd.
1425	Trisaccharides A and B	Biosynject	4/15/1988	Prevention of ABO medical hemolytic reactions arising from ABO-incompatible bone marrow transplantation.	Chembiomed, Ltd.
1426	Trisodium citrate concentration	Hemocitrate	6/15/1995	For use in leukapheresis procedures.	Hemotec Medical Products, Inc.
1427	Trisodium zinc Diethylenetriaminepentaacetate	n/a	2/27/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination.	CustomCare Pharmacy
1428	Trypan blue	Membraneblue	8/2/2006	Selectively staining epiretinal membranes during ophthalmic surgical vitrectomy procedures	Dutch Ophthalmic Research Center Int'l BV
1429	Tumor necrosis factor-binding protein 1	n/a	1/6/1993	Treatment of symptomatic patients with AIDS including all patients with CD4 counts less than 200 cells per mm3.	EMD Serono, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1430	Tumor necrosis factor-binding protein II	n/a	1/6/1993	Treatment of symptomatic patients with the AIDS including all patients with CD4 T-cell counts less than 200 cells per mm ³ .	EMD Serono, Inc.
1431	Tyloxapol	Supervent	3/8/1995	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
1432	Type 1 native bovine skin collagen	n/a	2/1/2008	Treatment of diffuse systemic sclerosis	arGentis Pharmaceuticals, LLC
1433	Ubiquinol, coenzyme Q10, ubiquinone	Ubi-Q-Nol	4/12/2004	Treatment of pediatric congestive heart failure	Gel-Tec, Division of TISHCON Corporation
1434	Ubiquinone	Ubi-Q-Gel	12/14/1999	Treatment of mitochondrial cytopathies.	Gel-Tec, Division of Tishcon Corp.
1435	Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody	n/a	3/22/2001	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH
1436	Urea for intravitreal injection	Neurosolve	12/14/2005	Treatment of retinitis pigmentosa	Vitreo Retinal Technologies, Inc
1437	Urofollitropin	Metrodin	11/25/1987	For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.	EMD Serono, Inc.
1438	Urogastrone	n/a	11/1/1984	For acceleration of corneal epithelial regeneration and healing of stromal incisions from corneal transplant surgery.	Chiron Vision

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1439	Ursodiol	Urso 250	6/20/1991	Treatment of patients with primary biliary cirrhosis	Aptalis Pharma US, Inc.
1440	Vaccinia Immune Globulin (Human) Intravenous	n/a	6/18/2004	Treatment of severe complications from the smallpox vaccine	DynPort Vaccine Company LLC
1441	Vaccinia Immune Globulin (Human) Intravenous	Cnj-016	6/18/2004	Treatment of complications of vaccinia vaccination	Cangene Corporation
1442	Valine, isoleucine and leucine	Vil	1/5/1996	Treatment of hyperphenylalaninemia	Leas Research Products
1443	Valproate	n/a	5/5/2008	Treatment of fragile X syndrome	Neuropharm Ltd,
1444	Valrubicin	Valstar	5/23/1994	Treatment of carcinoma in situ of the urinary bladder.	Anthra Pharmaceuticals, Inc.
1445	Vapreotide	Sanvar	4/6/2004	Treatment of symptomatic carcinoid tumors	H3 Pharma, Inc.
1446	Varbulin	Azixa	11/5/2009	Treatment of glioblastoma multiforme.	Myrexis, Inc.
1447	Varicella Zoster Immune Globulin (Human)	Varizig	11/7/2006	Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella	Cangene bioPharma, Inc.
1448	Vasoactive intestinal peptide	n/a	3/9/2001	Treatment of Acute Respiratory Distress Syndrome.	mondoBIOTECH
1449	Vasoactive intestinal polypeptide	n/a	6/23/1993	Treatment of acute esophageal food impaction.	Research Triangle Pharmaceuticals
1450	Virulizin	Virulizin	2/1/2001	Treatment of pancreatic cancer.	ZOR Pharmaceuticals, LLC

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1451	Water-miscible vitamin A palmitate	Aquasol A Parenteral	3/26/2010	Prevention of bronchopulmonary dysplasia.	Fox Pharma, Inc.
1452	Xenogeneic hepatocytes	Hepatassist Liver Assist System	11/27/1998	Treatment of severe liver failure.	Circe Biomedical, Inc.
1453	Yttrium (90Y) antiferritin polyclonal antibodies	Ferritarg P	9/18/2006	Treatment of Hodgkin's disease.	MAT Biopharma
1454	Yttrium(90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10	n/a	12/3/2012	Treatment of soft tissue sarcoma	OncoTherapy Science, Inc.
1455	Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembryonic antigen IgG antibody	Cea-Cide	8/3/1999	Treatment of ovarian carcinoma.	Immunomedics, Inc.
1456	Zalcitabine	n/a	12/9/1986	Treatment of AIDS.	National Cancer Institute, DCT
1457	Zalcitabine	Hivid	6/28/1988	Treatment of AIDS.	Hoffmann-La Roche, Inc.
1458	Zidovudine	Retrovir	7/17/1985	Treatment of AIDS related complex.	Glaxo Wellcome Inc.
1459	Zinc acetate	Galzin	11/6/1985	Treatment of Wilson's disease.	Lemmon Company
1460	Zoledronate	Zometa, Zabel	8/18/2000	Treatment of tumor induced hypercalcemia.	Novartis Pharmaceuticals Corp.
1461	Zosuquidar trihydrochloride	n/a	12/15/2005	Treatment of acute myeloid leukemia	Kanisa Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1462	[131I]-N-(2-(diethylamino) ethyl-4-(4 fluobenzamido)-5-(iodo)-2-methoxybenzamide	n/a	9/17/2008	Treatment of metastatic melanoma, stages IIB, IIC, III and IV	Molecular Insight Pharmaceuticals, Inc.
1463	[5,10,15,20-tetrakis(1,3-diethylimidazolium-2-yl)porphyrinato] manganese(III)pentachloride	n/a	11/4/2003	Treatment of Amyotrophic Lateral Sclerosis	Aeolus Pharmaceuticals, Inc.
1464	[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride salt	n/a	2/14/2014	Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath	Plexxikon, Inc.
1465	[5-Amino-1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxy-propoxy)-phenyl]-methanone	n/a	10/20/2014	Treatment of pancreatic cancer	Synovo GmbH
1466	[AC3-yCD2(V)] and Flucytosine (5-FC XR)	n/a	1/12/2011	Treatment of glioblastoma multiforme	Tocagen, Inc.
1467	[Lu-177]-DOTA-Tyr3-Octreotate	n/a	1/12/2009	Treatment of gastro-entero-pancreatic neuroendocrine tumors	Advanced Accelerator Applications
1468	[Nle4, D-Phe7]-a-melanocyte stimulating hormone	n/a	7/17/2008	Treatment of erythropoietic porphyrias	Clinuvel Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1469	[a-N-(2'succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr	n/a	5/14/2014	Treatment of glioblastoma multiforme	Angiochem, Inc.
1470	[met5]-enkephalin	Opioid Growth Factor	1/24/2013	Treatment of pancreatic cancer	TNI BioTech, Inc.
1471	a live attenuated bioengineered Listeria monocytogenes cancer immunotherapy	n/a	4/29/2014	Treatment of Stage II to IV invasive cervical carcinoma	Advaxis, Inc.
1472	a-Galactosidase A	Plant-Produced Human A-Glactosidase A	1/21/2003	Treatment of Fabry's disease	iBio, Inc.
1473	aaeno-associated viral vector, serotype 2, containing the human choroideremia gene encoding human Rab escort protein 1	n/a	9/12/2013	Treatment of choroideremia due to mutations in the human choroideremia gene (CHM)	Sparks Therapeutics, Inc.
1474	abatacept	Orencia	5/30/2013	Treatment of type 1 diabetes mellitus patients with residual beta cell function	Orban Biotech LLC
1475	abeotaxane inhibitor of microtubules	n/a	4/18/2011	Treatment of pediatric neuroblastoma.	Cortice Biosciences
1476	abeotaxane inhibitor of microtubules	n/a	10/7/2011	Treatment of gliomas	Cortice Biosciences
1477	acadesine	n/a	3/3/2011	Treatment of chronic lymphocytic leukemia	Avanced In Vitro Cell Technologies, S.L.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1478	acadesine	n/a	5/4/2011	Treatment of multiple myeloma	Advancell-Advanced In Vitro Cell Technologies S.A.
1479	acamprosate	n/a	3/25/2013	Treatment of fragile X syndrome	Confluence Pharmaceuticals, LLC
1480	acetyl-l-carnitine	n/a	7/24/2012	Treatment of Fragile X syndrome	Sigma-Tau Pharmaceuticals, Inc.
1481	acetyl-l-carnitine (ALC)	n/a	3/18/2011	Treatment of Rett syndrome	sigma-tau Pharmaceuticals, Inc.
1482	acetylcysteine	Acetadote	10/19/2001	For the intravenous treatment of moderate to severe acetaminophen overdose	Cumberland Pharmaceuticals, Inc.
1483	acetylcysteine effervescent tablets for oral solution	n/a	2/24/2015	Preventing hepatic injury from acetaminophin overdose	Arbor Pharmaceuticals, LLC
1484	acyclovir	n/a	12/13/2010	Treatment of acute herpetic keratitis caused by Herpes Simplex Virus type 1 and 2	Fera Pharmaceuticals
1485	adalimumab	Humira	5/11/2011	Treatment of pediatric patients with ulcerative colitis	AbbVie, Inc.
1486	adalimumab	Humira	10/19/2006	Treatment of pediatric Crohn's disease.	AbbVie Inc.
1487	adalimumab	Humira	3/21/2005	Treatment of juvenile rheumatoid arthritis	AbbVie Inc.
1488	adalimumab	n/a	7/10/2014	Treatment of Behcet's disease	Mucora

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1489	adalimumab	Humira	5/13/2014	Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis	AbbVie, Inc.
1490	adeno associated viral vector containing human ARSB gene	n/a	3/17/2011	Treatment of mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy syndrome)	Fondazione Telethon
1491	adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs	n/a	5/6/2013	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo type A syndrome)	Lysogene
1492	adeno associated virus with modified transthyretin and sequence encoding factor IX variant gene	n/a	3/14/2014	Treatment of hemophilia B	Baxter Healthcare Corporation
1493	adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin in combination with an adeno-associated viral vector containing DNA encoding a rhodopsin gene	n/a	12/13/2012	treatment of retinitis pigmentosa	Genable Technologies Limited
1494	adeno-associated viral vector containing modified U11 snRNA	n/a	9/15/2010	Treatment of Duchenne muscular dystrophy.	uniQure B.V.
1495	adeno-associated viral vector containing the human NADH Dehydrogenase 4 Gene	n/a	11/20/2013	Treatment of Leber Hereditary Optic Neuropathy	Gen Sight Biologics

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1496	adeno-associated viral vector expressing human retinoschisin-1 gene	n/a	5/21/2007	Treatment of X-linked juvenile retinoschisis (XLRS).	Applied Genetic Technologies Corporation
1497	adeno-associated viral vector serotype 2 containing the human Rab escort protein 1 gene	n/a	11/5/2014	Treatment of choroideremia	NightstaRx Ltd.
1498	adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene	n/a	12/27/2012	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)	Laboratorios del Dr. Esteve, S.A.
1499	adeno-associated virus serotype 9 expressing the human Survival Motor Neuron gene	n/a	9/30/2014	Treatment of spinal muscular atrophy	AveXis, Inc.
1500	adeno-associated virus transgene of follistatin	n/a	11/19/2012	Treatment of Duchennes and Becker's muscular dystrophy	Milo Biotechnology
1501	adeno-associated virus vector serotype 9 expressing human sulfamidase	n/a	6/1/2011	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A Syndrome).	Laboratorios del Dr. Esteve, S.A.
1502	adenovirus containing a human FAS-c gene	n/a	4/2/2012	Treatment of malignant glioma	Vascular Biogenics Ltd
1503	adenovirus delta 24-RGD, an oncolytic adenovirus genetically modified for treatment of glioma	n/a	10/1/2014	Treatment of glioma	DNAtrix, Inc.
1504	adult adherent bone marrow-derived multipotent stem cells	Multistem	7/6/2012	Treatment of MPS-1, including Hurler syndrome	Athersys, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1505	aerosolized beractant	n/a	3/11/2013	Treatment of respiratory distress syndrome	Beena G. Sood, MD, MS
1506	afamelanotide	n/a	5/14/2014	Treatment of familial benign chronic pemphigus (Hailey-Hailey disease)	Clinuvel, Inc.
1507	afamelanotide	n/a	12/11/2009	Treatment of solar urticaria	Clinuvel, Inc.
1508	afatinib	Gilotrif	12/3/2012	Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).	Boehringer Ingelheim Pharmaceuticals, Inc.
1509	afatinib	Gilotrif(R)	6/4/2014	Treatment of malignant brain and central nervous system tumors	Boehringer Ingelheim Pharmaceuticals, Inc.
1510	aldoxorubicin	n/a	9/24/2014	Treatment of glioblastoma multiforme	CytRx Corporation
1511	aldoxorubicin	n/a	9/24/2014	Treatment of small cell lung cancer	CytRx Corporation
1512	aldoxorubicin	n/a	9/24/2014	Treatment of ovarian cancer	CytRx Corporation
1513	alectinib	n/a	1/27/2015	Treatment of ALK-positive non-small cell lung cancer	Genentech, Inc.
1514	alemtuzumab	Campath	10/20/1997	Treatment of chronic lymphocytic leukemia.	Genzyme Corporation
1515	alfimeprase	n/a	9/20/2012	Treatment of ST-elevation myocardial infarcted patients who are undergoing primary percutaneous coronary intervention	Niche Therapeutics, LLC
1516	algenpantucel-L	Hyperacute(R)-Pancreatic Cance	10/21/2010	Treatment of pancreatic cancer.	NewLink Genetics Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1517	alicaforsen	n/a	6/24/2008	Treatment of pouchitis.	Atlantic Healthcare Limited
1518	alisertib	n/a	5/14/2012	Treatment of peripheral T-cell lymphoma	Millennium Pharmaceuticals, Inc.
1519	alisertib	n/a	7/12/2013	Treatment of small cell lung cancer	Millennium Pharmaceuticals, Inc.
1520	all-cis-docosa-4,7,10,13,16,19-hexaenoic acid	Retriacyl	5/21/2014	Treatment of retinitis pigmentosa	Natac Pharma, S.L.
1521	allantoin	Alwextin	11/21/2002	Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa	Scioderm, Inc.
1522	allogeneic cord blood cells, ex vivo modulated with 16,16 dimethyl prostaglandin E2 (dmPGE2)	n/a	12/2/2010	Enhancement of stem cell engraftment through ex vivo treatment of human allogeneic hematopoietic stem cells (treatment of neutropenia, thrombocytopenia, lymphopenia, and anemia).	Fate Therapeutics, Inc.
1523	allogeneic ex-vivo expanded placental adherent stromal cells	n/a	8/22/2011	Treatment of thromboangiitis obliterans (Buerger's disease)	Pluristem Therapeutics, Inc.
1524	allogeneic ex-vivo expanded placental adherent stromal cells	n/a	2/18/2013	Treatment of Aplastic Anemia	Pluristem Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1525	allogeneic hematopoietic stem cell	Atir(Tm)	2/2/2010	Prevention (reduction) of transplant related mortality (TRM, which is caused by graft versus host disease and/or infections) following mismatched (haploidentical) allogeneic hematopoietic stem cell transplantation.	Kiadis Pharma Netherlands B.V.
1526	allogeneic mesenchymal precursor cells derived from ex vivo healthy donors harvested from iliac crest.	n/a	9/12/2008	Treatment of insufficient hematopoietic stem cell production in patients with hematologic malignancies who have failed treatment with conventional chemotherapy.	Mesoblast, Inc.
1527	allogenic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	n/a	7/24/2012	Treatment of macular telangiectasia type 2 (MacTel)	Neurotech USA, Inc.
1528	allopregnanolone	n/a	7/12/2013	Treatment of Neimann-Pick disease, type C	La Jolla Pharmaceutical Company, Inc.
1529	allopregnanolone	n/a	4/20/2014	Treatment of status epilepticus	Sage Therapeutics
1530	alpha melanotropin	n/a	9/2/2010	Treatment of chronic beryllium disease	mondoBIOTECH Laboratories AG
1531	alpha-1 proteinase inhibitor (human)	Glassia	7/28/2011	Treatment of patients with recent onset (Kamada, Ltd.
1532	alpha-1 proteinase inhibitor (human)	Glassia	10/23/2014	Treatment of graft versus host disease	Kamada Ltd.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1533	alpha-tocotrienol quinone	n/a	10/21/2010	Treatment of inherited mitochondrial respiratory chain diseases.	Edison pharmaceuticals, Inc.
1534	alpha1 proteinase inhibitor (human)	n/a	1/29/2010	Treatment of emphysema secondary to congenital alpha1-antitrypsin deficiency.	Grifols Therapeutics, Inc.
1535	alpha1-proteinase inhibitor (human)	n/a	2/20/2009	Treatment of cystic fibrosis	CSL Behring LLC
1536	alpha1-proteinase inhibitor (human)	n/a	4/6/2012	Treatment of cystic fibrosis	Grifols Therapeutics, Inc.
1537	alteplase	Activase	1/27/2003	Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage	Daniel F. Hanley, MD
1538	altiratinib	n/a	8/19/2014	Treatment of glioblastoma multiforme.	Deciphera Pharmaceuticals, LLC
1539	amatuximab	n/a	9/28/2012	Treatment of mesothelioma	Morphotek, Inc.
1540	ambrisentan	Letairis	7/16/2004	Treatment of pulmonary arterial hypertension	Gilead Colorado
1541	ambroxol	n/a	6/29/2011	Treatment of Gaucher disease	Belrose Pharma, Inc.
1542	amikacin sulfate	n/a	1/5/2015	Management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections	PlumeStars s.r.l.
1543	aminolevulinic acid hydrochloride	Levulan	3/20/2007	Treatment of esophageal dysplasia	DUSA Pharmaceuticals, Inc.
1544	aminosidine	Paromomycin	3/29/2005	Treatment of visceral leishmaniasis	The Institute for One World Health

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1545	amitriptyline and ketamine	Epicept(TM) Np-1	1/19/2010	Treatment of postherpetic neuralgia	EpiCept Corporation
1546	ammonium tetrathiomolybdate	n/a	5/5/2008	Treatment of idiopathic pulmonary fibrosis	Pipex Pharmaceuticals, Inc.
1547	amphotericin B	n/a	9/15/2010	Treatment of visceral leishmaniasis.	iCo Therapeutics Inc.
1548	amrubicin	n/a	3/10/2008	Treatment of small cell lung cancer	Celgene Corporation
1549	an adeno-associated viral vector containing a codon-optimised human factor IX gene (AAV5-hFIXco)	n/a	12/22/2011	Treatment of hemophilia B	uniQure, B.V.
1550	anakinra	Kineret	8/19/2010	Treatment of cryopyrin-associated periodic syndromes	Swedish Orphan Biovitrum AB (publ)
1551	andexanet alfa	n/a	2/23/2015	For reversing the anticoagulant effect of direct or indirect factor Xa inhibitors in patients experiencing a serious uncontrolled bleeding event or who require urgent or emergent surgery	Portola Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1552	angiotensin (1-7)	n/a	8/30/2013	Treatment of patients requiring stem cell transplantation to accelerate the mobilization of hematopoietic stem cells (CD34+) from the bone marrow to the peripheral blood when combined with a granulocyte colony-stimulating factor	US Biotest, Inc.
1553	angiotensin (1-7)[A(1-7)]	n/a	7/25/2013	Treatment of Duchenne muscular dystrophy	US Biotest, Inc.
1554	angiotensin 1-7	n/a	1/29/2010	Treatment of sarcoma.	W. Jeffrey Petty, MD
1555	angiotensin 1-7	n/a	6/17/2010	To accelerate engraftment of hematopoietic cells (treatment of neutropenia, thrombocytopenia, lymphoma, and anemia)in hematopoietic stem cell transplants.	US Biotest, Inc.
1556	antagonist of the complement 5a receptor	n/a	11/17/2014	Treatment of atypical hemolytic uremic syndrome	ChemoCentryx, Inc.
1557	antagonist of the complement 5a receptor	n/a	6/2/2014	Treatment of anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or Wegener's granulomatosis), microscopic polyangiitis, and Churg-Strauss syndrome.	ChemoCentryx, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1558	antagonist of the endosomal Toll-like receptors (TLRs) 7, 8, and 9	n/a	12/23/2014	Treatment of Waldenstrom's macroglobulinemia	Idera Pharmaceuticals, Inc.
1559	anthrax immune globulin	n/a	9/3/2009	Treatment of inhalation anthrax disease	Emergent Biosolutions, Inc.
1560	anthrax immune globulin (human)	n/a	7/29/2008	Treatment of toxemia associated with inhalational anthrax.	Cangene Corp. - Emergent Biosolutions
1561	anti human Nogo-A human monoclonal antibody	n/a	10/20/2008	Treatment of acute spinal cord injury	Novartis Pharmaceuticals Corporation
1562	anti-Beta 1 integrin monoclonal antibody	n/a	1/13/2015	Treatment of ovarian cancer	OncoSynergy, Inc.
1563	anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein	n/a	9/13/2013	Treatment of graft versus host disease	Xenikos BV
1564	anti-CD30 Fc engineered humanized monoclonal antibody	n/a	12/2/2008	Treatment of Hodgkin lymphoma	Xencor, Inc.
1565	anti-Lewis Y humanized monoclonal antibody	n/a	3/9/2012	Treatment of ovarian cancer	Recepta Biopharma S.A.
1566	anti-T-lymphocyte immune globulin, rabbit	Atg-Fresenius(R)	3/26/2010	Prevention of graft versus host disease (GVHD)	Neovii Biotech NA, Inc.
1567	anti-T-lymphocyte immune globulin, rabbit	n/a	9/12/2008	Prophylaxis of acute allograft rejection in adult recipients in solid organ transplantation	Neovii Biotech NA, Inc.
1568	anti-TCR murine monoclonal antibody (MAB, type IgM)	n/a	1/12/2011	Treatment of pediatric multiple sclerosis in patients less than or equal to 16 years of age	Tolera Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1576	anti-tumor necrosis factor (TNF) polyclonal antibody (bovine)	n/a	11/17/2014	Treatment of pediatric ulcerative colitis (0 through 16 years of age)	Avaxia Biologics, Incorporated
1577	antiangiogenic components extracted from marine cartilage	Neovastat (Ae-941)	10/16/2002	Treatment of renal cell carcinoma	AEterna Zentaris, Inc.
1578	antibody drug conjugate consisting of fully human anti-guananyl cyclase C monoclonal antibody linked to the cytotoxic drug monomethyl auristatin E	n/a	7/21/2014	Treatment of gastric cancer	Millennium Pharmaceuticals, Inc.
1579	antihemophilic factor (recombinant), Fc fusion protein	Eloctate	11/23/2010	Treatment of hemophilia A	Biogen Idec Inc.
1580	antihemophilic factor (recombinant), porcine sequence	Obizur	3/16/2004	Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII	Baxter Healthcare Corporation
1581	antimesothelin-ADC (antibody drug conjugate)	n/a	7/5/2012	Treatment of mesothelioma	Bayer HealthCare Pharmaceuticals, Inc.
1582	antineoplaston A10, antineoplaston AS2-1	n/a	10/30/2008	Treatment of gliomas	Burzynski Research Institute, Inc.
1583	antinuclear antibody conjugated liposomal doxorubicin	n/a	2/3/2015	Treatment of Ewing's sarcoma.	NanoSmart Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1584	antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA]	Gti-2040	3/12/2003	Treatment for renal cell carcinoma	Lorus Therapeutics, Inc
1585	antisense oligonucleotide targeted to human transthyretin (TTR) mRNA	n/a	7/24/2012	Treatment of familial amyloid polyneuropathy	Isis Pharmaceuticals, Inc.
1586	antroquinonol	n/a	1/21/2015	Treatment of pancreatic cancer	Golden Biotechnology Corp.
1587	apolipoprotein E mimetic peptide	n/a	12/3/2012	Treatment of homozygous familial hypercholesterolemia	LipimetiX Development, LLC
1588	apremilast	n/a	1/17/2013	Treatment of Behcet's disease	Celgene Corporation
1589	arimoclomol	n/a	3/29/2005	Treatment of amyotrophic lateral sclerosis	CytRx Corporation
1590	arimoclomol citrate	n/a	1/13/2015	Treatment of Neimann-Pick disease, type C	Orphazyme ApS
1591	aripiprazole	Abilify	1/25/2006	Treatment of Tourette's syndrome	Otsuka Pharmaceutical Development
1592	arsenic	Trisenox	11/2/2001	Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7	Teva Branded Pharmaceutical Products R&D, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1593	arsenic trioxide	Trisenox	10/18/2001	Treatment of chronic myeloid leukemia	Teva Branded Pharmaceutical Products R*D, Inc.
1594	arsenic trioxide	Trisenox	7/17/2000	Treatment of myelodysplastic syndrome.	Teva Branded Pharmaceutical Products R&D, Inc.
1595	arsenic trioxide	Trisenox	6/13/2003	Treatment of liver cancer	Teva Branded Pharmaceutical Products R&D, Inc.
1596	artemether/lumefantrine	Coartem	8/31/2007	For the treatment of infections due to Plasmodium falciparum or mixed infections including P. falciparum.	Novartis Pharmaceuticals
1597	arylsulfatase A (rhASA)	n/a	2/27/2008	Treatment of metachromatic leukodystrophy	Shire Human Genetic Therapies, Inc.
1598	astuprotimut-R	n/a	5/29/2009	Treatment of MAGE-A3 positive non-small cell lung cancer	GlaxoSmithKline Biologicals, S.A.
1599	astuprotimut-R	n/a	5/29/2009	Treatment of MAGE-A3 positive stages IIb to IV malignant melanoma	GlaxoSmithKline Biologicals, S.A.
1600	ataluren	Translarna	12/10/2014	Treatment of mucopolysaccharidosis type I	PTC Therapeutics, Inc.
1601	ataluren	n/a	3/10/2008	Treatment of spinal muscular atrophy	PTC Therapeutics, Inc.
1602	ataluren	n/a	1/10/2005	Treatment of Muscular Dystrophy resulting from premature stop mutations in the dystrohin gene	PTC Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1603	ataluren	n/a	9/1/2004	For use in the treatment of cystic fibrosis resulting from a nonsense (premature stopcodon) mutation in the cystic fibrosis transmembrane conductance regulatory gene	PTC Therapeutics, Inc.
1604	auranofin	Ridaura	4/30/2010	Treatment of amebiasis	Ctr for Discovery & Innovation in Parasitic Diseases
1605	autologous CD34+ bone marrow derived stem cells transduced with a self-inactivating gammaretroviral vector encoding the human IL2RG (yc)	n/a	1/15/2015	Treatment of severe combined immune deficiency-X1	Boston Children's Hospital
1606	autologous CD34+ hematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA	n/a	4/19/2012	Treatment of adrenoleukodystrophy	bluebird bio, Inc.
1607	autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	n/a	2/26/2014	For the treatment of Sickle Cell Disease	bluebird bio Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1608	autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	n/a	3/18/2013	Treatment of B-thalassemia major and intermedia	bluebird bio, Inc.
1609	autologous CD4+CD25hiFoxP3+regulatory T cells	n/a	11/19/2013	Prevention of graft rejection following solid organ transplantation	iREG Medical AB
1610	autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	n/a	3/14/2014	Treatment of chronic lymphocytic leukemia	Novartis Pharmaceuticals Corporation
1611	autologous adipose derived mesenchymal stromal cells	n/a	10/22/2014	Treatment of amyotrophic lateral sclerosis	Mayo Clinic
1612	autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 - based lentiviral vector, EFS-ADA	n/a	10/21/2014	Treatment of adenosine deaminase deficient severe combined immunodeficiency	Donald B. Kohn, MD - Professor, UC-UCLA
1613	autologous dendritic cells pulsed with allogeneic tumor cell lysate	n/a	5/6/2014	Treatment of malignant mesothelioma	Amphera BV
1614	autologous ex vivo expanded CD4+-enriched leukocytes treated with the demethylating agent 5-aza-2-â-â-â-â-deoxycytidine	Alecsat	9/13/2013	Treatment of glioblastoma multiforme	CytoVac A/S

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1615	autologous genetically modified human dermal fibroblasts	n/a	6/10/2014	Treatment of dystrophic epidermolysis bullosa.	Fibrocell Technologies, Inc.
1616	autologous lymphocytes depleted ex vivo of immunoreactive T cells using 4,5	Theralux Photodynamic Therapy	4/3/2008	Treatment of chronic graft versus host disease	Kiadis Pharma Canada, Inc.
1617	autologous neo-uninary conduit	n/a	6/7/2011	Treatment of bladder dysfunction requiring incontinent urinary diversion.	Tengion, Inc.
1618	autologous olfactory neural progenitors	Rhinocytes	12/31/2008	Treatment of amyotrophic lateral sclerosis	RhinoCyte, Inc.
1619	autologous peripheral blood T lymphocytes transduced with retroviral vector containing anti CD19 CD28/CD3 zeta chimeric antigen receptor	n/a	3/27/2014	Treatment of diffuse large B-cell lymphoma.	Kite Pharma, Inc.
1620	autologous tumor-derived gp96 heat shock protein-peptide complex	Oncophage	5/10/2002	Treatment of renal cell carcinoma	Agenus, Inc.
1621	autologous tumor-derived gp96 heat shock protein-peptide complex	Oncophage	7/11/2002	Treatment of metastatic melanoma	Agenus, Inc.
1622	autologous umbilical cord blood	n/a	7/24/2012	Treatment of pediatric (0-16 yrs old inclusive) cerebral palsy due to acquired brain injury	Duke University

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1623	autologus CD34+ cells transfected with retroviral vector containing adenosine deaminase gene	n/a	8/26/2009	Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency.	Glaxo Group Limited
1624	aviptadil	n/a	2/22/2005	Treatment of pulmonary arterial hypertension	Mondobiotech Laboratories AG
1625	azacitidine	Vidaza	12/3/2001	Treatment of myelodysplastic syndromes	Celgene Corporation
1626	aztreonam	Cayston	3/12/2002	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	Gilead Sciences (formerly Corus Pharma)
1627	baclofen	Lioresal Intrathecal	11/10/1987	Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy).	Medtronic, Inc.
1628	baclofen	n/a	12/16/1991	Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.	Infusaid, Inc.
1629	baclofen	n/a	12/2/2003	Treatment of dystonia	Medtronic Neurological
1630	bacterium Bacteroides thetaiotaomicron	n/a	9/26/2013	Treatment of active Crohn's disease in the pediatric population	GT Biologics Ltd

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1631	beclomethasone	n/a	3/4/2009	Treatment of pediatric patients with ulcerative colitis	Aptalis Pharma US, Inc.
1632	beclomethasone 17,21-dipropionate	n/a	11/19/2012	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Soligenix, Inc
1633	beclomethasone 17,21-dipropionate	Bec	8/28/2001	Prevention of gastrointestinal graft-versus-host disease	Soligenix, Inc.
1634	beclomethasone 17,21-dipropionate	Orbec(R)	7/24/2009	Treatment of gastrointestinal symptoms with chronic grafted host disease in patients undergoing allogeneic hematopoietic cell transplantation	Soligenix, Inc.
1635	beclomethasone 17,21-dipropionate	n/a	12/18/2007	Treatment of pediatric patients with Crohn disease.	Soligenix, Inc.
1636	bedaquiline; (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol	Sirturo	1/10/2005	Treatment of active tuberculosis	Janssen Research & Development, LLC
1637	belatacept	Nulojix	2/20/2008	Prophylaxis of organ rejection in renal allograft recipients	Bristol-Myers Squibb Company
1638	beloranib	n/a	1/15/2013	Treatment of Prader-Willi syndrome	Zafgen, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1639	bendamustine for 50 ml admixture	n/a	7/2/2014	Treatment of chronic lymphocytic leukemia	Eagle Pharmaceuticals, INC.
1640	bendamustine for 50ml admixture	n/a	7/2/2014	Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)	Eagle Pharmaceuticals, Inc.
1641	bendamustine hydrochloride	Treanda	11/26/2013	Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)	Cephalon, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1642	bendamustine hydrochloride with betadex sulfobutyl ether sodium	n/a	9/10/2013	Treatment of chronic lymphocytic leukemia	Supratek Pharma, Inc.
1643	benznidazole	n/a	4/14/2014	Treatment of Chagas disease	Chemo Research, S.L.
1644	benzoate	n/a	7/6/2012	Treatment of pediatric schizophrenia	SyneuRx International (Taiwan) Corp.
1645	benzoate/phenylacetate	Ammonul	11/22/1993	Treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	Medicis Pharmaceutical Corp.
1646	beraprost sodium 314d	n/a	12/22/2011	Treatment of pulmonary arterial hypertension	Lung Rx, Inc.
1647	bevacizumab	Avastin	5/26/2006	Treatment of malignant glioma	Genentech, Inc.
1648	bevacizumab	Avastin	11/23/2010	Treatment of fallopian tube carcinoma	Genentech, Inc.
1649	bevacizumab	Avastin	11/2/2010	Treatment of primary peritoneal carcinoma.	Genentech, Inc.
1650	bevacizumab	n/a	10/21/2010	Treatment of hereditary hemorrhagic telangiectasia	Terence M. Davidson, MD
1651	bevacizumab	Avastin	11/20/2009	In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.	Genentech, Inc.
1652	bevacizumab	Avastin	10/13/2009	Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen	Genentech, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1653	bevacizumab	Avastin	2/9/2006	Therapeutic treatment of patients with ovarian cancer	Genentech, Inc.
1654	bevacizumab	Avastin	10/20/2004	Treatment of pancreatic cancer	Genentech, Inc.
1655	bevacizumab	Avastin	11/6/2003	Treatment of renal cell carcinoma	Genentech, Inc.
1656	bezafibrate	Bezalip	7/24/2013	For therapeutic treatment of Barth syndrome	Barth Syndrome Foundation, Inc.
1657	bi-shRNA furin and GMCSF Autologous Tumor Cell Vaccine	Fang	10/22/2014	Treatment of Ewing's sarcoma	Gradalis, Inc.
1658	bi-shRNA furin and granulocyte macrophage colony stimulating factor augmented autologous tumor cell vaccine	Fang	4/18/2011	Treatment of ovarian cancer	Gradalis, Inc.
1659	bi-shRNA furin and granulocyte macrophage colony stimulating factor augmented autologous tumor cell vaccine	Fang	2/17/2012	Treatment of stage IIB to IV melanoma	Gradalis, Inc.
1660	bifidobacterium infantis 35624	n/a	3/24/2008	Treatment of pediatric ulcerative colitis	Alimentary Health Limited
1661	bifidobacterium longum infantis 35624	n/a	1/16/2003	Treatment of pediatric Crohn's disease	Alimentary Health Limited
1662	binimetinib	n/a	11/19/2013	Treatment Stage IIB-IV melanoma.	Novartis Pharmaceuticals Corporation
1663	binimetinib	n/a	7/31/2014	Treatment of ovarian cancer	Array Biopharma, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1664	biocarbonate infusate	Normocarb Hf	8/9/2005	Use in the management of patients undergoing continuous renal replacement therapy with hemofiltration	Dialysis Solutions, Inc.
1665	bisantrene HCl	n/a	2/14/2014	Treatment of acute myeloid leukemia	Update Pharma, Inc.
1666	bispecific antibody (monoclonal antibody)	n/a	8/8/2013	Treatment of HER2-expressing advanced adenocarcinoma of the stomach and gastroesophageal junction	Merrimack Pharmaceuticals, inc.
1667	bispecific antibody (monoclonmal antibody)	n/a	8/8/2013	Treatment of HER2-expressing adenocarcinoma of the esophagus	Merrimack Pharmaceuticals, Inc.
1668	bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13)	n/a	9/14/2011	Treatment of idiopathic pulmonary fibrosis.	Sanofi-Aventis US, Inc.
1669	bivalent anti-human myostatin adnectin-IgG1	n/a	2/11/2015	Treatment of duchenne muscular dystrophy	Bristol-Myers Squibb Co.
1670	bivalirudin	Angiomax	11/2/2005	For use as an anticoagulant in patients with or at risk of heparin-induced thrombocytopenia/heparin-induced thrombocytopenia thrombosis syndrome	The Medicines Company
1671	blinatumomab	n/a	2/6/2006	Treatment of indolent B-cell lymphoma, excluding CLL and NHL with CNS involvement	Amgen, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1672	blinatumomab	n/a	5/16/2008	Treatment of prolymphocytic leukemia	Amgen, Inc.
1673	blinatumomab	n/a	5/16/2008	Treatment for hairy cell leukemia.	Amgen, Inc.
1674	blinatumomab	n/a	5/16/2008	Treatment of acute lymphocytic leukemia	Amgen, Inc.
1675	bortezomib	Velcade	2/3/2015	Treatment of acute lymphoblastic leukemia	Millennium Pharmaceuticals, Inc.
1676	bortezomib	Velcade	1/4/2011	Treatment of follicular non-Hodgkin lymphoma	Millennium Pharmaceuticals, Inc.
1677	bortezomib	Velcade For Injection	5/30/2012	Treatment of mantle cell lymphoma.	Millennium Pharmaceuticals, Inc.
1678	bortezomib	Velcade	1/15/2003	Treatment of multiple myeloma	Millennium Pharmaceuticals, Inc.
1679	bosutinib	Bosulif	2/24/2009	Treatment of chronic myelogenous leukemia	Wyeth Pharmaceuticals, Inc.
1680	botulism antitoxin heptavalent (A, B, C, D, E, F, G) (Equine)	n/a	6/29/2011	Treatment of botulism.	Cangene Corporation
1681	bovine lactoferrin	n/a	2/19/2015	Prevention of late-onset sepsis in very low birth weight infants	Metrodora Therapeutics, Inc.
1682	bovine lactoferrin	n/a	2/23/2015	Prevention of necrotizing enterocolitis in very low birth weight infants (birth weight less than or equal to 1500 grams)	Metrodora Therapeutics, INC.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1683	brentuximab vedotin	Adcetris	10/23/2008	Treatment of anaplastic large cell lymphoma	Seattle Genetics, Inc.
1684	brentuximab vedotin	Adcetris	4/15/2013	Treatment of patients with peripheral T-cell lymphoma, not otherwise specified	Seattle Genetics, Inc.
1685	brentuximab vedotin	Adcetris(R)	1/31/2014	Treatment of patients with diffuse large B-cell lymphoma.	Seattle Genetics, Inc.
1686	brentuximab vedotin	Adcetris	9/13/2013	Treatment of patients with angioimmunoblastic T-cell lymphoma	SeattleGenetics, Inc.
1687	brentuximab vedotin	Adcetris	11/19/2012	Treatment of mycosis fungoides	Seattle Genetics, Inc.
1688	brentuximab vedotin	Adcetris	1/30/2007	Treatment of Hodgkin's lymphoma	Seattle Genetics, Inc.
1689	brilliant blue G	Brilliant Peel	12/16/2009	For use in ophthalmic surgery to aid in the removal of the inner limiting membrane of the eye.	Fluron GmbH - Subsidiary of Geuder AG
1690	bryostatin-1	n/a	12/3/2001	For use in combination with paclitaxel in the treatment of esophageal cancer	GPC Biotech, Inc.
1691	budesonide	Uceris	5/6/2013	Treat of ulcerative colitis in pediatric patients aged 0 through 16 years.	Santarus, Inc.
1692	budesonide	Nefecon	5/17/2010	To slow the progression of immunoglobulin A nephropathy & delay kidney failure in patients affected by the disease.	Pharmalink AB

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1693	bupivacaine	Transdur	6/18/2008	Relief of persistent pain associated with postherpetic neuralgia	Impax Laboratories, Inc.
1694	buprenorphine in combination with naloxone	Suboxone	10/27/1994	Treatment of opiate addiction in opiate users	Reckitt Benckiser Pharmaceuticals, Inc.
1695	busulfan	Partaject	11/25/2002	Preparative therapy for pediatric patients undergoing bone marrow transplantation	SuperGen, Inc.
1696	cabozantinib	Cometriq	11/29/2010	Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.	Exelixis, Inc.
1697	caffeine and sodium benzoate	n/a	8/22/2012	Treatment of seizure prolongation in patients undergoing electroconvulsive therapy	Luitpold Pharmaceuticals, Inc.
1698	calcium benzoate and risperidone	n/a	12/20/2010	Treatment of pediatric patients with schizophrenia	University of California, Los Angeles
1699	camostat	n/a	5/18/2011	Treatment of chronic pancreatitis	NIXS Corporation
1700	canakinumab	Ilaris	12/5/2013	Treatment of familial mediterranean fever	Novartis Pharmaceuticals Corporation
1701	canakinumab	n/a	9/4/2012	Treatment of TNF-receptor associated periodic syndrome (TRAPS)	Novartis Pharmaceuticals Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1702	canakinumab	Ilaris	12/18/2007	Treatment of cryopyrin-associated periodic syndromes	Novartis Pharmaceuticals Corporation
1703	canakinumab	Ilaris	12/5/2013	Treatment of hyperimmunoglobulinemia D and periodic fever syndrome	Novartis Pharmaceuticals Corporation
1704	canakinumab	Ilaris	9/30/2008	Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.	Novartis Pharmaceuticals Corporation
1705	cannabidiol	n/a	6/23/2014	Treatment of Lennox-Gastaut syndrome	Insys Therapeutics, Inc.
1706	cannabidiol	n/a	7/1/2014	Treatment of Dravet syndrome	Insys Therapeutics, Inc.
1707	cannabidiol	n/a	8/20/2014	Treatment of glioblastoma multiforme	Insys Therapeutics, Inc.
1708	cannabidiol	n/a	11/17/2014	Treatment of pediatric schizophrenia (pediatrics is defined as 0 through 16 years of age)	Insys Therapeutics, Inc.
1709	cannabidiol	n/a	9/24/2014	Treatment of glioma	Insys Therapeutics, Inc.
1710	cantharidin	n/a	7/24/2012	Treatment of perforating diseases, including Kyrle's disease, reactive perforating collagenosis, perforating folliculitis and elastosis perforans serpiginosa	Orenova Group, LLC
1711	caprine hyperimmune serum against HIV lysate	n/a	2/14/2014	Treatment of systemic sclerosis	Daval International Limited
1712	caprine hyperimmune serum against HIV lysate	n/a	10/28/2009	Treatment of amyotrophic lateral sclerosis	Daval International Limited

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1713	capsaicin	Qutenza	5/2/2003	Treatment of painful HIV-associated neuropathy	Acorda Therapeutics, Inc.
1714	capsaicin	n/a	10/23/2002	Treatment of erythromelgia	Acorda Therapeutics, Inc.
1715	capsaicin	Qutenza	5/22/2009	Management of neuropathic pain in patients with postherpetic neuralgia	Acorda Therapeutics, Inc.
1716	carbenoxolone	n/a	7/2/2014	Treatment of Huntington's Disease	Oxalys Pharmaceuticals, Inc.
1717	carbetocin	n/a	4/10/2014	Treatment of Prader Willi syndrome	Ferring Pharmaceuticals, Inc.
1718	carbon monoxide	n/a	9/28/2012	Treatment of sickle cell disease	Hillhurst Biopharmaceuticals, Inc.
1719	carboxy pyrrolidine hexanoyl pyrrolidine carboxylate	n/a	2/10/2015	Treatment of AL amyloidosis	Glaxo Group Limited, England d/b/a GlaxoSmithKline
1720	cardiotrophin-1	n/a	9/13/2011	Treatment of acute liver failure	Digna Biotech S.L.
1721	cardiotrophin-1	n/a	6/24/2008	To protect the liver from ischemia-reperfusion injury inherent to the procedure of transplantation.	Digna Biotech, S.L.
1722	cardiotrophin-1	n/a	10/16/2014	Prevention of ischemia-reperfusion injury in kidney transplant recipients	Digna Biotech, S.L.
1723	carfilzomib	Kyprolis	1/18/2008	Treatment of multiple myeloma	Onyx Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1724	carglumic acid	Carbaglu	6/17/2014	Treatment of organic acidemias	Orphan Europe SARL
1725	carglumic acid	Carbaglu	1/20/1998	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe SARL
1726	carisbamate	n/a	3/16/2012	Management of patients with infantile spasms	SK Life Science, Inc.
1727	carlumab	n/a	10/24/2006	Treatment of pancreatic cancer	Centocor, Inc.
1728	catumaxomab	n/a	7/1/2009	Treatment of gastric cancer	Neoviibiotech North America, Inc.
1729	cediranib	n/a	12/13/2010	Treatment of glioblastoma	National Institutes of Health
1730	celiprolol	n/a	1/5/2015	Treatment of Ehlers-Danlos syndrome	Acer Therapeutics, INC.
1731	cell based therapeutic composed of allogeneic donor apoptotic cells	Apocell	3/18/2013	Prevention of graft versus host disease	Enlivex Therapeutics Ltd.
1732	cenersen	Aeza	2/27/2008	Treatment of chronic lymphocytic leukemia	Eleos, Inc.
1733	cenersen	Aeza	6/18/2008	Treatment of stage IIB through IV melanoma	Eleos, Inc.
1734	cenersen	n/a	5/8/2006	Treatment of acute myeloid leukemia	Eleos, Inc.
1735	ceritinib	Zykadia	9/27/2013	Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive	Novartis Pharmaceuticals Corp.
1736	cethromycin	Restanza(TM)	9/9/2009	Prophylactic treatment of tularemia due to Francisella tularensis.	Advanced Life Sciences, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1737	cethromycin	Restanza(TM)	9/9/2009	Prophylactic treatment of plague due to Yersinia pestis	Advanced Life Sciences, Inc.
1738	cethromycin	n/a	2/28/2007	Prophylactic treatment of patients exposed to inhalation anthrax.	Advanced Life Sciences, Inc.
1739	cetuximab	Erbitux	7/3/2000	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor	ImClone Systems Incorporated
1740	chelmab-y or chelamusab-Y	Oncorad Ov103	4/24/1990	Treatment of ovarian cancer.	Cytogen Corporation
1741	chenodeoxycholic acid	n/a	2/12/2007	Treatment of cerebrotendinous xanthomatosis	Sigma-Tau Pharmaceuticals, Inc.
1742	chenodiol	Chenix	9/21/1984	For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age	Solvay
1743	chenodiol	Chenadal	3/22/2010	Treatment of cerebrotendinous xanthomatosis	Manchester Pharmaceuticals, Inc.
1744	chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2	n/a	11/25/2014	Treatment of mucopolysaccharidosis III Type B (MPS IIIB, Sanfilippo Syndrome Type B)	BioMarin Pharmaceutical, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1745	chimeric monoclonal antibody against Claudin 6	n/a	3/18/2013	Treatment of ovarian cancer	Ganymed Pharmaceuticals AG
1746	chimeric monoclonal antibody against claudin-18 splice variant 2	n/a	9/26/2013	Treatment of pancreatic cancer	GANYMED Pharmaceuticals AG
1747	chimeric monoclonal antibody to claudin 18 splice variant 2	n/a	11/20/2012	Treatment of gastric cancer	GANYMED Pharmaceuticals AG
1748	chlorobutanol/propylene glycol/hydrochloric acid	Patul-End	2/18/1997	Treatment of patulous eustachian tube	Ear Foundation
1749	chloropyramine	n/a	10/22/2010	Treatment of pancreatic cancer	CurFAKtor Pharmaceuticals, LLC
1750	chlorotoxin	n/a	12/2/2008	Treatment of stage IIb, IIc, III & IV melanoma	Morphotek, Inc.
1751	cholest-4-en-3-one, oxime	n/a	2/17/2009	Treatment of spinal muscular atrophy.	Trophos SA
1752	cholic acid (3 alpha, 7 alpha, 12 alpha trihydroxy 5-beta cholanoic acid)	Cholbam(R)	7/18/2003	Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism	Asklepion Pharmaceuticals, LLC
1753	choline tetrathiomolybdate	n/a	8/25/2011	Treatment of Wilson's disease.	Wilson Therapeutics AB
1754	chromium picolinate and chromium histidinate	n/a	12/22/2014	Treatment of pediatic polycystic ovary syndrome (0 through 16 years of age)	JDS Therapeutics, LLC

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1755	cinacalcet	Sensipar	4/30/2010	Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery	Amgen, Inc.
1756	cinacalcet	Sensipar	5/12/2003	Treatment of hypercalcemia in patients with parathyroid carcinoma	Amgen, Inc.
1757	ciprofloxacin	n/a	6/1/2011	The management of bronchiectasis	Aradigm Corporation
1758	ciprofloxacin DPI	Ciprofloxacin Pulmosphere(R)	2/2/2010	Management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients	Bayer HealthCare Pharmaceuticals, Inc.
1759	ciprofloxacin dry powder inhaler	n/a	4/17/2014	Treatment of non-cystic fibrosis bronchiectasis	Bayer HealthCare Pharmaceuticals, Inc.
1760	cis-adamantane-2-spiro-3'-8'-[4'-[2'-(4'-morpholinyl)ethoxy]phenyl]-1',2,'4'-trioxaspiro[4.5] decane mesylate	n/a	1/19/2010	Treatment of malaria caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, or Plasmodium malariae	Medicines for Malaria Venture (MMV)
1761	civamide	Zucapsaicin	12/9/2002	Treatment of postherpetic neuralgia of the trigeminal nerve	Winston Laboratories, Inc.
1762	civamide	n/a	2/17/2009	Treatment of postherpetic neuralgia.	Winston Laboratories, Inc.
1763	clarithromycin, rifabutin, clofazimine	n/a	4/26/2011	Treatment of pediatric Crohn's disease.	RedHill Biopharma Ltd.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1764	clenbuterol	Spiropent, Ventipulmin	10/27/2014	Adjunctive therapy with enzyme replacement therapy in the treatment of Pompe disease	Duke University Medical Center
1765	clobazam	Onfi	12/18/2007	Treatment of Lennox-Gastaut Syndrome	Lundbeck, Inc.
1766	clofarabine	Clolar	2/7/2002	Treatment of acute lymphoblastic leukemia	Genzyme Corporation
1767	clofarabine	Clofarex	3/14/2002	Treatment of acute myelogenous leukemia	Genzyme Corp (Ilex Products, Inc.)
1768	clofazimine	Lamprene	6/25/2014	Treatment of active tuberculosis	Novartis Pharmaceuticals Corp.
1769	coagulation factor IX (recombinant)	Rixubis	10/31/2012	Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding)	Baxter Healthcare Corporation
1770	coagulation factor VIIa (recombinant)	Novoseven Rt	6/18/2004	Treatment of bleeding episodes in Glanzmann's thrombasthenia	Novo Nordisk Inc.
1771	coagulation factor XIII A-subunit (recombinant)	Tretten	11/6/2003	Prophylaxis of bleeding associated with congenital factor XIII deficiency	Novo Nordisk, Inc.
1772	cobimetinib	n/a	1/31/2014	Treatment of stage IIb, IIc, III, and IV melanoma with BRAFV600 mutation	Genentech, Inc.
1773	cobiprostone	n/a	11/14/2002	Treatment of cystic fibrosis	Sucampo Pharma Americas, LLC.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1774	coccidioidin SD Skin Test Antigen	n/a	12/19/2007	For the diagnosis of Coccidioidomycosis	Allermed Laboratories, Inc.
1775	coenzyme Q10 and d-alpha-tocopherol	n/a	3/14/2011	Treatment of Friedreich's Ataxia.	NBI Pharmaceuticals, Inc.
1776	colchicine	Colcrys	9/25/2007	Treatment of familial Mediterranean fever	AR Holding Company, Inc.
1777	collagenase clostridium histolyticum	Xiaflex	3/12/1996	Treatment of Peyronie's disease.	Auxilium Pharmaceuticals, Inc.
1778	collagenase clostridium histolyticum	Xiaflex	5/23/1996	Treatment of advanced (involuntional or residual stage) Dupuytren's disease.	Auxilium Pharmaceuticals, Inc.
1779	combretastatin A 1 diphosphate	n/a	11/19/2012	Treatment of acute myelogenous leukemia	Oxigen, Inc.
1780	conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)	Transmid	12/3/2001	Treatment of malignant tumors of the central nervous system	Xenova Biomedix Limited
1781	conjugated bile acids	Cobartin	7/18/2003	Treatment of steatorrhea in patients with short bowel syndrome	Jarrow Formulas, Inc.
1782	copanlisib	n/a	2/5/2015	Treatment of follicular lymphoma	Bayer HealthCare Pharmaceuticals, Inc.
1783	copper histidine	n/a	5/14/2012	Treatment of Menkes disease	Stephen G. Kaler, M.D.
1784	corifungin	n/a	7/6/2011	Treatment of visceral leishmaniasis	Sandler Center for Drug Discovery
1785	corifungin	n/a	8/22/2011	Treatment of amebic meningoencephalitis.	Ctr for Discovery & Innovation in Parasitic Diseases

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1786	creatine	Creapure	2/12/2002	Treatment of amyotrophic lateral sclerosis	Avicena Group, Inc.
1787	crenolanib	n/a	3/11/2011	Treatment of soft tissue sarcoma	AROG Pharmaceuticals, LLC
1788	crenolanib	n/a	10/31/2012	Treatment of acute myelogenous leukemia	AROG Pharmaceuticals, LLC
1789	crenolanib	n/a	12/20/2010	Treatment of malignant glioma	AROG Pharmaceuticals, LLC
1790	cridanimod	n/a	1/12/2011	Treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy.	Kevelt Ltd.
1791	crizotinib	Xalkori	9/28/2012	Treatment of anaplastic large cell lymphoma	Pfizer, Inc.
1792	crizotinib	Xalkori	10/31/2012	Treatment of neuroblastoma	Pfizer
1793	crizotinib	Xalkori	9/13/2010	Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer	Pfizer, Inc.
1794	cultured, partially T-Cell depleted, allogenic thymic tissue for transplantation	n/a	8/15/2003	As a therapy for primary immune deficiency resulting from athymia associated with complete DiGeorge Syndrome	Duke University Medical Center
1795	cyclic pyranopterin monophosphate (cPMP)	n/a	11/5/2009	Treatment of molybdenum cofactor deficiency type A (MoCD)	Alexion Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1796	cyclo(-γ-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonyl-L-phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt	n/a	6/24/2013	Treatment of acromegaly	Aspireo Pharmaceuticals Limited
1797	cyclocreatine	n/a	6/18/2012	Treatment of creatine transporter deficiency	Lumos Pharma
1798	cyclophosphamide	Cyrevia(Tm)	6/7/2011	Treatment of systemic sclerosis.	Accentia Biopharmaceuticals, Inc.
1799	cyclophosphamide	Cyrevia(Tm)	6/17/2011	Prevention of graft versus host disease following allogeneic hematopoietic stem cell transplant	Accentia Biopharmaceuticals, Inc.
1800	cyclosporine	n/a	2/17/2009	Prophylaxis of graft-versus-host disease	Sigmoid Pharma Limited
1801	cyclosporine	n/a	2/17/2009	Treatment of graft-versus-host disease	Sigmoid Pharma Limited
1802	cyclosporine 2% ophthalmic ointment	n/a	8/1/1991	For use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including Mooren's ulcer	Allergan, Inc.
1803	cyclosporine A	n/a	9/30/2008	Prevention of corneal graft rejection	Novagali Pharma S.A.
1804	cyclosporine A	Nova22007	4/9/2008	Treatment of herpes simplex virus stromal keratitis	Novagali Pharma S.A.
1805	cyclosporine; ciclosporin	Neurostat(R)/Ciclomulsion (R)	11/23/2010	Treatment of moderate to severe traumatic brain injury.	NeuroVive Pharmaceutical AB

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1806	cysteamine	n/a	9/11/2013	Treatment of pancreatic cancer	Raptor Pharmaceuticals, Inc.
1807	cysteamine	n/a	5/9/2008	Treatment of Huntington's disease	Raptor Therapeutics
1808	cysteamine	n/a	8/6/2008	Treatment of neuronal ceroid lipofuscinoses (Batten disease)	Raptor Pharmaceuticals, Inc.
1809	cysteamine enteric coated	Procysbi	10/24/2006	Treatment of cystinosis	Raptor Therapeutics, Inc.
1810	cytarabine liposome	Depocyt	1/30/2007	Treatment of gliomas	Bruce Frankel, MD
1811	cytochrome C, flavin mononucleotide and thiamin diphosphate	n/a	6/17/2011	Treatment of mitochondrial disorders	NBI Pharmaceuticals, Inc
1812	cytochrome P450 isoform 2B1 gene transfected human embryonic kidney 293 cells encapsulated in polymeric cellulose sulphate	n/a	12/17/2014	Treatment of pancreatic cancer in combination with ifosfamide	Nuvilex, Inc.
1813	d6-tetrabenazine, deutetrabenazine	n/a	11/5/2014	Treatment of Huntington's Disease	Auspex Pharmaceuticals, Inc.
1814	dabrafenib	Tafinlar	1/12/2011	Treatment BRAF V600 mutation positive Stage IIB through IV melanoma	GlaxoSmithKline, LLC
1815	dabrafenib	Tafinlar	10/20/2014	Treatment of patients with BRAF mutation positive non-small cell lung cancer	GlaxoSmithKline
1816	dacetuzumab	n/a	8/13/2004	Treatment of multiple myeloma.	Seattle Genetics, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1817	dacetuzumab	n/a	10/6/2005	Treatment of chronic lymphocytic leukemia	Seattle Genetics, Inc.
1818	dalfampridine	Ampyra	6/2/1987	Relief of symptoms of multiple sclerosis	Acorda Therapeutics
1819	dantrolene sodium	n/a	9/25/2012	Treatment of heat stroke	Eagle Pharmaceuticals, Inc.
1820	dantrolene sodium suspension for injection	Ryanodex	8/16/2013	Treatment of malignant hyperthermia syndrome	Eagle Pharmaceuticals, Inc.
1821	daratumumab	Humax(R)-Cd38	5/6/2013	Treatment of multiple myeloma.	Janssen Research & Development, LLC
1822	dasiprotimut-T	Biovaxid	10/28/2009	Treatment of follicular lymphoma	Biovest International, Inc.
1823	dasiprotimut-T	Biovax Id	6/17/2010	Treatment of mantle cell lymphoma	Biovest International, Inc.
1824	daunorubicin citrate liposome	Daunoxome	4/15/2013	Treatment of acute myeloid leukemia	Galen Limited
1825	davunetide	n/a	12/7/2009	Treatment of progressive supranuclear palsy.	Allon Therapeutics, Inc.
1826	debrase	Debridase	8/20/2003	Debridement of acute, deep dermal burns in hospitalized patients	MediWound, Ltd.
1827	decitabine	Dacogen	3/8/1999	Treatment of myelodysplastic syndromes.	Otsuka Pharmaceutical Development
1828	decitabine	n/a	9/9/2002	Treatment of sickle cell anemia	Otsuka Pharmaceutical Development &

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1829	decitabine	Dacogen	8/4/2006	Treatment of acute myeloid leukemia	Otsuka Pharmaceutical Development &
1830	decitabine	n/a	3/8/1999	Treatment of chronic myelogenous leukemia.	Otsuka Pharmaceutical Development &
1831	defactinib	n/a	2/12/2015	Treatment of ovarian cancer	Verastem, Inc.
1832	deferasirox	Exjade	2/24/2015	Treatment of chronic iron overload in alpha-thalassemia	Novartis Pharmaceuticals Corporation
1833	deferiprone	Ferriprox	12/12/2001	Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy	ApoPharma, Inc. A Division of
1834	deferiprone	n/a	7/31/2008	Treatment of Friedreich's ataxia	ApoPharma, Inc.
1835	deferiprone	n/a	9/1/2011	Treatment of superficial siderosis	ApoPharma, Inc.
1836	deferoxamine starch conjugate	n/a	12/21/1998	Treatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.	Biomedical Frontiers, Inc.
1837	deferoxamine starch conjugate	n/a	1/28/2005	Treatment of acute iron poisoning	Biomedical Frontiers, Inc.
1838	defibrotide	n/a	5/21/2003	For the treatment of hepatic veno-occlusive disease	Gentium SpA
1839	defibrotide	n/a	1/8/2007	For the prevention of hepatic veno-occlusive disease.	Gentium SpA

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1840	deflazacort	n/a	8/16/2013	Treatment of Duchenne muscular dystrophy	Marathon Pharmaceuticals, LLC
1841	deflazacort	Calcort	9/16/2010	Treatment of Duchenne muscular dystrophy	University of Rochester Medical Center
1842	dehydrated alcohol	n/a	3/16/2012	Treatment of trigeminal neuralgia	Luitpold Pharmaceuticals, Inc.
1843	dehydrated alcohol	Ablysinol	9/11/2013	Treatment of hypertrophic obstructive cardiomyopathy	Belcher Pharmaceuticals, LLC
1844	delta-1,4,9(11)-pregnatriene-17-alpha,21-dihydroxy-16-alpha-methyl-3,20-dione	n/a	12/2/2011	Treatment of Duchenne muscular dystrophy.	ReveraGen Biopharma
1845	demcizumab	n/a	4/30/2014	Treatment of pancreatic cancer	OncoMed Pharmaceuticals, Inc.
1846	dendritic cells pulsed with synthetic peptides derived from antigens MAGE1, HER-2, AIM-2,TRP-2, gp100 and interleukin-13 receptor alpha	n/a	6/7/2010	Treatment of glioblastoma or brain stem glioma	ImmunoCellular Therapeutics Ltd.
1847	dendritic hybrid cell vaccine	Neuroblaxin	9/23/2011	Treatment of neuroblastoma	Orbis Health Solutions, LLC
1848	denileukin diftitox	n/a	7/12/2013	Treatment of cutaneous T-cell lymphoma	Eisai Inc.
1849	denileukin diftitox	Ontak	4/30/2010	Treatment of peripheral T-cell lymphoma	Eisai, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1850	denileukin diftitox	Ontak	8/21/1996	Treatment of patients with cutaneous T-cell lymphoma	Eisai, Inc.
1851	denileukin diftitox	n/a	6/29/2011	Treatment of peripheral T-cell lymphoma (PTCL)	Eisai, Inc.
1852	denosumab	Xgeva	9/11/2013	Treatment of hypercalcemia in malignancy	Amgen, Inc.
1853	denosumab	Xgeva	12/20/2010	Treatment of patients with giant cell tumor of bone	Amgen, Inc.
1854	deutetrabenazine	n/a	1/13/2015	Treatment of Tourette syndrome in the pediatric population (defined as 0 through 16 years of age)	Auspex Pharmaceuticals
1855	dexamethasone intravitreal implant	Ozurdex	9/11/1998	Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis	Allergan
1856	dexamethasone phosphate	n/a	12/2/2008	Treatment of corneal graft rejection.	EyeGate Pharmaceuticals, Inc.
1857	dexamethasone sodium phosphate encapsulated in autologous erythrocytes	n/a	7/24/2012	Treatment of ataxia-telangiectasia	EryDel S.p.A.
1858	dexanabinol	n/a	8/11/2004	For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain injury	Pharmos Corporation
1859	dexpramipexole	n/a	10/11/2007	Treatment of amyotrophic lateral sclerosis	Knopp Biosciences LLC

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1860	dexrazoxane	Totect(R)	3/25/2004	Treatment of anthracycline extravasation during chemotherapy	Biocodex
1861	dexrazoxane hydrochloride	n/a	8/19/2014	Prevention of cardiomyopathy for children and adolescents 0 through 16 years of age treated with anthracyclines	Satiscor, LLC
1862	dextran 1	n/a	3/21/2003	Treatment of cystic fibrosis	BCY LifeSciences Inc.
1863	diacerein	n/a	10/15/2014	Treatment of epidermolysis bullosa	TWI Biotechnology, Inc.
1864	diannexin	n/a	10/28/2009	Prevention of ischemia-reperfusion injury in solid organ transplants	Astellas Pharma Global Development, Inc.
1865	diazepam (intranasal)	n/a	7/31/2012	Management of patients with acute repetitive seizures	Acorda Therapeutics, Inc.
1866	diazepam auto-injector	n/a	5/30/2013	Management of selected, refractory patients with epilepsy on stable regimens of antiepileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity	Meridian Medical Technologies-a Pfizer subsidiary
1867	diazoxide	n/a	12/3/2012	Treatment of Prader Willi Syndrome	Sedogen, LLC
1868	diazoxide choline	n/a	5/13/2014	Treatment of Prader-Willi Syndrome	Essentialis, Inc.
1869	dichlorphenamide	n/a	9/2/2010	Treatment of primary periodic paralyses	Taro Pharmaceuticals

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1870	diethylenetriaminepentaacetate (DPTA)	n/a	4/14/2004	For treatment of patients with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination.	CIS-US
1871	diferuloylmethane	n/a	6/13/2003	Treatment of cystic fibrosis	Allertein Therapeutics, LLC
1872	difluprednate	Durezol	9/30/2008	Treatment of endogenous and traumatic anterior uveitis and panuveitis.	Alcon Pharmaceuticals. Ltd.
1873	digitoxin	n/a	5/27/2005	Treatment of cystic fibrosis	Silver Pharmaceuticals
1874	digitoxin	n/a	10/18/2001	Treatment of soft tissue sarcomas	PrimeCyte, Inc.
1875	digitoxin	n/a	11/2/2001	Treatment of ovarian cancer	PrimeCyte, Inc.
1876	digoxin immune fab (ovine)	n/a	2/3/2012	Treatment of severe preeclampsia and eclampsia	Glenveigh Medical, LLC
1877	dihydroartemisinin and piperazine	Eurartesim	1/8/2007	Treatment of uncomplicated malaria caused by "Plasmodium falciparum," Plasmodium vivax," Plasmodium malariae," or "Plasmodium ovale."	Sigma-Tau Pharmaceuticals, Inc.
1878	dimebon	n/a	5/12/2009	Treatment of Huntington's Disease.	Medivation, Inc.
1879	dimethyl fumarate	n/a	9/11/2013	Treatment of Friedreich's Ataxia	Gino Cortopassi
1880	dimethyl sulfoxide	n/a	5/9/2008	For use in combination with antimicrobial drugs for the treatment of drug resistant tuberculosis	Abela Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1881	dinaciclib	n/a	8/25/2011	Treatment of chronic lymphocytic leukemia.	Merck Sharp & Dohme Ltd.
1882	dinutuximab	n/a	12/20/2010	Treatment of neuroblastoma	United Therapeutics Corporation
1883	diphenylcycloenone	n/a	6/13/2003	Treatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU])	Lloyd E. King, Jr.
1884	docosahexaenoic acid, DHA	n/a	12/17/2014	Treatment of primary sclerosing cholangitis	Sancilio and Company, Inc.
1885	docosahexanoic acid-paclitaxel	Taxoprexin	3/5/2001	Treatment of hormone-refractory prostate cancer.	Luitpold Pharmaceuticals, Inc.
1886	domperidone	n/a	9/2/2011	Treatment of hypoprolactinemia in breastfeeding mothers, and in some hypoprolactinemic conditions following the use of cabergoline or bromocriptine in mothers who wish to initiate or return to breastfeeding	Thomas W. Hale, RPh, PhD
1887	double stranded RNA which targets the mutated KRAS oncogene	n/a	1/26/2015	Treatment of pancreatic cancer	Silenseed Ltd
1888	dovitinib	n/a	9/26/2013	Treatment of adenoid cystic carcinoma	Novartis Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1889	doxofylline	n/a	2/14/2014	Treatment of bronchiectasis	Alitair Pharmaceuticals, Inc.
1890	doxorubicin	n/a	8/25/2009	Treatment of hepatocellular carcinoma.	Delcath Systems, Inc.
1891	doxorubicin HCL liposome injection	Doxil	12/29/2004	Treatment of multiple myeloma	Johnson & Johnson Pharmaceutical Research & Dev.
1892	doxorubicin PIHCA nanoparticles	Doxorubicin Transdrug	3/14/2005	Treatment of hepatocellular carcinoma	BioAlliance Pharma
1893	doxorubicin with pluronics F-127 and L-61	n/a	2/20/2008	Treatment of gastric cancer	Supratek Pharma, Inc.
1894	droxidopa	Northera	1/17/2007	Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy.	Lundbeck LLC
1895	dry extract from Betulae Cortex (birch bark)	n/a	8/7/2014	Treatment of epidermolysis bullosa	Birken AG
1896	duvoglustat hydrochloride	n/a	6/18/2007	Treatment of Pompe disease	Amicus Therapeutics, Inc
1897	ecallantide	Kalbitor	2/4/2003	Treatment of angioedema	Dyax Corp.
1898	echothiophate iodide	n/a	6/2/2014	Treatment of Stargardt's disease	Makindus, Inc.
1899	ecopipam hydrochloride	n/a	9/29/2010	Treatment of Tourette's syndrome in children 0-16 years old.	Psyadon Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1900	ecopipam hydrochloride	n/a	7/21/2009	Symptomatic treatment of self injurious behaviors in patients with Lesch-Nyhan disease.	Psyadon Pharmaceuticals, Inc.
1901	eculizumab	n/a	6/13/2014	Treatment of Myasthenia Gravis.	Alexion Pharmaceuticals, Inc.
1902	eculizumab	Soliris	1/10/2014	Prevention of delayed graft function after renal transplantation	Alexion Pharmaceuticals, Inc.
1903	eculizumab	n/a	3/5/2001	Treatment of idiopathic membranous glomerular nephropathy	Alexion Pharmaceuticals, Inc.
1904	eculizumab	Soliris	6/24/2013	Treatment of neuromyelitis optica	Alexion Pharmaceuticals, Inc.
1905	eculizumab	Soliris	10/18/2011	Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome	Alexion Pharmaceuticals, Inc.
1906	eculizumab	Soliris	8/20/2003	Treatment of paroxysmal nocturnal hemoglobinuria	Alexion Pharmaceuticals, Inc.
1907	eculizumab	Soliris	4/29/2009	Treatment of atypical hemolytic uremic syndrome	Alexion Pharmaceuticals, Inc.
1908	efaproxiral	n/a	7/28/2004	Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer	Allos Therapeutics, Inc.
1909	eflornithine	n/a	2/4/2011	Treatment of Familial Adenomatous Polyposis	Cancer Prevention Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1910	eflornithine	n/a	11/23/2010	Treatment of neuroblastoma	Cancer Prevention Pharmaceutical, Inc.
1911	eflornithine plus sulindac	n/a	1/22/2013	Treatment of familial adenomatous polyposis	Cancer Prevention Pharmaceuticals, Inc.
1912	eicosapentaenoic acid	n/a	3/8/2011	Treatment of familial adenomatous polyposis	S.L.A. Pharma Ltd. (UK)
1913	elacytarabine	n/a	6/18/2008	Treatment of acute myeloid leukemia (AML)	Clavis Pharma ASA
1914	elafin	n/a	12/28/2012	Treatment of pulmonary arterial hypertension	Proteo Biotech AG
1915	eliglustat	Cerdelga	9/17/2008	Treatment of Type I Gaucher disease	Genzyme Corporation
1916	elosulfase alfa	Vimizim	5/15/2009	Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome)	BioMarin Pharmaceutical Inc.
1917	elotuzumab	n/a	9/1/2011	Treatment of multiple myeloma	Bristol-Myers Squibb Company
1918	eltrombopag	Promacta	11/8/2013	Treatment of aplastic anemia	GlaxoSmithKline LLC
1919	eltrombopag	Promacta	5/5/2008	Treatment of idiopathic thrombocytopenia purpura	GlaxoSmithKline
1920	emricasan	n/a	11/20/2013	Treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease	Conatus Pharmaceuticals Inc.
1921	enalapril maleate (powder for oral solution)	Epaned	1/30/2013	Treatment of hypertension in pediatric patients	Silvergate Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1922	enchochleate amphotericin B	n/a	1/10/2014	Treatment of visceral leishmaniasis	Aquarius Biotechnologies, Inc.
1923	encorafenib	n/a	11/19/2013	Treatment of Stage IIB-IV melanoma positive for BRAF mutation	Novartis Pharmaceuticals Corporation
1924	encorafenib + binimetinib	n/a	11/19/2013	Treatment in Stage IIB-IV melanoma positive for the BRAF mutation.	Novartis Pharmaceuticalues Corporation
1925	eniluracil	n/a	12/15/2005	Treatment of hepatocellular carcinoma.	Adherex Technologies, Inc.
1926	ensituximab	n/a	10/21/2010	Treatment of pancreatic cancer.	Neogenix Oncology, Inc.
1927	enzastaurin	n/a	3/4/2009	Treatment of diffuse large B-cell lymphoma	Eli Lilly and Company
1928	epoprostenol	Flolan	3/22/1999	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	GlaxoSmithKline
1929	epratuzumab	n/a	9/30/2008	Treatment of acute lymphoblastic leukemia	Immunomedics, Inc.
1930	epratuzumab	Lymphocide	7/13/1998	Treatment of non-Hodgkin's lymphoma	Immunomedics, Inc.
1931	eptifibatide and iloprost	n/a	4/20/2012	Treatment of purpura fulminans	Thrombologic
1932	erdosteine	n/a	12/20/2013	Treatment of bronchiectasis.	Alitair Pharmaceuticals, Inc.
1933	eribulin mesylate	Halaven(R)	5/14/2012	Treatment of advanced soft tissue sarcoma	Eisai, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1934	estradiol Gel	n/a	10/31/2006	Estrogen replacement therapy in females with Turner syndrome	Ascend Therapeutics US, LLC
1935	etanercept	Enbrel	10/27/1998	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Immunex Corporation
1936	etarfolatide	n/a	2/16/2000	For the identification of ovarian carcinomas	Endocyte, Inc.
1937	eteplirsen	n/a	10/23/2007	Treatment of Duchenne Muscular Dystrophy.	Sarepta Therapeutics, Inc.
1938	ethanolamine	Ethamolin	1/17/2014	Prophylactic use in pediatric patients (age 0 through 16 years) with esophageal varices that are at risk of bleeding to obliterate varices and to prevent bleeding	QOL Medical, LLC
1939	ethiodized oil injection	Lipiodol	9/26/2013	Management of patients with known hepatocellular carcinoma (HCC)	Guerbet LLC
1940	etirinotecan pegol	n/a	4/18/2011	Treatment of ovarian cancer.	Nektar Therapeutics
1941	everolimus	Afinitor(R)	6/2/2014	Treatment of diffuse large B-cell lymphoma.	Novartis Pharmaceuticals Corp.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1942	everolimus	Afinitor	2/14/2008	Treatment of neuroendocrine tumors	Novartis Pharmaceuticals Corporation
1943	everolimus	Afinitor	6/8/2009	Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangiomyomatosis (LAM)	Novartis Pharmaceuticals Corporation
1944	everolimus	Afinitor	7/23/2012	Treatment of hepatocellular carcinoma	Novartis Pharmaceuticals Corporation
1945	ex vivo cultured human mesenchymal stromal cells	n/a	5/8/2014	Prevention of graft rejection following solid organ transplantation	iCell Science AB
1946	ex-vivo cultered adult human mesenchymal stem cells	Prochymal(R)	4/30/2010	Treatment of Type 1 diabetes patients with residual beta cell function	Mesoblast, Inc.
1947	ex-vivo expanded autologous bone marrow-derived mesenchymal stem cells	n/a	12/20/2010	Treatment of Amyotrophic Lateral Sclerosis	TCA Cellular Therapy, LLC
1948	exendin-(9-39)	n/a	6/1/2011	Treatment of congenital hyperinsulinemic hypoglycemia and other causes of hyperinsulinemic hypoglycemia in adults and children	The Children's Hospital of Philadelphia

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1949	exon 53 specific phosphorothioate oligonucleotide	n/a	1/23/2013	treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 53	Prosensa Therapeutics B.V.
1950	expanded allogeneic human dermal fibroblasts in hypothermosol(r)-FRS	n/a	8/20/2009	Treatment of Dystrophic Epidermolysis Bullosa.	Intercytex Ltd.
1951	expanded human allogeneic neural retinal progenitor cells extracted from neural retina	n/a	8/22/2013	Treatment of retinitis pigmentosa	ReNeuron Ltd
1952	extract of sorghum bicolor extract	n/a	11/19/2012	Treatment of sickle cell disease	Invenux, LLC
1953	ezatiostat hydrochloride	Telintra	1/9/2013	Treatment of myelodysplastic syndrome	Telik, Inc.
1954	factor VIII mimetic bispecific antibody	n/a	1/10/2014	Treatment of hemophilia A	Genentech
1955	factor XIII concentrate (human)	Corifact	1/16/1985	Treatment of congenital factor XIII deficiency	CSL Behring LLC
1956	farletuzumab	n/a	6/16/2006	Treatment of ovarian cancer	Morphotek, Inc.
1957	fecal microbiota	n/a	3/10/2014	Treatment of recurrent Clostridium difficile infection (Clostridium difficile gastrointestinal disease)	Rebiotx, Inc.
1958	fenfluramine HCl	Brabafen	12/20/2013	For the Treatment of Dravet Syndrome	Brabant Pharma Limited
1959	fenretinide	n/a	2/1/2007	Treatment of Ewing's sarcoma family of tumors.	Cancer Research UK
1960	fenretinide	n/a	9/4/2013	Treatment of peripheral T-cell lymphoma	CerRx, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1961	fenretinide	n/a	9/4/2013	Treatment of cutaneous T-cell lymphoma	CerRx, Inc.
1962	ferric hexacyanoferrate (II) "Prussian Blue"	n/a	6/26/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Degussa AG
1963	ferumoxytol	n/a	10/7/2011	For use in magnetic resonance imaging in brain metastases	Oregon Health & Science University
1964	ferumoxytol	Feraheme	4/29/2011	For use in MR imaging for the mangement of brain tumors	Edward A. Neuwelt, MD
1965	ferumoxytol	n/a	4/6/2012	For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)	ArsNova Partners, LLC
1966	fialuridine	n/a	7/24/1992	Adjunctive treatment of chronic active hepatitis B.	Oclassen Pharmaceuticals, Inc.
1967	fidaxomicin	Dificid	12/13/2010	Treatment of pediatric Clostridium difficile infection	Optimer Pharmaceuticals, Inc.
1968	filanesib	n/a	5/6/2014	Treatment of multiple myeloma.	Array BioPharma, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1969	filgrastim	n/a	11/20/2013	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Amgen, Inc.
1970	filgrastim	n/a	1/27/2015	Treatment of amyotrophic lateral sclerosis (ALS)	Neurovision Pharma GmbH
1971	fingolimod	n/a	4/30/2010	Treatment of chronic inflammatory demyelinating polyneuropathy	Novartis Pharmaceutical Corporation
1972	firtecan pegol	n/a	4/18/2011	Treatment of neuroblastoma.	Enzon Pharmaceuticals, Inc.
1973	flubendazole	n/a	10/25/2013	Treatment of onchocerciasis caused by Onchocerca volvulus	Janssen Research & Development, LLC
1974	flubendazole	n/a	1/23/2014	Treatment of lymphatic filariasis caused by nematodes of the family Filariodidea, in children and adults.	Janssen Research and Development, LLC
1975	flunarizine hydrochloride	n/a	6/24/2013	Treatment of alternating hemiplegia	Marathon Pharmaceuticals, LLC
1976	fluticasone propionate	n/a	1/19/2011	Treatment of pediatric and adult eosinophilic esophagitis	Forest Laboratories, Inc.
1977	fosfomycin/tobramycin	n/a	11/28/2008	Treatment of pulmonary infections associated with cystic fibrosis	CURx Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1978	fresolimumab	n/a	10/21/2010	Treatment of primary focal segmental glomerulosclerosis	Genzyme
1979	fusion protein analog with recombinant human growth hormone (rhGH) at once-a-month dosing	n/a	10/16/2013	Treatment of growth hormone deficiency	Versartis, Inc.
1980	gabapentin	Neurontin	7/5/1995	Treatment of amyotrophic lateral sclerosis	Warner-Lambert Company
1981	gabapentin	Gralise	11/8/2010	Management of postherpetic neuralgia	Depomed, Inc.
1982	gabapentin enacarbil	Horizant	6/7/2011	Treatment of postherpetic neuralgia	XenoPort, Inc.
1983	ganciclovir	Zirgan	3/22/2007	Treatment of acute herpetic keratitis (dendritic and geographic ulcers)	Sirion Therapeutics, Inc.
1984	gefitinib	n/a	8/26/2014	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer.	AstraZeneca Pharmaceuticals LP
1985	gemcabene	n/a	2/6/2014	Treatment of homozygous familial hypercholesterolemia	Michigan Life Therapeutics, LLC
1986	gene encoding chimeric CD40 ligand	n/a	2/4/2009	Treatment of chronic lymphocytic leukemia	Memgen, LLC
1987	genetically engineered herpes simplex virus (G207)	n/a	4/29/2002	Treatment of malignant glioma	Aettis, Inc.
1988	gevokizumab	n/a	2/21/2014	Treatment of pyoderma gangrenosum	XOMA (US) LLC
1989	gevokizumab	n/a	7/27/2010	Treatment of Behcet's disease	XOMA (US) LLC

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1990	gevokizumab	n/a	8/20/2012	Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis	XOMA (US) LLC
1991	givinostat	n/a	4/12/2013	Treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	Italfarmaco SpA
1992	glatiramer acetate	Copaxone	11/14/2007	Treatment of amyotrophic lateral sclerosis (ALS).	Teva Neurosciences, Inc.
1993	glioma derived cell lysates and irradiated cells	n/a	1/12/2011	Treatment of glioma.	Epitopoietic Research Corp.
1994	glucagon	n/a	12/5/2012	Prevention of hypoglycemia in the congenital hyperinsulinism population	Biodel, Inc.
1995	glucagon infusion	G-Pump (Tm)	9/25/2014	Prevention of chronic, severe hypoglycemia related to congenital hyperinsulinism	Xeris Pharmaceuticals, Inc.
1996	glucarpidase	Voraxaze	8/19/2003	Treatment of patients at risk of methotrexate toxicity	BTG International Inc.
1997	glufosfamide	n/a	9/18/2006	For treatment of pancreatic cancer.	Eleison Pharmaceuticals LLC
1998	glycylafilin	n/a	8/22/2008	Prevention of delayed graft function after solid organ transplantation	ProtAffin Biotechnologie AG
1999	glycerol phenylbutyrate	Ravicti	4/27/2009	Maintenance treatment of patients with deficiencies in enzymes of the urea cycle	Hyperion Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2000	glycopyrrolate	Cuvposa	6/9/2006	Treatment of pathologic (chronic moderate to severe) drooling in pediatric patients	Shionogi, Inc.
2001	glycopyrrolate 2%	n/a	6/17/2010	Treatment of Frey's syndrome	Wellesley Therapeutics, Inc.
2002	glycosylated recombinant human interleukin-7	n/a	9/27/2012	Treatment of progressive multifocal leukoencephalopathy	Cytheris, Inc.
2003	glycyl-L-2-methylprolyl-L-glutamic Acid	n/a	10/23/2013	Treatment of Fragile X Syndrome	Neuren Pharmaceuticals, Ltd.
2004	glycyl-L-2-methylpropyl-L-glutamic acid	n/a	2/11/2015	Treatment of Rett syndrome	Neuren Pharmaceuticals, Ltd.
2005	golimumab	Simponi	3/16/2012	Treatment of pediatric ulcerative colitis	Janssen Biotech, Inc.
2006	golnerminogene pradenovec	Tnferade(Tm) Biologic	10/28/2009	Treatment of pancreatic cancer.	GenVec, Inc.
2007	granulocyte macrophage colony stimulating factor	n/a	8/27/2008	Treatment of cystic fibrosis	DrugRecure Aps
2008	granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus, Ad5/3-D24-GMCSF	n/a	7/24/2013	Treatment of soft tissue sarcoma	Oncos Therapeutics Ltd
2009	guanfacine	Tenex	8/5/1999	Treatment of fragile X syndrome.	Watson Laboratories, Inc.
2010	gusperimus trihydrochloride	n/a	6/29/2011	Treatment of Wegener's granulomatosis	Nordic Group B.V.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2011	glyceryl tri (4-pheynlybutyrate)	n/a	9/3/2009	For intermittent or chronic treatment of patients with cirrhosis and any grade hepatic encephalopathy.	Hyperion Therapeutics, Inc.
2012	hRS7-SN-38 IgG Conjugate	n/a	11/27/2013	Treatment of small cell lung cancer	Immunomedics, INc.
2013	halofuginone hydrobromide	n/a	10/13/2011	Treatment of Duchenne Muscular Dystrophy	Halo Theraeputics, LLC
2014	heat killed Mycobacterium w immunomodulator	Cadi Mw	9/3/2004	Active tuberculosis	Cadila Pharmaceuticals Limited, Inc.
2015	heat killed mycobacterium w immunomodulator	Cadi Mw	11/21/2002	Adjuvant to multi-drug therapy in the management of multibacillary leprosy	CPL, Inc.
2016	heat killed mycobacterium w immunomodulator	Cadi-Mw	7/31/2012	Treatment of non-small cell lung cancers that express desmocollin-3	Cadila Pharmaceuticals Limited
2017	heat killed whole cell mycobacterium obuense	n/a	9/23/2014	Treatment of pancreatic cancer	Immodulon Therapeutics Limited
2018	hematopoietic stem and progenitor cells expanded ex-vivo with a low molecular weight aryl hydrocarbon receptor (AHR) antagonist	n/a	8/27/2014	Hematopoietic support in patients with acute lymphoblastic leukemia (ALL)	Novartis Pharmaceuticals Corporation
2019	heparan sulfate mimetic	n/a	5/29/2014	Treatment of pancreatic cancer	Momenta Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2020	heparin activated recombinant human fibroblast growth factor 1 (FGF1)in combination with a surgically implanted biodegradable device	n/a	10/24/2011	Treatment of patients with a confirmed traumatic complete spinal cord injury where no motor or sensory function is preserved below the injury(Scale A)	BioArctic Neuroscience AB
2021	hepatitis B immune globulin (human)	Hepagam	3/24/2008	Prevention of hepatitis B recurrence following orthotopic liver transplant	Cangene Corporation
2022	hepatitis B virus neutralizing human monoclonal antibody	Hepabig Gene	5/6/2013	Prevention of hepatitis B recurrence following liver transplantation	Green Cross Corp.
2023	hepcortespensilisimut-L	n/a	12/17/2014	Treatment of hepatocellular carcinoma	Immunitor, Inc.
2024	herpes simplex Type-1 virus encoded with human granulocyte-	Oncovexgm-Csf	3/14/2011	Treatment of stage IIb-stage IV melanoma	BioVex, Inc.
2025	herpes simplex type 1 virus containing cellular B-myb gene as tumor-specific promoter	n/a	12/23/2014	Treatment of pancreatic cancer	Karcinolys S.A.S.
2026	heterologous human adult liver derived progenitor cells (HHALPC)	n/a	1/13/2012	Treatment of urea cycle disorders	Promethera Biosciences
2027	heterologous human liver derived progenitor cells	n/a	3/9/2012	Treatment of Crigler-Najjar syndrome	Promethera Biosciences
2028	hexasodium phytate	n/a	12/2/2012	Treatment of calciphylaxis	Laboratoris Sanifit, S.L.
2029	homoharringtonine	n/a	2/8/2002	Treatment for chronic myelogenous leukemia	American BioScience, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2030	human Hepatocarcinoma-Intestine-pancreas/pancreatitis associated protein	n/a	5/11/2011	Treatment of acute liver failure	Alfact Innovation SAS
2031	human IgG1k monoclonal antibody	n/a	10/16/2013	Treatment of systemic sclerosis	MedImmune
2032	human MHC non-restricted cytotoxic T-cell line	n/a	7/6/2012	Treatment of ovarian cancer	Galileo Research srl
2033	human allogeneic bone marrow derived osteoblastic cells	Allob	1/10/2014	Treatment of osteonecrosis	Bone Therapeutics SA
2034	human anti-CD4 monoclonal antibody	Humax-Cd4	8/13/2004	Treatment of mycosis fungoides	Emergent Product Development Seattle, LLC
2035	human anti-cellular adhesion molecule-1 monoclonal antibody	n/a	7/29/2008	Treatment of multiple myeloma	BioInvent International AB
2036	human anti-transforming growth factor-B1,2,3	n/a	7/9/2004	Treatment of idiopathic pulmonary fibrosis	Genzyme Corporation
2037	human coagulation factor VIII	Octanate	12/3/2012	Immune tolerance induction in hemophilia A patients with inhibitors	OCTAPHARMA USA, Inc.
2038	human coagulation factor XI	Hemoleven	11/8/2007	Treatment of severe congenital Factor XI deficiency.	Laboratoire francais du Fractionnement et des Biot
2039	human fibrinogen concentrate, pasteurized	Riastap	3/13/2008	Treatment of fibrinogen deficient patients.	CSL Behring, LLC
2040	human fully IgG1 antibody specific for CD33	n/a	6/19/2014	Treatment of acute myeloid leukemia	Boehringer Ingelheim Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2041	human gammaglobulin	Oralgam	5/25/2001	Treatment for juvenile rheumatoid arthritis	Latona Life Sciences, Inc.
2042	human gammaglobulin	Oralgam	11/14/2003	Treatment of idiopathic inflammatory myopathies	Latona Life Sciences, Inc.
2043	human gammaglobulin	Oralgam	9/16/2002	Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism in pediatric patients.	Latona Life Sciences, Inc.
2044	human glial restricted progenitor cells and their progeny	Q-Cells	9/11/2013	Treatment of amyotrophic lateral sclerosis	Q Therapeutics, Inc.
2045	human haptoglobin	n/a	11/19/2013	Treatment of sickle cell disease	BioProducts Laboratory Limited
2046	human heterologous liver cells	n/a	2/14/2011	Treatment of urea cycle disorders	Cytonet GmbH & Co. KG
2047	human insulin beta chain peptide with incomplete Freund's adjuvant vaccine	n/a	2/11/2013	Treatment of Type 1 diabetes patients with residual beta cell function	Orban Biotech, LLC
2048	human interleukin-3 genetically conjugated to diphtheria toxin protein	n/a	6/6/2013	Treatment of blastic plasmacytoid dendritic cell neoplasm	Stemline Therapeutics, Inc.
2049	human interleukin-3 genetically conjugated to diphtheria toxin protein	n/a	2/18/2011	Treatment of acute myeloid leukemia.	Stemline Therapeutics, Inc.
2050	human laminin-111	n/a	9/23/2011	Treatment of merosin (laminin-alpha2) deficient congenital muscular dystrophy type 1A.	Prothelia, Inc.
2051	human leukocyte antigen-A2 restricted peptides	n/a	1/26/2015	Treatment of glioma.	Stemline Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2052	human leukocyte-derived cytokine mixture	n/a	7/7/2005	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	IRX Therapeutics, Inc.
2053	human monoclonal IgG2 to human proprotein convertase subtilisin/kexin type 9	n/a	9/12/2013	Treatment of homozygous familial hypercholesterolemia	Amgen Inc.
2054	human monoclonal anti-PA antibody	n/a	10/21/2010	For post-exposure prophylaxis and treatment of inhalation anthrax.	Emergent Product Development Gaithersburg, Inc.
2055	human monoclonal antibody against human interleukin 13 (IL-13)	n/a	10/15/2013	Treatment of eosinophilic esophagitis	Novartis Pharmaceuticals Corporaton
2056	human monoclonal antibody directed against active plasma kallikrein	n/a	11/16/2013	Treatment of hereditary angioedema (HAE)	Dyax Corporation
2057	human monoclonal antibody directed against serotype O1 Pseudomonas aeruginosa	n/a	1/6/2010	Treatment of pneumonia caused by serotype O1 positive Pseudomonas aeruginosa	Kenta Biotech Limited
2058	human plasminogen	n/a	6/7/2010	Treatment of ligneous conjunctivitis	Kedrion, S.p.A.
2059	human platelet antigen-1a immunoglobulin (anti-HPA-1a)	Tromplate	6/27/2013	Prevention of fetal and neonatal alloimmune thrombocytopenia	Prophylix Pharma AS
2060	human recombinant DNA-derived, IgG1 kappa monoclonal anti-body to connective growth factor	n/a	7/6/2012	Treatment of idiopathic pulmonary fibrosis	FibroGen, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2061	human recombinant mesencephalic, astrocyte derived neurotrophic factor	n/a	12/22/2014	Treatment of retinitis pigmentosa	Amarantus BioScience Holdings, Inc.
2062	human retinal progenitor cells	n/a	7/23/2012	Treatment of retinitis pigmentosa	jCyte, Inc.
2063	human spinal cord derived neural stem cells	n/a	2/4/2011	Treatment of amyotrophic lateral sclerosis	Neuralstem, Inc.
2064	human trivalent, bi-specific monoclonal antibody that binds and co-inhibits two growth factor receptors; insulin-like growth factor receptor 1 (IGF-1R) and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (ErbB3)	n/a	10/22/2014	Treatment of pancreatic cancer	Merrimack Pharmaceuticals, Inc.
2065	human tumor necrosis factor coupled to the C terminus of CNGRCG peptide	n/a	10/1/2009	Treatment of liver cancer	Molecular Medicine S.p.A. (Molmed)
2066	human umbilical cord blood-derived mesenchymal stem cells	Pneumostem	11/26/2013	Prevention of bronchopulmonary dysplasia	MEDIPOST America, Inc.
2067	humanized Fc engineered monoclonal antibody against CD19	n/a	12/1/2014	Treatment of diffuse large B-cell lymphoma.	MorphoSys AG
2068	humanized Fc engineered monoclonal antibody against CD19	n/a	4/29/2014	Treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma	MorphoSys AG

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2069	humanized IgG1 anti-serum amyloid A monoclonal antibody	n/a	2/17/2012	Treatment of AA amyloidosis and AL amyloidosis	Onclave Therapeutics Limited
2070	humanized IgG1 monoclonal anti-CD20 antibody	n/a	5/26/2011	Treatment of follicular lymphoma	MENTRIK Biotech, LLC
2071	humanized IgG2 antibody	n/a	7/22/2008	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	Selexys Pharmaceuticals Corp.
2072	humanized IgG4 monoclonal antibody	n/a	12/12/2011	Prevention of ischemia/reperfusion injury associated with solid organ transplantation	Opsona Therapeutics
2073	humanized anti-IL-6R receptor neutralizing IgG2 monoclonal antibody	n/a	6/30/2014	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	Chugai Pharma USA, LLC
2074	humanized immunoglobulin monoclonal antibody against CD38	n/a	5/22/2014	Treatment of multiple myeloma.	Sanofi-Aventis U.S., LLC
2075	humanized monoclonal antibodies hu1B7 and hu11E6	n/a	9/11/2014	Treatment of Bordetella pertussis	Synthetic Biologics, Inc.
2076	humanized monoclonal antibody against human integrin alphaVbeta6	n/a	8/5/2010	Treatment of idiopathic pulmonary fibrosis	Biogen Idec, Inc.
2077	humanized monoclonal antibody to tissue factor	n/a	4/26/2011	Treatment of pancreatic cancer.	Morphotek, Inc.
2078	humanized monoclonal antibody against human integrin alphaVbeta6	n/a	6/18/2008	Treatment of fibrosis-associated chronic allograft nephropathy in kidney transplant patients.	Stromedix, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2079	humanized single chain monoclonal antibody(scFV: IgG1 hinge: IgG1 CH2 and CH3 domains)	n/a	11/17/2011	Treatment of chronic lymphocytic leukemia	Emergent Product Development Seattle, LLC
2080	humanized, afucosylated IgG1 kappa monoclonal antibody	n/a	12/3/2009	Treatment of scleroderma	MedImmune
2081	hyaluronic acid	n/a	3/19/2002	Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency	CoTherix
2082	hydralazine - magnesium valproate	Transkrip(R)	3/17/2011	Treatment of myelodysplastic syndrome	Neolpharma S.A. de C.V.
2083	hydralazine - magnesium valproate	Transkrip(R)	3/17/2011	Treatment of cutaneous T-cell lymphoma.	Neolpharma S.A.DE C.V.
2084	hydrocortisone modified release tabs	Duocort	6/18/2008	Treatment of adrenal insufficiency	Shire ViroPharma, Inc.
2085	hydroxycarbamide (hydroxyurea)	Siklos	7/24/2013	Treatment of sickle cell disease in patients under 18 years of age	addmedica Laboratories
2086	hydroxyprogesterone caproate	Makena	1/25/2007	Prevention of preterm birth in singleton pregnancies	KV Pharmaceutical Company
2087	hydroxyurea	n/a	4/15/2005	Treatment of pediatric patients with sickle cell anemia.	UPM Pharmaceuticals, Inc.
2088	ibalizumab	n/a	10/20/2014	Treatment of HIV-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of HIV-1 replication despite ongoing antiretroviral therapy	TaiMed Biologics, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2089	ibrutumomab tiuxetan	Zevalin	9/6/1994	Treatment of B-cell non-Hodgkin's lymphoma.	Spectrum Pharmaceuticals, Inc.
2090	ibrutinib	Imbruvica	2/5/2015	Treatment of nodal marginal zone lymphoma	Pharmacyclics, Inc.
2091	ibrutinib	Imbruvica	2/5/2015	Treatment of splenic marginal zone lymphoma	Pharmacyclics, Inc.
2092	ibrutinib	Imbruvica	4/6/2012	Treatment of chronic lymphocytic leukemia (CLL)	Pharmacyclics, Inc.
2093	ibrutinib	Imbruvica	12/3/2012	Treatment of mantle cell lymphoma	Pharmacyclics, Inc.
2094	ibrutinib	n/a	5/30/2013	Treatment of small lymphocytic lymphoma	Pharmacyclics, Inc.
2095	ibrutinib	n/a	5/16/2013	Treatment of multiple myeloma	Pharmacyclics, Inc.
2096	ibrutinib	n/a	10/23/2013	Treatment of diffuse large B-cell lymphoma	Pharmacyclics, Inc.
2097	ibrutinib	Imbruvica	10/15/2013	Treatment of Waldenstrom's macroglobulinemia	Pharmacyclics, Inc.
2098	ibrutinib	n/a	9/8/2014	Treatment of follicular lymphoma	Pharmacyclics, Inc.
2099	icatibant	Firazyr	11/25/2003	Treatment of angioedema	Shire Orphan Therapies
2100	idebenone	n/a	3/25/2004	Treatment of Friedreich's ataxia	Santhera Pharmaceuticals LLC
2101	idebenone	n/a	2/16/2007	Treatment of Duchenne muscular dystrophy	Santhera Pharmaceuticals Limited
2102	idebenone	n/a	10/31/2006	Treatment of Leber's hereditary optic neuropathy.	Santhera Pharmaceuticals Limited

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2103	idebenone	n/a	5/22/2009	Treatment of mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes syndrome (MELAS)	Santhera Pharmaceuticals Limited
2104	idelalisib	n/a	10/15/2013	Treatment of extranodal marginal zone lymphoma	Gilead Sciences, Inc.
2105	idelalisib	n/a	10/15/2013	Treatment of nodal marginal zone lymphoma.	Gilead Sciences, Inc.
2106	idelalisib	Zydelig	9/26/2013	Treatment of follicular lymphoma	Gilead Sciences, Inc.
2107	idelalisib	n/a	9/26/2013	Treatment of lymphoplasmacytic lymphoma with or without Walenstrom's macroglobulinemia	Gilead Sciences, Inc.
2108	idelalisib	Zydelig	10/15/2013	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Gilead Sciences, Inc
2109	idelalisib	n/a	10/15/2013	Treatment of splenic marginal zone lymphoma	Gilead Sciences, Inc.
2110	idelalisib	n/a	8/25/2011	Treatment of chronic lymphocytic leukemia	Gilead Sciences, Inc.
2111	idursulfase	Elaprase	11/28/2001	Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome)	Shire Human Genetic Therapies, Inc.
2112	idursulfase IT	n/a	9/3/2009	For treatment of neurocognitive symptoms associated with Hunter Syndrome	Shire Human Genetic Therapies

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2113	idursulfase beta	n/a	2/11/2013	Treatment of Hunter Syndrome (mucopolysaccharidoses)	Green Cross Corp.
2114	iduvec	n/a	1/21/2011	Treatment of Mucopolysaccharidosis Type I	Zebraic Corporation
2115	iferanserin (S-MPEC)	n/a	12/13/2010	For use in pulmonary arterial hypertension.	Sam Amer & Company, Inc.
2116	iloprost	n/a	4/6/2012	Treatment of pulmonary arterial hypertension	Algorithm Sciences, LLC
2117	imatinib	Gleevec	10/11/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Novartis Pharmaceuticals Corporation
2118	imatinib mesylate	Gleevec	12/19/2005	Treatment of dermatofibrosarcoma protuberans	Novartis Pharmaceuticals Corporation
2119	imatinib mesylate	Gleevec	11/1/2001	Treatment of gastrointestinal stromal tumors	Novartis Pharmaceuticals Corp.
2120	imatinib mesylate	n/a	5/6/2014	Treatment of progressive multifocal leukencephalopathy	Inhibikase Therapeutics, Inc.
2121	imexon	Amplimexon	8/12/2005	Treatment of ovarian cancer.	AmpliMed Corporation
2122	immune globulin (human)	n/a	3/2/2010	Treatment of Guillain-Barre syndrome	Octapharma USA, Inc.
2123	immune globulin infusion (human)	Gammagard Liquid	7/20/2006	Treatment of multifocal motor neuropathy	Baxter Healthcare Corporation
2124	immune globulin intravenous (human)	Gammaplex	4/29/2011	Treatment of idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia)	Bio Products Laboratory

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2125	inBreath airway transplant system	n/a	9/4/2014	To restore the structure and/or function of the trachea subsequent to tracheal damage due to cancer, injury or infection	Harvard Apparatus Regenerative Technology, Inc.
2126	infliximab	Remicade	11/14/1995	Treatment of Crohn's disease	Centocor, Inc.
2127	infliximab	Remicade	11/12/2003	Treatment of pediatric (0 to 16 years of age) ulcerative colitis	Janssen Biotech Inc.
2128	infliximab	Remicade	10/23/2002	Treatment of juvenile rheumatoid arthritis	Centocor, Inc.
2129	inhibitor of microRNA-451	n/a	2/4/2011	Treatment of polycythemia vera	miRagen Therapeutics, Inc.
2130	inolimomab	Leukotac	10/23/2002	Treatment of graft versus host disease	Jazz Pharmaceuticals
2131	inotuzumab ozogamicin	n/a	3/25/2013	Treatment of B-cell acute lymphoblastic leukemia	Pfizer, Inc.
2132	insecticidal toxin derived from Bacillus thuringiensis	n/a	9/5/2008	Treatment of soil transmitted helminth infection strongyloidiasis	University of California, San Diego
2133	interferon gamma	n/a	11/4/2011	Treatment of Friedreich's ataxia	Roberto Testi, MD
2134	interferon gamma-1b	Actimmune	10/1/2014	Treatment of Friedreich's Ataxia	Horizon Pharma Ireland Limited
2135	interferon-alpha secreting autologous micro-organ tissue converting into a biopump	Infradure Biopump	6/14/2012	Treatment of chronic hepatitis D	Medgenics, Inc.
2136	intravenous carbamazepine	n/a	6/27/2013	Treatment of epilepsy patients who cannot take anything by mouth (NPO)	Lundbeck, LLC

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2137	iobenguane I 131	n/a	7/5/2007	Treatment of neuroendocrine tumors	Jubilant DraxImage, Inc.
2138	iobenguane sulfate I-123	Omaclear	10/21/2005	For the detection, localization, and staging of pheochromocytomas.	Brogan Pharmaceuticals, Inc.
2139	ipilimumab	Yervoy	6/3/2004	Treatment of high risk Stage II, Stage III, and Stage IV melanoma	Bristol-Myers Squibb Pharmaceutical Research Insti
2140	iron(III)-hexacyanoferrate(II)	Radiogardase	5/1/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Heyl Chemisch-Pharmzeitische Fabrik GMBH & Co, KG
2141	isavuconazonium sulfate	n/a	5/6/2013	Treatment of invasive aspergillosis.	Astellas
2142	isavuconazonium sulfate	n/a	10/25/2013	Treatment of zygomycosis	Astellas
2143	isavuconazonium sulfate	n/a	10/20/2014	Treatment of invasive candidiasis/candidemia	Astellas Pharma Global Development, Inc.
2144	isocitrate dehydrogenase 2-mutant inhibitor	n/a	6/12/2014	Treatment of acute myelogenous leukemia	Celgene Corporation
2145	isofagomine tartrate	n/a	1/10/2006	Treatment of Gaucher disease	Amicus Therapeutics, Inc.
2146	isotretinoin	n/a	4/10/2014	Treatment of congenital ichthyosis	Patagonia Pharmaceuticals, LLC
2147	ivacaftor	Kalydeco	12/20/2006	Treatment of patients with cystic fibrosis	Vertex Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2148	ixazomib citrate	n/a	2/18/2011	Treatment of multiple myeloma	Millennium Pharmaceuticals
2149	ketotifen	n/a	2/25/2015	Treatment of mastocytosis	Melbourne Laboratories LLC
2150	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Steptococci)	n/a	1/15/2002	Treatment of active chronic pouchitis	VSL Pharmaceuticals, Inc.
2151	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)	n/a	1/15/2002	Prevention of disease relapse in patients with chronic pouchitis	VSL Pharmaceuticals, Inc.
2152	lactobacillus brevis CD2	n/a	10/4/2011	Treatment Behcet's disease	VSL Pharmaceuticals, Inc.
2153	laminin-111 (human)	n/a	7/21/2011	Treatment of Duchenne Muscular Dystrophy	Prothelia, Inc.
2154	lanreotide acetate	n/a	9/8/2011	Treatment of symptoms associated with carcinoid syndrome	Ipsen Biopharmaceuticals, Inc.
2155	lanreotide acetate	Somatuline Depot	8/25/2011	Treatment of neuroendocrine tumors	Ipsen Biopharmaceuticals, Inc.
2156	lapatinib	Tykerb	5/29/2009	Treatment of ErbB2 positive gastric cancer	GlaxoSmithKline
2157	lapatinib ditosylate hydrochloride	Tykerb	5/29/2009	Treatment of ErbB2 positive esophageal cancer	GlaxoSmithKline
2158	laromustine	Onorigin	10/21/2004	Treatment of acute myelogenous leukemia	Vion Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2159	laronidase	Aldurazyme	9/24/1997	Treatment of patients with mucopolysaccharidosis-I.	BioMarin Pharmaceutical, Inc.
2160	late stage human motor neuron progenitors	Motorgraft(Tm)	11/25/2009	Treatment of spinal muscular atrophy	California Stem Cell, Inc.
2161	lenalidomide	Revlimid	9/13/2013	Treatment of follicular lymphoma	Celgene Corporation
2162	lenalidomide	Revlimid	4/27/2009	Treatment of mantle cell lymphoma	Celgene Corporation
2163	lenalidomide	Revlimid	1/17/2007	Treatment of chronic lymphocytic leukemia	Celgene Corporation
2164	lenalidomide	Revlimid	9/20/2001	Treatment for multiple myeloma	Celgene Corporation
2165	lenalidomide	Revlimid	1/29/2004	Treatment of myelodysplastic syndromes	Celgene Corporation
2166	lenalidomide	Revlimid	3/28/2011	Treatment of diffuse large B-cell lymphoma	Celgene Corporation
2167	lenvatinib	n/a	3/27/2014	Treatment of hepatocellular carcinoma	Eisai, Inc.
2168	lenvatinib	n/a	3/26/2014	Treatment of stage IIB to Stage IV melanoma	Eisai, Inc.
2169	lenvatinib	Lenvima	12/27/2012	Treatment of follicular, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer	Eisai, Inc.
2170	lestaurtinib	n/a	9/3/2009	Treatment of Philadelphia-negative classic myeloproliferative disorders	Teva Branded Pharmaceutical Products R&D, Inc.
2171	letermovir	n/a	12/12/2011	Prevention of human cytomegalovirus viremia and disease in at risk populations	Merck Sharpe & Dhome Corporation

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2172	leukocyte interleukin	Multikine	5/4/2007	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	CEL-SCI Corporation
2173	leukotriene A4 hydrolase inhibitor	n/a	1/26/2015	Treatment of cystic fibrosis	Celtaxsys, Inc.
2174	levetiracetam	Keppra	4/30/2010	Treatment of neonatal seizures	University of California
2175	levoleucovorin	Fusilev	12/18/1990	For use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum	Spectrum Pharmaceuticals, Inc.
2176	levomefolate calcium	n/a	2/10/2015	Treatment of megaloblastic anemia caused by folate deficiency	Cox Biosciences LLC
2177	levothyroxine sodium	n/a	4/26/2011	The preservation of organ function in brain-dead organ donors.	Fera Pharmaceuticals, LLC
2178	liarozole	n/a	6/18/2004	Treatment of congenital ichthyosis	Stiefel Laboratories, Inc.
2179	liposomal amikacin	Arikace	3/25/2013	Treatment infections caused by non-tuberculous mycobacteria	Insmed Incorporated
2180	liposomal amikacin	Arikace	8/25/2009	Treatment of bronchiectasis in patients with Pseudomonas aeruginosa or other susceptible microbial pathogens	Insmed, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2181	liposomal busulfan	Busulipo	6/24/2013	For use as a conditioning regimen for patients with malignancies undergoing autologous or allogenic hematopoietic stem cell transplantation	Pharmalink AB
2182	liposomal ciprofloxacin plus ciprofloxacin	n/a	6/1/2012	For the management of cystic fibrosis	Aradigm Corporation
2183	liposomal cyclosporine	n/a	5/11/2009	Treatment of bronchiolitis obliterans	PARI Pharma GmbH
2184	liposomal cyclosporine for inhalation	n/a	6/24/2008	Prevention of bronchiolitis obliterans.	PARI Pharma GmbH
2185	liposomal encapsulated paclitaxel	n/a	1/21/2015	Treatment of ovarian cancer	Insys Therapeutics, Inc.
2186	liposomal gadodiamide	n/a	11/12/2008	Treatment of glioma.	MedGenesis Therapeutix, Inc.
2187	liposomal irinotecan	n/a	7/21/2011	Treatment of pancreatic cancer	Merrimack Pharmaceuticals, Inc.
2188	liposomal p-ethoxy growth receptor bound protein-2 antisense product	n/a	12/5/2003	Treatment of chronic myelogenous leukemia	Bio-Path, Inc.
2189	liposomal topotecan hydrochloride	n/a	10/30/2008	Treatment of gliomas	MedGenesis Therapeutix, Inc.
2190	liposomal β -galactosylceramide	Lip. Alpha Galactosylceramide	9/28/2012	Prevention of graft-versus-host disease	REGiMMUNE Corporation
2191	liposome encapsulated paclitaxel	n/a	12/3/2014	Treatment of gastric cancer	Insys Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2192	lisinopril oral solution	n/a	1/27/2015	Treatment of primary hypertension with complications and secondary hypertension in pediatric patients (ages 0 through 16 years of age)	codaDose, Inc.
2193	listeria monocytogenes	n/a	9/5/2013	Treatment of pancreatic cancer	Aduro BioTech, Inc.
2194	lisuride	n/a	1/17/2013	Treatment of pulmonary arterial hypertension	Sinova Pharma GmbH
2195	lithium citrate tetrahydrate (in reverse micelle formulation)	n/a	12/13/2010	Treatment of Huntington's disease.	Medesis Pharma
2196	live attenuated E. Coli expressing Beta catenin shRNA	n/a	12/20/2010	Treatment of Familial Adenomatous Polyposis	Marina Biotech
2197	live attenuated bioengineered Listeria monocytogenes immunotherapy	n/a	5/21/2014	Treatment of osteosarcoma.	Advaxis, Inc.
2198	live attenuated bioengineered Listeria monocytogenes immunotherapy	n/a	11/4/2013	Treatment of human papilloma virus-associated head and neck cancer	Advaxis, Inc.
2199	lomitapide	n/a	3/3/2011	Treatment of Familial Chylomicronemia	Aegerion Pharmaceuticals, Inc.
2200	lomitapide	Juxtapid	10/23/2007	Treatment of homozygous familial hypercholesterolemia	Aegerion Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2201	lonafarnib	n/a	4/18/2011	Treatment of Hutchinson-Gilford progeria syndrome	The Progeria Research Foundation, Inc.
2202	long acting recombinant Factor VIIa-CTP3	n/a	2/27/2014	Treatment and prophylaxis of bleeding episodes in patients with hemophilia A or B with inhibitors to factor VIII or factor IX	PROLOR Biotech, Ltd
2203	losartan	n/a	12/12/2011	Treatment of Marfan Syndrome	National Marfan Foundation
2204	low molecular weight dextran sulfate	lbsolvmir(R)	7/6/2011	Treatment to mobilize progenitor cells prior to stem cell transplantation	TikoMed AB
2205	low molecular weight dextran sulfate	lbsolvmir	10/20/2009	Prevention of graft rejection during pancreatic islet transplantation	TikoMed AB
2206	lumacaftor and ivacaftor	n/a	6/30/2014	Treatment of cystic fibrosis	Vertex Pharmaceuticals Inc.
2207	lurbinectedin	n/a	8/20/2012	Treatment of ovarian cancer	Pharma Mar USA Inc.
2208	lyso-thermosensitive liposomal doxorubicin	Thermodox (R)	3/17/2009	Treatment of hepatocellular carcinoma	Celsion Corporation
2209	lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase	n/a	9/10/2008	Treatment of mucopolysaccharidosis Type IVA (Morquio Syndrome)	Vivendy Therapeutics LTD
2210	mPEG-r-crisantaspase	Asparec(Tm)	2/1/2010	Treatment of acute lymphoblastic leukemia.	Jazz Pharmaceuticals, Inc.
2211	mTOR kinase inhibitor (CC-223)	n/a	10/16/2013	Treatment of hepatocellular carcinoma	Celgene Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2212	macitentan	Opsumit	9/3/2009	Treatment of pulmonary arterial hypertension	Actelion Pharmaceuticals Ltd
2213	manganese (II) chloride tetrahydrate (with L-alanine and vitamin D3 as promoters of absorption)	n/a	9/26/2013	Use as a targeted contrast agent for diagnostic MRI for the detection and localization of focal liver lesions in patients where gadolinium based contrast agents are contraindicated or cannot be administered	CMC Contrast AB
2214	mannopentaose phosphate sulfate	n/a	4/27/2004	Treatment of high-risk Stage II, Stage III, and Stage IV melanoma	Medigen Biotechnology Corp.
2215	maribavir	n/a	2/1/2007	Prevention of cytomegalovirus viremia and disease in the populations at risk.	Shire ViroPharma, Inc.
2216	maribavir	n/a	6/7/2011	Treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients.	Shire ViroPharma, Inc.
2217	masitinib	n/a	4/20/2005	Treatment of malignant gastrointestinal stromal tumors	AB Science
2218	masitinib	n/a	7/21/2009	Treatment of patients with pancreatic cancer	AB Science
2219	maytansinoid conjugated humanized monoclonal antibody against FOLRI	n/a	7/14/2014	Treatment of ovarian cancer	ImmunoGen, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2220	mebendazole	Vermox 500 Mg Chewable Tablets	9/3/2014	Treatment of single or mixed gastrointestinal infestations by Trichuris trichiura (whipworm), Ascaris lumbricoides (large roundworm), and Ancylostoma duodenale and Nectar americanus (hookworm).	Janssen Pharmaceutical Research & Development, LLC
2221	mecasermin	Iplex	12/3/2007	Treatment of myotonic dystrophy	Insmmed, Inc.
2222	mecasermin rinfabate	Iplex	5/17/2002	Treatment of growth hormone insensitivity syndrome (GHIS)	Insmmed, Inc.
2223	mecasermin rinfabate	n/a	9/20/2012	Prevention of retinopathy of prematurity in premature infants born at risk for the disease	Premacure AB
2224	mecasermin rinfabate	Iplex	7/23/2012	Treatment of amyotrophic lateral sclerosis	PCUT BioPartners, Inc.
2225	meclorothamine	Valchlor	8/17/2004	Treatment of mycosis fungoides	Actelion Pharmaceuticals Ltd.
2226	mefloquine HCL	Lariam	4/13/1988	For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs	Hoffmann-La Roche, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2227	melarsoprol-hydroxypropylbetadex	n/a	9/13/2013	Treatment of human African trypanosomiasis (sleeping sickness)	Peter Kennedy, CBE, MD, PhD, DSc, FRCP FMedSci,
2228	melatonin	n/a	4/12/2013	Treatment of neonatal hypoxic ischemic encephalopathy	Scharper S.p.A.
2229	meloxicam	Mobic	11/22/2002	Treatment of juvenile rheumatoid arthritis	Boehringer Ingelheim Pharmaceuticals, Inc.
2230	melphalan	n/a	11/19/2012	Treatment of retinoblastoma	Icon Bioscience, Inc.
2231	melphalan	n/a	11/24/2008	High dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation	Spectrum Pharmaceuticals, INC.
2232	melphalan	n/a	11/19/2012	Treatment of Stage IIB through IV melanoma	OncoTx, LLC
2233	melphalan hydrochloride	n/a	9/26/2013	Treatment of patients with hepatocellular carcinoma	Delcath Systems, Inc.
2234	melphalan hydrochloride	n/a	11/12/2008	Treatment of patients with cutaneous melanoma.	Delcath Systems, Inc.
2235	melphalan hydrochloride	n/a	11/12/2008	Treatment of patients with ocular (uveal) melanoma.	Delcath Systems, Inc.
2236	melphalan hydrochloride	n/a	5/22/2009	Treatment of neuroendocrine tumors	Delcath Systems, Inc.
2237	menadione sodium bisulfite	n/a	5/14/2014	Treatment of autosomal dominant polycystic liver disease	IC-MedTech Corporation
2238	menaquinone	Menaquinonegold	9/4/2012	Treatment of calciophylaxis	Nu Science Trading, LLC

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2239	menatetrenone	Mk4	3/17/2011	Treatment of acute myeloid leukemia	NBI Pharmaceuticals, Inc.
2240	menatetrenone	Mk4(R)	11/2/2010	Treatment of hepatocellular carcinoma (HCC).	NBI Pharmaceuticals, Inc.
2241	menatetrenone	Mk4(R)	11/2/2010	Treatment of acute promyelocytic leukemia.	NBI Pharmaceuticals, Inc.
2242	menatetrenone	Mk4(R)	2/4/2011	Treatment of myelodysplastic syndrome.	NBI Pharmaceuticals, Inc.
2243	menatetrenone and Vitamin D3	n/a	8/22/2011	Treatment of myelodysplastic syndrome	NBI Pharmaceuticals, Inc.
2244	mepivacaine	n/a	10/18/2006	Treatment of painful HIV-associated neuropathy	Relmada Therapeutics, Inc.
2245	mepivacaine	n/a	1/8/2007	Treatment of postherpetic neuralgia	Relmada Therapeutics, Inc.
2246	mepolizumab	n/a	7/14/2011	Treatment of Churg-Strauss Syndrome.	GlaxoSmithKline LLC
2247	mepolizumab	n/a	5/28/2004	For first-line treatment in patients with hypereosinophilic syndrome	GlaxoSmithKline LLC
2248	mercaptopurine oral solution	Purixan	8/20/2012	Treatment of acute lymphoblastic leukemia in pediatric patients	Nova Laboratories Limited
2249	mesalamine	Canasa	1/19/2010	Treatment of pediatric ulcerative colitis	Aptalis Pharma US, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2250	mesalamine and N-acetylcysteine	n/a	9/10/2009	Treatment of pediatric patients with ulcerative colitis (inclusive through age 16 years)	Altheus Therapeutics, Inc.
2251	mesalamine; 5-aminosalicylic acid	Lialda	2/27/2008	Treatment of ulcerative colitis in pediatric patients (revised indication 10/21/2010).	Shire
2252	mesenchymal stromal cells secreting neurotrophic factors	Nurown	2/4/2011	Treatment of Amyotrophic Lateral Sclerosis	BrainStorm Cell Therapeutics Ltd.
2253	met-enkephalin; Met-N	n/a	2/18/2011	Treatment of pancreatic cancer.	NBI Pharmaceuticals, Inc.
2254	metadoxine	n/a	12/16/2013	Treatment of Fragile X Syndrome	Alcobra, Inc.
2255	metformin	n/a	5/29/2014	Treatment of pediatric polycystic ovary syndrome	EffRx Pharmaceuticals SA
2256	methotrexate	n/a	8/20/2009	Treatment of acute lymphoblastic leukemia	Orbona Pharma Ltd
2257	methylene blue	n/a	7/24/2012	Treatment of methemoglobinemia	Fera Pharmaceuticals, LLC
2258	methylene blue injection	n/a	8/11/2012	Treatment of congenital and acquired methemoglobinemia	Luitpold Pharmaceuticals, Inc.
2259	methylene blue0.5%	n/a	12/18/2012	Treatment of hereditary and acquired methemoglobinemia	Provepharm SAS

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2260	methylparaben suberohydroxamic acid phenyl ester	n/a	4/15/2013	Treatment of cutaneous T-cell lymphoma	TetraLogic Pharmaceuticals
2261	metreleptin	Myalept	8/22/2001	Treatment of metabolic disorders secondary to lipodystrophy	Aegerion Pharmaceuticals, Inc.
2262	metreleptin	n/a	8/22/2001	Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy	Aegerion Pharmaceuticals, Inc.
2263	metronidazole	n/a	4/26/2011	Treatment of pouchitis.	S.L.A. Pharma Limited (UK)
2264	metronidazole	n/a	9/17/2008	Treatment of pouchitis	Formac Pharmaceuticals, NV
2265	metyrapone	n/a	9/25/2012	Treatment of Cushing's syndrome	Laboratoire HRA Pharma
2266	metyrosine	Demser	7/25/2008	Treatment of velocardiofacial syndrome associated psychosis.	Cerberus Princeton, LLC
2267	mexiletine	n/a	9/2/2010	Treatment of nondystrophic myotonia	University of Rochester Medical Center
2268	mibefradil	n/a	10/16/2008	Treatment of pancreatic cancer.	Tau Therapeutics, LLC
2269	mibefradil	n/a	8/25/2009	Treatment of glioblastoma multiforme.	Tau Therapeutics, LLC
2270	mibefradil	n/a	6/15/2007	Treatment of ovarian cancer	Tau Therapeutics, LLC

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2271	miconazole	n/a	5/22/2014	Treatment of fungal otitis externa (otomycosis)	Hill Dermaceuticals, Inc.
2272	midazolam	n/a	10/20/2009	Rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. acute repetitive seizures, seizure clusters)	Upsher-Smith Laboratories, Inc.
2273	midazolam	n/a	7/24/2012	Treatment of nerve agent-induced seizures	Meridian Medical Technologies, Inc.
2274	midazolam	n/a	5/8/2006	Treatment of bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam	UCB, Inc
2275	mifamuritide	Junovan	6/5/2001	Treatment of osteosarcoma	Millennium Pharmaceuticals, Inc.
2276	mifepristone	Korlym	7/5/2007	Treatment of the clinical manifestations of endogenous Cushing's syndrome	Corcept Therapeutics, Inc.
2277	migalastat hydrochloride	n/a	2/25/2004	Treatment of Fabry Disease	Amicus Therapeutics, Inc.
2278	miglustat	Zavesca	5/29/1998	Treatment of Gaucher disease.	Actelion Pharmaceuticals Ltd

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2279	miglustat	Zavesca (R)	11/12/2008	Treatment of the neurological manifestations of Niemann-Pick disease,type C.	Actelion Pharmaceuticals Ltd
2280	milatuzumab	n/a	6/24/2008	Treatment of chronic lymphocytic leukemia.	Immunomedics, Inc.
2281	milatuzumab	n/a	3/10/2008	Treatment of multiple myeloma	Immunomedics, Inc.
2282	milciclib maleate	n/a	9/20/2012	Treatment of thymic epithelial tumors.	Nerviano Medical Sciences S.r.l.
2283	miltefosine	Miltex/Impavido	3/18/2009	Topical treatment of cutaneous lymphoma encompassing cutaneous manifestations of T-cell lymphoma and B-cell lymphoma	ExperGen Drug Development GmbH
2284	miltefosine	Impavido	10/10/2006	Treatment of leishmaniasis.	Knight Therapeutics (USA)
2285	mipomersen	Kynamro	5/23/2006	Treatment of homozygous familial hypercholesterolemia	Genzyme Corporation
2286	misoprostol	Gymiso	1/10/2005	Treatment of intrauterine fetal death not accompanied by complete expulsion of the products of conception in the second and third trimesters of pregnancy.	Gynuity Health Projects, LLC
2287	mitomycin	n/a	6/1/2011	Prevention of corneal sub-epithelial haze formation following surface ablation laser keratectomy	Mobius Therapeutics, LLC

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2288	mitomycin	n/a	1/13/2011	Prevention of recurrence of pterygium after its surgical excision.	Mobius Therapeutics, LLC
2289	mitomycin	Mitogel	9/8/2014	Treatment of upper tract urothelial cell cancers (transitional cell carcinoma of the renal pelvis and ureter)	TheraCoat, Ltd.
2290	mitomycin-C	Mitosol	1/8/2008	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	Mobius Therapeutics, LLC
2291	mocetinostat	n/a	8/7/2014	Treatment of diffuse large B-cell lymphoma	Mirati Therapeutics, Inc.
2292	modified recombinant human C-type natriuretic peptide (CNP)	n/a	1/17/2013	Treatment of achondroplasia	BioMarin Pharmaceutical, Inc.
2293	modified recombinant human Factor VIIa (rFVIIa) molecule	n/a	5/30/2013	Treatment of bleeding episodes in hemophilia A or B subjects with inhibitors	Bayer HealthCare Pharmaceuticals, Inc.
2294	modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain	n/a	8/20/2012	Treatment of inherited mitochondrial respiratory chain disease	Gencia Corporation
2295	mogamulizumab	n/a	7/14/2011	Treatment of adult T-cell leukemia/lymphoma (ATLL).	Kyowa Hakko Kirin Pharma, Inc.
2296	mogamulizumab	n/a	11/2/2010	Treatment of peripheral T-cell lymphoma.	Kyowa Hakko Kirin Pharma, Inc.
2297	mogamulizumab	n/a	11/2/2010	Treatment of patients with cutaneous T-cell lymphoma.	Kyowa Hakko Kirin Pharma, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2298	monarsen	n/a	11/14/2003	Treatment of myasthenia gravis	Bioline Rx, Ltd.
2299	monoclonal antibody	n/a	1/21/2011	Prevention of congenital cytomegalovirus (CMV) infection following primary CMV infection in pregnant women.	Theraclone Sciences
2300	monoclonal antibody 11-1F4	n/a	12/7/2009	For use as a radioimaging agent in amyloidosis	Alan Solomon, M.D.
2301	monoclonal antibody 11-1F4	n/a	12/11/2009	For use as a therapeutic agent for patients AL amyloidosis.	Alan Solomon, M.D.
2302	monoclonal antibody 3F8	n/a	10/16/2008	Treatment of neuroblastoma	United Therapeutics Corporation
2303	monoclonal antibody Hu3F8	n/a	1/10/2014	Treatment of osteosarcoma	Memorial Sloan-Kettering Cancer Center
2304	monoclonal antibody consisting of three mouse/human chimeric IgG1 monoclonal antibodies (c2G4, c4G7, and c13C6) that target Ebola virus	n/a	8/25/2014	Treatment of Ebola virus infection	LeafBio, Inc.
2305	monoclonal antibody directed at hepatitis C virus E2 glycoprotein	n/a	11/4/2013	Prevention of Hepatitis C recurrence in patients receiving liver transplantation	MassBiologics-University of MA Medical School
2306	monoclonal antibody targeting eotaxin-2	n/a	1/6/2015	Treatment of systemic sclerosis	ChemomAb, Ltd.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2307	monomethyl auristatin E conjugated to a monoclonal antibody which targets guanylyl cyclase C	n/a	7/29/2014	Treatment of pancreatic cancer.	Millennium Pharmaceuticals, Inc.
2308	motexafin gadolinium	Xcytrin	1/27/2003	For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors	Pharmacyclics, Inc.
2309	mouse-human chimeric monoclonal anti-GD2 IgG1 antibody	n/a	9/20/2012	Treatment of neuroblastoma.	APEIRON Biologics AG
2310	moxetumomab pasudotox	n/a	6/28/2013	Treatment of acute lymphoblastic leukemia	MedImmune, LLC
2311	moxetumomab pasudotox	n/a	11/15/2007	Treatment of CD22-positive chronic lymphocytic leukemia	MedImmune, LLC
2312	moxetumomab pasudotox	n/a	11/15/2007	Treatment of hairy cell leukemia	MedImmune, LLC
2313	moxidectin	n/a	9/29/2010	Treatment of onchocerciasis volvulus in children and adults.	Medicines Development Limited
2314	multi-vitamin infusion without vitamin K	M.V.I.-12	3/8/2004	Prevention of vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type anticoagulant therapy	Mayne Pharma (USA) Inc.
2315	murine monoclonal antibody against CD26	Begedina	2/18/2011	Treatment of graft versus host disease	Adienne S.A.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2316	mycobacterium vaccae	n/a	8/20/2010	Treatment of tuberculosis	Immodulon Therapeutics Ltd
2317	myo-inositol	n/a	4/7/2005	Prevention of retinopathy of prematurity in preterm infants at risk for developing retinopathy of prematurity	Abbott Nutrition
2318	nabumetone	n/a	5/5/2008	Treatment of pediatric juvenile rheumatoid arthritis	Cook Pharma
2319	naloxone	n/a	11/23/2010	Topical treatment of pruritus associated with mycosis fungoides	Elorac, Inc.
2320	naltrexone	n/a	2/23/2015	Treatment of postherpetic neuralgia	Allodynic Therapeutics, LLC
2321	naltrexone	n/a	1/19/2010	Treatment of Crohn's disease in pediatric patients	TNI BioTech, Inc.
2322	naltrexone	n/a	1/13/2015	Treatment of autoimmune hepatitis	TaiwanJ Pharmaceuticals Co., Ltd.
2323	naltrexone/clonidine combination	n/a	4/14/2014	Treatment of postherpetic neuralgia	Allodynic Therapeutics LLC
2324	natural human lymphoblastoid interferon-alpha	n/a	11/18/2002	Treatment of polycythemia vera	Amarillo Biosciences, Inc.
2325	nelarabine	n/a	9/2/1999	Treatment of chronic lymphocytic leukemia.	GlaxoSmithKline LLC
2326	nelarabine	Arranon	8/10/2004	Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma	GlaxoSmithKline LLC
2327	neostigmine	n/a	3/18/2013	Treatment of acute colonic pseudo-obstruction	Luitpold Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2328	neostigmine methylsulfate	n/a	2/17/2012	Treatment of Myasthenia Gravis	Luitpold Pharmaceuticals, Inc.
2329	neridronate	n/a	3/25/2013	Treatment of complex regional pain syndrome (CRPS-1, CRPS-II, CRPS-NOS)	Grunenthal USA, Inc.
2330	nevirapine	n/a	11/25/2009	Prevention of HIV infection in pediatric patients under the age of 16 years	Auritec Pharmaceuticals
2331	nifurtimox	n/a	12/31/2013	Treatment of Chagas disease	MetronomX Therapeutics, LLC
2332	nifurtimox	Lampit	8/5/2010	Treatment of Chagas disease (American Trypanosomiasis) caused by T. cruzi	Bayer HealthCare Pharmaceuticals, Inc.
2333	nilotinib	Tasigna	4/27/2006	Treatment of chronic myelogenous leukemia	Novartis Pharmaceutical Corporation
2334	nimodipine	Nymalize	9/16/2011	Treatment of subarachnoid hemorrhage.	Arbor Pharmaceuticals, Inc.
2335	nintedanib	Ofev	6/29/2011	Treatment of patients with idiopathic pulmonary fibrosis.	Boehringer Ingelheim Pharmaceuticals, Inc.
2336	niprisan	Hemoxin	8/15/2003	Treatment of sickle cell disease	Xechem International, Inc.
2337	niraparib	n/a	4/30/2010	Treatment of ovarian cancer	TESARO, Inc.
2338	nitazoxanide	Alinia	2/14/2002	Treatment of intestinal giardiasis	Romark Laboratories, L.C.
2339	nitazoxanide	Cryptaz	10/23/2001	Treatment for intestinal amebiasis	Romark Laboratories, L.C.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2340	nitric oxide	Inomax	12/28/2011	Treatment of pulmonary arterial hypertension	Bellerophon Therapeutics
2341	nitric oxide	n/a	9/23/2014	Treatment of cystic fibrosis	Advanced Inhalation Therapies Ltd.
2342	nitric oxide	Inomax (R)	9/5/2008	Use in combination with a drug delivery device for acute treatment of sickle cell vaso-occlusive crisis (pain crises)	INO Therapeutics
2343	nitric oxide	n/a	6/18/2012	Treatment of persistent pulmonary hypertension in newborns	GeNO, LLC
2344	nivolumab	n/a	1/23/2013	Treatment of Stage IIb to IV melanoma	Bristol-Myers Squibb Co.
2345	nivolumab	n/a	8/7/2014	Treatment of Hodgkin lymphoma	Bristol-Myers Squibb Co.
2346	non-peptide small molecule orally available agonist of the parathyroid hormone receptor type I	n/a	12/15/2014	Treatment of hypoparathyroidism	Chugai Pharma USA, LLC
2347	non-replicating adeno-associated viral vector, serotype 8, expressing human myotubularin gene	At001	12/3/2014	Treatment of x-linked myotubular myopathy	Audentes Therapeutics, Inc.
2348	non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channelrhodopsin-2 protein	n/a	10/20/2014	Treatment of retinitis pigmentosa	RetroSense Therapeutics, LLC

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2349	obeticholic acid	n/a	4/9/2008	Treatment of primary biliary cirrhosis	Intercept Pharmaceuticals, Inc.
2350	obinutuzumab	n/a	2/17/2012	Treatment of diffuse large B cell lymphoma	Genentech, Inc.
2351	obinutuzumab	Gazyva	2/17/2012	Treatment of chronic lymphocytic leukemia	Genentech, Inc.
2352	oblimersen	Genasense	7/31/2000	Treatment of advanced malignant melanoma (Stages II,III, IV).	Genta, Inc.
2353	oblimersen	Genasense	8/28/2001	Treatment of chronic lymphocytic leukemia	Genta, Inc,
2354	oblimersen	Genasense	8/28/2001	Treatment of acute myelocytic leukemia	Genta Inc.
2355	oblimersen	Genasense	8/28/2001	Treatment of multiple myeloma	Genta, Inc.
2356	octreotide	Sandostatin Lar	8/5/2010	Treatment of neuroendocrine tumors	Novartis Pharmaceuticals Corporation
2357	octreotide (oral)	Octreolin(Tm)	6/17/2010	For the oral treatment of acromegaly	Chiasma, Inc.
2358	octreotide acetate subcutaneous implant	n/a	12/7/2009	Treatment of acromegaly	Endo Pharmaceuticals Solutions, Inc.
2359	ofatumumab	Arzerra	3/10/2009	Treatment of chronic lymphocytic leukemia	Glaxo Group Limited d/b/a GlaxoSmithKline
2360	ogluflanide disodium	n/a	9/24/2001	Treatment of ovarian cancer	Implicit Bioscience Pty Ltd
2361	olaparib	Lynparza	10/16/2013	Treatment of ovarian cancer	AstraZeneca Pharmaceuticals LP

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2362	olaptosed pegol	n/a	8/19/2014	Treatment of glioblastoma in conjunction with radiotherapy.	Noxxon Pharma AG
2363	olaratumab	n/a	10/9/2014	Treatment of soft tissue sarcoma	Eli Lilly and Company
2364	oleylphosphocholine	n/a	10/25/2013	Treatment of leishmaniasis	Dafra Pharma International nv
2365	oligopeptide containing 6 amino acids (H-Phe-Ser-Arg-Tyr-Ala-Arg-OH)	n/a	2/27/2014	Treatment of amyotrophic lateral sclerosis	Genervon Biopharmaceuticals, LLC
2366	olipudase alfa	n/a	8/3/2000	Treatment of acid sphingomyelinase deficiency (Niemann-Pick disease)	Genzyme Corporation
2367	omacetaine mepesuccinate	n/a	1/12/2009	Treatment of myelodysplastic syndromes	IVAX International GmbH
2368	omacetaxine mepesuccinate	Synribo	3/10/2006	Treatment of chronic myelogenous leukemia	IVAX International GmbH
2369	ombrabulin; N-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]phenyl}-L-serinamide hydrochloride	n/a	3/3/2011	Treatment of soft tissue sarcoma	Sanofi-Aventis U.S., Inc.
2370	omeprazole-lansoprazole with buffer	n/a	2/10/2015	Treatment of esophageal ulcers	Effexus Pharmaceuticals, LLC
2371	omigapil	n/a	6/24/2008	Treatment of congenital muscular dystrophy.	Santhera Pharmaceuticals Limited
2372	onartuzumab	n/a	1/23/2013	Treatment of gastric cancer including gastroesophageal cancer	Genentech, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2373	onartuzumab (MetMab)	n/a	12/16/2013	Treatment of hepatocellular carcinoma	Genentech, Inc.
2374	oncophage	n/a	4/14/2009	Treatment of glioma	Agenus, Inc.
2375	opioid growth factor	n/a	4/16/2013	Treatment of liver and intrahepatic bile duct cancer	Primocure Pharma, Inc.
2376	opium tincture	n/a	12/2/2011	Treatment of chronic diarrhea in short bowel syndrome patients with an inadequate response to anti-diarrheal treatment	Valeant Pharmaceuticals International, Inc.
2377	oprozomib	n/a	10/28/2014	Treatment of multiple myeloma	Onyx Therapeutics, Inc.
2378	oprozomib	n/a	8/25/2014	Treatment of Waldenstrom's macroglobulinemia	Onyx Therapeutics, Inc.
2379	optically pure phenylalanine derivative	n/a	8/20/2012	Treatment of narcolepsy	Jazz Pharmaceuticals International III Limited
2380	oral unfractionated heparin	n/a	1/29/2004	Treatment of sickle cell disease	TRF Technologies, Inc.
2381	osilodrostat	n/a	9/13/2013	Treatment of Cushing's disease	Novartis Pharmaceuticals corporation
2382	otelixizumab	n/a	2/6/2006	Treatment of new-onset type I diabetes mellitus	GlaxoSmithKline
2383	oxaloacetate	n/a	7/24/2012	Treatment of gliomas	Terra Biological LLC
2384	oxfendazole	n/a	7/14/2014	Treatment of cysticercosis (including neurocysticercosis)	Robert H. Gilman, MD, DTMH and
2385	oxybate	Xyrem	11/7/1994	Treatment of narcolepsy.	Jazz Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2386	oxytocin	n/a	11/24/2014	Treatment of Prader-Willi syndrome	Pr Maithe Tauber
2387	p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt	n/a	3/7/2001	For the treatment of cystic fibrosis	Inspire Pharmaceuticals, Inc.
2388	p38 mitogen-activated kinase inhibitor	n/a	5/27/2014	Treatment of dilated cardiomyopathy, including dilated cardiomyopathy secondary to lamin A/C gene mutations	Array BioPharma, Inc.
2389	paclitaxel	n/a	5/1/2009	Treatment of pancreatic cancer	MediGene AG
2390	paclitaxel aqueous gel	Oncogel(Tm)	2/1/2008	Treatment of esophageal cancer	BTG International, Inc.
2391	paclitaxel aqueous gel	Oncogel (Tm)	12/23/2008	Treatment of brain cancer.	BTG International, Inc
2392	paclitaxel nanoparticles	n/a	1/3/2013	Treatment of pancreatic cancer	CIRJ Co., Ltd.
2393	paclitaxel poliglumex	Opaxio	9/20/2012	Treatment of glioblastoma multiforme	CTI BioPharma Corporation
2394	paclitaxel protein-bound particles	Abraxane	9/3/2009	Treatment of pancreatic cancer.	Abraxis BioScience, LLC
2395	paclitaxel, micellar	Paclical	4/3/2009	Treatment of ovarian cancer	Oasmia Pharmaceutical AB
2396	pacritinib	n/a	3/13/2008	Treatment of myeloproliferative disorders with the JAK2 V617F mutation	CTI BioPharma Corporation
2397	pafuramidine maleate	n/a	11/17/2006	Treatment of pneumocystis jiroveci pneumonia	Immtech Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2398	palovarotene	n/a	7/21/2014	Treatment of fibrodysplasia ossificans progressiva	Clementia Pharmaceuticals, Inc.
2399	panobinostat	Farydak	8/20/2012	Treatment of multiple myeloma	Novartis Pharmaceuticals Corporation
2400	paquinimod	n/a	1/17/2014	Treatment of systemic sclerosis	Active Biotech AB
2401	parathyroid hormone	Natpara	8/31/2007	Treatment of hypoparathyroidism	NPS Pharmaceuticals, Inc.
2402	paromomycin	n/a	2/11/2015	Treatment of cutaneous leishmaniasis (Old World and New World)	The Surgeon General, Dept. of the Army
2403	paromomycin sulfate/gentamicin sulfate	n/a	1/18/2008	Treatment of all uncomplicated cutaneous leishmaniasis (both New World and Old World)	Office of the Surgeon General
2404	pasireotide	n/a	8/25/2009	Treatment of acromegaly	Novartis Pharmaceuticals Corporation
2405	pasireotide	Signifor	7/24/2009	Treatment of Cushing's disease	Novartis Pharmaceuticals Corporation
2406	pazopanib	Votrient	10/20/2009	Treatment of soft tissue sarcomas	GlaxoSmithKline
2407	pazopanib	n/a	5/6/2013	Treatment of ovarian cancer.	Glaxo Wellcome Mfg Pte Ltd
2408	pegargiminase	n/a	7/21/2014	Treatment of mesothelioma.	Polaris Group
2409	peginterferon alfa-2b	Sylatron	4/9/2008	Treatment of malignant melanoma stages IIb through IV.	Schering-Plough Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2410	pegloticase	Krystexxa	2/21/2001	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Crealta Pharmaceuticals LLC
2411	pegsitacase	Uricase-Peg 20	12/3/2009	Treatment of Lesch-Nyhan syndrome.	EnzymeRx, LLC
2412	pegylated arginine deiminase	Hepacid	3/26/1999	Treatment of hepatocellular carcinoma	Polaris Pharmaceuticals, Inc.
2413	pegylated carboxyhemoglobin	n/a	10/21/2010	Treatment of acute painful sickling crises in patients with sickle cell disease	Sangart, Inc.
2414	pegylated carboxyhemoglobin bovine	Sanguinate	1/15/2015	Treatment of the comorbidities associated with Sickle Cell Disease	Prolong Pharmaceuticals, LLC
2415	pegylated granulocyte colony stimulating factor	n/a	4/30/2014	Treatment of patients at risk of developing myelosuppression following a radiological or nuclear incident	PharmaEssentia
2416	pegylated proline interferon alpha-2b	n/a	4/10/2014	Treatment of myelofibrosis	PharmaEssentia, Corporation
2417	pegylated proline interferon alpha-2b	n/a	4/11/2014	Treatment of essential thrombocythemia	PharmaEssentia, Corporation
2418	pegylated proline-interferon alpha-2b; PEG-P-IFNa-2b	n/a	4/2/2012	Treatment of polycythemia vera	PharmaEssentia Corporation
2419	pelareorep	Reolysin(R)	2/24/2015	Treatment of primary peritoneal cancer	Oncolytics Biotech, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2420	pelareorep	Reolysin(R)	2/10/2015	Treatment of ovarian cancer	Oncolytics Biotech, Inc.
2421	pelareorep	Reolysin(R)	2/11/2015	Treatment of pancreatic cancer	Oncolytics Biotech, Inc.
2422	pelareorep	Reolysin(R)	2/24/2015	Treatment of fallopian tube cancer	Oncolytics Biotech, Inc.
2423	pembrolizumab	Keytruda	11/19/2012	Treatment of Stage IIB through IV malignant melanoma	Merck, Sharp & Dohme Corp.
2424	pemetrexed disodium	Alimta	8/28/2001	Treatment of malignant pleural mesothelioma	Eli Lilly and Company
2425	pentagastrin	n/a	5/29/2009	To aid in the diagnosis of medullary thyroid carcinoma	Medical Defense Technologies, LLC
2426	pentamidine	n/a	8/12/2013	Treatment of liver and intrahepatic bile duct cancer	Oncozyme Pharma, Inc.
2427	pentapeptide with sequence Ac-VSRRR-NH2	n/a	1/13/2015	Treatment of intracerebral hemorrhage	CereNOva, LLC
2428	pentetate trisodium	Diethylenetriaminepentaaacetate	4/12/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium.	Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG
2429	pentosan polysulfate sodium	n/a	11/21/2008	Treatment of sickle cell disease.	TRF Pharma, Inc.
2430	pentosan polysulfate sodium	Lysosan (Tm)	1/5/2015	Treatment of mucopolusaccharidosis (MPS)type VI	Plexcera Therapeutics, LLC
2431	pentosan polysulfate sodium	n/a	9/16/2011	Treatment of sickle cell disease.	Vanguard Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2432	pentoxifylline	n/a	6/14/2012	Treatment of Behcet's disease	Keck Graduate Institute of Applied Life Sciences
2433	peptide YY	n/a	4/18/2011	Treatment of hepatocellular carcinoma.	mondoBIOTECH Laboratories AG
2434	peptide-based vaccine targeting telomerase reverse transcriptase	n/a	2/20/2009	Treatment of telomerase reverse transcriptase (TERT) positive non-small cell lung cancer in HLA-A*0201 positive patients	VAXON-Biotech
2435	peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO)	n/a	9/3/2009	Treatment of Duchenne muscular dystrophy in patients with a deletion, duplication or frame shift mutation correctable by skipping of exon 50 of the dystrophin gene to allow restoration of the reading frame (including mutations within exons 51, 51-53, or 51-55).	Sarepta Therapeutics, Inc.
2436	peptides mimicking antigen receptors on autoimmune B cells and autoimmune T cells associated with myasthenia gravis	n/a	2/4/2011	Treatment of myasthenia gravis	CuraVac Europe SPRL
2437	perampanel	Fycompa	12/7/2012	Treatment of Lennox-Gastaut Syndrome	Eisai, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2438	peretinoin	n/a	9/23/2011	Treatment of hepatocellular carcinoma.	Kowa Pharmaceutical Europe Co. Ltd.
2439	perhexiline maleate	n/a	6/14/2012	Treatment of moderate to severe symptomatic (NYHA class III or IV) hypertrophic cardiomyopathy	Heart Metabolics, Limited.
2440	perifosine	n/a	7/9/2010	Treatment of neuroblastoma	Aeterna Zentaris GmbH
2441	perillyl alcohol	n/a	4/18/2011	Treatment of glioma	NeOnc Technologies, Inc.
2442	pertuzumab	n/a	6/8/2009	Treatment of ovarian cancer	Genentech, Inc.
2443	pertuzumab	n/a	7/12/2013	Treatment of gastric cancer	Genentech, Inc.
2444	pexastimogene devacirepvec	n/a	5/6/2013	Treatment of hepatocellular carcinoma	SillaJen Biotherapeutics, Inc.
2445	phenobarbital sodium injection	n/a	10/23/2013	Treatment of hypoxic-ischemic encephalopathy to prevent seizures in neonates	Fera Pharmaceuticals, LLC
2446	phenylephrine	n/a	2/14/2002	Treatment of ileal pouch anal anastomosis related fecal incontinence	S.L.A. Pharma
2447	phenylephrine	n/a	1/31/2012	Treatment of Tetralogy of Fallot	Luitpold Pharmaceuticals, Inc.
2448	phosphorothioate antisense oligonucleotide against EWS-Fli-1	n/a	9/22/2008	Treatment of Ewing's sarcoma	The Cure Our Children Foundation
2449	phoxilium	n/a	2/14/2014	For use as a replacement solution in patients undergoing continuous renal replacement therapy	Gambro Renal Products, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2450	picibanil	n/a	5/15/2009	Treatment of patients with lymphatic malformations	Royds Pharmaceuticals, Inc.
2451	picibanil	n/a	3/17/2011	Treatment of lymphatic malformations	Richard Smith, M.D.
2452	pirfenidone	n/a	11/19/2013	Treatment of systemic sclerosis (including the associated interstitial lung disease)	InterMune, Inc.
2453	pirfenidone	Esbriet	3/5/2004	Treatment of idiopathic pulmonary fibrosis	InterMune, Inc.
2454	pirfenidone	n/a	7/31/2014	Treatment of idiopathic pulmonary fibrosis	Genoa Pharmaceuticals, Inc.
2455	plasmid DNA encoding the human cystic fibrosis transmembrane conductance regulator gene complexed with a nonviral cationic lipid based gene transfer agent	n/a	6/30/2014	Treatment of cystic fibrosis	Imperial Innovations Limited
2456	plasmin (human)	n/a	3/30/2009	Treatment of acute peripheral arterial occlusion	Grifols Therapeutics, Inc.
2457	plasminogen (human)	n/a	3/5/2013	Treatment of hypoplasminogenemia, or type I plasminogen deficiency	ProMetic Biotherapeutics, Inc.
2458	pleconaril	n/a	12/22/2014	Treatment of symptomatic entoviral infection in the neonate	AntiVirus Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2459	plerixafor	Mozobil (R)	7/10/2003	For use to improve the yield of progenitor cells in the apheresis product for subsequent stem cell transplantation following myelosuppressive or myeloablative chemotherapy	Genzyme Corporation
2460	polidocanol	n/a	2/19/2015	Treatment of congenital venous malformations	Provensis Ltd
2461	polifeprosan 20 with carmustine	Gliadel	12/13/1989	Treatment of malignant glioma.	Guilford Pharmaceuticals, Inc.
2462	polifeprosan 20 with carmustine	Gliadel	12/13/1989	Treatment of malignant glioma	Guilford Pharmaceuticals, Inc.
2463	poloxamer 188	n/a	11/8/2013	Treatment of Acute Limb Ischemia	Mast Therapeutics, Inc
2464	poloxamer 188 (purified)	n/a	6/27/1989	Treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease)	Mast Therapeutics Inc.
2465	poloxamer-188 NF	n/a	1/19/2010	Treatment of Duchenne muscular dystrophy	Phrixus Pharmaceuticals, Inc.
2466	poly(lactide-co-glycolide) carboxylated microparticle	n/a	10/25/2013	Treatment of acute encephalitis syndrome	Cour Pharmaceutical Development Company, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2467	polyinosinic-polycytidilic acid	Poly-Iclc	3/3/2003	Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses	Oncovir
2468	polyinosinic-polycytidilic acid	Poly-Iclc	8/2/2002	As an adjuvant to smallpox vaccination	Oncovir
2469	polyinosinic-polycytidilic acid (Poly-ICLC)	Hiltonol	11/19/2002	Treatment for orthopox virus infections	Oncovir
2470	polymer surgical mesh delivering paclitaxel	n/a	7/15/2014	For use as local administration at the time of curative surgery in the treatment of stage 0 to III non-small cell lung cancer.	AcuityBio, Inc.
2471	polyphenon E	n/a	7/17/2008	Treatment of chronic lymphocytic leukemia	Mitsui Norin Co., Ltd
2472	pomalidomide	Pomalyst	1/15/2003	Treatment of multiple myeloma	Celgene Corporation
2473	pomalidomide	n/a	9/21/2010	Treatment of persons with myeloproliferative neoplasm-associated myelofibrosis and anemia who are red blood cell tranfusion dependent.	Celgene Corporation
2474	pomalidomide	n/a	8/22/2013	Treatment of systemic sclerosis	Celgene Corporation
2475	ponatinib	Iclusig	11/20/2009	Treatment of chronic myeloid leukemia	ARIAD Pharmaceuticals Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2476	ponatinib	Iclusig	11/20/2009	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)	ARIAD Pharmaceuticals Inc.
2477	porcine GM1 ganglioside	n/a	12/3/2012	Treatment of acute spinal cord injury	TRB Chemedica International S.A.
2478	porfimer	Photofrin	10/19/2001	For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy	Axcan Scandipharm Inc.
2479	potassium sodium aluminosilicate	n/a	1/8/2007	For treatment of poisoning by or exposure to cesium.	Framework Therapeutics, LLC
2480	pracinostat	n/a	2/27/2014	Treatment of acute myeloid leukemia	MEI Pharma Inc.
2481	pralatrexate	n/a	5/3/2010	Treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder	Allos Therapeutics, Inc.
2482	pralatrexate	n/a	10/20/2008	Treatment of follicular lymphoma	Allos Therapeutics, Inc.
2483	pralatrexate	n/a	10/20/2008	Treatment of diffuse large B-cell lymphoma	Allos Therapeutics, Inc.
2484	pralatrexate	Folotyn	7/20/2006	Treatment of T-cell lymphoma	Allos Therapeutics, Inc.
2485	pralmorelin hydrochloride	n/a	10/18/2012	As a diagnostic agent for the detection of growth hormone deficiency	Sella Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2486	pramipexole	Mirapex	1/31/2008	Treatment of Tourette's syndrome in pediatric patients	Boehringer-Ingelheim Pharmaceuticals, Inc.
2487	pratumumab	n/a	10/28/2014	Treatment of glioma	Nascent Biotech, Inc.
2488	profimer sodium	Photofrin(R)	12/2/2011	Treatment of malignant mesothelioma	Concordia Laboratories, Inc.
2489	progesterone	n/a	12/22/1994	Establishment and maintenance of pregnancy in women undergoing in vitro fertilization or embryo transfer procedures.	Watson Laboratories, Inc.
2490	prolactin receptor antagonist	Prolanta	4/15/2013	Treatment of ovarian cancer	Oncolix, Inc.
2491	propranolol	Hemangeol	9/5/2008	Treatment of proliferating infantile hemangiomas requiring systemic therapy	Pierre Fabre Dermatologie
2492	propranolol hydrochloride and etodolac	n/a	2/24/2015	Treatment of hepatocellular carcinoma	Vicus Therapeutics, LLC
2493	prothrombin complex concentrate (human)	Kcentra	12/27/2012	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	CSL Behring
2494	purified bovine type collagen	n/a	4/27/2009	Treatment of idiopathic pulmonary fibrosis	ImmuneWorks, Inc.
2495	pyridoxine; vitamin B6	n/a	3/3/2011	Treatment of pyridoxine dependent seizures.	NBI Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2496	pyrimethamine	n/a	8/16/2011	Treatment of GM-2 gangliosidoses (Tay-Sachs disease and Sandhoff disease).	ExSAR Corporation
2497	pyrvinium	n/a	1/5/2015	Treatment of familial adenomatous polyposis	StemSynergy Therapeutics, Inc.
2498	quinacrine	n/a	9/28/2012	Treatment of hepatocellular carcinoma	Cleveland BioLabs, Inc & Incuron, LLC Joint Ventur
2499	quinine Sulfate	n/a	6/3/2004	Treatment of malaria	AR Holding Company, Inc.
2500	quinine sulfate	n/a	12/2/2008	Treatment of malaria excluding Plasmodium faliparum	Zydus Pharmaceuticals, Inc.
2501	rAAV2-CB-hRPE65	n/a	2/11/2005	Treatment of type II Leber's Congenital Amaurosis	Applied Genetic Technologies Corp.
2502	rSP-C lung surfactant	Venticute	4/3/2000	Treatment of adult respiratory distress syndrome.	Byk Gulden Pharmaceuticals
2503	rSP-C surfactant	Venticute	9/18/2006	For use in patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygen impairment	Altana Pharma
2504	rVIIa-FP	n/a	12/22/2011	Treatment and prophylaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor VIII or IX	CSL Behring

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2505	radiolabeled somastatin analog	Galiomedix(Tm)	12/31/2013	Diagnostic for the management of neuroendocrine tumors	RadioMedix, Inc.
2506	raloxifene	Evista	7/14/2005	Reduction of the risk of breast cancer in postmenopausal women	Eli Lilly and Company
2507	raloxifene hydrochloride	Evista	8/20/2010	Treatment of hereditary hemorrhagic telangiectasia	Consejo Superior de Investigaciones Cientificas
2508	ramucirumab	Cyramza	2/16/2012	Treatment of gastric cancer	Eli Lilly and Company
2509	ramucirumab	n/a	11/4/2011	Treatment of hepatocellular carcinoma	ImClone Systems LLC
2510	ranagengliotucel-L	Glionix(Tm)	5/29/2009	Treatment of astrocytic tumors	NovaRx Corporation
2511	ranprinase	Onconase	1/25/2007	Treatment of malignant mesothelioma	Alfacell Corporation
2512	rasburicase	Elitek	10/11/2000	Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research
2513	raxibacumab	Abthraxtm	11/12/2003	Treatment of anthrax	Human Genome Sciences, Inc.
2514	recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase	n/a	4/29/2014	Treatment of mucopolysaccharidosis type III-A (Sanfilippo Syndrome Type A)	Abeona Therapeutics
2515	recombinant DNA plasmid	n/a	1/31/2014	Treatment of stage IIb, IIc, III and IV melanoma.	Scancell Ltd.
2516	recombinant IgA protease of bacterium Heamophilus influenzae	n/a	4/18/2011	Treatment of immunoglobulin A nephropathy (IgAN, Berger's disease).	Shire Human Genetics Therapies

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2517	recombinant adeno-associated virus vector AAV2/rh8 expressing human B-hexosaminidase A and B subunits	n/a	3/25/2013	For the treatment of Sandhoff disease	Nat'l Tay-Sachs & Allied Diseases Association
2518	recombinant adeno-associated virus alpha 1-antitrypsin vector	Raav-Aat	1/27/2003	Treatment of alpha1-antitrypsin deficiency	Applied Genetic Technologies Corp.
2519	recombinant adeno-associated virus encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP)	n/a	8/25/2009	Treatment of Huntington's disease.	Neurologix, Inc.
2520	recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel beta subunit (rAAV-CNGB3)	n/a	2/4/2011	Treatment of achromatopsia caused by mutations in the CNGB3 gene.	Applied Genetic Technologies Corporation
2521	recombinant adenovirus vector AAV2/rh8 expressing human B-hexosaminidase A & B subunits	n/a	3/25/2013	Treatment of Tay-Sachs disease	Na't Tay-Sachs & Allied Diseases Association
2522	recombinant chimeric monoclonal antibody to anthrax	Anthim	6/9/2006	Treatment of exposure to B. anthracis spores	Elusys Therapeutics, Inc.
2523	recombinant derivative of C3 transferase	Cethrin	11/18/2005	Treatment of acute spinal cord injury	Vertex Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2524	recombinant elafin	n/a	3/18/2013	Prevention of inflammatory complications of transthoracic esophagectomy	Proteo Biotech AG
2525	recombinant fusion protein consisting of a modified form of extracellular domain of human Activin receptor IIB	n/a	3/18/2013	Treatment of myelodysplastic syndrome	Acceleron Pharma, Inc
2526	recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB (ActRIIB) linked to a human IgG1 Fc domain	n/a	3/11/2013	Treatment of B-thalassemia	Acceleron Pharma, Inc.
2527	recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)	n/a	4/27/2012	Treatment of patients with congenital factor IX deficiency (hemophilia B).	CSL Behring LLC
2528	recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)	n/a	5/6/2013	Treatment of congenital factor VII deficiency which includes treatment and prophylaxis of bleeding episodes in patients with congenital factor VII deficiency	CSL Behring
2529	recombinant fusion protein with a truncated form of the cytotoxic protein Pseudomonas exotoxin	Proxinium	1/28/2005	Treatment of Ep-CAM-positive squamous cell carcinoma of the head and neck	Viventia Biotech, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2530	recombinant glycosylated independent lysosomal targeting (GILT) tagged human acid alpha glucosidase	n/a	8/20/2010	Treatment of Pompe disease.	BioMarin Pharmaceutical, Inc.
2531	recombinant human GM-CSF, molgramostim	n/a	10/31/2012	Treatment of pulmonary alveolar proteinosis	Serendex ApS
2532	recombinant human IgG1 monoclonal antibody	n/a	12/14/2009	Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets)	Ultragenyx Pharmaceutical, Inc.
2533	recombinant human Naglu-insulin-like growth factor II	n/a	3/5/2013	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B)	Shire Human Genetic Therapies, Inc.
2534	recombinant human Pentraxin-2	n/a	8/26/2014	Treatment of myelofibrosis	Promedior, Inc.
2535	recombinant human Pentraxin-2; recombinant human Serum Amyloid P	n/a	2/17/2012	Treatment of idiopathic pulmonary fibrosis.	Promedior, Inc.
2536	recombinant human acid ceramidase	Plexcerase(Tm)	12/24/2013	Treatment of Farber disease	Plexcera Therapeutics, LLC
2537	recombinant human alpha 1-antitrypsin (rAAT)	n/a	11/20/2001	Treatment of cystic fibrosis	AiroMedica LLC
2538	recombinant human alpha-1 antitrypsin	n/a	3/6/1998	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Limited
2539	recombinant human alpha-1 antitrypsin (rAAT)	n/a	8/28/2001	To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis	AiroMedica LLC

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2540	recombinant human alpha-N-acetylglucosaminidase	n/a	4/15/2013	Treatment of mucopolysaccharidosis IIIB (Sanfilippo B syndrome)	Synageva BioPharma Corp.
2541	recombinant human alpha-glucosidase conjugated with synthetic bis-mannose-6-phosphate-Man6 glycan	n/a	11/19/2013	Treatment of Pompe Disease	Genzyme, a Sanofi Company
2542	recombinant human anti-GDF-8 monoclonal antibody	n/a	7/24/2012	Treatment of Duchenne Muscular Dystrophy.	Pfizer, Inc.
2543	recombinant human antithrombin	Atryn	12/7/2007	Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures	GTC Biotherapeutics, Inc.
2544	recombinant human beta-glucuronidase	n/a	2/16/2012	Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)	Ultragenyx Pharmaceutical, Inc.
2545	recombinant human collagen alpha-1 (VII) chain homotrimer (rC7)	n/a	3/17/2014	Treatment of dystrophic epidermolysis bullosa	Shire Human Genetic Therapies, Inc.
2546	recombinant human deoxyribonuclease I	n/a	8/19/2014	Treatment of graft-vs-host disease	SciVac Ltd
2547	recombinant human deoxyribonuclease I (DNase I)	n/a	8/18/2014	Prevention of graft-vs-host disease	SciVac Ltd.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2548	recombinant human endostatin protein	n/a	2/21/2002	Treatment of metastatic melanoma	EntreMed, Inc.
2549	recombinant human erythropoietin (rHuEPO)	n/a	5/26/2011	Treatment of mutiple myeloma	XTL Biopharmaceuticals, Ltd
2550	recombinant human fucosyltransferase VI [FTVI] + GDP-fucose	n/a	1/27/2015	To increase the activity of regulatory T-cells (Tregs) used in the prevention of graft versus host disease in patients undergoing hematopoietic stem cell transplantation	TargaZyme, Inc.
2551	recombinant human galactocerebrosidase (rhGALC);	Galaczym	12/12/2011	Treatment of globoid cell leukodystrophy (Krabbe Disease)	ACE BioSciences A/S
2552	recombinant human growth hormone in an ocular delivery system	n/a	12/3/2012	Treatment of persistent corneal epithelial defects	Jade Therapeutics LLC
2553	recombinant human histone H1.3; recombinant human N-bis-met-histone H1.3	Oncohist	10/20/2008	Treatment of acute myeloid leukemia	Xenetic Biosciences Plc
2554	recombinant human lecithin:cholesterol acyltransferase (rhLCAT)	n/a	9/2/2010	Treatment of LCAT deficiency syndromes	AlphaCore Pharma, LLC
2555	recombinant human minibody against complement component	Mubodina(R)	6/7/2011	Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system.	Adienne S.A

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2556	recombinant human minibody against complement component C5	Mubodina	2/4/2009	Treatment of primary membranoproliferative glomerulonephritis	Adienne S.A.
2557	recombinant human minibody against complement component C5 fused with RGD-motif	n/a	2/4/2009	Prevention of ischemia/reperfusion injury associated with solid organ transplantation.	Adienne S.A.
2558	recombinant human monoclonal IgM antibody targeting glucose regulated protein 78	n/a	10/25/2013	Treatment of multiple myeloma	Patrys Ltd.
2559	recombinant human monoclonal antibody against activin receptors type II	n/a	6/18/2012	Treatment of inclusion body myositis	Novartis Pharmaceuticals Corp.
2560	recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor	n/a	8/19/2014	Treatment of pigmented villonodular synovitis, including giant cell tumor of the tendon sheath	Novartis Pharmaceuticals Corp
2561	recombinant human monoclonal antibody to hsp90	Mycograb	9/16/2002	Treatment of invasive candidiasis	Novartis Pharmaceuticals Corp.
2562	recombinant human nerve growth factor	n/a	8/8/2013	Treatment of retinitis pigmentosa	Dompe s.p.a.
2563	recombinant human nerve growth factor	n/a	6/23/2014	Treatment of neurotrophic keratitis	Dompe s.p.a.
2564	recombinant human neutrophil inhibitor (hNE)	n/a	12/9/2003	Treatment of cystic fibrosis	Dyax Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2565	recombinant human platelet derived growth factor-BB	n/a	8/6/2010	Treatment of osteochondritis dissecans	Biomimetic Therapeutics, Inc.
2566	recombinant human porphobilinogen deaminase	Porphozyme	9/9/2002	Treatment of acute intermittent porphyria attacks	Zymenex A/S
2567	recombinant human porphobilinogen deaminase, erythropoetic form	n/a	7/11/2002	Treatment of acute intermittent porphyria preventing attacks	ZymenexA/S
2568	recombinant human proinsulin (Including rhPI-Methionine)	n/a	12/10/2008	Treatment of retinitis pigmentosa	ProRetina Therapeutics, S.L.
2569	recombinant human surfactant protein D	n/a	6/23/2014	Prevention of bronchopulmonary dysplasia	Airway Therapeutics LLC
2570	recombinant human tripeptidyl-peptidase 1 (rhTPP1)	n/a	4/1/2013	Treatment of neuronal ceroid lipofuscinosis type 2	BioMarin Pharmaceutical, Inc.
2571	recombinant human type I pancreatic elastase	n/a	4/3/2009	Prevention of arteriovenous fistula and arteriovenous graft failure in patients with chronic kidney disease (CKD) who are receiving hemodialysis or preparing for hemodialysis	Proteon Therapeutics, Inc.
2572	recombinant human type VII collagen	n/a	6/18/2008	Treatment of hereditary dystrophic epidermolysis bullosa (DEB)	David T. Woodley, MD and Mei Chen, MD
2573	recombinant human vascular endothelial growth factor	n/a	6/7/2010	Treatment of amyotrophic lateral sclerosis	NeuroNova AB

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2574	recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR)	n/a	4/12/2013	Treatment of sickle cell disease	NKT Therapeutics, Inc.
2575	recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)	n/a	5/17/2011	Treatment of pancreatic cancer.	Gilead Sciences, Inc.
2576	recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody	n/a	2/11/2015	Treatment of eosinophilic esophagitis	Receptos, Inc.
2577	recombinant humanized anti-tau antibody	n/a	1/22/2015	Treatment of progressive supranuclear palsy	C2N Diagnostics, LLC
2578	recombinant humanized monoclonal antibody of the immunoglobulin G1 subclass directed against colony stimulating factor-1 receptor expressed on macrophages	n/a	5/14/2014	Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor	Genentech, Inc.
2579	recombinant kallikrein inhibitor	n/a	11/23/2010	Treatment of Netherton Syndrome.	Dermadis SA
2580	recombinant lens epithelium derived growth factor 1-326	n/a	5/19/2014	Treatment of retinitis pigmentosa	Ocugen, Inc.
2581	recombinant monoclonal antibody to human serum amyloid P component	n/a	2/10/2015	Treatment of AL amyloidosis	Glaxo Group Limited, England d/b/a GlaxoSmithKline
2582	recombinant nematode anticoagulant protein c2 (rNAPc2)	n/a	12/8/2014	Treatment of viral hemorrhagic fever post-exposure to Ebola virus (treatment of Ebola)	ARCA Biopharma, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2583	recombinant neuroglobin (rNgb) containing mutations H64Q/C46G/C55S/C120S	n/a	11/17/2014	Treatment of patients with carbon monoxide poisoning	University of Pittsburgh
2584	recombinant ovine interferon tau	Tauferon	1/25/2005	Treatment of pediatric multiple sclerosis	PEPGEN Corporation
2585	recombinant thymidine phosphorylase encapsulated with autologous erythrocytes	n/a	12/13/2010	Treatment of mitochondrial neurogastrointestinal encephalomyopathy due to thymidine phosphorylase deficiency.	St. George's University of London
2586	recombinant von Willebrand factor (rhVWF)	n/a	11/23/2010	Treatment of von Willebrand disease.	Baxter Healthcare Corporation
2587	refanalin	n/a	5/25/2010	To improve renal function and prevent delayed graft function following renal transplantation	Angion Biomedica Corporation
2588	regorafenib	Stivarga	1/12/2011	Treatment gastrointestinal stromal tumors	Bayer HealthCare Pharmaceuticals, Inc.
2589	reparixin	n/a	1/27/2003	Prevention of delayed graft function in solid organ transplant	Dompe S.p.A.
2590	reparixin	n/a	9/25/2012	Prevention of graft loss in pancreatic islet transplantation	Dompe S.p.A.
2591	replication-deficient recombinant serotype 2 adeno-associated viral vector containing hAQP1 cDNA	n/a	5/3/2013	Treatment of symptoms of Grade 2 and Grade 3 late xerostomia from parotid gland hypofunction caused by radiotherapy for cancer of the oral cavity.	John A. Chiorini, PhD

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2592	repository corticotropin injection	H.P. Acthar Gel	6/28/2013	Treatment of amyotrophic lateral sclerosis	Questor Pharmaceuticals, Inc.
2593	repository corticotropin or adrenocorticotrophic hormone	H.P. Acthar Gel	5/21/2003	Treatment of infantile spasms	Questcor Pharmaceuticals, Inc.
2594	resiniferatoxin	n/a	5/13/2003	Treatment of intractable pain at end-stage disease	Sorrento Theraeputics, Inc.
2595	reslizumab	Cinquil	1/12/2011	Treatment of hypereosinophilic syndrome	Teva Pharmaceuticals, Inc.
2596	reslizumab	n/a	12/19/2007	Treatment of children with eosinophilic esophagitis	Cephalon, Inc.
2597	resminostat	n/a	9/16/2011	Treatment of Hodgkin's lymphoma.	4SC AG
2598	resminostat	n/a	6/29/2011	Treatment of hepatocellular carcinoma	4SC AG
2599	retroviral gamma-c cDNA containing vector	n/a	4/29/2002	Treatment of X linked severe combined immune deficiency disease	AVAX technologies, Inc.
2600	rh-microplasmin, ocriplasmin	Jetrea	3/16/2004	Adjunct to surgery in cases of pediatric vitrectomy	ThromboGenics Inc.
2601	rhIGF-I/rhIGFBP-3	Somatokine	12/9/2003	Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)	Insmmed, Inc.
2602	ribavirin	Rebetol	4/4/2003	Treatment of chronic hepatitis C in pediatric patients	Schering Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2603	ribavirin	Virazole	4/12/1991	Treatment of hemorrhagic fever with renal syndrome	Valeant Pharmaceuticals International
2604	ribavirin elaidate	n/a	9/2/2011	Treatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer	Translational Therapeutics, Inc.
2605	riboflavin ophthalmic solution & ultraviolet A	n/a	9/2/2011	Treatment of keratoconus	Avedro, Inc.
2606	riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation	n/a	12/2/2011	Treatment of corneal ectasia following refractive surgery	Avedro, Inc.
2607	ricin vaccine	Rivax(R)	1/7/2011	Prevention of ricin intoxication.	Soligenix, Inc.
2608	rifaximin	Normix	2/10/1998	Treatment of hepatic encephalopathy	Salix Pharmaceuticals, Inc.
2609	rigisertib	n/a	3/18/2011	Treatment of pancreatic cancer.	Onconova Therapeutics, Inc
2610	rigisertib	n/a	9/3/2009	Treatment of myelodysplastic syndromes	Onconova Therapeutics, Inc.
2611	rigosertib	n/a	3/16/2012	Treatment of ovarian cancer	Onconova Therapeutics, Inc.
2612	rilonacept	Arcalyst	1/9/2013	Treatment of familial Mediterranean fever	Philip J Hashkes, MD, MSc.
2613	rilotumumab	n/a	6/18/2012	Treatment of gastric cancer including gastroesophageal junction adenocarcinoma	Amgen, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2614	rindopepimut	n/a	11/19/2007	Treatment of EGFRvIII-expressing glioblastoma multiforme	Celldex Therapeutics, Inc.
2615	riociguat	Adempas	9/19/2013	Treatment of chronic thromboembolic pulmonary hypertension	Bayer HealthCare Pharmaceuticals, Inc.
2616	riociguat	Adempas	9/19/2013	Treatment of pulmonary arterial hypertension.	Bayer HealthCare Pharmaceuticals, Inc.
2617	riociguat	Adempas	7/24/2014	Treatment of systemic sclerosis	Bayer HealthCare Pharmaceuticals
2618	rituximab	Rituxan	3/12/2002	Treatment of immune thrombocytopenic purpura	Genentech, Inc.
2619	rituximab	Rituxan	2/14/2006	Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)	Genentech, Inc.
2620	rituximab	Rituxan	1/29/2004	Treatment of chronic lymphocytic leukemia	Genentech, Inc.
2621	rituximab	Rituxan	6/13/1994	Treatment of non-Hodgkin's B-cell lymphoma	Genentech, Inc.
2622	rituximab	Rituxan(R); Mabthera(R)	2/23/2015	Treatment of pemphigus vulgaris.	Genentech, Inc.
2623	rofecoxib	Vioxx	3/16/2004	Treatment of juvenile rheumatoid arthritis	MERCK & Co., Inc.
2624	romidepsin	Istodax	9/30/2004	Treatment of non-Hodgkin T-cell lymphomas	Celgene Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2625	romiplostim	n/a	10/31/2007	Treatment of thrombocytopenia associated with myelodysplasia syndrome	Amgen Inc.
2626	romiplostim	Nplate	3/27/2003	Treatment of immune thrombocytopenic purpura	Amgen, Inc.
2627	rosuvastatin	Crestor	2/14/2014	For the treatment of pediatric homozygous familial hypercholesterolemia	AstraZeneca Pharmaceuticals LP
2628	rozrolimupab	n/a	9/13/2010	Treatment of primary immune thrombocytopenia.	Symphogen A/S
2629	rsATP7A cDNA	n/a	1/10/2014	Treatment of Menkes disease	Stephen G. Kaler, MD
2630	rt-PA	Activase	10/20/2014	Treatment of plastic bronchitis	Kathleen A Stringer, PharmD, FCCP - Professor
2631	rubitecan	n/a	7/17/2002	Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome	SuperGen, Inc.
2632	rucaparib	n/a	7/31/2012	Treatment of ovarian cancer	Clovis Oncology, Inc.
2633	rufinamide	Banzel	10/8/2004	Treatment of Lennox-Gastaut Syndrome.	Eisai, Inc.
2634	ruxolitinib	Jakafi	8/16/2013	Treatment of pancreatic cancer	Incyte Corporation
2635	ruxolitinib	Jakafi	3/26/2010	Treatment of polycythemia vera	Incyte Corporation
2636	ruxolitinib phosphate	Jakafi	3/22/2010	Treatment of essential thrombocythemia	Incyte Corporation

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2637	ruxolitinib phosphate	Jakafi	9/5/2008	Treatment of myelofibrosis	Incyte Corporation
2638	salicylic acid 6%	n/a	2/17/2012	Treatment of rare congenital ichthyoses.	Orenova Group, LLC
2639	salirasib	n/a	12/18/2006	Treatment of pancreatic cancer.	Kadmon Corporation, LLC
2640	salmeterol xinafoate/fluticasone propionate	n/a	10/29/2009	Treatment of symptomatic exophthalmos associated with thyroid related eye disease.	Lithera, Inc.
2641	saposin C	n/a	2/3/2015	Treatment of glioblastoma multiforme	Bexion Pharmaceuticals, LLC
2642	sapropterin	Kuvan	1/29/2004	Treatment of hyperphenylalaninemia	Biomarin Pharmaceutical Inc.
2643	sarcosine	n/a	10/12/2011	Treatment of obsessive compulsive disorder in pediatric patients (0 to 16 years of age)	Guochuan Emil Tsai, MD, PhD
2644	sdTD-K6a.513a.12; small interfering RNA composed of 2 strands of hybridized RNAs	n/a	4/15/2013	Treatment of pachyonychia congenita	TransDerm, Inc.
2645	sebelipase alfa	n/a	7/1/2010	Treatment of lysosomal acid lipase deficiency	Synageva BioPharma Corp.
2646	selective antagonist of the chemokine receptor type 4	n/a	9/5/2013	Treatment of acute myeloid leukemia	BioLineRx, Ltd.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2647	selective deacylglycerol acyltransferase 1 inhibitor	n/a	3/28/2011	Treatment of hypertriglyceridemia in te setting of Type I hyperlipoproteinemia, also known as Familial Chylomicronema Syndrome	Novartis Pharmaceuticals Corporation
2648	selective inhibitor of fungal lanosterol demethylase	n/a	8/19/2014	Treatment of cryptococcal meningitis	Viamet Pharmaceuticals, Inc.
2649	selexipag	n/a	4/30/2010	Treatment of pulmonary arterial hypertension	Actelion Ltd
2650	self-complimentary adeno-associated virus vector, serotype 9, packaging the full lenght GAN gene in the viral capsid	n/a	9/27/2013	Treatment of Giant Axonal Neuropathy	Hannah's Hope Fund
2651	selinexor	n/a	1/5/2015	Treatment of multiple myeloma	Karyopharm Therapeutics, Inc.
2652	selisistat	n/a	12/7/2009	Treatment of Huntington's disease	Siena Biotech SpA
2653	sialic acid	n/a	9/23/2011	Treatment of hereditary inclusion body myopathy.	Ultragenyx Pharmaceutical, Inc.
2654	sildenafil	Revatio	7/28/2011	Treatment of pediatic (defined as children less than 17 years of age) pulmonary arterial hypertension	Pfizer, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2655	silibinin-C-2',3-dihydrogensuccinate, disodium salt	Legalon(R) Sil	9/11/2014	Treatment of amatoxin poisoning, which includes the prevention and treatment of amatoxin induced hepatic failure	Rottapharm S.p.A.
2656	siltuximab	Sylvant	5/26/2006	Treatment of Castleman's disease	Janssen Biotech, Inc.
2657	simtuzumab	n/a	1/5/2015	Treatment of primary sclerosing cholangitis	Gilead Sciences, Inc.
2658	single stranded, chemically modified oligonucleotide that binds to and inhibits the function of micro RNA-21	n/a	7/17/2014	Treatment of Alport syndrome	Regulus Therapeutics, Inc.
2659	siponimod	n/a	7/10/2014	Treatment of dermatomyositis	Novartis Pharmaceuticals Corporation
2660	sirolimus	Rapamune(R)	10/31/2012	Treatment of lymphangioleiomyomatosis	Pfizer, Inc.
2661	sirolimus	n/a	3/18/2013	Treatment of pachyonychia congenita	TransDerm, Inc.
2662	sirolimus	n/a	6/25/2014	Treatment of lymphangioleiomyomatosis	LAM Therapeutics, Inc.
2663	sirolimus	n/a	11/17/2011	Treatment of lymphangioleiomyomatosis	Cote Orphan Consulting, LLC

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2664	sirolimus	n/a	11/4/2011	Treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (NICUPS).	Santen Inc.
2665	sirolimus in an implantable collagen matrix	Coll-R, Sirogen	5/10/2012	Prevention of arteriovenous(AV) fistula or AV graft failure in patients with end stage renal disease, receiving hemodialysis or preparing for hemodialysis	Vascular Therapies, LLC
2666	sitimagene ceradenovec	Cerepro	7/31/2001	Use with gancyclovir in the treatment of malignant glioma	Finvector Vision Therapies Ltd
2667	skin tissue	Stratagraft	5/21/2012	Treatment of hospitalized patients with complex skin defects resulting from partial and full thickness skin burns requiring excision and grafting	Stratatech Corporation
2668	small molecule inhibitor of histone methyltransferase DOT1L	n/a	8/8/2013	Treatment of acute lymphoblastic leukemia (ALL)	Epizyme Inc.
2669	small molecule inhibitor of phosphodiesterase 10	n/a	9/26/2013	Treatment of Huntington's disease	Omeros Corporation
2670	small molecule normalizing the p53 function	n/a	6/12/2014	Treatment of ovarian cancer	Critical Outcome Technologies, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2671	smilagenin	Cogane	7/21/2011	Treatment of amyotrophic lateral sclerosis	Junaxo, Inc.
2672	sobetirome	n/a	4/29/2011	Treatment of X-linked adrenoleukodystrophy	NeuroVia, Inc.
2673	sodium 2, 2 dimethylbutyrate	n/a	7/25/2008	Treatment of sickle cell disease.	HemaQuest Pharmaceuticals, Inc.
2674	sodium 4-phenylbutyrate	n/a	10/18/2011	Treatment of spinal muscular atrophy	GMP-Orphan SAS
2675	sodium 4-{ [9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-d] [2] benzazepin-2-yl]-2-methoxybenzoate	n/a	4/3/2009	Treatment of ovarian cancer	Millennium Pharmaceuticals, Inc.
2676	sodium ascorbate and menadione sodium bisulfite	Apatone(R)	4/15/2013	Treatment of autosomal dominant polycystic liver disease	IC-Medtech Corporation
2677	sodium ascorbate and menadione sodium bisulfite	Apatone	4/15/2013	Treatment of autosomal dominant polycystic kidney disease	IC-MedTech Corporation
2678	sodium benzoate and clozapine	n/a	12/22/2011	Treatment of treatment-resistant schizophrenia	Guochuan Emil Tsai, MD, PhD
2679	sodium chlorite	n/a	8/22/2011	For slowing the progression of amyotrophic lateral sclerosis.	Neuraltus Pharmaceuticals, Inc.
2680	sodium dichloroacetate	n/a	7/3/2003	Use as an antidote in the management of systemic monochloroacetic acid poisoning	EBD Group
2681	sodium dichloroacetate	n/a	11/29/2010	For pulmonary arterial hypertension.	Peter W. Stackpoole, PhD, MD

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2682	sodium fusidate	n/a	10/23/2013	Treatment of patients with prosthetic joint infections	Cempra Pharmaceuticals, Inc.
2683	sodium nitrate	n/a	1/9/2012	Treatment of chlorine gas poisoning	Hope Pharmaceuticals
2684	sodium nitrite	n/a	9/3/2009	Prevention of ischemia reperfusion injury to donor organ tissue associated with solid organ transplantation	Hope Pharmaceuticals
2685	sodium nitrite	n/a	7/8/2008	Treatment of pulmonary arterial hypertension	Mast Therapeutics, Inc.
2686	sodium nitrite and sodium thiosulfate	Nithiodote	4/9/2008	Treatment of known or suspected cyanide poisoning	Hope Pharmaceuticals
2687	sodium phenylbutyrate	n/a	7/2/1992	Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy.	Medicis Pharmaceutical Corp.
2688	sodium phenylbutyrate	n/a	1/19/2010	Treatment of urea cycle disorder.	Navinta LLC
2689	sodium phenylbutyrate	Pheburane	6/6/2013	Treatment of urea cycle disorders	Lucane Pharma SA
2690	sodium phenylbutyrate	n/a	8/19/2014	Treatment of maple syrup urine disease	Acer Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2691	sodium phenylbutyrate	Buphenyl	11/22/1993	Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency.	Medicis Pharmaceutical Corp.
2692	sodium stibogluconate	n/a	10/28/2009	Treatment of cutaneous leishmaniasis	Surgeon General of the US Army
2693	sodium sulfate, potassium sulfate, and magnesium sulfate	Suprep	10/31/2012	For cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in children and adolescents	Braintree Laboratories, Inc.
2694	sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride	Suclear	9/4/2013	For use in cleansing of the colon in preparation for colonoscopy in children and adolescents	Braintree Laboratories, Inc.
2695	sodium thiosulfate	n/a	10/28/2014	Treatment of dermatomyositis	Hope Pharmaceuticals
2696	sodium thiosulfate	n/a	12/2/2010	Treatment of extravasation of meclorethamine hydrochloride into subcutaneous tissues.	Hope Pharmaceuticals
2697	sodium thiosulfate	n/a	3/3/2011	Treatment of sulfur mustard poisoning	Hope Pharmaceuticals
2698	sodium thiosulfate	n/a	11/9/2011	Treatment of uremic and non-uremic calciphylaxis	Hope Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2699	sodium thiosulfate	n/a	10/13/2011	Prevention of platinum-induced ototoxicity in pediatric patients	Hope Pharmaceuticals
2700	sodium thiosulfate	n/a	11/19/2012	Treatment of calciphylaxis	Edinburg BioQuarter
2701	solvent/detergent treated non-blood-group specific human coagulation active plasma	Uniplas	12/12/2005	Treatment of thrombotic thrombocytopenic purpura	Octapharma USA, Inc.
2702	somatorelin	Somatrel	8/8/1989	Diagnostic measure of the capacity of the pituitary gland to release growth hormone.	Ferring Laboratories, Inc.
2703	somatropin [rDNA]	Genotropin	12/27/2000	Treatment of growth failure in children who were born small for gestational age.	Pharmacia and Upjohn Company
2704	sorafenib	Nexavar	12/12/2011	Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer	Bayer HealthCare Pharmaceuticals, Inc.
2705	sotalol (IV)	So-Aqueous	7/25/2008	For ventricular tachycardia, ventricular fibrillation, or the maintenance of sinus rhythm in patients converted from atrial fibrillation or atrial flutter when oral administration is not possible.	Academic Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2706	sotalol hydrochloride	n/a	2/10/2014	Treatment of life-threatening ventricular arrhythmias in pediatric patients	Arbor Pharmaceuticals, LLC
2707	sotatercept	n/a	12/5/2013	Treatment of beta-thalassemia intermedia and major	Celgene Corporation
2708	sotatercept	n/a	4/28/2014	Treatment of anemias associated with myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasms.	Celgene Corporation
2709	sparsentan	n/a	1/5/2015	Treatment of Focal Segmental Glomerulosclerosis	Retrophin, LLC
2710	spherical carbon adsorbent	n/a	12/19/2007	Treatment of chronic pouchitis	Ocera Therapeutics, Inc.
2711	spironolactone	Aldactone	5/22/2014	Use in pediatric patients with primary hyperaldosteronism	CMP Pharma, Inc.
2712	squalamine lactate	n/a	5/11/2001	Treatment of ovarian cancer refractory or resistant to standard chemotherapy	Genaera Corporation
2713	stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Nicord(R)	11/13/2014	Treatment of Hodgkin lymphoma.	Gambia Cell Ltd.
2714	stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Nicord(R)	11/13/2014	Treatment of acute lymphoblastic leukemia.	Gambia Cell Ltd.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2715	stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Nicord(R)	11/13/2014	Treatment of myelodysplastic syndrome.	Gamida Cell Ltd.
2716	stiripentol	Diacomit	10/30/2008	Treatment of Dravet syndrome	Biocodex
2717	sulfamidase	n/a	5/22/2008	For treatment of Sanfilippo Syndrome (MPS IIIA)	Shire Human Genetic Therapies, Inc.
2718	sulfonated monophosphorylated mannose oligosaccharide	n/a	2/17/2012	Treatment of hepatocellular carcinoma	Medigen Biotechnology Corporation
2719	sulthiame	n/a	7/25/2013	Treatment of patients with benign epilepsy of childhood with centrotemporal spikes (BECTS) also known as rolandic epilepsy	Marathon Pharmaceuticals, LLC
2720	superoxide dismutase, gliadin	Etr019	4/30/2010	Treatment of amyotrophic lateral sclerosis	Verius Limited
2721	synthetic double-stranded siRNA oligonucleotide against antithrombin (AT) mRNA	n/a	8/16/2013	Treatment of hemophilia A	Alnylam Pharmaceuticals
2722	synthetic double-stranded siRNA oligonucleotide against antithrombin mRNA	n/a	8/12/2013	Treatment of hemophilia B	Alnylam Pharmaceuticals
2723	synthetic double-stranded siRNA oligonucleotide against p53 mRNA	n/a	12/23/2009	Prophylaxis of delayed graft function in renal transplant patients	Quark Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2724	synthetic double-stranded siRNA oligonucleotide against transthyretin (TTR) mRNA	n/a	6/14/2012	Treatment of familial amyloidotic polyneuropathy	Alnylam Pharmaceuticals, Inc.
2725	synthetic oligomer of 16 nucleotides	n/a	1/15/2015	Treatment of myotonic dystrophy Type I	Isis Pharmaceuticals, Inc.
2726	synthetic peptide H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH	n/a	10/12/2011	Treatment of necrotizing soft tissue infections (NSTI)	Atox Bio, Inc.
2727	synthetic peptide; cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-ALA-Lys-Pro-Trp-Tyr-Cys	n/a	1/15/2013	Treatment of high altitude pulmonary edema	Apeptico Forschung und Entwicklung GmbH
2728	synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue	n/a	3/16/2012	Treatment of preterm neonatal respiratory distress syndrome	Chiesi Pharmaceuticals, Inc.
2729	tabalumab	n/a	11/19/2012	Treatment of multiple myeloma	Eli Lilly and Company
2730	taberminogene vadenovec	Trinam	10/24/2000	Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.	Finvector Vision Therapies, Ltd.
2731	tacrolimus	n/a	7/6/2012	Treatment of hemorrhagic cystitis	Lipella Pharmaceuticals Inc.
2732	tadalafil	Adcirca	12/18/2006	Treatment of pulmonary arterial hypertension	Eli Lilly and Company

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2733	tafamidis	n/a	5/23/2006	Treatment of familial amyloid polyneuropathy	Pfizer, Inc.
2734	tafamidis meglumine	n/a	2/17/2012	Treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy.	Pfizer, Inc.
2735	tafenoquine	n/a	1/15/2013	Treatment of malaria	Glaxo Group Limited, England
2736	talactoferrin alfa	n/a	8/20/2003	For the prevention of graft-versus-host disease	Agennix, Inc.
2737	talactoferrin alfa	n/a	8/20/2003	For the treatment of graft versus host disease	Agennix, Inc.
2738	talarazole	n/a	3/16/2012	Treatment of congenital ichthyosis	Stiefel Laboratories, Inc.
2739	tarextumab	n/a	1/26/2015	Treatment of small cell lung cancer	OncoMed Pharmaceuticals, Inc.
2740	tarextumab	n/a	1/26/2015	Treatment of pancreatic cancer	OncoMed Pharmaceuticals, Inc.
2741	tasimelteon	Hetlioz	1/19/2010	Non-24-hour sleepwake disorder in blind individuals without light perception	Vanda Pharmaceuticals, Inc.
2742	tasimelteon	n/a	4/30/2010	Treatment of sleep-wake disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion	Vanda Pharmaceuticals, Inc.
2743	taurine	n/a	3/22/2010	Treatment of cystathionine beta-synthase deficient homocystinuria	Johan L. Van Hove, MD, PhD

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2744	technetium Tc 99m tilmanocept	Lymphoseek	9/17/2014	Use in sentinel lymph node detection (SLN) with a hand-held gamma-counter, with scintigraphic imaging, in patients with cancer of the head and neck	Navidea Biopharmaceuticals
2745	tecovirimat	n/a	12/27/2006	Treatment of smallpox.	SIGA Technologies, Inc.
2746	tecovirimat	n/a	12/18/2006	post exposure prophylaxis against smallpox	SIGA Technologies, Inc.
2747	tecovirimat	n/a	9/29/2010	Treatment of orthopoxvirus infections.	SIGA Technologies, Inc.
2748	teduglutide [rDNA origin]	Gattex	6/29/2000	Treatment of short bowel syndrome.	NPS Pharmaceuticals, Inc.
2749	telatinib	n/a	5/17/2010	Treatment of gastric cancer	ACT Biotech Inc.
2750	temocillin sodium	Negaban	4/21/2004	Treatment of pulmonary infections caused by Burkholderia cepacia	Belpharma S.A.
2751	temozolomide	Temodar	10/5/1998	Treatment of recurrent malignant glioma.	Schering-Plough Research Institute
2752	tenofovir	Viread	3/17/2009	Treatment of pediatric HIV infection.	Gilead Sciences, Inc.
2753	teprotumumab	n/a	5/6/2013	Treatment of active (dynamic) phase Grave's orbitopathy	River Vision, Inc.
2754	terguride	Mysalfon, Teluron	5/17/2013	Treatment of systemic sclerosis	Serodapharm UG
2755	teriparatide	Forteo	4/18/2014	Treatment of hypoparathyroidism	Entera Bio, Ltd.
2756	terlipressin	n/a	10/29/2004	Treatment of Hepatorenal Syndrome	Ikaria (INO Therapeutics)

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2757	tesetaxel	n/a	12/22/2008	Treatment of gastric cancer	Genta Inc.
2758	tesetaxel	n/a	11/21/2008	Treatment of stages IIB, IIC, III, and stage IV melanoma	Genta, Inc.
2759	testosterone undecanoate (oral)	n/a	2/13/2013	Treatment of constitutional delay in growth and puberty in adolescent boys (14-17 yrs of age)	SOV Therapeutics, Inc.
2760	tetra substituted porphyrin derivative containing manganese (III)	n/a	1/17/2014	For use in patients exposed to radiation following a nuclear accident or detonation in order to treat or mitigate acute radiation syndrome.	Aeolus Pharmaceuticals, Inc.
2761	tetrabenazine	n/a	7/1/2009	Treatment of Tourette's Syndrome in school-age children, ages 5-16	Valeant International (Barbados) SRL
2762	tetracosactide hexaacetate (beta 1-24-corticotrophin)	Synacthen Depot, S. Retard	10/31/2012	Treatment of infantile spasms	Cerium Pharmaceuticals, Inc.
2763	theranost 68Ga-RGD	n/a	12/8/2014	Diagnostic for clinical management of patients with neuroblastoma	Advanced Imaging Projects, LLC
2764	thymopentin	n/a	2/4/2011	Treatment of sarcoidosis.	mondoBIOTECH Laboratories, AG
2765	thymosin beta 4	n/a	12/31/2013	Treatment of patients with neurotrophic keratopathy	RegeneRx Biopharmaceuticals, Inc.
2766	tigecycline	n/a	10/23/2013	Treatment of acute myeloid leukemia.	Trillium Therapeutics, Inc.
2767	tin ethyl etiopurpurin	n/a	11/4/2003	Prevention of access graft disease in hemodialysis patients	Miravant Medical Technologies

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2768	tinidazole	Tindamax	4/18/2002	Treatment of giardiasis	Presutti Laboratories, Inc.
2769	tipelukast	n/a	10/20/2014	Treatment of idiopathic pulmonary fibrosis	MediciNova, Inc.
2770	tiptorelin pamoate	n/a	8/20/2012	Treatment of central precocious puberty	Debiopharm
2771	tirapazamine	n/a	10/23/2002	Treatment of head and neck cancer	Sanofi-Aventis US, Inc.
2772	tisagenlecleucel-T	n/a	2/3/2015	Treatment of diffuse large B-cell lymphoma	Novartis Pharmaceuticals Corporation
2773	tivantinib	n/a	10/16/2013	Treatment of hepatocellular carcinoma	Daiichi Sankyo Pharma Development
2774	tocilizumab	Actemra	4/17/2013	Treatment of systemic sclerosis	Genentech, Inc.
2775	tocilizumab	Actemra	7/31/2012	Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis	Genentech, Inc.
2776	tolerogen	n/a	2/5/2015	Treatment of myasthenia gravis	Toleranzia AB
2777	tolvaptan	Samsca	4/6/2012	Treatment of autosomal dominant polycystic kidney disease	Otsuka Pharmaceuticals Co., Ltd.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2778	topiramate injection	n/a	7/24/2013	Treatment of partial onset or primary generalized tonic-clonic seizures for hospitalized epilepsy patients or epilepsy patients being treated in an emergency care setting who are unable to take oral topiramate	CURx Pharmaceuticals, Inc.
2779	trabectedin	Yondelis	9/30/2004	Treatment of soft tissue sarcoma	Janssen Research & Development, LLC
2780	trabectedin	Yondelis	3/29/2005	Treatment of patients with ovarian cancer	Janssen Research & Development, LLC
2781	trabedersen	n/a	7/21/2009	Treatment of pancreatic cancer.	Isarna Therapeutics GmbH
2782	trabedersen	n/a	8/22/2011	Treatment of Stage IIB through Stage IV malignant melanoma.	Isarna Therapeutics GmbH
2783	trabedersen	Oncomun	6/5/2002	Treatment of malignant glioma	Isarna Therapeutics GmbH
2784	tralokinumab	n/a	7/24/2012	Treatment of idiopathic pulmonary fibrosis	MedImmune Ltd.
2785	trametinib	Mekinist	12/20/2010	Treatment of Stage IIb through Stage IV melanoma	GlaxoSmithKline, LLC
2786	trametinib and dabrafenib	Mekinist And Tafinlar	9/20/2012	Treatment of Stage IIb through IV melanoma.	GlaxoSmithKline, LLC

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2787	tranilast	Rizaben	12/23/2010	Prevention of scarring following glaucoma filtration surgery	Altacor Ltd
2788	trans sodium crocetinate	n/a	12/3/2012	Treatment of brain metastasis	Diffusion Pharmaceuticals, LLC
2789	trans sodium crocetinate	n/a	7/21/2011	Treatment of glioblastoma in conjunction with radiotherapy	Diffusion Pharmaceuticals, LLC
2790	transforming growth factor-beta receptor 1 kinase inhibitor	n/a	3/11/2013	Treatment of glioma	Eli Lilly and Company
2791	transforming growth factor-beta receptor 1 kinase inhibitor	n/a	4/1/2013	Treatment of hepatocellular carcinoma	Eli Lilly and Company
2792	trastuzumab	Herceptin	12/14/1999	Treatment of patients with pancreatic cancer that overexpress p185HER2.	Genentech, Inc.
2793	trastuzumab	Herceptin	10/13/2009	Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction	Genentech, Inc.
2794	trastuzumab emtansine	Kadcyla ... ®	10/25/2013	For the treatment of gastric cancer including gastroesophageal junction cancer.	Genetech, Inc.
2795	trebananib	n/a	8/30/2013	Treatment of ovarian cancer	Amgen, Inc.
2796	trehalose	Cabaletta	10/25/2013	Treatment of oculopharyngeal muscular dystrophy	BIOBLAST PHARMA LTD.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2797	trehalose	n/a	11/17/2014	Treatment of spinal cerebellar ataxia type 3 (also known as SCA3 or Machado Joseph disease)	BioBlast Pharma Ltd
2798	tremelimumab	n/a	9/18/2006	Treatment of stage IIb to stage IV metastatic melanoma	MedImmune
2799	treprostinil	Remodulin	6/4/1997	Treatment of pulmonary arterial hypertension.	United Therapeutics Corp.
2800	treprostinil (inhalational)	Tyvaso	6/17/2010	Treatment of pulmonary arterial hypertension	LungRx, Inc.
2801	tri-antennary glycotriptide derivative of 5-fluorodeoxyuridine monophosphate	n/a	11/23/2001	Treatment for hepatocellular carcinoma	Cell Works Inc.
2802	tricitabine	n/a	2/1/2008	Treatment of multiple myeloma	VioQuest Pharmaceuticals, Inc.
2803	trientine hydrochloride	Syprine(R)	11/2/2010	Treatment of manganism.	Cerberus Princeton, LLC
2804	trifarotene	n/a	6/6/2014	Treatment of congenital ichthyosis	Galderma R&D, LLC
2805	triheptanoin	n/a	10/21/2014	Treatment of glucose transporter type-1 deficiency syndrome	Ultragenyx Pharmaceutical, Inc.
2806	triterpenoid saponin	n/a	7/23/2014	Treatment of mantle cell lymphoma	Avicin Therapeutics, Ltd.
2807	tryptophan hydroxylase (TPH) inhibitor	n/a	3/9/2012	Management of symptoms of carcinoid syndrome associated with carcinoid tumor	Lexicon Pharmaceuticals, Inc.
2808	tyrosine kinase inhibitor	n/a	9/14/2005	Treatment of mastocytosis	AB Science

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2809	ubiquinol	Ubi-Q-Nol, Li-Q-Nol	4/12/2004	Treatment of Huntington's Disease	Gel-Tec, Division of Tishcon Corp
2810	ublituximab	n/a	8/6/2010	Treatment of chronic lymphocytic leukemia	TG Therapeutics, Inc.
2811	ublituximab	n/a	9/5/2013	Treatment of Nodal marginal zone lymphoma	TG Therapeutics, Inc.
2812	ublituximab	n/a	9/5/2013	Treatment of Extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, MALT)	TG Therapeutics, Inc.
2813	ulocuplumab	n/a	1/12/2015	Treatment of acute myeloid leukemia	Bristol-Myers Squibb Company
2814	unoprostone isopropyl	Rescula	9/16/2010	Treatment of retinitis pigmentosa	Sucampo Pharma Americas, LLC
2815	urea	n/a	11/7/2011	Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosiform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis).	Orenova Group, LLC
2816	uridine triacetate	n/a	8/9/2013	Treatment of hereditary orotic aciduria	Wellstat Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2817	uridine triacetate	n/a	5/1/2009	An antidote in the treatment of 5-fluorouracil poisoning	Wellstat Therapeutics Corp.
2818	uridine triacetate	n/a	9/3/2009	Treatment of mitchondrial disease	Wellstat Therapeutics Corporation
2819	ursodiol	Ursofalk Suspension	10/23/2007	Treatment of cystic fibrosis liver disease	Asklepiion Pharmaceuticals, LLC
2820	ustekinumab	Stelara	11/29/2010	Treatment of type 1 diabetes mellitus patients with residual beta-cell function.	Johnson & Johnson Pharmaceutical & Development LLC
2821	valine-valine-ganciclovir	n/a	5/21/2007	Treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HSV1 and HSV2.	Verenta Pharmaceuticals, Inc.
2822	vancomycin	n/a	12/27/2012	Treatment of endophthalmitis	Fera Pharmaceuticals, LLC
2823	vancomycin hydrochloride (inhalational)	n/a	9/20/2012	Treatment of persistent methicillin-resistant S. aureus lung infection in patients with cystic fibrosis	Savara Pharmaceuticals, Inc.
2824	vandetanib	Caprelsa(R)	10/21/2005	Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma	AstraZeneca Pharmaceutical LP

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2825	vapreotide	Octastatin	3/6/2000	Prevention of early postoperative complications following pancreatic resection.	Debiopharm S.A.
2826	vapreotide	Octastatin	1/10/2000	Treatment of gastrointestinal and pancreatic fistulas.	Debiopharm S.A.
2827	vapreotide	Sanvar	1/10/2000	Treatment of esophageal variceal hemorrhage patients with portal hypertension.	Debiovision, Inc.
2828	vapreotide	Sanvar	11/4/2003	Treatment of acromegaly	H3 Pharma, Inc.
2829	vascular endothelial growth factor 165b	n/a	6/24/2008	Treatment of advanced melanoma stages IIb through IV.	PhiloGene, Inc.
2830	vasoactive intestinal peptide (VIP)-elastin-like peptide (ELP) fusion protein	n/a	5/13/2014	Treatment of pulmonary arterial hypertension, WHO Group 1	PhaseBio Pharmaceuticals, Inc.
2831	vatiquinone	Vincerinone	11/17/2014	Treatment of Rett syndrome	Edison Pharmaceuticals, Inc.
2832	vatiquinone	Vincerinone	6/4/2014	Treatment of Leigh Syndrome	Edison Pharmaceuticals, Inc.
2833	vatiquinone	Vincerinone	1/31/2014	Treatment of Friedreich's ataxia	Edison Pharmaceuticals, Inc.
2834	velaglucerase-alfa	Vpriv	6/8/2009	Treatment of Gaucher disease	Shire Human Genetics Therapies, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2835	veliparib	n/a	9/3/2009	Treatment of epithelial ovarian cancer in combination with DNA-damaging agents	AbbVie, Inc.
2836	veliparib	n/a	11/20/2009	Treatment of hepatocellular carcinoma in combination with DNA-damaging agents	AbbVie, Inc.
2837	veliparib	n/a	5/9/2008	Treatment of glioblastoma multiforme when used in combination with DNA-damaging agents	AbbVie, Inc.
2838	veliparib	n/a	12/17/2014	Treatment of brain metastases when used in combination with DNA-damaging agents	AbbVie Inc.
2839	veltuzumab	n/a	11/17/2014	Treatment of pemphigus	Immunomedics, Inc.
2840	veltuzumab	n/a	8/28/2008	Treatment of chronic lymphocytic leukemia	Immunomedics, Inc.
2841	vemurafenib	Zelboraf	12/20/2010	Treatment of patients with IIb to Stage IV melanoma positive for the BRAF(v600) mutation	Hoffmann-La Roche, Inc.
2842	vemurafenib	Zelboraf	11/26/2013	Treatment of anaplastic thyroid carcinoma and advanced papillary thyroid cancer whose tumors harbor a BRAF V600 mutation	Genentech, Inc.
2843	vemurafenib	Zelboraf(R)	9/8/2014	Treatment of patients with non-small cell lung cancer (NSCLC) with BRAF V600E mutation	Genentech, Inc.

**Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015**

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2844	vemurafenib	Zelboraf (R)	8/26/2014	Treatment of hairy cell leukemia (HCL).	Genentech, Inc.
2845	verteporfin	Visudyne(R)	3/9/2012	Treatment of chronic or recurrent central serous chorioretinopathy	Valeant Pharmaceuticals North America LLC
2846	vibriolysin	Vibrilase	6/16/2006	Debridement of severe, deep dermal burns in hospitalized patients	BioMarin Pharmaceutical Inc.
2847	vigabatrin	Sabril	6/12/2000	Treatment of infantile spasms.	H. Lundbeck A/S
2848	vinCRISStine sulfate LIPOSOME injection	Marqibo	1/8/2007	Treatment of acute lymphoblastic leukemia	Talon Therapeutics, Inc.
2849	vincristine sulfate liposomes	Marqibo	6/24/2008	Treatment of metastatic uveal melanoma.	Talon Therapeutics
2850	vintafolide	n/a	12/16/2013	Treatment of ovarian cancer	Endocyte, Inc.
2851	volasertib	n/a	4/14/2014	Treatment of acute myeloid leukemia	Boehringer Ingelheim Pharmaceuticals, Inc.
2852	von Willebrand Factor Human Concentrate	Wilfactin	5/29/2014	Treatment of Von Willebrand Disease	rEVO Biologics, Inc.
2853	vorinostat	Zolinza	3/16/2004	Treatment of T-cell non-Hodgkin's lymphoma	Merck & Co., Inc.
2854	vosaroxin	n/a	10/28/2009	Treatment of acute myeloid leukemia	Sunesis Pharmaceuticals, Inc.
2855	xenon gas	n/a	12/3/2014	Treatment of hypoxic ischemic encephalopathy	Neuroprotexon
2856	zidovudine	Retrovir	7/17/1985	Treatment of AIDS	Glaxo Wellcome Inc.

Orphan Drug Designations and Approvals List as of 03-02-2015
Governs April 1, 2015 - June 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2857	zoledronic acid	Zometa, Reclast, Aclasta	5/6/2013	Treatment of complex regional pain syndrome (CRPS).	Axsome Therapeutics, Inc.
2858	{2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl]}(3H-benzo[f]azepin-4-yl)}-N,N-dipropylcarboxamide	n/a	4/10/2014	Treatment of ovarian cancer	VentiRx Pharmaceuticals, Inc.
2859		Dysport(R)	12/5/1991	Treatment of essential blepharospasm.	Ipsen Biopharmaceuticals, Inc.
2860		Nicord	4/28/2014	For the treatment of acute myeloid leukemia	Gamida Cell Ltd
2861		Biothrax	4/11/2014	For post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed Bacillus anthracis exposure	Emergent Product Development Gaithersburg, Inc.